

Medication use in pregnancy: a multinational perspective

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-004365
Article Type:	Research
Date Submitted by the Author:	30-Oct-2013
Complete List of Authors:	Lupattelli, Angela; University of Oslo, School of Pharmacy Spigset, Olav; St Olav's University Hospital, Department of Clinical Pharmacology; Children's and Women's Health, Norwegian University of Science and Technology, Department of Laboratory Medicine Twigg, Michael; University of East Anglia, School of Pharmacy Zagorodnikova, Ksenia; Northwest State Medical University n.a.I.I. Mechnikov, Northwest Medical Center for Drug Safety in Pregnancy & Lactation Mårdby, Ann-Charlotte ; The Sahlgrenska Academy, University of Gothenburg, Department of Public Health and Community Medicine Moretti, Myla; The Hospital for Sick Children, University of Toronto, The Motherisk Program, Division of Clinical Pharmacology and Toxicology Drozd, Mariola; Medical University of Lublin, Faculty of Pharmacy Panchaud, Alice; University of Geneva and Lausanne, School of Pharmaceutical Sciences Hämeen-Anttila, Katri; Finnish Medicines Agency, Rieutord, Andre; APHP, GH HUPS, Hop Antoine Béclère,, Service Pharmacie, Clamart France and Européenne de Formation pour les Pharmaciens Gjergja Juraski, Romana; Children's Hospital Srebrnjak, Neuropediatric Unit Odalovic, Marina; Faculty of pharmacy, University of Belgrade, Department of Social Pharmac; University Medical Centre Ljubljana, Clinical Institute of Medical Genetics Juch, Herbert; Medical University of Graz, Research Unit Human Teratogens, Institute for Cell Biology, Histology and Embryology Passier, Anneke; Netherlands Pharmacovigilance Centre Lareb, Teratology Information Service (TIS), Björnsdóttir, Ingunn; University of Iceland, Nordeng, Hedvig; University of Oslo, School of Pharmacy; Norwegian Institute of Public Health, Division of Mental Health
Primary Subject Heading :	Obstetrics and gynaecology
Secondary Subject Heading:	Obstetrics and gynaecology, Pharmacology and therapeutics, Public health
Keywords:	Maternal medicine < OBSTETRICS, THERAPEUTICS, Public health < INFECTIOUS DISEASES

Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.

Herbal Survey revised submission-1.pdf

SCHOLARONE[™]

Medication use in pregnancy: a multinational perspective

Lupattelli A,¹ Spigset O,^{2,3} Twigg MJ,⁴ Zagorodnikova K,⁵ Mårdby AC,⁶ Moretti ME,⁷ Drozd M,⁸ Panchaud A,⁹ Hameen-Anttila K,¹⁰ Rieutord A,¹¹ Gjergja Juraski R,¹² Odalovic M,¹³ Kennedy D,¹⁴ Rudolf G,¹⁵ Juch H,¹⁶ Passier JLM,¹⁷ Björnsdóttir I,¹⁸ Nordeng H^{1,19}.

¹School of Pharmacy, University of Oslo, Norway

²Department of Clinical Pharmacology, St Olav's University Hospital, Trondheim, Norway ³Department of Laboratory Medicine, Children's and Women's Health, Norwegian University

of Science and Technology, Trondheim, Norway

⁴School of Pharmacy, University of East Anglia, Norwich Research Park, United Kingdom ⁵Northwest Medical Center for Drug Safety in Pregnancy & Lactation, Northwest State

Medical University n.a.I.I.Mechnikov, St. Petersburg, Russia

⁶Department of Public Health and Community Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁷The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Ontario, Canada

⁸Faculty of Pharmacy, Medical University of Lublin, Poland

⁹School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland

¹⁰Finnish Medicines Agency, Kuopio, Finland

¹¹APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacie, Clamart France and Européenne de Formation pour les Pharmaciens, France

¹²Children's Hospital Srebrnjak, Neuropediatric Unit, Zagreb, Croatia

¹³Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of pharmacy, University of Belgrade, Serbia

¹⁴MotherSafe, Royal Hospital for Women and University of NSW, Randwick, Australia

¹⁵Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Slovenia

¹⁶Research Unit Human Teratogens, Institute for Cell Biology, Histology and Embryology, Medical University of Graz, Austria

¹⁷Teratology Information Service (TIS), Netherlands Pharmacovigilance Centre Lareb, Den Bosch, the Netherlands

¹⁸University of Iceland, Reykjavík, Iceland

¹⁹Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway

Corresponding author:

Angela Lupattelli, MScPharm,

Department of Pharmacy, School of Pharmacy, University of Oslo,

PO Box 1068 Blindern, 0316 Oslo, Norway

e-mail: angela.lupattelli@farmasi.uio.no; phone: +47 41343628 ; fax: +4722854402

1	
2	
3	Key words: pregnancy; drug utilization, maternal health; health behaviour; public health
4 5	
6	
7	Word count (excluding title page, abstract, references, figures and tables): 3333
8	
9	
10	
11	
12	
13	
14 15	
16	
17	
18	
19	
20	
21	
22 23	
24	
25	
26	
27	
28	
29 30	
31	
32	
33	
34	
35	
36 37	
38	
39	
40	
41	
42 43	
43 44	
45	
46	
47	
48	
49	
50 51	
52	
53	
54	
55	
56 57	
57 58	
59	
60	

ABSTRACT

Objectives: Inter-country comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and determinants of medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilized and indication for use.

Design: Cross-sectional, internet-based study performed within the period from 1-Oct-2011 to 29-Feb-2012. Uniform collection of drug utilization data was performed via an anonymous online questionnaire.

Setting: Multinational study in Europe (Western, Northern, and Eastern), North and South America, and Australia.

Participants: Pregnant women and new mothers with children less than one year of age.

Primary and secondary outcome measures: Prevalence and determinants of medication use for acute illnesses, chronic disorders and over-the-counter (OTC) medication use.

Results: The study population included 9,459 women whereof 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. OTC medication use occurred in 66.9% of the pregnancies. The extent of self-reported medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting use of chronic medication. Immigrant women in Western (aOR: 0.55, 95% CI: 0.34-0.87) and

BMJ Open

2
3
4
5
6
-
1
8
à
3
10
11
12
10
13
14
15
16
10
17
18
10
00
20
21
22
22
4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 8 9 10 112 3 12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
24
25
26
20
27
28
20
29
30
31
32
02
33
34
35
26
30
37
38
30
39
40
41
42 43
43
44
45
46
47
47
48
49
50
51
52
53
54
55
56
57
58
59
60
0.07

Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83) were less likely to report chronic medication use during pregnancy than non-immigrants.

Conclusions: There is a substantial inter-region variability in the extent of medication use during pregnancy. In certain subgroups of the population there is a specific need for information about medications in pregnancy. Future research should focus on this specific group of women, but also address more insights into the outcome of sub-optimal medication of severe conditions in pregnancy.

ARTICLE SUMMARY

Strengths and limitations of this study

- Uniform data collection of drug utilization data across all participating countries allows for intercountry comparability of the prevalence of medication use during pregnancy, up to now impeded by differences in study design and methodology.
- The study adds a multinational perspective on OTC medication use during pregnancy to the limited number of studies quantifying the extent of self-medication during pregnancy.
- Lack of validity of the self-reported diagnoses since all disorders and related medication use were self-reported by the study participants.
- An internet survey as a study method impedes calculation of a conventional response rate and may cause selection bias of the target population.

FUNDING STATEMENT

This work was supported by the Norwegian Research Council grant number 216771/F11 and by the Foundation for Promotion of Norwegian Pharmacies and the Norwegian Pharmaceutical Society.

COMPETING INTERESTS: None declared

INTRODUCTION

Ethical reasons preclude inclusion of pregnant women in the vast majority of pre-marketing clinical trials.[1] As a consequence, most medications are placed onto the market without a directly established safety profile in human pregnancy.[2] So far, few medications have been shown to be major teratogens, yet the risk of minor teratogenicity or of more subtle effects on fetal development still have to be determined for most of them.[3] Despite this, medication use during pregnancy is common. Mitchell et al. found that use of medications, either prescribed or purchased over-the-counter (OTC), occurred in 88.8% of all pregnancies in the USA.[4] In Europe, prevalence estimates of prescribed medication use vary considerably across countries, ranging from 26% in Serbia to 93% in France.[5-10] Such inter-country variability could, at least in part, be caused by differences in study design, methodology and exposure ascertainment across studies.[11] Uniform collection of drug utilization data during pregnancy between countries may overcome such drawbacks, allowing for inter-country comparability of prevalence estimates and shedding light on differences in prenatal care in the various countries.

Prior studies have addressed research priorities in this area such as presenting results on an individual drug level according to the indication of use, quantifying the extent of OTC and prescribed medication use during pregnancy, and taking into account inter-country comparability.[4] Only a few studies have individually examined maternal factors associated with specific types of medication use during pregnancy.[11-14]

The objectives of the current study were to examine patterns of medication use in pregnancy from a multinational perspective, with special emphasis on type of medication utilized, including OTC medications, and self-reported indications for use, and to identify maternal

background factors potentially associated with the use of specific types of medication during pregnancy.

METHODS

Study design and data collection

This is a multinational, cross-sectional, internet-based study. Pregnant women at any gestational week and mothers with children less than one year of age were eligible to participate. Member countries of the European Network of Teratology Information Services (ENTIS), The Organization of Teratology Information Specialists (OTIS) in North America, MotherSafe in Australia and European institutions conducting public health research were invited to take part in the project. Of these, 18 countries participated (Australia, Austria, Canada, Croatia, Finland, France, Iceland, Italy, Netherlands, Norway, Poland, Russia, Serbia, Slovenia, Sweden, Switzerland, United Kingdom and USA). Data originating from some South and Central American countries were also collected through OTIS. Because of the low number of participants on the individual country level, the region of Central America was excluded and countries in South America were aggregated into one region. Data selection to achieve the final study sample was performed as depicted in Figure 1. Participants were categorized according to the reported country of residency and grouped into six regions: Western Europe, Northern Europe, Eastern Europe, North America, South America and Australia.

Data were collected through an anonymous on-line questionnaire administered by Quest Back (http://www.questback.com) and accessible for a period of two months in each participating country within the period 1-Oct-2011 to 29-Feb-2012. The questionnaire was open to the public via utilization of banners (invitations to participate in the study) on national websites and/or social networks commonly visited and consulted by pregnant women and/or new

mothers. Detailed information about recruitment tools utilized and internet penetration rates is summarized in Appendix 1.

The questionnaire was first developed in Norwegian and English and then translated into the other relevant languages. A pilot study was carried out in September 2011 (n=47) and elicited no major change to the questionnaire. Collected data were scrutinized for the presence of potential duplicates (based on reported country of residency, socio-demographic characteristics, date and exact time of questionnaire completion) but none were identified.

Exposure variables

Maternal socio-demographics (i.e. region of residency, age, educational level, mother tongue, working status, previous children, marital status and unplanned pregnancy) and life-style characteristics (i.e. smoking status before and during pregnancy and alcohol consumption after awareness of pregnancy) constituted the exposure variables. To assess external validity, we compared socio-demographic and life-style characteristics of our study population on an individual country level with those of the general birthing population in the same country. Reports of National Statistics Bureaus or previous national studies were utilized for this purpose. The ratio between the number of respondents and the estimated number of live births in the 2-months period was also examined for each country (Appendix 2).

Outcome variables

Use of prescribed medication for acute/short-term illnesses or chronic/long-term disorders and OTC medication use during pregnancy constituted the outcome variables. Participants were first confronted with a list of the most common acute/short-term illnesses (i.e. nausea, heartburn, constipation, common cold, urinary tract infections (UTIs), other infections, pain in the neck/back/pelvic girdle, headache, sleeping problems) and the most prevalent

BMJ Open

chronic/long-term disorders (i.e. asthma, allergy, hypothyroidism, rheumatic disorders, diabetes, epilepsy, depression, anxiety, cardiovascular disease, other disorders) and asked whether they suffered/had suffered from these conditions during pregnancy. In case of an affirmative response, women were questioned about medication use for each individual indication as a free-text entry. Use of OTC medications was also recorded. Recall was aided with a list of five OTC categories: painkillers, nasal spray/drops, antinauseants, antacids and laxatives, along with examples of brand name products of relevance in each country. Timing of exposure (gestational weeks 0-12 (1st trimester), 13-24 (2nd trimester) and 25-delivery (3rd trimester)) could be reported for each of the medication use questions.

We defined a medicine as a single product containing one or more active ingredients. We initially identified the main active ingredient(s) and formulation of the reported medicinal products either in the relevant national medicines database or in the "Martindale" textbook.[15] All recorded medications were coded into the corresponding Anatomical Therapeutic Chemical (ATC) codes at the ATC 5th level (i.e. the substance level) whenever possible, otherwise into the 2nd- 4th levels as appropriate, in accordance with the World Health Organization ATC index.[16] The OTC status of medications was crosschecked with the prescription policies within each country. Whenever a prescription medication was reported under the OTC question, this record was omitted from the analysis of OTC use but counted in the estimation of total medication use (including prescription and OTC). Iron, mineral supplements, vitamins, herbal remedies and any type of alternative medicine were recorded separately and excluded from the estimation of medication use.

Ethics

All participants gave informed consent by answering "Yes" to the question "Are you willing to participate in the study?" The study was approved by the Regional Ethics Committee,

Region South-East in Norway. Ethical approval or study notification to the relevant national Ethics Boards was achieved in specific countries as required by national legislation. All data were handled and stored anonymously.

Statistical analysis

Descriptive statistics were utilized as appropriate. Univariate and multivariate logistic regression analyses were used to examine the association between maternal characteristic and three categorical outcome measures (Yes/No): Medication use for acute/short-term illnesses; medication use for chronic/long-term disorders; OTC medication use. P-values of <0.05 were considered statistically significant. Data are presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). The analyzed explanatory variables included all maternal socio-demographics and life-style characteristics. After fitting the univariate logistic regression model for all explanatory variables, the multivariate model was built and adjusted for all remaining covariates. The Hosmer and Lemeshow test was used to assess goodness of fit of the final multivariate model.[17] Analogue sub-analyses on individual region level were performed. In these instances, region of residency was not included in the model. All statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM[®] SPSS[®] Statistics).

RESULTS

Population characteristics

A total of 9,615 women accessed the on-line questionnaire whereof 98.6% completed it. The participant flow-chart to achieve final study population (n=9,459) is depicted in Figure 1. A total of 5,089 women (53.8%) were pregnant at the time of completion of the questionnaire whereas 4,370 women (46.2%) had delivered their babies within the previous year.

BMJ Open

Overall, the birthing population in each participating country was reflected quite well by the sample with respect to age, parity and smoking habits (Appendix 2). However, there was a difference in terms of educational level; on average, the women in the study had higher education than the general birthing population in each country. In addition, participants in Sweden, Austria, Iceland and Italy were slightly more often primiparous, whereas the responders in Australia, USA, Netherlands, Slovenia and Croatia were somewhat older than the general birthing population.

Total medication use

After exclusion of vitamins, mineral supplements and iron, use of at least one medication either prescribed or OTC at any time during pregnancy was reported by 7,678 out of 9,459 women (81.2%). Figure 2 depicts prevalence estimates of total medication use during pregnancy by region and country of residence, with specific rates according to inclusion or exclusion of vitamins, mineral supplements and iron. The extent of OTC medication use is also outlined. The highest prevalence of total medication use during pregnancy was observed in The Netherlands (95.1%), Iceland (93.0%) and Finland (92.3%). The overall prevalence estimates of medication use in pregnancy according to timing and drug class (ATC level 1 and 2) are presented in Appendix 3. Medications for the nervous system (ATC class N) were the most commonly used during pregnancy (57.5%), mostly due to paracetamol (acetaminophen) and its combinations.

Medication use according to indication

Headache, heartburn, pain, nausea and UTIs constituted the leading indications for use of medication during pregnancy among the acute/short-term illnesses analyzed. Hypothyroidism, asthma, allergy and depression were the leading indications for chronic/long-term medication use. Observed prevalence rates of these disorders, overall and by region of residency, are

presented in Appendices 4 and 5, respectively, along with rates of total and specific medication use. Table 1 outlines prevalence estimates of OTC medication use during pregnancy by region and indication for use. Only the most common medication groups reported are presented. Inter-region variations in rates and types of medication used during pregnancy were observed both for acute/short-term illnesses (e.g. nausea and UTIs), chronic/long-term disorders (e.g. asthma and depression) and OTC medications (e.g. nasal spray).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 BMJ Open

 Table 1: Use of OTC medication at any time during pregnancy by ATC level, indication for use and region (n=9,459)

7 8				REG	GION			-
9 10 11 12 13	OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n</i> (%)	Northern Europe n=2,820 <i>n</i> (%)	Eastern Europe n=2,342 <i>n (%)</i>	North America n=533 n (%)	South America n=346 n (%)	Australian n=217 n (%)	Total n=9,459 n (%)
14	OTC painkillers, total	1,714 (53.5)	1,773 (62.9)	734 (31.3)	284 (53.3)	127 (36.7)	151 (69.9)	4,783 (50.6)
15	By drug group	, , ,	, , ,		()	()	()	
16	Paracetamol (incl. combinations) (N02BE)	1,655 (51.7)	1,735 (61.5)	630 (26.9)	263 (49.3)	87 (25.1)	146 (67.3)	4,516 (47.7)
17 18	Non-steroideal antiinflammatory drugs (M01A)	70 (2.2)	182 (6.5)	68 (2.9)	40 (7.5)	59 (17.1)	7 (3.2)	426 (4.5)
19	Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	11 (0.4)	32 (1.4)	2 (0.4)	2 (0.6)	1 (0.5)	55 (0.6)
20	Metamizole (N02BB02)	-	6 (0.2)	31 (1.3)	1 (0.2)	12 (3.5)	-	50 (0.5)
21	OTC antacids, total	1,011 (31.6)	883 (31.3)	583 (24.9)	129 (24.2)	48 (13.9)	76 (35.0)	2,730 (28.9)
22	By drug group)- ()					()) ()
23 24	Antacids (aluminium, salts combinations, antiflatulents)	472 (14.7)	550 (19.5)	508 (21.7)	47 (8.8)	36 (10.4)	54 (24.9)	1,667 (17.6)
24 25	Alginic acid complex/sucralfate/bismuth (A02BX)	606 (18.9)	421 (14.9)	87 (3.7)	4 (0.8)	1 (0.3)	17 (7.8)	1,136 (12.0)
26	H_2 receptor antagonists (A02BA)	20 (0.6)	20 (0.7)	16 (0.7)	57 (10.1)	10 (2.9)	17 (7.8)	137 (1.4)
27	Antacids with calcium (A02AC)	23 (0.7)	12 (0.4)	10 (0.4)	69 (12.9)	2 (0.6)	10 (4.6)	126 (1.3)
28	Proton pump inhibitors (A02BC)	38 (1.2)	52 (1.8)	_	10 (1.9)	2 (0.6)	5 (0.3)	107 (1.1)
29 30	OTC nasal sprays/drops, total	272 (8.5)	742 (26.3)	451 (19.3)	35 (6.6)	7 (2.0)	14 (6.5)	1,521 (16.1)
31	By drug group							
32	Sympathomimetic nasal decongestants (R01AA/R01BB)	204 (6.4)	683 (24.2)	365 (15.6)	20 (3.8)	3 (0.9)	4 (1.8)	1,279 (13.5)
33	Nasal corticosteroids (R01AD)	31 (1.0)	49 (1.7)	12 (0.5)	5 (0.9)	2 (0.6)	10 (4.6)	109 (1.2)
34	Nasal immunostimulants (low dose interferon) (L03A)	-	-	28 (1.2)	-	-	-	28 (0.3)
35 36	OTC laxatives, total	240 (7.5)	227 (8.0)	237 (10.1)	50 (9.4)	8 (2.3)	19 (8.8)	781 (8.3)
37	By drug group							
38	Osmotically acting laxatives (A06AD)	159 (5.0)	171 (6.1)	197 (8.4)	2 (0.4)	2 (0.6)	8 (3.7)	539 (5.7)
39	Contact laxatives (A06AB)	28 (0.9)	44 (1.6)	18 (0.8)	7 (1.3)	6 (1.7)	2 (0.9)	105 (1.1)
40								14
41								

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

			REG	ION			-
OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n (%)</i>	Northern Europe n=2,820 <i>n</i> (%)	Eastern Europe n=2,342 <i>n</i> (%)	North America n=533 n (%)	South America n=346 n (%)	Australian n=217 <i>n</i> (%)	Total n=9,459 n (%)
Enemas (A06AG)	3 (0.1)	25 (0.9)	34 (1.5)	4 (0.8)	-	2 (0.9)	68 (0.7)
Softeners, emollients (A06AA)	8 (0.2)	-	_	38 (7.1)	-	6 (2.8)	52 (0.5)
OTC antinauseants, total	263 (8.2)	273 (9.7)	41 (1.8)	60 (11.3)	28 (8.1)	40 (18.4)	705 (7.5)
By drug group							
First generation antihistamines (R06A)	141 (4.4)	256 (9.1)	7 (1.5)	55 (10.3)	5 (1.4)	5 (2.3)	469 (5.0)
Metoclopramide/domperidone/bromopride (A03FA)	113 (3.5)	5 (0.2)	18 (0.8)	2 (0.4)	19 (5.5)	27 (12.4)	184 (1.9)
Total OTC medication use	2,163 (67.6)	2,155 (76.4)	1,347 (57.5)	342 (64.2)	156 (45.1)	168 (77.4)	6,331 (66.9)

 *Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, and herbal or alternative medicine products.

Abbreviations: OTC: Over-The-Counter medications.

BMJ Open

Determinants of medication use

Determinants of medication use during pregnancy according to type of medication utilized are presented in table 2. Use of chronic/long-term medications during pregnancy was reported in a significant larger extent by women in Northern Europe (aOR:1.68, 95% CI:1.46-1.94), North America (aOR:1.80, 95% CI:1.42-2.28) and Australia (aOR:2.76, 95% CI:2.03-3.76) compared to women in Western Europe. Older women or housewives, those with low education or with an unplanned pregnancy, were the ones most often reporting use of chronic/long-term medication. Sub-analysis on individual region level revealed that women not having the official language of the country of residency as mother tongue were less likely to report chronic/long-term medication use in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83), but not in the other regions.



			Medi	cation use		
		For acute/short-term illnesses (n=6,469)		For chronic/long-term disorders (n=1,604)		OTC =6,331)
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)
Region of residency [†]						
Western Europe	2,224 (69.5)	Reference	462 (14.4)	Reference	2,163 (67.6)	Reference
Northern Europe	1,954 (69.3)	0.96 (0.86-1.08)	593 (21.0)	1.68 (1.46-1.94)	2,155 (76.4)	1.54 (1.36-1.74
Eastern Europe	1,474 (62.9)	0.69 (0.61-0.78)	322 (13.7)	1.03 (0.87-1.21)	1,347 (57.5)	0.60 (0.53-0.67
North America	403 (75.6)	1.28 (1.03-1.60)	119 (22.3)	1.80 (1.42-2.28)	342 (64.2)	0.81 (0.66-0.99
South America	250 (82.3)	1.03 (0.79-1.34)	38 (11.0)	0.70 (0.48-1.01)	156 (45.1)	0.34 (0.27-0.44
Australia	164 (75.6)	1.29 (0.93-1.79)	70 (32.3)	2.76 (2.03-3.76)	168 (77.4)	1.57 (1.12-2.20
Maternal age (years)						
≤20	232 (70.5)	1.22 (0.93-1.60)	761 (14.7)	0.58 (0.39-0.87)	205 (62.3)	1.05 (0.81-1.36
21-30	3,531 (68.2)	Reference	33 (10.0)	Reference	3,461 (66.8)	Reference
31-40	2,576 (68.6)	0.90 (0.82-1.00)	764 (20.4)	1.44 (1.27-1.63)	2,531 (67.4)	0.85 (0.77-0.94
<u>≥</u> 41	130 (66.3)	0.73 (0.54-1.00)	46 (23.5)	1.61 (1.13-2.29)	134 (68.4)	0.86 (0.62-1.19
Previous children						
No	3,082 (65.5)	Reference	735 (15.6)	Reference	2,949 (62.6)	Reference
Yes	3,387 (71.3)	1.34 (1.22-1.47)	869 (18.3)	1.08 (0.96-1.21)	3,382 (71.2)	1.58 (1.44-1.74
Marital status						
Married/cohabiting	6,066 (68.5)	Reference	1,503 (17.0)	Reference	5,960 (67.3)	Reference
Single/divorced/others	403 (66.3)	0.91 (0.75-1.10)	101 (16.6)	1.06 (0.83-1.35)	371 (61.0)	0.91 (0.75-1.10
Working status						
Employed, but not as HCP	3,737 (66.8)	Reference	905 (16.2)	Reference	3,667 (65.6)	Reference
HCP	934 (74.4)	1.41 (1.23-1.63)	240 (19.1)	1.13 (0.96-1.33)	944 (75.2)	1.42 (1.23-1.64
Student	592 (69.1)	1.11 (0.94-1.31)	128 (14.9)	1.04 (0.84-1.30)	578 (67.4)	1.10 (0.93-1.30
Housewife	608 (72.6)	1.14 (0.96-1.35)	170 (20.3)	1.34 (1.10-1.63)	577 (68.9)	1.05 (0.88-1.24
Job seeker	281 (66.0)	0.96 (0.78-1.20)	66 (15.5)	1.03 (0.78-1.36)	258 (60.6)	0.85 (0.68-1.05
Other than above	311 (65.2)	0.91 (0.75-1.12)	94 (19.7)	1.29 (1.01-1.65)	302 (63.3)	0.91 (0.74-1.12
Educational level						

$(m=0, 450)^*$ Table 1. D • c adianti •

	Medication use							
	For acute/short-term illnesses For c (n=6,469)			For chronic/long-term disorders (n=1,604)		OTC =6,331)		
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)		
High school	1,864 (68.7)	Reference	428 (15.8)	Reference	1,779 (65.6)	Reference		
Less than high school	331 (72.7)	1.17 (0.93-1.49)	92 (20.2)	1.51 (1.15-1.97)	317 (69.7)	1.32 (1.04-1.67)		
More than high school	3,574 (68.4)	0.99 (0.89-1.11)	916 (17.5)	1.04 (0.91-1.20)	3,489 (66.8)	1.07 (0.96-1.19)		
Others, unspecified	700 (65.7)	0.82 (0.70-0.96)	168 (15.8)	0.94 (0.77-1.16)	746 (70.0)	1.13 (0.97-1.33)		
Alcohol use after awareness of pregn	ancy							
No	5,270 (67.1)	Reference	1,322 (16.8)	Reference	5,133 (65.3)	Reference		
Yes	1,144 (75.7)	1.59 (1.39-1.81)	270 (17.9)	1.11 (0.95-1.29)	1,150 (76.1)	1.95 (1.71-2.23)		
Smoking during pregnancy								
No	5,835 (68.5)	Reference	1,441 (16.9)	Reference	5,716 (67.0)	Reference		
Yes, but less than before pregnancy	530 (69.0)	1.08 (0.91-1.27)	130 (16.9)	1.01 (0.82-1.25)	511 (66.5)	1.06 (0.90-1.26		
Yes, the same or more than before				. ,				
pregnancy	88 (67.7)	0.95 (0.64-1.40)	28 (21.5)	1.19 (0.74-1.90)	89 (68.5)	1.21 (0.81-1.82)		
Planned pregnancy								
Yes	5,836 (68.4)	Reference	1,427 (16.7)	Reference	5,727 (67.2)	Reference		
No	616 (68.4)	0.96 (0.82-1.12)	173 (19.2)	1.29 (1.06-1.56)	587 (65.1)	1.00 (0.85-1.17		
First language different from the off	icial main langu	age in the country of	f residency					
No	6,089 (68.5)	Reference	1,530 (17.2)	Reference	5,972 (67.1)	Reference		
Yes	363 (67.2)	0.93 (0.76-1.12)	71 (13.1)	0.66 (0.50-0.86)	347 (64.3)	0.89 (0.74-1.08		

Abbreviation: HCP: health care provider.

*Numbers may not add up due to missing values. Missing values are less than 5% of the total. Mineral supplements, vitamins, iron, herbal or alternative medicine products are not included in the medication use estimates.

[†]Countries are grouped into regions as shown in Figure 1.

DISCUSSION

This is the first internet-based study examining patterns and determinants of medication use during pregnancy on a multinational level. In specific countries (Australia, Canada, France, Russia, The Netherlands, and the USA) the study sample was a small proportion of the general birthing population; hence the generalizability of our findings for these specific countries should be interpreted with caution. In all regions, approximately eight out of ten women reported use of at least one medication, either prescribed or OTC, during the course of their pregnancy. This finding is in line with previous research conducted in Europe, North America, South America and Australia,[4,18-23] though our estimates were somewhat higher in some of the Eastern European countries, e.g. Serbia, than those observed in a previous study.[5] Different recruitment strategies, i.e. internet-based in our study versus maternity care unit-/community pharmacy-based in the previous study could explain such discrepancy.

Overall, analgesics, antacids, nasal decongestants/antiallergics and systemic antibiotics were the medication groups dominating the drug utilization scenario, as also shown by previous research.[4,18-20] However, our study also provides insights into the proportion of medicated women among those suffering from a specific illness during pregnancy across the six regions. We found that approximately seven out of ten women who reported UTIs were treated with antibiotics during pregnancy. This related to all regions, except Eastern Europe where it was only four out of ten women. Since women may perceive dysuria without ascertainment of bacteriuria in the urine as UTI, an over-reporting of the illness could have occurred. Yet, a sub-optimal treatment of UTIs during pregnancy in Eastern Europe cannot be ruled out. The inter-country variability in the types of antibiotics used for UTIs could simply be explained by differences in prescribing practice,[24] presence of screening for bacteriuria in early pregnancy, or specific antibiotic resistance patterns.

BMJ Open

Even though nausea was the condition affecting most women in all six regions, the corresponding proportions of medicated nausea were generally low. This scenario is probably due to two main factors: a) the predominantly mild character of nausea and the possibility of non-pharmacological management (e.g. dietary advices); b) the reluctance of general practitioners to prescribe antinauseants even though safety profile assessments are in place.[25,26] As also shown in previous studies,[4,27] use of serotonin antagonists in North America and Australia is increasing also in pregnancy compared to the other regions, eliciting the need of sound studies assessing the safety profile of this drug group in pregnancy.

In most regions, the self-reported prevalence of hypothyroidism was somewhat higher than the reported hormone substitution rate. Because of its known association with adverse pregnancy outcomes,[28] the unexpected finding of potential sub-optimal treatment of hypothyroidism during pregnancy deserves attention. It could probably be due to a lack of information about hypothyroidism typology and its diagnostic ascertainment in our study.

In our study, depression was self-reported and not based on any psychometric assessment, thus the observed substantial inter-regional variability in the extent of this disorder and related medication use could have certainly been affected by women's attitudes in reporting. Our estimate of medication use for depression in Australia was higher than that observed in a recent study (10.6% versus 2.1%).[29] However, the similarity in self-reported depression itself (11.5% versus 15.6%) suggests that our population might mostly comprise women who did not discontinue their pharmacological therapy once they became pregnant. Our estimates for North America and Western Europe were in line with recent literature showing an increase in antidepressant use in pregnancy during the last years.[4,30]

In most regions approximately 60-70% of women reported use of at least one OTC medication during the course of their pregnancy, mostly for pain conditions, heartburn and

upper airways disorders, indicating a substantially high rate of self-medication during pregnancy. This estimate aligns with previous research carried out in North America.[31] Of note, self-medication with OTC sympathomimetic nasal decongestants was more extensive in Northern and Eastern Europe than in the remaining regions; this could be explained by the time of the year when the data collection was performed.

Region of residency was an important factor associated with medication use during pregnancy. As also shown by Cleary et al.,[32] we found that rates of medication use among women originally from Eastern Europe and South America were significantly lower than those observed in Western Europe, North America and Australia. Such geographical differences could be due to culture, variations in prenatal care assistance or access to medications in the various regions and the related costs.

Women working as health care providers, those consuming alcohol during pregnancy and those with previous children were those more likely to use short-term and OTC medications, possibly reflecting higher confidence in self-treatment and use of medications in general in the former instance, and less anxiety for the pregnancy outcome in the latter two instances. One factor negatively associated with chronic/long-term medication use was not having the official language of the country of residency as mother tongue. This tendency was detected in Western and Northern Europe, rising concerns about the potential health risks for immigrant women in these two regions. As shown by Hameen-Anttila et al., 57% of pregnant women have perceived information needs about medications during pregnancy.[33] Thus, identification of potential users or non-users of medication about medication safety or outcome of sub-optimal medication of severe medical conditions in pregnancy.

BMJ Open

Strengths and limitations

The main strength is that data collection was performed uniformly across all participating countries, allowing for inter-country comparison of the prevalence of medication use during pregnancy. By quantifying the extent of self-medication with OTC drugs and medication use according to self-reported indication, it was possible to determine the leading causes for medication use among pregnant women. Categorization of maternal characteristics positively associated with the various types of medications used during pregnancy enabled us to identify which groups of women are more likely to need information about medication use during pregnancy. The utilization of an anonymous web-based questionnaire enabled us to reach a large proportion of the birthing population in several countries worldwide. However, we cannot exclude the possibility that the women who decided to participate in the study differed from the general birthing population in other ways that our analysis could not control for.

One main limitation of the study is the lack of validity of the self-reported diagnoses. All disorders were self-reported by the participants and hence dependent on the women's perception of the medical condition. Similarly, information about medication use during pregnancy was dependent on the accuracy of the women's reporting and recall. For new mothers, data were registered retrospectively; hence a risk of recall bias cannot be ruled out. The questionnaire was only available through internet websites; by using this kind of approach a conventional response rate cannot be calculated. However, recent epidemiological studies indicate reasonable validity of web-based recruitment methods.[34,35] Also, the penetration rate of the internet either in households or at work is relatively high among women in childbearing age.[36-40] Hence, the degree to which our findings can be extrapolated to the target population is based on the representativeness of the respondents to the general birthing populations in each country. The sample in each country had a somewhat

higher educational level than the general birthing populations. Inclusion of pregnant women at any gestational week might have inflated the prevalence of non-users of medications during pregnancy. Also, women with specific disorders or in need of information about medication use during pregnancy might have been more likely to consult internet websites and therefore participate in this study.

CONCLUSIONS

Use of medications for acute and chronic disorders as well as use of OTC medications, were common during pregnancy. The extent of medicated illnesses and types of medications used for the different indications varied across the six regions. This was especially relevant for acute/short-term illnesses such as nausea and UTIs, but also for chronic/long-term disorders such as hypothyroidism or depression. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting use of chronic/long-term medication and may therefore be more in need of information about medication during pregnancy. Moreover, maternal-fetal health among immigrants residing in Western and Northern Europe might be jeopardized. Future research should definitely focus on this specific group of women, but also address more insights into the outcome of sub-optimal medication of severe conditions in pregnancy.

ACKNOWLEDGMENTS

We thank OTIS, ENTIS Scientific Board who reviewed the study protocol and all website providers who contributed to the recruitment phase. We are grateful to all the participating women who took part in this study.

AUTHOR'S CONTRIBUTION: AL, OS and HN conceived the idea for the study and participated in its design and coordination. AL drafted the manuscript and analyzed the data. MJT, KZ, ACM, MEM, MD, AP, KHA, AR, RGJ, MO, DK, GR, HJ, AP and IB contributed to the data collection. All authors contributed to the interpretation of the results and revised the manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

DATA SHARING STATEMENT: No additional data are available. Researchers can apply for data access for subprojects within the overall aims of the main study 'Medication Use in Pregnancy—an International Study'.

REFERENCES

ACOG Committee Opinion No. 377: Research involving women. Obstet Gynecol 2007;110(3):731-6.

 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157(3):175-82.
 Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. [S.l.]: Lippincott Williams & Wilkins, 2011.

 Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205(1):51 e1-8.
 Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012;34(5):719-27.

 Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008;64(11):1125-32.

7. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;65(5):653-60.

8. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;**113**(5):559-68.

9. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009;65(8):839-46.
 10. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol 2003;59(2):127-33.

1	
2 3	11. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during pregnancy in
4 5	developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011; 20 (9):895-902.
6 7	12. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in
8 9 10	pregnancy. J Clin Epidemiol 1993;46(6):581-89.
11	
12 13	13. McKenna L, McIntyre M. What over-the-counter preparations are pregnant women
14	taking? A literature review. J Adv Nurs 2006;56(6):636-45.
15	
16 17	14. Odalovic M, Vezmar Kovacevic S, Nordeng H, et al. Predictors of the use of medications
18 19	before and during pregnancy. Int J Clin Pharm 2013; 35 (3):408-16.
20	15. Martindale W, Sweetman SC. Martindale : the complete drug reference. London:
21 22	
23	Pharmaceutical Press, 2011:2 b. : ill.
24 25	16 WIIO Calleborating Contro for Drugs Statistics Mathedalagy, ATC/DDD index 2012
26	16. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD index 2012.
27	http://www.whocc.no/atc_ddd_index/ (accessed 17 March, 2012).
28 29	
30	17. Hosmer DW, Lemeshow S, editors. Applied logistic regression. 2nd ed. New York:
31	Wiley-Interscience, 2000.
32 33	
34	18. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications
35 36	
37	and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66(2):207-14.
38	19. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from
39 40	
41	the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;60(5):355-
42	61.
43 44	01.
45	20. Medication during pregnancy: an intercontinental cooperative study. Collaborative Group
46 47	
48	on Drug Use in Pregnancy (C.G.D.U.P.). Int J Gynaecol Obstet 1992; 39 (3):185-96.
49 50	21. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J
51 52	Clin Pharmacol 2000; 56 (4):323-8.
53 54	22. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAR
55 56	study. Aust N Z J Obstet Gynaecol 2000;40(2):165-72.
57 58	2
59	Σ.
60	

23. Marín G, Cañas M, Homar C, et al. Uso de fármacos durante el período de gestación en embarazadas de Buenos Aires, Argentina. Rev salud pública 2010;**12**(5):722-31.

24. European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2010. Stockholm: ECDC, 2013.

25. Smith J, Refuerzo J, Ramin S. Treatment and outcome of nausea and vomiting of pregnancy. In: Basow D, ed. UpToDate. Waltham, MA: UpToDate, 2013.

26. Gadsby R, Barnie-Adshead T, Sykes C. Why won't doctors prescribe antiemetics in pregnancy? BMJ 2011;**343**:d4387.

27. Raymond SH. A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. Aust N Z J Obstet Gynaecol 2013.

28. Ross DS. Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment. In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate, 2013.

29. Lewis AJ, Bailey C, Galbally M. Anti-depressant use during pregnancy in Australia: findings from the Longitudinal Study of Australian Children. Aust N Z J Public Health 2012;**36**(5):487-8.


30. Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011;**72**(7):979-85.


31. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of Over-the-Counter Medications and Herbal Remedies in Pregnancy. Amer J Perinatol 2005;**22**(EFirst):321,24.

32. Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010;**19**(4):408-17.

33. Hameen-Anttila K, Jyrkka J, Enlund H, et al. Medicines information needs during pregnancy: a multinational comparison. BMJ open 2013;**3**(4).

29 of 54	BMJ Open
	34. Ekman A, Dickman P, Klint Å, et al. Feasibility of Using Web-based Questionnaires in
	Large Population-based Epidemiological Studies. Eur J Epidemiol 2006; 21 (2):103-11.
	35. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in
	epidemiology? Am J Epidemiol 2010; 172 (11):1292-8.
	36. Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in
	focus. 2011. http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-11-066/EN/KS-
	SF-11-066-EN.PDF (accessed 13 November, 2012).
	37. Internet World Stats. Usage and population statistics. 2012.
	http://www.internetworldstats.com/ (accessed 13 November, 2012).
	38. Australian Bureau of Statistics. Household Use of Information Technology, Australia,
	2010-11
	http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main%20Features12010-
	11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11#=&view=
	(accessed 13 November, 2012).
	39. Statistics Canada. Individual Internet use and E-commerce (2010). 2011.
	http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm (accessed November
	13th, 2012).
	40. United States Census Bureau. The 2012 Statistical Abstract. Information &
	Communications: Internet Publishing and Broadcasting and Internet Usage. 2010.
	http://www.census.gov/compendia/statab/cats/information_communications/internet_publishi
	ng_and_broadcasting_and_internet_usage.html (accessed 13 November, 2012).
	28






Western Europe	Northern Europe	Eastern Europe	North America	South America	Australia
n=3,201 (33.8)	n=2,820 (29.8)	n=2,342 (24.8)	n=533 (5.6)	n=346 (3.7)	n=217 (2.3)
United Kingdom (n=1,120) Italy (n=926) Switzerland (n=618) France (n=374) The Netherlands (n=82) Austria (n=81)	Norway (n=1,288) Sweden (n=887) Finland (n=574) Iceland (n=71)	Russia (n=1,008) Poland (n=679) Croatia (n=286) Serbia (n=220) Slovenia (n=149)	USA (n=297) Canada (n=236)	Uruguay (n=151) Paraguay (n=63) Argentina (n=47) Peru (n=18) Bolivia (n=17) Venezuela (n=17) Colombia (n=12) Chile (n=12) Ecuador (n=4) Brazil (n=5)	Australia (n=217)

BMJ Open

Figure 2: Proportion of respondents reporting use of any medication - prescribed and/or OTC - during pregnancy (%), including and excluding vitamins, mineral supplements and iron, and proportion of respondents reporting OTC medication use during pregnancy, according to region and country of residency



1 2	
3	
4	
3 4 5 6 7 8	
7	
8 0	
9 10	
11	
12 13	
14	
15	
16 17	
18	
19	
20 21	
22	
23	
9 10 11 12 13 14 15 16 17 18 19 20 21 22 32 4 25 26 27 28 29 30 32	
26	
27	
28 29	
30	
31	
32 33 34 35 36 37 38 39	
34	
35	
30 37	
38	
40 41	
42 43	
43 44	
44 45	
46	
47 48	
40 49	
50	
51 52	
53	
54	
55 56	
57	
58	
59 60	

Appendix 1: Websites used for recruitment and internet penetration rates in each participating country

Country	Website used for recruitment	Internet		
		penetration rates [*]		
	Western Europe			
United Kingdom	Targeted email to pregnancy forum subscribers:	93% ¹		
	www.bounty.com			
	Pregnancy Forums: www.pregnancyforum.co.uk;			
	www.pregnancyforum.org.uk			
Italy	Pregnancy Forums: www.gravidanzaonline.it;	70% ¹		
	www.forumsalute.it; www.mammole.it;			
	www.pianetamamma.it; www.miobambino.it			
	Targeted email to pregnancy forum subscribers:			
	www.gravidanzaonline.it			
Switzerland	www.bebe-bebe.com; www.swissmom.ch	84.2 [%] ²		
France	www.aufeminin.com (Including ipad application to website	91% ¹		
	subscribers)			
The Netherlands	www.lareb.nl; www.gezondzwangerzijn.nl;	98% ¹		
	www.babybytes.nl			
Austria	www.schwangerschaft.at; www.schwangerschafts-blog.at;	93% ¹		
	www.fratz.at; www.netdoctor.at; www.babycenter.at;			
	www.baby-boom.at; www.ekiz-dachverband.at;			
	www.babyguide.at			
	Northern Europe			
Norway	www.barnimagen.com; www.klikk.no; www.jormorsiri.no;	99% ¹		
	www.tryggmamamedisin.no	,		
Sweden	www.barntotal.se; www.minbebis.com;	99% ¹		
	www.se.babycenter.com; www.socmed.gu.se			
Finland	www.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi	99% ¹		
Iceland	Pregnancy Forums: www.bland.is	100% ¹		
	Eastern Europe			
Russia	www.babyblog.ru; www.littleone.ru	47.7% ²		
	Pregnancy Forums: www.woman.ru; www.9months.ru;			
	www.bemam; www.280dney.ru; www.iampregnant.ru			
	www.pregnancy.org.ua; www.baby.ru; www.mama66.ru;			
	www.spuzom.ru			
Poland	www.zzief.umlub.pl	84% ¹		
	<i>Pregnancy Forums</i> : www.ebrzuszek.pl; www.babyboom.pl;			
	www.zapytajpolozna.pl; www.planujemydziecko.pl;			
	www.twoja-ciaza.com.pl			
Croatia	www.cybermed.hr	80% ¹ (data from		
	5	2010)		

Country	Website used for recruitment	recruitment Internet penetration rates*	
Serbia	www.ringeraja.rs	$52\%^{\prime}$ (data from	
Slovenia	Pregnancy Forums: www.med.over.net	2009) 92% ¹	

^{*}Indicates the frequency of internet access - at least once a week, including every day - among individuals aged 25- 34 years. Differences between men and women were relatively small. Slightly more than two thirds of men (70%) and 65% of women used the Internet regularly.

Country	Website used for recruitment	Internet penetration rates	
North America			
USA/Canada	www.otispregnancy.org; Facebook page of OTIS; www.babyontheway.com.ca; www.justmommies.com	Canada: 94% ^{3 **} USA: 80.2% ^{4 §}	
	Pregnancy Forums: www.babyandbump.com www.babycentre.com.ca; www.thecradle.com; www.talk.sheknows.com; www.parenting.com		
South America	www.otispregnancy.org; Facebook page of OTIS <i>Pregnancy Forums</i> : www.semanaasemana.com; www.univision.com; www.elembarazo.net	South America: 48.2% ²	

** Indicates individuals aged 16-45 years who used the internet for personal use.

[§]Indicates individuals > 18 years old, access from anywhere; household internet for women is equal to 68.1%; higher percentages are observed for people aged 25-54 years.

Country	Website used for recruitment	Internet penetration rates ^{§§}
Australia	www.mothersafe.org.au; www.bubhub.com.au	83%5
	Pregnancy Forums: www.abds.org.au;	
887 1	www.birth.com.au	

^{§§}Indicates households with access to the internet at home.

Sources of internet penetration rates:

1.

Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus; 2011.

2. Internet World Stats. Usage and population statistics. Available at: http://www.internetworldstats.com/. Accessed November 20, 2012.

3. Statistics Canada. Individual Internet use and E-commerce (2010). Available at:

http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed November 20, 2012.

4. United States Census Bureau. The 2012 Statistical Abstract. Information & Communications: Internet Publishing and Broadcasting and Internet Usage. Available at:

http://www.census.gov/compendia/statab/cats/information_communications/internet_publishing_and_broadcasting_and_internet_usage.html. Accessed November 13th, 2012.

5. Australian Bureau of Statistics. Household Use of Information Technology, Australia, 2010-11 Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main%20Features12010-11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11&num=&view=. Accessed November 13, 2012.

Appendix 2: Socio-demographic characteristics of the study population and general birthing population on individual country[¶]

Appendix 2a: Socio-demographic characteristics in Western European countries (United Kingdom (UK), Italy and Switzerland)

	Study sample in the UK n=1,120 (%)	General birthing population in UK* LB=723,165 ¹ (%)	Study sample in Italy n=926 (%)	General birthing population in Italy LB=546,606 ² (%)	Study sample in Switzerland n=618 (%)	General birthing population in Switzerland LB=80,808 ² (%)
Mean Age ± sd	30.5 ± 5.2	29.6 ¹	32.3 ± 5.0	31.3 ³	31.6 ± 4.3	31.4 ⁴
Marital status						
In marriage	63.3	53.2 ¹	68.8	75.1 ²	80.0	80.7^{4}
Outside marriage	36.7	46.8 ¹	31.2	31.5 ²	20.0	19.3 ⁴
Parity						
No previous children	48.0^{\dagger}	41.9 ¹ †	59.7	48.7^{5}	53.2	-
Educational level						
Less than high school	0.6	16.5 ¹	7.0	25.2^{6}	11.0	11.7^{6}
High school	27.9	37.2 ¹	47.2	49.2^{6}	13.6	49.2^{6}
More than high school	52.1	46.3 ¹	44.3	25.6^{6}	47.2	39 .1 ⁶
Other	19.3	-	1.5	-	28.2	-
Women smoking before pregnancy	25.2	25.7 ⁷	34.2	33.3 ³	25.1	25.4 ⁷
Women smoking during pregnancy	7.1 [‡]	13.2 ⁸ ‡	10.5	22.79	5.5	6.6 ¹⁰
Use of alcohol during pregnancy	28.3	24.0^{11} §	17.9	17.7 ⁹	20.7	29.9^{10}
No. of respondents/No. live births **	0.9%		1.0%		4.6%	

[¶]No Statistics Bureaus reports/studies were found for South America.

*The figures shown here are statistic estimates for England and Wales. Scotland and Northern Ireland have separate statistical reports. Since more than 85% of the study population in UK were resident in England and about 8% in Wales, we are only showing national statistic data for these two parts of the UK.

[†]Among married women only – as provided by the Statistics Bureau in the UK.

[‡]Among women resident in England only (as provided by the Statistics Bureau in the UK, data on 4th Quarter of 2011).

[§]Women reporting at least one occasion during pregnancy of consuming more than four drinks in a day.

**The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Study sample in France n=374	General birthing population in France LB=824,263 ²	Study sample in The Netherlands n=81	General birthing population in The Netherlands LB=180,060 ²	Study sample in Austria n=82	General birthing population in Austria LB=78,109 ²
	(%)	(%)	(%)	(%)	(%)	(%)
Mean Age ± sd	29.6 ± 4.9	30.112	32.0 ± 6.4	31.0 ¹³	30.6 ± 4.6	30.0 ¹⁴
Marital status						
In marriage	48.9	45.0^{2}	69.1	58.2 ¹³	48.8	59.6 ¹⁵
Outside marriage	51.1	55.0 ²	30.8	41.8 ¹³	51.2	40.4 ¹⁵
Parity						
No previous children	52.9	44.2 ¹⁶	38.3	46.4 ¹³	63.4	47.96 ¹⁵
Educational level						
Less than high school	1.6	15.4 ⁶	9.9	15.9^{6}	9.8	13.3 ⁶
High-school	25.1	37.4 ⁶	66.7	40.2^{6}	32.9	64.1 ⁶
More than high school	57.0	47.2^{6}	23.5	43.9^{6}	40.2	22.7^{6}
Other	16.3	-		-	17.1	-
Women smoking before pregnancy	39.3	39 .0 ¹⁶	34.6	29.5 ⁷	31.7	32.1 ¹⁷
Women smoking during pregnancy	14.2	28.0^{16}	14.8	17.1 ¹⁸	4.9	-
Use of alcohol during pregnancy	11.5	52.0 ¹⁹	11.1	16-35 ¹³	13.4	-
No. of respondents/No. live births *	0.3%		0.3%		0.6%	

• .• • • • • E. TT1) 1 (1 1 1 1 J. 31. C. · · (F

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

36

 BMJ Open

	Study sample in Norway n=1,228	General birthing population in Norway LB=60,220 ²	Study sample in Sweden n=887	General birthing population in Sweden LB=111,770 ²	Study sample in Finland n=574	General birthing population in Finland LB=59,961 ²
	(%)	(%)	(%)	(%)	(%)	(%)
Mean Age ± sd	29.0 ± 4.6	29.8 ± 5.3^{20}	29.8 ± 5.3	30.3 ²¹	29.0±5.1	30.1 ²²
Marital status						
In marriage	39.1	46.0^{20}	40.7	45.8 ²	59.4	57.8 ²²
Outside marriage	60.9	53.4 ²⁰	59.3	54.2 ²	40.6	42.0^{22}
Unknown	-	0.6 ²⁰			-	0.2^{22}
Parity						
No previous children	41.4	42.4^{20}	63.1	44.9^{21}	35.5	42.2^{22}
Educational level		-				
Less than high school	4.5	14.7 ⁶	5.2	11.1 ⁶	8.2	7.1^{6}
High-school	28.0	31.4 ⁶	30.0	38.2 ⁶	36.4	44.5^{6}
More than high school	46.9	53.9 ⁶	60.6	50.6 ⁶	52.6	48.4^{6}
Other	20.7	-	4.2	-	2.8	-
Women smoking before pregnancy	33.5	36.5 ⁷	25.0	27.2^{7}	36.7	19.7^{7}
Women smoking during pregnancy	6.8	7.0^{20}	5.4	6.5 ²¹	11.7	15.2^{22}
Use of alcohol during pregnancy	4.1	7.4 ²³	7.2	5.9 ²⁴	13.9	-
No. of respondents/No. live births *	12.2%		4.8%		5.7%	

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

	Study sample in Iceland n=70	General birthing population in Iceland LB=4,492 ²
	(%)	(%)
Age range (years)		
15-20	11.3	5.1 ²⁵
21-25	16.9	19.3 ²⁵
26-30	42.3	34.2 ²⁵
31-35	15.5	27.3 ²⁵
36-40	12.7	11.7 ²⁵
≥41	1.4	2.4 ²⁵
Marital status		
In marriage	31.0	35.0 ²⁵
Outside marriage	69.0	65.0 ²⁵
Parity		
No previous children	47.9	38.1 ²⁵
Educational level		
Less than high school	25.4	21.4^{6}
High-school	18.3	30.5 ⁶
More than high school	43.7	48.16
Other	12.7	
Women smoking before pregnancy	40.8	35.57
<i>Women smoking before pregnancy</i> <i>No. of respondents/No. live births</i> [*]	40.8 9.3%	35.5

Abbreviations: LB: Number of live births per year.

 *The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

BMJ Open

	Study sample in Russia n=1,008	General birthing population in Russia LB=1,796,629 ²	Study sample in Poland n=679	General birthing population in Polanc LB=388,416 ²
	(%)	(%)	(%)	(%)
Mean Age ± sd	27.7 ± 4.8	27.4 ²⁶	27.1 ± 4.1	28.6 ^{27 *}
Marital status				
In marriage	85.3	73.9 ²⁶	85.0	79.4 ²⁷
Outside marriage	14.7	26.1 ²⁶	15.0	20.6 ²⁷
Parity				
No previous children	57.9	-	40.6	50.1 ²⁷
Educational level				
Less than high school	1.6	-	1.9	8.7 ²⁷
High-school	9.3	-	31.1	49.6 ²⁷
More than high school	75.1		65.1	41.6 ²⁷
Other	14.0		1.9	-
Women smoking before pregnancy	46.1	30.8 ²⁸	49.2	25.0^{29}
Women smoking during pregnancy	9.6	4.3-6.5 ^{30,31}	12.8	$22-30^{29}$
Use of alcohol during pregnancy	26.0	60.0 ³²	9.6	15.3 ³³
No. of respondents/No. live births †	0.3%		1.0%	

abia abarastaristics in Eastern Europa atrias (Dussia and Daland) . dir Jan Casia da

Abbreviations: LB: Number of live births per year.

*Median age of women at birth, not mean age.

[†]The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

	Study sample in Croatia n=286	General birthing population in Croatia LB=41,197 ²	Study sample in Serbia n=220	General birthing population in Serbia LB=65,598 ²	Study sample in Slovenia n=149	General birthing population in Slovenia LB=21,947 ²
	n (%)	(%)	n (%)	(%)	n (%)	(%)
Mean Age ± sd	$29.1 \pm 4.5^*$	27.7 ³⁴	$29.2 \pm 3.9^{*}$	28.7 ³⁵	31.7 ± 4.5	30.4 ³⁶
Marital status						
In marriage	83.9	86.7 ³⁴	90.1	76.1 ³⁵	47.0	43.2 ³⁶
Outside marriage	16.1	13.3 ³⁴	9.9	23.9 ³⁵	53.0	56.8 ³⁶
Unknown	-		-	-	-	-
Parity						
No previous children	50.7	46.9 ³⁴	46.8	51.1 ³⁵	45.6	48.5 ³⁶
Educational level						
Less than high school	1.0	3.1 ³⁴	0.9	15.9 ³⁷	2.0	8.5 ³⁶
High-school	36.7	52.5 ³⁴	33.6	54.9 ³⁷	24.8	48.5 ³⁶
More than high school	61.2	44.4 ³⁴	61.8	29.2 ³⁷	69.1	43.0 ³⁶
Other	1.0	-	3.6	-	4.0	-
Women smoking before pregnancy	50.0	34.4 ³⁴	49.1	29.9 ³⁸	32.9	34.4 ⁷
Women smoking during pregnancy	18.8	23.1 ³⁹	18.2	18.4^{40}	6.7	9.6-11.2 ⁴¹
Use of alcohol during pregnancy	12.6	15.5 ⁴²	15.0		32.2	-
No. of respondents/No. live births [†]	4.2%		2.0%		4.1%	

· · · · Frank - · · · · 1:-- 26. C - -: 1 1 · 1 1 01 • \

Abbreviations: LB: Number of live births per year.

 *Mean age for first child (as it is available from the Statistics Bureau reports in Croatia and Serbia).

[†]The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

 BMJ Open

Appendix 2g: Socio-demographic characteristics in North American countries (USA, Canada) and Australia.

	Study sample in The USA	General birthing population in USA ⁴³	Study sample in Canada	General birthing population in Canada ⁴⁴	Study sample in Australia	General birthin population in Australia ⁴⁵
	n=297	LB=3,999,386	n=236	LB=377,636	n=217	LB=301,617
	n (%)	(%)	n (%)	(%)	n (%)	(%)
Age range (years)						
15-19	4.7	9.3 ⁴³	2.1	3.944	2.3	3.8 ⁴⁵
20-24	18.2	23.8 ⁴³	25.0	14.644	8.8	13.8 ⁴⁵
25-29	28.3	28.3 ⁴³	30.1	30.244	31.8	27.9 ⁴⁵
30-34	29.3	24.1 ⁴³	30.5	32.244	27.6	31.7 ⁴⁵
35-39	15.2	11.643	11.0	15.644	22.1	18.4 ⁴⁵
40-44	4.0	2.743	1.3	3.144	6.9	4.0 ⁴⁵
≥45	0.3	0.243	-	0.244	0.5	0.2^{45}
Mean $Age \pm sd$	29.3 ± 6.1		28.3 ± 5.2	29.6 ⁴⁴	31.1 ± 5.7	30.7 ⁴⁵
Marital status						
In marriage	67.0	59.2 ⁴⁶	42.4	60.4 ⁴⁴	70.5	65.8 ⁴⁵
Outside marriage	33.0	39 .9 ⁴⁶	57.6	28.8 ⁴⁴	29.5	34.2 ⁴⁵
Unknown	-	0.9^{46}	-	10.844	-	-
Parity						
No previous children	41.1	40.1 ⁴³	48.3	43.344	47.9	43.8 ⁴⁵
Educational level						
Less than high school	2.7	17.4^{47}	1.3	8.448	0.5	2 0 c ⁴⁹
High-school	25.3	24.4^{47}	24.6	_	29.0	20.6 ⁴⁹
More than high school	62.0	58.2 ⁴⁷	67.8	69.6 ⁴⁸	63.1	56.0 ⁵⁰
Other	10.1	-	6.4	-	7.4	-
Women smoking before pregnancy	28.3	21.5 ⁵¹	29.2	22.0^{52}	29.1	29.9 ⁵³
Women smoking during pregnancy	8.1	10.2^{54}	16.1	13.4^{48}	14.3	14.5 ⁵⁵
Use of alcohol during pregnancy	17.5	15.5 ⁵¹	16.1	10.5^{48}	27.2	29.0^{56}

	Study sample in	General birthing	Study sample	General birthing	Study sample	General birthing
	The USA	population in	in Canada	population in	in Australia	population in
		USA ⁴³		Canada ⁴⁴		Australia ⁴⁵
	n=297	LB=3,999,386	n=236	LB=377,636	n=217	LB=301,617
	n (%)	(%)	n (%)	(%)	n (%)	(%)
No. of respondents/No. live births*	0.04%		0.4%		0.4%	

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

Sources of socio-demographic characteristics of the general birthing population:

1. UK National Statistics. Characteristics of Birth 1 and 2/of mother 1 and 2, England and Wales. 2010; http://www.statistics.gov.uk/hub/population/births-and-fertility/maternities/index.html. Accessed November 12th, 2012.

2. Eurostat. Live births by mother's age at last birthday and legal marital status. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_fagec&lang=en. Accessed November 6th, 2012.

3. Istat - Istituto nazionale di statistica. Demography in figures. 2011; http://demo.istat.it/index_e.html.

4. Swiss Statistics. Components of population change – Data, indicators. http://www.bfs.admin.ch/bfs/portal/en/index/themen/01/06/blank/key/01.html.

5. Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among Italian women. Eur. J. Clin. Pharmacol. Jul 2000;56(4):323-328.

6. Eurostat. Persons with a given education attainment level by sex and age groups (%).

http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/dataset?p_product_code=EDAT_LFS_9903. Accessed November 6th, 2012.

7. Eurostat. Smokers by sex. http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/dataset?p_product_code=TPS00169. Accessed November 6th, 2012.

8. The Health and Social Care Information Centre. Statistics on women's smoking status at time of delivery: England, Quarter 1, 2012/13. 2012;

http://www.ic.nhs.uk/pubs/wsstd1213q1. Accessed November 12th, 2012.

9. De Santis M, De Luca C, Mappa I, Quattrocchi T, Angelo L, Cesari E. Smoke, alcohol consumption and illicit drug use in an Italian population of pregnant women. Eur. J. Obstet. Gynecol. Reprod. Biol. Nov 2011;159(1):106-110.

10. Lemola S, Grob A. Drinking and smoking in pregnancy: what questions do Swiss physicians ask? Swiss Med. Wkly. Jan 27 2007;137(3-4):66-69.

11. Sayal K, Heron J, Golding J, et al. Binge pattern of alcohol consumption during pregnancy and childhood mental health outcomes: longitudinal population-based study. Pediatrics. Feb 2009;123(2):e289-296.

12. National Institute of Statistics and Economic Studies INSEE. Population. http://www.insee.fr/en/themes/theme.asp?theme=2. Accessed November 7th, 2012.

Statline, Centraal Bureaus voor de Statistiek. Population. 2012. http://www.cbs.nl/en-GB/menu/themas/bevolking/nieuws/default.htm. Accessed November 10th,
 2012.

BMJ Open

14. Novem	Statistics Austria. Births. Long-term and current final annual results. 2011; http://www.statistik.at/web_en/statistics/population/births/index.html. Accessed uber 6th, 2012.
15.	STATcube - Statistical Database of Statistics Austria. http://statcube.at/superweb/login.do?guest=guest. Accessed November 6th, 2012.
16.	Menai M, Heude B, Slama R, et al. Association between maternal blood cadmium during pregnancy and birth weight and the risk of fetal growth restriction: The
EDEN	mother-child cohort study. Reprod. Toxicol. 12// 2012;34(4):622-627.
17.	Jahrbuch der Gesundheitsstatistik. Wien2011.
18.	Leermakers ET, Taal HR, Bakker R, Steegers EA, Hofman A, Jaddoe VW. A common genetic variant at 15q25 modifies the associations of maternal smoking
pregnai	ncy with fetal growth: the generation R study. PLoS One. 2012;7(4):e34584.
19.	de Chazeron I, Llorca PM, Ughetto S, et al. Is pregnancy the time to change alcohol consumption habits in France? Alcohol. Clin. Exp. Res. May 2008;32(5):8
873.	
20.	Norwegian Institue of Public Health. Medisinsk fødselsregisters statistikkbank - statistikk om alle fødsler i Norge. 2011; http://mfr-nesstar.uib.no/mfr/. Access
Novem	aber 6th, 2012.
21.	Nordic Perinatal Statistics 2010. National Institute for Health and Welfare.
22.	The National Institute for Health and Welfare, Helsinki Finland. Liitetaulukot - Bilagetabeller - Appendix Tables. 2010.
23.	Ystrom E, Vollrath ME, Nordeng H. Effects of personality on use of medications, alcohol, and cigarettes during pregnancy. Eur. J. Clin. Pharmacol. May
2012;6	8(5):845-851.
24.	Nilsen P, Holmqvist M, Hultgren E, Bendtsen P, Cedergren M. Alcohol use before and during pregnancy and factors influencing change among Swedish wom
Acta O	bstet. Gynecol. Scand. 2008;87(7):768-774.
25.	Births and Deaths. Statistics Iceland. http://www.statice.is/Statistics/Population/Births-and-deaths. Accessed November 6th, 2012.
26.	The Demographic Yearbook of Russia - statistical handbook. Moscow: Federal State Statistics Service (Rosstat);2010.
27.	Demographic Yearbook of Poland. Warsaw: Central Statistical Office of Poland;2011.
28.	Current tobacco use and secondhand smoke exposure among women of reproductive age - 14 countries, 2008-2010. MMWR Morb. Mortal. Wkly. Rep. Nov 2
2012;6	1:877-882.
29.	Przewoźniak K, Zatoński W. Ekspertyza "zachowania zdrowotne kobiet w ciąży". Warszawa: Zakład Epidemiologii i Prewencji Nowotworów, Centrum Onkc
Instytu	t w Warszawie. Posiedzenie Plenarne Rady Naukowej przy Ministrze Zdrowia, Ministerstwo Zdrowia; 24-03-2010 2010.
30.	Kelmanson IA, Erman LV, Litvina SV. Maternal smoking during pregnancy and behavioural characteristics in 2 - 4-month-old infants. Klin. Padiatr. Nov-Dec
2002;2	14(6):359-364.
31.	Hugg TT, Jaakkola MS, Ruotsalainen RO, Pushkarev VJ, Jaakkola JJ. Parental smoking behaviour and effects of tobacco smoke on children's health in Finland
Russia.	. Eur. J. Public Health. Feb 2008;18(1):55-62.
32.	Kristjanson AF, Wilsnack SC, Zvartau E, Tsoy M, Novikov B. Alcohol use in pregnant and nonpregnant Russian women. Alcohol. Clin. Exp. Res. Feb
	1(2):299-307.
33. mother	Wojtyla A, Kapka-Skrzypczak L, Diatczyk J, Fronczak A, Paprzycki P. Alcohol-related Developmental Origin of Adult Health - population studies in Poland is and newborns (2010-2012). Ann. Agric. Environ. Med. Sep 20 2012;19(3):365-377.

1

- 34. Statistical Yearbook of the Republic of Croatia. Zagreb: Croatian Bureau of Statistics; 2011 December 2011.
- 35. Statistical Yearbook of the Republic of Serbia. Demographic Yearbook in Republic of Serbia. Belgrade: Statistical Office of the Republic of Serbia;2011.
- 36. Statistical Office of the Republic of Slovenia. SI-STAT Data Portal. Population. http://pxweb.stat.si/pxweb/Database/Demographics/Demographics.asp. Accessed November 7th, 2012.
- 37. Krstev S, Marinkovic J, Simic S, Kocev N, Bondy SJ. Prevalence and predictors of smoking and quitting during pregnancy in Serbia: results of a nationally representative survey. Int J Public Health. Sep 16 2011.
- 38. Statistical Office of the Republic of Serbia. Women and Men in the Republic of Serbia, Belgrade 2011. 2011.
- 39. Strinic T, Bukovic D, Sumilin L, Radic A, Hauptman D, Klobucar A. Socio-demographic characteristics and lifestyle habits of pregnant women smokers. Coll. Antropol. Dec 2005;29(2):611-614.
- 40. Odalovic M, Vezmar Kovacevic S, Ilic K, Sabo A, Tasic L. Drug use before and during pregnancy in Serbia. Int. J. Clin. Pharm. Oct 2012;34(5):719-727.
- 41. Antolič B, Geršak K, Verdenik I, Novak-Antolič Ž. Adverse effects of thyroid dysfunction on pregnancy and pregnancy outcome: Epidemiologic study in Slovenia. Journal of Maternal-Fetal and Neonatal Medicine. 2006;19(10):651-654.
- 42. Petkovic G, Barisic I. FAS prevalence in a sample of urban schoolchildren in Croatia. Reprod. Toxicol. Apr 2010;29(2):237-241.
- 43. Hamilton B, Martin J, Ventura S. National Vital Statistics Reports. Births: Preliminary Data for 2010. U.S. Department of health and human services. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System;2011.
- 44. Statistics Canada. Births. 2010; http://www.statcan.gc.ca/daily-quotidien/111220/dq111220g-eng.htm. Accessed 12 November 2012.
- 45. Australian Bureau of Statistics. Births, Australia. 2011; http://www.abs.gov.au/AUSSTATS/abs@.nsf/mf/3301.0. Accessed November 13th, 2012.
- 46. OECD. Panorama de la société 2011. OECD Publishing.
- 47. The 2012 Statistical Abstract. The National Data Book. Women With Births in the Past 12 Months by Citizenship Status, Educational Attainment, and Poverty Status, by State. 2009; http://www.census.gov/compendia/statab/cats/births_deaths_marriages_divorces/births.html. Accessed November 12th, 2012.
- 48. Canadian Perinatal Health Report, 2008 Edition. Ottawa: Public Health Agency of Canada;2008.
- 49. Sawicki E, Stewart K, Wong S, Leung L, Paul E, George J. Medication use for chronic health conditions by pregnant women attending an Australian maternity hospital. Aust. N. Z. J. Obstet. Gynaecol. 2011;51(4):333-338.
- 50. Australian Bureau Statistitics. Australian Social Trends, Sep 2012. 2012; http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4102.0Main+Features20Sep+2012. Accessed November 13th, 2012.
- 51. Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings.
- NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration;2011.
- 52. Public Health Agency of Canada. What Mothers Say: The Canadian Maternity Experiences Survey. Ottawa2009.
- 53. Hotham E, Ali R, White J, Robinson J. Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. Aust. N. Z. J. Obstet. Gynaecol. Jun 2008;48(3):248-254.
- 54. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD: National Center for Health Statistics; 2012.
- 55. Australia's mothers and babies 2009. Perinatal statistics series no. 25. Cat. no. PER 52. Canberra: AIHW;2011.

BML 56. Maloney E, Hutchinson D, Burns L, Mattick RP, Black E. Prevalence and predictors of alcohol use in pregnancy and breastfeeding among Australian women. Birth. Mar 2011;38(1):3-9.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Appendix 3: Overall medication use on 1st and 2nd ATC level according to timing of use in pregnancy (n=9,459)*

	Anatomical Therapeutic Chemical (ATC) classification index 1 st and 2 nd levels	Anytime during pregnancy	1 st trimester	2 nd trimester	3 rd trimester
		n (%)	n (%)	n (%)	n (%)
Α	Alimentary tract and metabolism	4,275 (45.2)	2,786 (29.5)	3,390 (35.8)	3,160 (33.4)
A01	Stomatological preparations	62 (0.7)	42 (0.4)	52 (0.5)	46 (0.5)
A02	Drugs for acid related disorders	3,242 (34.3)	2,034 (21.5)	2,634 (27.8)	2,615 (27.6)
A03	Drugs for functional gastrointestinal disorders	650 (6.9)	543 (5.7)	512 (5.4)	381 (4.0)
A04	Antiemetics and antinauseants	136 (1.4)	124 (1.3)	114 (1.2)	81 (0.9)
A05	Bile and liver therapy	24 (0.3)	15 (0.2)	17 (0.2)	16 (0.2)
A06	Laxatives	978 (10.3)	696 (7.4)	835 (8.8)	735 (7.8)
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	89 (0.9)	61 (0.6)	69 (0.7)	57 (0.6)
A09	Digestives, incl. enzymes	9 (0.1)	7 (0.1)	8 (0.1)	3 (0.0)
A10	Drugs used in diabetes	85 (0.9)	57 (0.6)	58 (0.6)	45 (0.5)
-	Unsecified medications for nausea	6 (0.1)	5 (0.1)	4 (0.0)	3 (0.0)
B	Blood and blood forming organs	148 (1.6)	89 (0.9)	102 (1.1)	79 (0.8)
B01	Antithrombotic agents	135 (1.4)	78 (0.8)	95 (1.0)	72 (0.8)
B02	Antihemorrhagics	5 (0.1)	4 (0.0)	2 (0.0)	3 (0.0)
B05	Blood substitutes and perfusion solutions	7 (0.1)	5 (0.1)	5 (0.1)	2 (0.0)
B06	Other hematological agents	3 (0.0)	2 (0.0)	2 (0.0)	3 (0.0)
С	Cardiovascular system	202 (2.1)	132 (1.4)	161 (1.7)	133 (1.4)
C01	Cardiac therapy	7 (0.1)	4 (0.0)	5 (0.1)	4 (0.1)
C02	Antihypertensives	56 (0.6)	34 (0.4)	42 (0.4)	31 (0.3)
C03	Diuretics	6 (0.1)	5 (0.1)	3 (0.0)	2 (0.0)
C04	Peripheral vasodilators	3 (0.0)	3 (0.0)	3 (0.0)	3 (0.0)
C05	Vasoprotectives	44 (0.5)	24 (0.3)	35 (0.4)	31 (0.3)
C07	Beta blocking agents	74 (0.8)	51 (0.5)	59 (0.6)	51 (0.5)
C08	Calcium channel blockers	21 (0.2)	16 (0.2)	18 (0.2)	13 (0.1)
C09	Agents acting on the renin-angiotensin system	4 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)
C10	Lipid modifying agents	5 (0.1)	3 (0.0)	4 (0.0)	4 (0.0)
-	Unspecified medications for hypertension	4 (0.0)	3 (0.0)	3 (0.0)	2 (0.0)

	Anatomical Therapeutic Chemical (ATC) classification index 1 st and 2 nd levels	Anytime during pregnancy	1 st trimester	2 nd trimester	3 rd trimester
		n (%)	n (%)	n (%)	n (%)
D	Dermatologicals	162 (1.7)	116 (1.2)	127 (1.3)	103 (1.1)
D01	Antifungals for dermatological use	38 (0.4)	28 (0.3)	33 (0.3)	27 (0.3)
D02	Emollients and protectives	14 (0.1)	11 (0.1)	12 (0.1)	10 (0.1)
D03	Preparations for treatment of wounds and ulcers	4 (0.0)	3 (0.0)	3 (0.0)	3 (0.0)
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	6 (0.1)	3 (0.0)	5 (0.1)	4 (0.0)
D05	Antipsoriatics	3 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)
D06	Antibiotics and chemotherapeutics for dermatological use	21 (0.2)	15 (0.2)	16 (0.2)	13 (0.1)
D07	Corticosteroids, dermatological preparations	56 (0.6)	40 (0.4)	39 (0.4)	31 (0.3)
D08	Antiseptics and disinfectants	14 (0.1)	9 (0.1)	10 (0.1)	9 (0.1)
D09	Medicated dressings	5 (0.1)	5 (0.1)	5 (0.1)	3 (0.0)
D10	Anti-acne preparations	4 (0.0)	4 (0.0)	4 (0.0)	2 (0.0)
D11	Other dermatological preparations	1 (0.0)	-	1 (0.0)	1 (0.0)
-	Unspecified medications for skin disorders	5 (0.1)	4 (0.0)	4 (0.0)	3 (0.0)
G	Genito urinary system and sex hormones	488 (5.2)	318 (3.4)	394 (4.2)	303 (3.2)
G01	Gynecological antiinfectives and antiseptics	406 (4.3)	255 (2.7)	337 (3.6)	258 (2.7)
G02	Other gynecologicals	13 (0.1)	10 (0.1)	10 (0.1)	8 (0.1)
G03	Sex hormones and modulators of the genital system	68 (0.7)	55 (0.6)	50 (0.5)	36 (0.4)
G04	Urologicals	12 (0.1)	8 (0.1)	7 (0.1)	8 (0.1)
H	Systemic hormonal preparations, excl. sex hormones and insulins	486 (5.1)	304 (3.2)	346 (3.7)	262 (2.8)
H01	Pituitary and hypothalamic hormones and analogues	4 (0.0)	4 (0.0)	3 (0.0)	4 (0.0)
H02	Corticosteroids for systemic use	93 (1.0)	64 (0.7)	78 (0.8)	63 (0.7)
H03	Thyroid therapy	397 (4.2)	242 (2.6)	273 (2.9)	201 (2.1)
J	Antiinfectives for systemic use	1,381 (14.6)	874 (9.2)	1,107 (11.7)	943 (10.0)
J01	Antibacterials for systemic use	1,325 (14.0)	840 (8.9)	1,061 (11.2)	908 (9.6)
J02	Antimycotics for systemic use	23 (0.2)	16 (0.2)	21 (0.2)	17 (0.2)
J05	Antivirals for systemic use	39 (0.4)	27 (0.3)	30 (0.3)	26 (0.3)
J06	Immune sera and immunoglobulins	4 (0.0)	2 (0.0)	3 (0.0)	4 (0.0)
J0 7	Vaccines	10 (0.1)	5 (0.1)	8 (0.1)	5 (0.1)

	Anatomical Therapeutic Chemical (ATC) classification index 1 st and 2 nd levels	Anytime during pregnancy	1 st trimester	2 nd trimester	3 rd trimester
		n (%)	n (%)	n (%)	n (%)
L	Antineoplastic and immunomodulating agents	134 (1.4)	83 (0.9)	117 (1.2)	97 (1.0)
L01	Antineoplastic agents	4 (0.0)	3 (0.0)	4 (0.0)	1 (0.0)
L03	Immunostimulants	96 (1.0)	58 (0.6)	86 (0.9)	78 (0.8)
L04	Immunosuppressants	34 (0.4)	22 (0.2)	27 (0.3)	18 (0.2)
Μ	Musculo-skeletal system	571 (6.0)	416 (4.4)	437 (4.6)	380 (4.0)
M01	Antiinflammatory and antirheumatic products	515 (5.4)	378 (4.0)	396 (4.2)	342 (3.6)
M02	Topical products for joint and muscular pain	54 (0.6)	37 (0.4)	41 (0.4)	41 (0.4)
M03	Muscle relaxants	8 (0.1)	8 (0.1)	4 (0.0)	1 (0.0)
M05	Drugs for treatment of bone diseases	1 (0.0)	-	1 (0.0)	-
M09	Other drugs for disorders of the musculo-skeletal system	2 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)
-	Unspecified medications for headache	2 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)
Ν	Nervous system	5,441 (57.5)	3,638 (38.5)	4,247 (44.9)	3,449 (36.5
N01	Anesthetics	13 (0.1)	10 (0.1)	7 (0.1)	8 (0.1)
N02	Analgesics	5,297 (56.0)	3,562 (37.7)	4,171 (44.1)	3,387 (35.8)
N03	Antiepileptics	76 (0.8)	46 (0.5)	49 (0.5)	42 (0.4)
N05	Psycholeptics	210 (2.2)	173 (1.8)	164 (1.7)	138 (1.5)
N06	Psychoanaleptics	275 (2.9)	211 (2.2)	213 (2.3)	179 (1.9)
N07	Other nervous system drugs	6 (0.1)	4 (0.0)	5 (0.1)	3 (0.0)
-	Unspecified analgesics/medications for the nervous system	52 (0.5)	38 (0.4)	43 (0.5)	35 (0.4)
Р	Antiparasitic products, insecticides and repellents	26 (0.3)	20 (0.2)	22 (0.2)	16 (0.2)
P01	Antiprotozoals	25 (0.3)	20 (0.2)	22 (0.2)	16 (0.2)
P02	Anthelmintics	1 (0.0)	-	-	
R	Respiratory system	2,609 (27.6)	1,878 (19.9)	2,047 (21.6)	1,702 (18.0
R01	Nasal preparations	1,547 (16.4)	1,079 (11.4)	1,229 (13.0)	1,046 (11.1)
R02	Throat preparations	167 (1.8)	110 (1.2)	131 (1.4)	122 (1.3)
R03	Drugs for obstructive airway diseases	396 (4.2)	269 (2.8)	304 (3.2)	242 (2.6)
R05	Cough and cold preparations	152 (1.6)	103 (1.1)	125 (1.3)	101 (1.1)
R06	Antihistamines for systemic use	912 (9.6)	777 (8.2)	740 (7.8)	580 (6.1)

	Anatomical Therapeutic Chemical (ATC) classification index 1 st and 2 nd levels			2 nd trimester	3 rd trimeste	
		n (%)	n (%)	n (%)	n (%)	
R07	Other respiratory system products	3 (0.0)	2 (0.0)	3 (0.0)	3 (0.0)	
-	Unspecified medications of the respiratory system	142 (1.5)	101 (1.1)	118 (1.2)	99 (1.0)	
S	Sensory organs	45 (0.5)	33 (0.3)	38 (0.4)	28 (0.3)	
S01	Ophthalmologicals	33 (0.3)	24 (0.3)	28 (0.3)	23 (0.2)	
S02	Otologicals	5 (0.1)	3 (0.0)	4 (0.0)	2 (0.0)	
S03	Ophthalmological and otological preparations	3 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)	
-	Unspecified medications for eye disorders	5 (0.1)	4 (0.0)	5 (0.1)	2 (0.0)	
V	Various	15 (0.2)	10 (0.1)	11 (0.1)	9 (0.1)	
Total	medication use (any ATC)	7,678 (81.2)	4,710 (49.8)	5,538 (58.5)	4,663 (49.3)	

*The most common medication groups within each ATC class are in italics. Exposure timing is defined as follows: 1st trimester (gestational weeks 0-12), 2nd trimester (gestational week 13-24), 3rd trimester (gestational week 25 and up to childbirth).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Appendix 4: Prevalence of acute/short-term illnesses and most common medications used at any time during pregnancy by ATC level, indication for use and region (n=9,459) *[†]

for use and region (n=9,459)							
			REG	ON			-
Prevalence of acute/short-term illnesses in pregnancy and related medication use, overall and by drug groups	Western Europe	Northern Europe	Eastern Europe	North America	South America	Australia	Total
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Prevalence of headache	1,699 (53.1)	1,657 (58.8)	1,138 (48.6)	373 (70.0)	197 (56.9)	147 (67.7)	5,211 (55.1)
Medication use for headache, total	1,027 (32.1)	1,057 (37.5)	522 (22.3)	226 (42.4)	121 (35.0)	109 (50.2)	3,062 (32.4)
By drug group							
Paracetamol (incl. combinations) (N02BE)	994 (31.1)	1,009 (35.8)	372 (15.9)	206 (38.6)	92 (26.6)	101 (46.5)	2,774 (29.3)
Non-steroidal antiinflammatory drugs (M01A)	28 (0.9)	78 (2.8)	37 (1.6)	18 (3.0)	18 (5.2)	2 (0.9)	179 (1.9)
Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	4 (0.1)	81 (3.5)	1 (0.2)	4 (1.2)	2 (0.9)	99 (1.0)
Opioid analgesics (N02A)	14 (0.4)	46 (1.6)	3 (0.1)	3 (0.6)	-	13 (6.0)	79 (0.8)
Selective serotonin (5-HT ₁) agonists (N02CC)	6 (0.2)	22 (0.8)	2 (0.1)	3 (0.6)	-	1 (0.5)	34 (0.4)
Prevalence of heartburn	2,196 (68.6)	1,875 (66.5)	1,425 (60.8)	374 (70.2)	248 (71.7)	141 (65.0)	6,259 (66.2)
Medication use for heartburn, total	984 (30.7)	885 (31.4)	525 (22.4)	202 (37.9)	88 (25.4)	72 (33.2)	2,756 (29.1)
By drug group							
Antacids (aluminium, salts combinations, antiflatulents)	384 (12.0)	503 (17.8)	440 (18.8)	51 (9.6)	63 (18.2)	20 (9.2)	1,461 (15.4)
Alginic acid complex/sucralfate/bismuth (A02BX)	569 (17.8)	332 (11.8)	86 (3.7)	4 (0.8)	3 (0.9)	14 (6.5)	1,008 (10.7)
Proton pump inhibitors (A02BC)	77 (2.4)	86 (3.0)	4 (0.2)	13 (2.4)	3 (0.9)	7 (3.2)	190 (2.0)
Antacid with calcium (A02AC)	20 (0.6)	13 (0.5)	10 (0.4)	123 (23.1)	2 (0.6)	9 (4.1)	177 (1.9)
H ₂ receptor antagonists (A02BA)	27 (0.8)	27 (1.0)	7 (0.3)	45 (8.4)	5 (1.4)	38 (17.5)	149 (1.6)
Prevalence of pain	2,150 (67.2)	2,067 (73.3)	1,484 (63.4)	369 (69.2)	248 (71.7)	157 (72.4)	6,475 (68.5)
Medication use for pain, total	533 (16.7)	426 (15.1)	147 (6.3)	110 (20.6)	80 (23.1)	59 (27.2)	1,355 (14.3)
By drug group							
Paracetamol (incl. combinations) (N02BE)	444 (13.9)	374 (13.3)	65 (2.8)	99 (18.6)	44 (12.7)	55 (25.3)	1,081 (11.4)
Non-steroidal antiinflammatory drugs (M01A)	19 (0.6)	36 (1.3)	21 (0.9)	11 (2.1)	24 (6.9)	3 (1.4)	114 (1.2)
Opioid analgesics (N02A)	39 (1.2)	51 (1.8)	2 (0.1)	4 (0.8)	-	12 (5.5)	108 (1.1)
							19

	REGION						
Prevalence of acute/short-term illnesses in pregnancy and related medication use, overall and by drug groups	d Western Europe	Northern Europe	Eastern Europe	North America	South America	Australia	Total
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Prevalence of nausea	2,324 (72.6)	2,244 (79.6)	1,503 (64.2)	409 (76.7)	238 (68.8)	173 (79.7)	6,891 (72.9
Medication use for nausea, total	413 (12.9)	380 (13.5)	140 (6.0)	128 (24.0)	71 (20.5)	39 (18.0)	1,171 (12.4
By drug group							
First generation antihistamines (R06A)	150 (4.7)	259 (9.2)	21 (0.9)	84 (15.9)	9 (2.6)	4 (1.8)	527 (5.6)
Metoclopramide/domperidone/bromopride (A03FA)	134 (4.2)	69 (2.4)	27 (1.2)	10 (1.9)	45 (13.0)	25 (11.5)	310 (3.3)
Serotonin antagonists (A04AA)	4 (0.1)	8 (0.3)	1 (0.0)	28 (5.3)	1 (0.3)	11 (5.1)	53 (0.6)
Prevalence of UTI	513 (16.0)	327 (11.6)	452 (19.3)	93 (17.4)	92 (26.6)	25 (11.5)	1,502 (15.9
Medication use for UTI, total	315 (9.8)	221 (7.8)	192 (8.2)	56 (10.5)	63 (18.2)	17 (7.8)	864 (9.1)
By drug group							
Unspecified penicillins (J01C-)	94 (2.9)	99 (3.5)	46 (2.0)	16 (3.0)	17 (4.9)	1 (0.5)	273 (2.9)
NOS Antibacterials for systemic use (J01-)	116 (3.6)	85 (3.0)	25 (1.1)	20 (3.8)	14 (4.0)	6 (2.8)	266 (2.8)
Penicillins with extended spectrum ± beta-lactamase	85 (2.7)	78 (2.8)	44 (1.9)	14 (2.6)	17 (4.9)	1 (0.5)	239 (2.5)
inhibitors (J01CA/J01CR)							
Nitrofurantoin (J01XE)	7 (0.2)	25 (0.9)	54 (2.3)	10 (1.9)	3 (0.9)	1 (0.5)	100 (1.1)
Cephalosporins (J01D)	20 (0.6)	10 (0.4)	36 (1.5)	2 (0.4)	11 (3.2)	6 (2.8)	85 (0.9)
Total prevalence of any acute/short-term illness	3,159 (98.7)	2,803 (99.4)	2,299 (98.2)	523 (98.1)	341 (98.6)	214 (98.6)	9,339 (98.7
Total medication use for any acute/short-term illness	2,224 (69.5)	1,954 (69.3)	1,474 (62.9)	403 (75.6)	250 (72.3)	164 (75.6)	6,469 (68.4

*Countries are grouped into regions as shown in Figure 1.

[†]Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron,

and herbal or alternative medicine products.

Abbreviations: UTI: Urinary tract infection; NOS: Not otherwise specified.

Appendix 5: Prevalence of chronic/long-term disorders and most common medications used at any time during pregnancy by ATC level, indication for use and region $(n=9,459)^{*\dagger}$

indication for use and region $(n=9,459)^{\uparrow\uparrow}$							
3			REG	ION			
 Prevalence of chronic/long-term disorders in pregnancy and related medication use overall and by drug groups 	Western	Northern	Eastern	North	South	Australia	Total
and related medication use, overall and by drug groups	Europe n=3,201	Europe n=2,820	Europe n=2,342	America n=533	America n=346	n=217	n=9,459
2	n (%)	n=2,820 n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
3 Prevalence of hypothyroidism	130 (4.1)	118 (4.2)	105 (4.5)	22 (4.1)	11 (3.2)	<u>6 (2.8)</u>	392 (4.1)
5 Medication use for hypothyroidism, total	118 (3.7)	113 (4.0)	96 (4.1)	22 (1.1) 21 (3.9)	9 (2.6)	6 (2.8) 6 (2.8)	363 (3.8)
By drug group		110 (110)	,	== (01)	> (200)	0 (210)	000 (010)
7 Thyroid hormone levothyroxine (H03 Δ Δ 01)	117 (3.7)	112 (4.0)	89 (3.8)	21 (3.9)	9 (2.6)	6 (2.8)	354 (3.7)
Prevalence of asthma	163 (5.1)	193 (6.8)	58 (2.5)	43 (8.1)	12 (3.5)	24 (11.1)	493 (5.2)
Medication use for asthma, total	122 (3.8)	133 (4.7)	38 (1.6)	35 (6.6)	8 (2.3)	24 (11.1)	360 (3.8)
By drug group							. ,
Inhalant selective beta-2 agonists (R03AC)	94 (2.9)	66 (2.3)	26 (1.1)	32 (6.0)	7 (2.0)	24 (11.1)	249 (2.6)
Adrenergics and other drugs for COPD (R03AK)	33 (1.0)	46 (1.6)	10 (0.4)	3 (0.6)	2 (0.6)	7 (3.2)	101 (1.1)
Inhalant glucocorticoids (R03BA)	28 (0.9)	40 (1.4)	13 (0.6)	12 (2.3)	-	4 (1.8)	97 (1.0)
Systemic selective beta-2 agonists (R03CC)	-	30 (1.1)	R-	2 (0.4)	-	-	32 (0.3)
Prevalence of allergy	205 (6.4)	372 (13.2)	163 (7.0)	51 (9.6)	20 (5.8)	23 (10.6)	834 (8.8)
Medication use for allergy, total	66 (2.1)	171 (6.1)	65 (2.8)	24 (4.5)	13 (3.8)	17 (7.8)	356 (3.8)
By drug group							
Second generation antihistamines (RU6A)	29 (0.9)	104 (3.7)	27 (1.2)	17 (3.2)	4 (1.2)	5 (2.3)	186 (2.0)
Nasal corticosteroids (R01AD)	11 (0.3)	32 (1.1)	17 (0.7)	-	-	7 (3.2)	67 (0.7)
First generation antihistamines (R06A)	13 (0.4)	29 (1.0)	10 (0.4)	9 (1.7)	6 (1.7)	4 (1.8)	71 (0.8)
Prevalence of depression	95 (3.0)	144 (5.1)	29 (1.2)	52 (9.8)	4 (1.2)	25 (11.5)	349 (3.7)
Medication use for depression, total	61 (1.9)	100 (3.5)	11 (0.5)	29 (5.4)	1 (0.3)	23 (10.6)	225 (2.4)
$\frac{By drug group}{SSDL (1)}$			- /				
3 SSRI antidepressants (N06AB)	44 (1.4)	82 (2.9)	6 (0.3)	14 (2.6)	-	14 (6.5)	160 (1.7)
9 SNRIs/mianserin/trazodone/mirtazapine/bupropionAnxiolytic	9 (0.3)	11 (0.4)	1 (0.0)	15 (2.8)	-	7 (3.2)	43 (0.5)
0							21

	REGION						-
Prevalence of chronic/long-term disorders in pregnancy and related medication use, overall and by drug groups	Western Europe	Northern Europe	Eastern Europe	North America	South America	Australia	Total
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
s, benzodiazepine (N05BA)	6 (0.2)	2 (0.1)	5 (0.2)	-	-	1 (0.5)	14 (0.1)
Antipsychotics quetiapine/olanzapine (N05AH)	2 (0.1)	4 (0.1)	-	3 (0.6)	-	3 (1.4)	12 (0.1)
Total prevalence of any chronic/long-term disorder	617 (19.3)	831 (29.5)	576 (24.6)	154 (28.9)	51 (14.7)	72 (33.2)	2,301 (24.3)
Total medication use for any chronic/long-term disorder	462 (14.4)	593 (21.0)	322 (13.7)	119 (22.3)	38 (11.0)	70 (32.3)	1,604 (17.0

oure 1. *Countries are grouped into regions as shown in Figure 1.

[†]Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron,

and herbal or alternative medicine products.

Abbreviations: COPD: Chronic obstructive pulmonary disease; SSRI: Selective serotonin re-uptake inhibitors; SNRI: Serotonin-noradrenaline reuptake inhibitors.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	
2 3 4	
5 6	
7 8 0	
9 10 11	
12 13	
14 15	
16 17 18	
19 20	
21 22	
23 24 25	
-3456789101123415167890011222242526789003132334556789001122324256789003132334556789000000000000000000000000000000000000	
28 29	
30 31 32	
33 34	
35 36	
37 38 39	
40 41	
42 43	
44 45 46	
47 48	
49 50 51	
51 52 53	
54 55	
56 57 58	
58 59 60	

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the
		abstract
		(b) Provide in the abstract an informative and balanced summary of what was
		done and what was found
Introduction		
Background/rationale	2	X Explain the scientific background and rationale for the investigation being
		reported
Objectives	3	X State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	X Present key elements of study design early in the paper
Setting	5	X Describe the setting, locations, and relevant dates, including periods of
C		recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of
Ĩ		participants
Variables	7	X Clearly define all outcomes, exposures, predictors, potential confounders, and
		effect modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	X For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group
Bias	9	X Describe any efforts to address potential sources of bias
Study size	10	✓ Explain how the study size was arrived at
Quantitative variables	11	✗ Explain how quantitative variables were handled in the analyses. If applicable,
Quantitative variables		describe which groupings were chosen and why
Statistical methods	12	✗ (a) Describe all statistical methods, including those used to control for
		confounding
		(b) Describe any methods used to examine subgroups and interactions
		✗ (c) Explain how missing data were addressed
		(d) If applicable, describe analytical methods taking account of sampling strategy
		(<i>e</i>) Describe any sensitivity analyses
D L		(E) Describe any sensitivity analyses
Results	13*	✗ (a) Report numbers of individuals at each stage of study—eg numbers potentially
Participants	13.	eligible, examined for eligibility, confirmed eligible, included in the study,
		completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
	144	(c) Consider use of a flow diagram
Descriptive data	14*	★ (a) Give characteristics of study participants (eg demographic, clinical, social)
		and information on exposures and potential confounders
0.4	1 ~	(b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	X Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates
		and their precision (eg, 95% confidence interval). Make clear which confounders
		were adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

		meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	X Summarise key results with reference to study objectives
Limitations	19	X Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	✗ Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	X Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	★ Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based


*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.



Medication use in pregnancy: a multinational perspective

10.000 - 11	PM1 Open
Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-004365.R1
Article Type:	Research
Date Submitted by the Author:	08-Jan-2014
Complete List of Authors:	Lupattelli, Angela; University of Oslo, School of Pharmacy Spigset, Olav; St Olav's University Hospital, Department of Clinical Pharmacology; Children's and Women's Health, Norwegian University of Science and Technology, Department of Laboratory Medicine Twigg, Michael; University of East Anglia, School of Pharmacy Zagorodnikova, Ksenia; Northwest State Medical University n.a.I.I. Mechnikov, Northwest Medical Center for Drug Safety in Pregnancy & Lactation Mårdby, Ann-Charlotte ; The Sahlgrenska Academy, University of Gothenburg, Department of Public Health and Community Medicine Moretti, Myla; The Hospital for Sick Children, University of Toronto, The Motherisk Program, Division of Clinical Pharmacology and Toxicology Drozd, Mariola; Medical University of Lublin, Faculty of Pharmacy Panchaud, Alice; University of Geneva and Lausanne, School of Pharmaceutical Sciences Hämeen-Anttila, Katri; Finnish Medicines Agency, Rieutord, Andre; APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacies, Clamart France and Européenne de Formation pour les Pharmaciens Gjergja Juraski, Romana; Children's Hospital Srebrnjak, Neuropediatric Unit Odalovic, Marina; Faculty of pharmacy, University of Belgrade, Department of Social Pharmacy and Pharmaceutical Legislation Kennedy, Debra; Royal Hospital for Women and University of NSW, MotherSafe Rudolf, Gorazd; University Medical Centre Ljubljana, Clinical Institute of Medical Genetics Juch, Herbert; Medical University of Graz, Research Unit Human Teratogens, Institute for Cell Biology, Histology and Embryology Passier, Anneke; Netherlands Pharmacovigilance Centre Lareb, Teratology Information Service (TIS), Björnsdóttir, Ingunn; University of Iceland, Nordeng, Hedvig; University of Oslo, School of Pharmacy; Norwegian Institute of Public Health, Division of Mental Health
Primary Subject Heading :	Obstetrics and gynaecology
Secondary Subject Heading:	Obstetrics and gynaecology, Pharmacology and therapeutics, Public health
Keywords:	Maternal medicine < OBSTETRICS, THERAPEUTICS, PUBLIC HEALTH



Medication use in pregnancy: a multinational perspective

Lupattelli A,¹ Spigset O,^{2,3} Twigg MJ,⁴ Zagorodnikova K,⁵ Mårdby AC,⁶ Moretti ME,⁷ Drozd M,⁸ Panchaud A,⁹ Hämeen-Anttila K,¹⁰ Rieutord A,¹¹ Gjergja Juraski R,¹² Odalovic M,¹³ Kennedy D,¹⁴ Rudolf G,¹⁵ Juch H,¹⁶ Passier JLM,¹⁷ Björnsdóttir I,¹ Nordeng H^{1,18}.

¹School of Pharmacy, University of Oslo, Norway

²Department of Clinical Pharmacology, St Olav's University Hospital, Trondheim, Norway

³Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway

⁴School of Pharmacy, University of East Anglia, Norwich Research Park, United Kingdom

⁵Northwest Medical Center for Drug Safety in Pregnancy & Lactation, Northwest State Medical University n.a.I.I.Mechnikov, St. Petersburg, Russia

⁶Department of Public Health and Community Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁷The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The

Hospital for Sick Children, University of Toronto, Ontario, Canada

⁸*Faculty of Pharmacy, Medical University of Lublin, Poland*

⁹School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland

¹⁰Finnish Medicines Agency, Kuopio, Finland

¹¹APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacie, Clamart France and Européenne de Formation pour les Pharmaciens, France

¹²Children's Hospital Srebrnjak, Neuropediatric Unit, Zagreb, Croatia

¹³Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of pharmacy, University of Belgrade, Serbia

¹⁴MotherSafe, Royal Hospital for Women and University of NSW, Randwick, Australia

¹⁵Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Slovenia

¹⁶Research Unit Human Teratogens, Institute for Cell Biology, Histology and Embryology, Medical University of Graz, Austria

¹⁷Teratology Information Service (TIS), Netherlands Pharmacovigilance Centre Lareb, the Netherlands

¹⁸Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway

Corresponding author:

Angela Lupattelli, MScPharm,

1	
2	
2 3 4	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	
21	
22	
23	
24	
25	
26	
27	
27 28 29	
29	
30	
31	
22	
33 34 35	
34	
35	
36	
36 37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Department of Pharmacy, School of Pharmacy, University of Oslo,

PO Box 1068 Blindern, 0316 Oslo, Norway

e-mail: angela.lupattelli@farmasi.uio.no; phone: +47 41343628 ; fax: +4722854402

Key words: pregnancy; drug utilization, maternal health; health behaviour; public

health

Word count (excluding title page, abstract, references, figures and tables): 3571

.xcluding title page,

ABSTRACT

Objectives: Inter-country comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and factors associated with medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilized and indication for use.

Design: Cross-sectional, internet-based study performed within the period from 1-Oct-2011 to 29-Feb-2012. Uniform collection of drug utilization data was performed via an anonymous online questionnaire.

Setting: Multinational study in Europe (Western, Northern, and Eastern), North and South America, and Australia.

Participants: Pregnant women and new mothers with children less than one year of age.

Primary and secondary outcome measures: Prevalence and factors associated with medication use for acute/short-term illnesses, chronic/long-term disorders and over-the-counter (OTC) medication use.

Results: The study population included 9,459 women whereof 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. Overall, OTC medication use occurred in 66.9% of the pregnancies, whereas 68.4% and 17.0% of women reported use of at least one medication for treatment of acute/short-term illnesses and chronic/long-term disorders, respectively. The extent of self-reported

BMJ Open

medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting use of medication for chronic/long-term disorders. Immigrant women in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83) were less likely to report use of medication for chronic/long-term disorders during pregnancy than nonimmigrants.

Conclusions:

In this study, the majority of women in Europe, North America, South America and Australia used at least one medication during pregnancy. There was a substantial inter-region variability in the types of medication used.

ARTICLE SUMMARY

Strengths and limitations of this study

- Uniform data collection of drug utilization data across all participating countries allows for inter-country comparability of the prevalence of medication use during pregnancy, up to now impeded by differences in study design and methodology.
- The study adds a multinational perspective on OTC medication use during pregnancy to the limited number of studies quantifying the extent of self-medication during pregnancy.
- Lack of validity of the self-reported diagnoses is a limitation since all disorders and related medication use were self-reported by the study participants.
- An internet survey as a study method impedes calculation of a conventional response rate and may cause selection bias of the target population.

BMJ Open

INTRODUCTION

Ethical reasons preclude inclusion of pregnant women in the vast majority of premarketing clinical trials.[1] As a consequence, most medications are placed onto the market without a directly established safety profile in human pregnancy.[2] So far, few medications have been shown to be major teratogens, yet the risk of minor teratogenicity or of more subtle effects on fetal development still have to be determined for most of them.[3] Despite this, medication use during pregnancy is common. Mitchell et al. found that use of medications, either prescribed or purchased over-the-counter (OTC), occurred in 88.8% of all pregnancies in the USA.[4] In Europe, prevalence estimates of prescribed medication use vary considerably across countries, ranging from 26% in Serbia to 93% in France.[5-10] Such inter-country variability could, at least in part, be caused by differences in study design, methodology and exposure ascertainment across studies.[11] Uniform collection of drug utilization data during pregnancy between countries may overcome such drawbacks, allowing for inter-country comparability of prevalence estimates and shedding light on differences in prenatal care in the various countries.

Prior studies have addressed research priorities in this area such as presenting results on an individual drug level according to the indication of use, quantifying the extent of OTC and prescribed medication use during pregnancy, and taking into account inter-country comparability.[4] Only a few studies have individually examined maternal factors associated with specific types of medication use during pregnancy.[11-14]

The objectives of the current study were to examine patterns of medication use in pregnancy from a multinational perspective, with special emphasis on type of medication utilized, including OTC medications, and self-reported indications for use, and to identify maternal background factors potentially associated with medication use for acute/short-term illnesses, medication use for chronic/long-term disorders and OTC medication use during pregnancy.

METHODS

Study design and data collection

This is a multinational, cross-sectional, internet-based study. Pregnant women at any gestational week and mothers with children less than one year of age were eligible to participate. Member countries of the European Network of Teratology Information Services (ENTIS), The Organization of Teratology Information Specialists (OTIS) in North America, MotherSafe in Australia and European institutions conducting public health research were invited to take part in the project. Of these, 18 countries participated (Australia, Austria, Canada, Croatia, Finland, France, Iceland, Italy, Netherlands, Norway, Poland, Russia, Serbia, Slovenia, Sweden, Switzerland, United Kingdom and USA). Data originating from some South and Central American countries were also collected through OTIS. Because of the low number of participants on the individual country level, the region of Central America was excluded and countries in South America were aggregated into one region. Data selection to achieve the final study sample was performed as depicted in Figure 1. Participants were categorized according to the reported country of residency and grouped into six regions: Western Europe, Northern Europe, Eastern Europe, North America, South America and Australia.

BMJ Open

Data were collected through an anonymous on-line questionnaire administered by Quest Back (http://www.questback.com) and accessible for a period of two months in each participating country within the period 1-Oct-2011 to 29-Feb-2012. The complete questionnaire is presented in Appendix 1. The questionnaire was open to the public via utilization of banners (invitations to participate in the study) on national websites and/or social networks commonly visited and consulted by pregnant women and/or new mothers. Detailed information about recruitment tools utilized and internet penetration rates is summarized in Appendix 2.

The questionnaire was first developed in Norwegian and English and then translated into the other relevant languages. A pilot study was carried out in September 2011 (n=47) and elicited no major change to the questionnaire. Collected data were scrutinized for the presence of potential duplicates (based on reported country of residency, socio-demographic characteristics, date and exact time of questionnaire completion) but none were identified.

Exposure variables

Maternal socio-demographics (i.e. region of residency, age, educational level, mother tongue, working status at time of conception, previous children, marital status and unplanned pregnancy) and life-style characteristics (i.e. smoking status before and during pregnancy and alcohol consumption after awareness of pregnancy) constituted the exposure variables. To assess external validity, we compared socio-demographic and life-style characteristics of our study population on an individual country level with those of the general birthing population in the same country. Reports of National Statistics Bureaus or previous national studies were utilized for this purpose. The ratio

between the number of respondents and the estimated number of live births in the 2months period was also examined for each country (Appendix 3).

Outcome variables

Use of any medication, medication for acute/short-term illnesses, medication for chronic/long-term disorders and OTC medication use during pregnancy constituted the outcome variables. Participants were first confronted with a list of the most common acute/short-term illnesses (i.e. nausea, heartburn, constipation, common cold, urinary tract infections (UTIs), other infections, pain in the neck/back/pelvic girdle, headache, sleeping problems) and the most prevalent chronic/long-term disorders (i.e. asthma, allergy, hypothyroidism, rheumatic disorders, diabetes, epilepsy, depression, anxiety, cardiovascular disease, other disorders) and asked whether they suffered/had suffered from these conditions during pregnancy. In case of an affirmative response, women were questioned about medication use for each individual indication as a freetext entry. Use of OTC medications was also recorded. Recall was aided with a list of five OTC medication categories: painkillers, nasal spray/drops, antinauseants, antacids and laxatives, along with examples of brand name products of relevance in each country. It was optional to report timing of exposure for each of the medication use questions (the alternatives were gestational weeks 0-12 (1st trimester), 13-24 (2nd trimester) and 25-delivery (3rd trimester)).

We defined a medicine as a single product containing one or more active ingredients. We initially identified the main active ingredient(s) and formulation of the reported medicinal products either in the relevant national medicines database or in the "Martindale" textbook.[15] All recorded medications were coded into the corresponding Anatomical Therapeutic Chemical (ATC) codes at the ATC 5th level

BMJ Open

(i.e. the substance level) whenever possible, otherwise into the 2nd- 4th levels as appropriate, in accordance with the World Health Organization ATC index.[16] The OTC status of medications was crosschecked with the prescription policies within each country. Whenever a prescription medication was reported under the OTC question, this record was omitted from the analysis of OTC use but counted in the estimation of total medication use (including prescription and OTC). Iron, mineral supplements, vitamins, herbal remedies and any type of alternative medicine were recorded separately and excluded from the estimation of medication use.

The required sample size calculation for the outcome variables on region and individual country levels are outlined in Appendix 4. The expected prevalence estimates were set according to results of previous studies.[5-10,17,18]

Ethics

All participants gave informed consent by answering "Yes" to the question "Are you willing to participate in the study?" The study was approved by the Regional Ethics Committee, Region South-East in Norway. Ethical approval or study notification to the relevant national Ethics Boards was achieved in specific countries as required by national legislation. All data were handled and stored anonymously.

Statistical analysis

Descriptive statistics were utilized as appropriate. Univariate and multivariate logistic regression analyses were used to examine the association between maternal characteristic and three categorical outcome measures (Yes/No): Medication use for acute/short-term illnesses; medication use for chronic/long-term disorders; OTC medication use. P-values of <0.05 were considered statistically significant. Data are

presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). The analyzed explanatory variables included all maternal socio-demographics and lifestyle characteristics. After fitting the univariate logistic regression model for all explanatory variables, the multivariate model was built and adjusted for all remaining covariates. The Hosmer and Lemeshow test was used to assess goodness of fit of the final multivariate model.[19] Analogue sub-analyses on individual region level were performed. In these instances, region of residency was not included in the model. All statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM[®] SPSS[®] Statistics).

RESULTS

Population characteristics

A total of 9,615 women accessed the on-line questionnaire whereof 98.6% completed it. The participant flow-chart to achieve final study population (n=9,459) is depicted in Figure 1. A total of 5,089 women (53.8%) were pregnant at the time of completion of the questionnaire, whereas 4,370 women (46.2%) had delivered their babies within the previous year. Of the former group, 1,095 (21.5%), 1,702 (33.4%) and 2,291 (45.0%) women were in the first, second and third trimester of pregnancy, respectively. Of the latter group, 1,320 (30.2%), 947 (21.7%) and 2,102 (48.1%) had a baby of age \leq 16 weeks, 17-28 weeks, and \geq 29 weeks, respectively. For two women the time of gestation/baby's age was unknown. Overall, the birthing population in each participating country was reflected quite well by the sample with respect to age, parity and smoking habits (Appendix 3). However, there was a difference in terms of educational level; on average, the women in the study had higher education than the general birthing population in each country. In addition, participants in Sweden,

BMJ Open

Austria, Iceland and Italy were slightly more often primiparous, whereas the responders in Australia, USA, The Netherlands, Slovenia and Croatia were somewhat older than the general birthing population.

Total medication use

After exclusion of vitamins, mineral supplements and iron, use of at least one medication either prescribed or OTC at any time during pregnancy was reported by 7,678 out of 9,459 women (81.2%). Figure 2 depicts prevalence estimates of total medication use during pregnancy by region and country of residence. The extent of OTC medication use, as well as medication use for acute/short-term illnesses and chronic/long-term disorders is also outlined. The highest prevalence of total medication use during pregnancy was observed in The Netherlands (95.1%), Iceland (93.0%) and Finland (92.3%). The overall prevalence estimates of medication use in pregnancy according to timing and drug class (ATC level 1 and 2) are presented in Appendix 5. Medications for the nervous system (ATC class N) were the most commonly used during pregnancy (57.5%), mostly due to paracetamol (acetaminophen) and its combinations.

A corollary analysis according to pregnancy status showed that pregnant women reported in a significantly lower degree than new mothers any medication use during pregnancy (78.8% vs. 84.0%, p-value<0.001), as well as OTC medication use (63.0% vs. 71.5%, p-value<0.001) and medication use for acute/short-term illnesses (66.2% vs. 70.9%, p-value<0.001). In contrast, the difference in medication use for chronic/long-term disorders was not significant (17.4% vs. 16.5%, p-value=0.271). None of the rates differed significantly when women in the third trimester of pregnancy were compared to new mothers.

Medication use according to indication

Headache, heartburn, pain, nausea and UTIs constituted the leading indications for use of medication during pregnancy among the acute/short-term illnesses analyzed. Hypothyroidism, asthma, allergy and depression were the leading indications for chronic/long-term medication use. Observed prevalence rates of these disorders, overall and by region of residency, are presented in Appendices 6 and 7, respectively, along with rates of total and specific medication use. Table 1 outlines prevalence estimates of OTC medication use during pregnancy by region and indication for use. Only the most common medication groups reported are presented. Inter-region variations in rates and types of medication used during pregnancy were observed both for acute/short-term illnesses (e.g. nausea and UTIs), chronic/long-term disorders (e.g. asthma and depression) and OTC medications (e.g. nasal spray).

Factors associated with medication use

Factors associated with medication use during pregnancy according to type of medication utilized are presented in table 2. Use of chronic/long-term medications during pregnancy was reported in a significant larger extent by women in Northern Europe (aOR:1.68, 95% CI:1.46-1.94), North America (aOR:1.80, 95% CI:1.42-2.28) and Australia (aOR:2.76, 95% CI:2.03-3.76) compared to women in Western Europe. Older women or housewives, those with low education or with an unplanned pregnancy, were the ones most often reporting use of chronic/long-term medication. Sub-analysis on individual region level revealed that women not having the official language of the country of residency as mother tongue were less likely to report chronic/long-term medication use in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83), but not in the other regions.

BMJ Open

Table 1: Use of OTC medication at any time during pregnancy by ATC level, indication for use and region (n=9,459) *†

	REGION						
OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n (%)</i>	Northern Europe n=2,820 <i>n</i> (%)	Eastern Europe n=2,342 <i>n</i> (%)	North America n=533 n (%)	South America n=346 n (%)	Australian n=217 n (%)	Total n=9,459 n (%)
OTC painkillers, total	1,714 (53.5)	1,773 (62.9)	734 (31.3)	284 (53.3)	127 (36.7)	151 (69.9)	4,783 (50.6)
By drug group							
Paracetamol (incl. combinations) (N02BE)	1,655 (51.7)	1,735 (61.5)	630 (26.9)	263 (49.3)	87 (25.1)	146 (67.3)	4,516 (47.7)
Non-steroideal antiinflammatory drugs (M01A)	70 (2.2)	182 (6.5)	68 (2.9)	40 (7.5)	59 (17.1)	7 (3.2)	426 (4.5)
Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	11 (0.4)	32 (1.4)	2 (0.4)	2 (0.6)	1 (0.5)	55 (0.6)
Metamizole (N02BB02)	_	6 (0.2)	31 (1.3)	1 (0.2)	12 (3.5)	-	50 (0.5)
OTC antacids, total	1,011 (31.6)	883 (31.3)	583 (24.9)	129 (24.2)	48 (13.9)	76 (35.0)	2,730 (28.9
By drug group							
Antacids (aluminium, salts combinations, antiflatulents)	472 (14.7)	550 (19.5)	508 (21.7)	47 (8.8)	36 (10.4)	54 (24.9)	1,667 (17.6
Alginic acid complex/sucralfate/bismuth (A02BX)	606 (18.9)	421 (14.9)	87 (3.7)	4 (0.8)	1 (0.3)	17 (7.8)	1,136 (12.0
H ₂ receptor antagonists (A02BA)	20 (0.6)	20 (0.7)	16 (0.7)	57 (10.1)	10 (2.9)	17 (7.8)	137 (1.4)
Antacids with calcium (A02AC)	23 (0.7)	12 (0.4)	10 (0.4)	69 (12.9)	2 (0.6)	10 (4.6)	126 (1.3)
Proton pump inhibitors (A02BC)	38 (1.2)	52 (1.8)	_	10 (1.9)	2 (0.6)	5 (0.3)	107 (1.1)
OTC nasal sprays/drops, total	272 (8.5)	742 (26.3)	451 (19.3)	35 (6.6)	7 (2.0)	14 (6.5)	1,521 (16.1
By drug group							
Sympathomimetic nasal decongestants (R01AA/R01BB)	204 (6.4)	683 (24.2)	365 (15.6)	20 (3.8)	3 (0.9)	4 (1.8)	1,279 (13.5
Nasal corticosteroids (R01AD)	31 (1.0)	49 (1.7)	12 (0.5)	5 (0.9)	2 (0.6)	10 (4.6)	109 (1.2)
Nasal immunostimulants (low dose interferon) (L03A)	-	-	28 (1.2)	-	-	-	28 (0.3)
OTC laxatives, total	240 (7.5)	227 (8.0)	237 (10.1)	50 (9.4)	8 (2.3)	19 (8.8)	781 (8.3)
By drug group							
Osmotically acting laxatives (A06AD)	159 (5.0)	171 (6.1)	197 (8.4)	2 (0.4)	2 (0.6)	8 (3.7)	539 (5.7)
Contact laxatives (A06AB)	28 (0.9)	44 (1.6)	18 (0.8)	7 (1.3)	6 (1.7)	2 (0.9)	105 (1.1)
							14

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

			REG	ION			_
OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n</i> (%)	Northern Europe n=2,820 <i>n</i> (%)	Eastern Europe n=2,342 <i>n</i> (%)	North America n=533 n (%)	South America n=346 n (%)	Australian n=217 n (%)	Total n=9,459 n (%)
Enemas (A06AG)	3 (0.1)	25 (0.9)	34 (1.5)	4 (0.8)	-	2 (0.9)	68 (0.7)
Softeners, emollients (A06AA)	8 (0.2)	-	-	38 (7.1)	-	6 (2.8)	52 (0.5)
OTC antinauseants, total	263 (8.2)	273 (9.7)	41 (1.8)	60 (11.3)	28 (8.1)	40 (18.4)	705 (7.5)
By drug group							
First generation antihistamines (R06A)	141 (4.4)	256 (9.1)	7 (1.5)	55 (10.3)	5 (1.4)	5 (2.3)	469 (5.0)
Metoclopramide/domperidone/bromopride (A03FA)	113 (3.5)	5 (0.2)	18 (0.8)	2 (0.4)	19 (5.5)	27 (12.4)	184 (1.9)
Total OTC medication use	2,163 (67.6)	2,155 (76.4)	1,347 (57.5)	342 (64.2)	156 (45.1)	168 (77.4)	6,331 (66.9)

 *Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, and herbal or alternative medicine products.

Abbreviations: OTC: Over-The-Counter medications.

 BMJ Open

Region of residency [†] Western Europe Northern Europe Eastern Europe North America South America	(n= <i>n</i> (%) 2,224 (69.5) 1,954 (69.3) 1,474 (62.9) 403 (75.6) 250 (82.3)	ort-term illnesses =6,469) <i>aOR (95% CI)</i> Reference 0.96 (0.86-1.08) 0.69 (0.61-0.78) 1.28 (1.03-1.60)	(n: <i>n</i> (%) 462 (14.4) 593 (21.0) 322 (13.7)	ng-term disorders =1,604) <i>aOR (95% CI)</i> Reference 1.68 (1.46-1.94) 1.03 (0.87-1.21)		OTC =6,331) <i>aOR (95% CI)</i> Reference
Western Europe Northern Europe Eastern Europe North America South America	2,224 (69.5) 1,954 (69.3) 1,474 (62.9) 403 (75.6) 250 (82.3)	Reference 0.96 (0.86-1.08) 0.69 (0.61-0.78) 1.28 (1.03-1.60)	462 (14.4) 593 (21.0) 322 (13.7)	Reference 1.68 (1.46-1.94)	2,163 (67.6)	Reference
Western Europe Northern Europe Eastern Europe North America South America	1,954 (69.3) 1,474 (62.9) 403 (75.6) 250 (82.3)	0.96 (0.86-1.08) 0.69 (0.61-0.78) 1.28 (1.03-1.60)	593 (21.0) 322 (13.7)	1.68 (1.46-1.94)	· · · ·	
Northern Europe Eastern Europe North America South America	1,954 (69.3) 1,474 (62.9) 403 (75.6) 250 (82.3)	0.96 (0.86-1.08) 0.69 (0.61-0.78) 1.28 (1.03-1.60)	593 (21.0) 322 (13.7)	1.68 (1.46-1.94)	· · · ·	
Eastern Europe North America South America	1,474 (62.9) 403 (75.6) 250 (82.3)	0.69 (0.61-0.78) 1.28 (1.03-1.60)	322 (13.7)		2,155 (76.4)	
North America South America	403 (75.6) 250 (82.3)	1.28 (1.03-1.60)		1 03 (0 87-1 21)		1.54 (1.36-1.74)
South America	250 (82.3)		110 (22.2)	1.05 (0.07-1.21)	1,347 (57.5)	0.60 (0.53-0.67)
	()		119 (22.3)	1.80 (1.42-2.28)	342 (64.2)	0.81 (0.66-0.99)
A (1'		1.03 (0.79-1.34)	38 (11.0)	0.70 (0.48-1.01)	156 (45.1)	0.34 (0.27-0.44)
Australia	164 (75.6)	1.29 (0.93-1.79)	70 (32.3)	2.76 (2.03-3.76)	168 (77.4)	1.57 (1.12-2.20)
Maternal age (years)						
≤20	232 (70.5)	1.22 (0.93-1.60)	761 (14.7)	0.58 (0.39-0.87)	205 (62.3)	1.05 (0.81-1.36
21-30	3,531 (68.2)	Reference	33 (10.0)	Reference	3,461 (66.8)	Reference
31-40	2,576 (68.6)	0.90 (0.82-1.00)	764 (20.4)	1.44 (1.27-1.63)	2,531 (67.4)	0.85 (0.77-0.94
<u>≥</u> 41	130 (66.3)	0.73 (0.54-1.00)	46 (23.5)	1.61 (1.13-2.29)	134 (68.4)	0.86 (0.62-1.19
Previous children						
No	3,082 (65.5)	Reference	735 (15.6)	Reference	2,949 (62.6)	Reference
Yes	3,387 (71.3)	1.34 (1.22-1.47)	869 (18.3)	1.08 (0.96-1.21)	3,382 (71.2)	1.58 (1.44-1.74
Marital status						
Married/cohabiting	6,066 (68.5)	Reference	1,503 (17.0)	Reference	5,960 (67.3)	Reference
Single/divorced/others	403 (66.3)	0.91 (0.75-1.10)	101 (16.6)	1.06 (0.83-1.35)	371 (61.0)	0.91 (0.75-1.10
Working status						
Employed, but not as HCP	3,737 (66.8)	Reference	905 (16.2)	Reference	3,667 (65.6)	Reference
HCP	934 (74.4)	1.41 (1.23-1.63)	240 (19.1)	1.13 (0.96-1.33)	944 (75.2)	1.42 (1.23-1.64
Student	592 (69.1)	1.11 (0.94-1.31)	128 (14.9)	1.04 (0.84-1.30)	578 (67.4)	1.10 (0.93-1.30
Housewife	608 (72.6)	1.14 (0.96-1.35)	170 (20.3)	1.34 (1.10-1.63)	577 (68.9)	1.05 (0.88-1.24
Job seeker	281 (66.0)	0.96 (0.78-1.20)	66 (15.5)	1.03 (0.78-1.36)	258 (60.6)	0.85 (0.68-1.05
Other than above	311 (65.2)	0.91 (0.75-1.12)	94 (19.7)	1.29 (1.01-1.65)	302 (63.3)	0.91 (0.74-1.12

	Medication use								
	For acute/short-term illnesses (n=6,469)			ong-term disorders =1,604)	OTC (n=6,331)				
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)			
Less than high school	331 (72.7)	1.17 (0.93-1.49)	92 (20.2)	1.51 (1.15-1.97)	317 (69.7)	1.32 (1.04-1.67			
High school	1,864 (68.7)	Reference	428 (15.8)	Reference	1,779 (65.6)	Reference			
More than high school	3,574 (68.4)	0.99 (0.89-1.11)	916 (17.5)	1.04 (0.91-1.20)	3,489 (66.8)	1.07 (0.96-1.19			
Others, unspecified	700 (65.7)	0.82 (0.70-0.96)	168 (15.8)	0.94 (0.77-1.16)	746 (70.0)	1.13 (0.97-1.33			
Alcohol use after awareness of pregn	ancy		. ,			*			
No	5,270 (67.1)	Reference	1,322 (16.8)	Reference	5,133 (65.3)	Reference			
Yes	1,144 (75.7)	1.59 (1.39-1.81)	270 (17.9)	1.11 (0.95-1.29)	1,150 (76.1)	1.95 (1.71-2.23			
Smoking during pregnancy									
No	5,835 (68.5)	Reference	1,441 (16.9)	Reference	5,716 (67.0)	Reference			
Yes, but less than before pregnancy	530 (69.0)	1.08 (0.91-1.27)	130 (16.9)	1.01 (0.82-1.25)	511 (66.5)	1.06 (0.90-1.26			
Yes, the same or more than before				× ,		× ×			
pregnancy	88 (67.7)	0.95 (0.64-1.40)	28 (21.5)	1.19 (0.74-1.90)	89 (68.5)	1.21 (0.81-1.82			
Planned pregnancy	~ /	× /				× ×			
Yes	5,836 (68.4)	Reference	1,427 (16.7)	Reference	5,727 (67.2)	Reference			
No	616 (68.4)	0.96 (0.82-1.12)	173 (19.2)	1.29 (1.06-1.56)	587 (65.1)	1.00 (0.85-1.17			
First language different from the off	icial main langu	age in the country of	· · ·		· /	*			
No	6,089 (68.5)	Reference	1,530 (17.2)	Reference	5,972 (67.1)	Reference			
Yes	363 (67.2)	0.93 (0.76-1.12)	71 (13.1)	0.66 (0.50-0.86)	347 (64.3)	0.89 (0.74-1.08			

Abbreviation: HCP: health care provider.

 *Numbers may not add up due to missing values. Missing values are less than 5% of the total. Mineral supplements, vitamins, iron, herbal or alternative medicine products are not included in the medication use estimates.

[†]Countries are grouped into regions as shown in Figure 1.

DISCUSSION

This is the first internet-based study examining patterns and factors associated with medication use during pregnancy on a multinational level. In all regions, approximately eight out of ten women reported use of at least one medication, either prescribed or OTC, during the course of their pregnancy. This finding is in line with previous research conducted in Europe, North America, South America and Australia,[4,20-25] though our estimates were somewhat higher in some of the Eastern European countries, e.g. Serbia, than those observed in a previous study.[5] Different recruitment strategies, i.e. internet-based in our study versus maternity care unit-/community pharmacy-based in the previous study could explain such discrepancy.

Overall, analgesics, antacids, nasal decongestants/antiallergics and systemic antibiotics were the medication groups dominating the drug utilization scenario, as also shown by previous research.[4,20-22] However, our study also provides insights into the proportion of medicated women among those suffering from a specific illness during pregnancy across the six regions. We found that approximately seven out of ten women who reported UTIs were treated with antibiotics during pregnancy. This related to all regions, except Eastern Europe where it was only four out of ten women. Since women may perceive dysuria without ascertainment of bacteriuria in the urine as UTI, an over-reporting of the illness could have occurred. Yet, a sub-optimal treatment of UTIs during pregnancy in Eastern Europe cannot be ruled out. The inter-country variability in the types of antibiotics used for UTIs could simply be explained by differences in prescribing practice,[26] presence of screening for bacteriuria in early pregnancy, or specific antibiotic resistance patterns.

Even though nausea was the condition affecting most women in all six regions, the corresponding proportions of medicated nausea were generally low. This scenario is probably due to two main factors: a) the predominantly mild character of nausea and the possibility of non-pharmacological management (e.g. dietary advices); b) the reluctance of general practitioners to prescribe antinauseants even though safety profile assessments are in place.[27,28] As also shown in previous studies,[4,29] use of serotonin antagonists in North America and Australia is increasing also in pregnancy compared to the other regions, eliciting the need of sound studies assessing the safety profile of this drug group in pregnancy.

In most regions, the self-reported prevalence of hypothyroidism was somewhat higher than the reported hormone substitution rate. Because of its known association with adverse pregnancy outcomes,[30] the unexpected finding of potential sub-optimal treatment of hypothyroidism during pregnancy deserves attention. It could probably be due to a lack of information about hypothyroidism typology and its diagnostic ascertainment in our study.

In our study, depression was self-reported and not based on any psychometric assessment, thus the observed substantial inter-regional variability in the extent of this disorder and related medication use could have certainly been affected by women's attitudes in reporting. Our estimate of medication use for depression in Australia was higher than that observed in a recent study (10.6% versus 2.1%).[31] However, the similarity in self-reported depression itself (11.5% versus 15.6%) suggests that our population might mostly comprise women who did not discontinue their pharmacological therapy once they became pregnant. Our estimates for North America and Western Europe were in line with recent literature showing an increase in antidepressant use in pregnancy during the last years.[4,32]

In most regions approximately 60-70% of women reported use of at least one OTC medication during the course of their pregnancy, mostly for pain conditions, heartburn and

BMJ Open

upper airways disorders, indicating a substantially high rate of self-medication during pregnancy. This estimate aligns with previous research carried out in North America.[17] Of note, self-medication with OTC sympathomimetic nasal decongestants was more extensive in Northern and Eastern Europe than in the remaining regions; this could be explained by the time of the year when the data collection was performed.

Region of residency was an important factor associated with medication use during pregnancy. As also shown by Cleary et al.,[33] we found that rates of medication use among women originally from Eastern Europe and South America were significantly lower than those observed in Western Europe, North America and Australia. Such geographical differences could be due to culture, variations in prenatal care assistance or access to medications in the various regions and the related costs.

Women working as health care providers, those consuming alcohol during pregnancy and those with previous children were those more likely to use short-term and OTC medications, possibly reflecting higher confidence in self-treatment and use of medications in general in the former instance, and less anxiety for the pregnancy outcome in the latter two instances. Contrary to previous studies indicating an association between higher maternal education and more prevalent use of medication during pregnancy,[14,17,23] we found that lower education was associated with a higher use of OTC medications as well as medication for chronic/long-term disorders (30-50% increased risk). Results of similar magnitude (30% increased risk) were also observed by Olesen et al.[34], whereas Stokholm et al. [35] identified a stronger association (2.3-fold increased risk) between low maternal education and use of antibiotic for respiratory tract infections during pregnancy. One factor negatively associated with chronic/long-term medication use was not having the official language of the country of residency as mother tongue. This tendency was detected in Western and Northern Europe,

rising concerns about the potential health risks for immigrant women in these two regions. As shown by Hameen-Anttila et al., 57% of pregnant women have perceived information needs about medications during pregnancy.[36] Thus, identification of potential users or non-users of medication during pregnancy might be of clinical relevance, allowing tailored evidence-based information about medication safety or outcome of sub-optimal medication of severe medical conditions in pregnancy.

Strengths and limitations

The main strength is that data collection was performed uniformly across all participating countries, allowing for inter-country comparison of the prevalence of medication use during pregnancy. By quantifying the extent of self-medication with OTC drugs and medication use according to self-reported indication, it was possible to determine the leading causes for medication use among pregnant women. Categorization of maternal characteristics positively associated with the various types of medications used during pregnancy enabled us to identify which groups of women are more likely to need information about medication use during pregnancy. The utilization of an anonymous web-based questionnaire enabled us to reach a large proportion of the birthing population in several countries worldwide. However, we cannot exclude the possibility that the women who decided to participate in the study differed from the general birthing population in other ways that our analysis could not control for. In most participating countries the study sample was large enough to warrant calculation of prevalence estimates with a precision of 5%. However, less precise estimates were permitted by the study sample in Austria, Iceland and The Netherlands (precision of 9-11%), as well as in Australia, Canada, Croatia, Serbia, Slovenia, and USA (precision of 6-7%).

One main limitation of the study is the lack of validity of the self-reported diagnoses. All disorders were self-reported by the participants and hence dependent on the women's

BMJ Open

perception of the medical condition. Similarly, information about medication use during pregnancy was dependent on the accuracy of the women's reporting and recall. For new mothers, data were registered retrospectively; hence a risk of recall bias cannot be ruled out. In specific countries (Australia, Canada, France, Russia, The Netherlands, and the USA) the study sample was a small proportion of the general birthing population; hence the generalizability of our findings for these specific countries should be interpreted with caution.

The questionnaire was only available through internet websites; by using this kind of approach a conventional response rate cannot be calculated and a selection bias of the target population cannot be ruled out. However, recent epidemiological studies indicate reasonable validity of web-based recruitment methods.[37,38] Also, the penetration rate of the internet either in households or at work is relatively high among women in childbearing age.[39-43] Hence, the degree to which our findings can be extrapolated to the target population is based on the representativeness of the respondents to the general birthing populations in each country. The sample in each country had a somewhat higher educational level than the general birthing populations. Such a limitation might have led to biased estimates of the association between maternal education and medication use during pregnancy. Since many ailments requiring pharmacotherapy occur in mid or late pregnancy, inclusion of pregnant women at early gestation in the total material has somewhat inflated the prevalence of non-users of medications during pregnancy. Also, women with specific disorders or in need of information about medication use during pregnancy might have been more likely to consult internet websites and therefore participate in this study.

CONCLUSIONS

Use of medications for acute/short-term illnesses and chronic/long-term disorders as well as use of OTC medications, were common during pregnancy. The extent of medicated illnesses

and types of medications used for the different indications varied across the six regions. This was especially relevant for acute/short-term illnesses such as nausea and UTIs, but also for chronic/long-term disorders such as hypothyroidism or depression. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting chronic/long-term medication use, as opposed to immigrants residing in Western and Northern Europe who reported the least use of this medication category. Future research should definitely focus on this specific group of women, but also address more insights into the outcome of sub-optimal medication of severe conditions in pregnancy.

ACKNOWLEDGMENTS

We thank OTIS, ENTIS Scientific Board who reviewed the study protocol and all website providers who contributed to the recruitment phase. We are grateful to all the participating women who took part in this study.

FUNDING: This work was funded by the Norwegian Research Council (grant no.

216771/F11) and the Foundation for Promotion of Norwegian Pharmacies and the Norwegian Pharmaceutical Society.

AUTHOR'S CONTRIBUTION: AL, OS and HN conceived the idea for the study and participated in its design and coordination. AL drafted the manuscript and analyzed the data. MJT, KZ, ACM, MEM, MD, AP, KHA, AR, RGJ, MO, DK, GR, HJ, AP and IB contributed to the data collection. All authors contributed to the interpretation of the results and revised the manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

COMPETING INTERESTS: None

DATA SHARING STATEMENT: No additional data are available. Researchers can apply for data access for subprojects within the overall aims of the main study 'The Multinational Medication Use in Pregnancy Study'.

REFERENCES

ACOG Committee Opinion No. 377: Research involving women. Obstet Gynecol 2007;110(3):731-6.

 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157(3):175-82.
 Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. [S.l.]: Lippincott

Williams & Wilkins 2011.

 Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205(1):51 e1-8.
 Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012;34(5):719-27.

6. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008;64(11):1125-32.

7. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;**65**(5):653-60.

8. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;**113**(5):559-68.

9. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009;65(8):839-46.
 10. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol 2003;59(2):127-33.

BMJ Open

e 27 of 109	BMJ Open	
	11. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during pregnancy in	
	developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011; 20 (9):895-902.	
	12. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in	
	pregnancy. J Clin Epidemiol 1993;46(6):581-89.	~
	13. McKenna L, McIntyre M. What over-the-counter preparations are pregnant women taking	;?
	A literature review. J Adv Nurs 2006; 56 (6):636-45.	
	14. Odalovic M, Vezmar Kovacevic S, Nordeng H, et al. Predictors of the use of medications	
	before and during pregnancy. Int J Clin Pharm 2013; 35 (3):408-16.	
	15. Martindale W, Sweetman SC. Martindale : the complete drug reference. London:	
	Pharmaceutical Press, 2011.	
	16. WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines for ATC	
	classification and DDD assignment 2013. Oslo, 2012. Available at:	
	http://www.whocc.no/atc_ddd_index/. Accessed 17 March, 2012.	
	17. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of Over-the-Counter Medications and	
	Herbal Remedies in Pregnancy. Amer J Perinatol 2005;22(EFirst):321,24.	
	18. Sawicki E, Stewart K, Wong S, et al. Medication use for chronic health conditions by	
	pregnant women attending an Australian maternity hospital. Aust N Z J Obstet Gynaecol	
	2011; 51 (4):333-38.	
	19. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley-Interscience	
	2000.	
	20. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications	
	and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66(2):207-14.	
	21. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from	
	the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;60(5):355-	
	61.	
	26	;

22. Medication during pregnancy: an intercontinental cooperative study. Collaborative Group on Drug Use in Pregnancy (C.G.D.U.P.). Int J Gynaecol Obstet 1992;**39**(3):185-96.

23. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000;**56**(4):323-8.

24. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAP study. Aust N Z J Obstet Gynaecol 2000;**40**(2):165-72.

25. Marín G, Cañas M, Homar C, et al. Uso de fármacos durante el período de gestación en embarazadas de Buenos Aires, Argentina. Rev salud pública 2010;**12**(5):722-31.

26. European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2010. Stockholm: ECDC, 2013.

27. Smith J, Refuerzo J, Ramin S. Treatment and outcome of nausea and vomiting of pregnancy. In: Basow D, ed. UpToDate. Waltham, MA: UpToDate, 2013.

28. Gadsby R, Barnie-Adshead T, Sykes C. Why won't doctors prescribe antiemetics in pregnancy? BMJ 2011;**343**:d4387.

29. Raymond SH. A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. Aust N Z J Obstet Gynaecol 2013.

30. Ross DS. Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment. In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate, 2013.

31. Lewis AJ, Bailey C, Galbally M. Anti-depressant use during pregnancy in Australia: findings from the Longitudinal Study of Australian Children. Aust N Z J Public Health 2012;**36**(5):487-8.

32. Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011;**72**(7):979-85.

BMJ Open

2
З
4
4
5
6
7
0
0
9
10
11
10
12
13
14
15
16
47
17
18
19
20
20
21
22
$\begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 2 \\ 13 \\ 4 \\ 15 \\ 16 \\ 17 \\ 18 \\ 9 \\ 20 \\ 12 \\ 23 \\ 4 \\ 25 \\ 27 \\ 28 \\ 9 \\ 01 \\ 33 \\ 34 \\ 35 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 21 \\ 23 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 21 \\ 23 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 33 \\ 34 \\ 35 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 21 \\ 23 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 33 \\ 34 \\ 35 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 21 \\ 23 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 21 \\ 23 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 33 \\ 34 \\ 35 \\ 6 \\ 7 \\ 8 \\ 9 \\ 01 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 $
24
27
25
26
27
28
20
29
30
31
32
22
33
34
35
36
27
37
38
39
40
41
42
43
44
45
46
47
48
49
49 50
51
52
53
53 54
55
56
57
58
59
60

33. Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010;**19**(4):408-17.

34. Olesen C, Thrane N, Henriksen TB, et al. Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women. Eur J Clin Pharmacol 2006;**62**(7):547-53.

35. Stokholm J, Schjorring S, Pedersen L, et al. Prevalence and Predictors of Antibiotic Administration during Pregnancy and Birth. PLoS One 2013;**8**(12):e82932.

36. Hameen-Anttila K, Jyrkka J, Enlund H, et al. Medicines information needs during pregnancy: a multinational comparison. BMJ Open 2013;**3**(4).

37. Ekman A, Dickman P, Klint Å, et al. Feasibility of Using Web-based Questionnaires in Large Population-based Epidemiological Studies. Eur J Epidemiol 2006;**21**(2):103-11.

38. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am J Epidemiol 2010;**172**(11):1292-8.

39. Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus. 2011; Available at: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-11-

066/EN/KS-SF-11-066-EN.PDF. Accessed 13 November, 2012.

40. Internet World Stats. Usage and population statistics. 2012; Available at:

http://www.internetworldstats.com/. Accessed 13 November, 2012.

41. Australian Bureau of Statistics. Household Use of Information Technology, Australia,

2010-11. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main

Features12010-11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-

11&num=&view=. Accessed 13 November, 2012.

42. Statistics Canada. Individual Internet use and E-commerce (2010). 2011; Available at: http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed 13 November, 2012.

43. United States Census Bureau. The 2012 Statistical Abstract. Information &

Communications: Internet Publishing and Broadcasting and Internet Usage. 2010; Available

at:

http://www.census.gov/compendia/statab/cats/information_communications/internet_publishi ng_and_broadcasting_and_internet_usage.html. Accessed 13 November, 2012.

Page 31 of 109

BMJ Open

2	
3	Medication use in pregnancy: a multinational perspective
4	
5	
6	Lupattelli A, ¹ Spigset O, ^{2,3} Twigg MJ, ⁴ Zagorodnikova K, ⁵ Mårdby AC, ⁶ Moretti ME, ⁷ Drozd M, ⁸ Panchaud A, ⁹ <u>Hämeen-Anttila Hameen-Anttila</u> -K, ¹⁰ Rieutord A, ¹¹ Gjergja Juraski R, ¹² Odalovic M, ¹³ Kennedy D, ¹⁴ Rudolf G, ¹⁵ Juch H, ¹⁶ Passier JLM, ¹⁷
7	MF^{7} Drozd M ⁸ Panchaud A ⁹ Hämeen Anttila Hameen Anttila K ¹⁰ Rieutord A ¹¹
8	Giergia Juraski R ¹² Odalovic M ¹³ Kennedy D ¹⁴ Rudolf G ¹⁵ Juch H ¹⁶ Passier II M ¹⁷
9	Björnsdóttir I, ¹⁸ Nordeng H ^{1,4918} .
10	bjoinsdouil I, Nordelig H .
11	
12	¹ School of Pharmacy, University of Oslo, Norway
13	² Department of Clinical Pharmacology, St Olav's University Hospital, Trondheim,
14	Norway
15	³ Department of Laboratory Medicine, Children's and Women's Health, Norwegian
16	
17	University of Science and Technology, Trondheim, Norway
18 19	⁴ School of Pharmacy, University of East Anglia, Norwich Research Park, United
20	Kingdom
21	⁵ Northwest Medical Center for Drug Safety in Pregnancy & Lactation, Northwest
22	
23	State Medical University n.a.I.I.Mechnikov, St. Petersburg, Russia
24	⁶ Department of Public Health and Community Medicine, The Sahlgrenska Academy,
25	University of Gothenburg, Gothenburg, Sweden
26	⁷ The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The
27	Hospital for Sick Children, University of Toronto, Ontario, Canada
28	
29	⁸ Faculty of Pharmacy, Medical University of Lublin, Poland
30	⁹ School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva,
31	Switzerland
32	¹⁰ Finnish Medicines Agency, Kuopio, Finland
33	¹¹ APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacie, Clamart France and
34	Européenne de Formation pour les Pharmaciens, France
35	¹² Children's Hospital Srebrnjak, Neuropediatric Unit, Zagreb, Croatia
36 37	
38	¹³ Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of
39	pharmacy, University of Belgrade, Serbia
40	¹⁴ MotherSafe, Royal Hospital for Women and University of NSW, Randwick,
41	Australia
42	¹⁵ Clinical Institute of Medical Genetics, University Medical Centre Ljubljana,
43	
44	Slovenia
45	¹⁶ Research Unit Human Teratogens, Institute for Cell Biology, Histology and
46	Embryology, Medical University of Graz, Austria
47	¹⁷ Teratology Information Service (TIS), Netherlands Pharmacovigilance Centre
48	Lareb, the Netherlands
49	
50	¹⁸ University of Iceland
51	¹⁸⁹ Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway
52 52	
53 54	
54 55	Corresponding author:
56	
57	Angela Lupattelli, MScPharm,
~ .	

Department of Pharmacy, School of Pharmacy, University of Oslo,

PO Box 1068 Blindern, 0316 Oslo, Norway

e-mail: angela.lupattelli@farmasi.uio.no; phone: +47 41343628 ; fax: +4722854402

Key words: pregnancy; drug utilization, maternal health; health behaviour; public

health

 Word count (excluding title page, abstract, references, figures and tables): 3571

ABSTRACT

Objectives: Inter-country comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and factors associated with medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilized and indication for use.

Design: Cross-sectional, internet-based study performed within the period from 1-Oct-2011 to 29-Feb-2012. Uniform collection of drug utilization data was performed via an anonymous online questionnaire.

Setting: Multinational study in Europe (Western, Northern, and Eastern), North and South America, and Australia.

Participants: Pregnant women and new mothers with children less than one year of age.

Primary and secondary outcome measures: Prevalence and factors associated with medication use for acute/short-term illnesses, chronic/long-term disorders and over-the-counter (OTC) medication use.

Results: The study population included 9,459 women whereof 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. Overall, OTC medication use occurred in 66.9% of the pregnancies, whereas 68.4% and 17.0% of women reported use of at least one medication for treatment of acute/short-term illnesses and chronic/long-term disorders, respectively. The extent of self-reported

medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting use of <u>medication for</u> <u>chronic/long-term ehronic medicationdisorders</u>. Immigrant women in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83) were less likely to report <u>use of medication for chronic/long-term disorders chronic</u> <u>medication use during pregnancy than non-immigrants</u>.

Conclusions:

In this study, the majority of women in Europe, North America, South America and Australia used at least one medication during pregnancy. There was a substantial inter-region variability in the types of medication used.

ARTICLE SUMMARY

Strengths and limitations of this study

- Uniform data collection of drug utilization data across all participating countries allows for inter-country comparability of the prevalence of medication use during pregnancy, up to now impeded by differences in study design and methodology.
- The study adds a multinational perspective on OTC medication use during pregnancy to the limited number of studies quantifying the extent of self-medication during pregnancy.
- Lack of validity of the self-reported diagnoses is a limitation since all disorders and related medication use were self-reported by the study participants.
- An internet survey as a study method impedes calculation of a conventional response rate and may cause selection bias of the target population.

FUNDING STATEMENT

This work was supported by the Norwegian Research Council grant number

216771/F11 and by the Foundation for Promotion of Norwegian Pharmacies and the

Norwegian Pharmaceutical Society.

COMPETING INTERESTS: None declared

INTRODUCTION

Ethical reasons preclude inclusion of pregnant women in the vast majority of premarketing clinical trials.[1] As a consequence, most medications are placed onto the market without a directly established safety profile in human pregnancy.[2] So far, few medications have been shown to be major teratogens, yet the risk of minor teratogenicity or of more subtle effects on fetal development still have to be determined for most of them.[3] Despite this, medication use during pregnancy is common. Mitchell et al. found that use of medications, either prescribed or purchased over-the-counter (OTC), occurred in 88.8% of all pregnancies in the USA.[4] In Europe, prevalence estimates of prescribed medication use vary considerably across countries, ranging from 26% in Serbia to 93% in France.[5-10] Such inter-country variability could, at least in part, be caused by differences in study design, methodology and exposure ascertainment across studies.[11] Uniform collection of drug utilization data during pregnancy between countries may overcome such drawbacks, allowing for inter-country comparability of prevalence estimates and shedding light on differences in prenatal care in the various countries.

Prior studies have addressed research priorities in this area such as presenting results on an individual drug level according to the indication of use, quantifying the extent of OTC and prescribed medication use during pregnancy, and taking into account inter-country comparability.[4] Only a few studies have individually examined maternal factors associated with specific types of medication use during pregnancy.[11-14]

The objectives of the current study were to examine patterns of medication use in pregnancy from a multinational perspective, with special emphasis on type of medication utilized, including OTC medications, and self-reported indications for use, and to identify maternal background factors potentially associated with medication use for acute/short-term illnesses, medication use for chronic/long-term disorders and OTC medication use during pregnancy.

METHODS

Study design and data collection

This is a multinational, cross-sectional, internet-based study. Pregnant women at any gestational week and mothers with children less than one year of age were eligible to participate. Member countries of the European Network of Teratology Information Services (ENTIS), The Organization of Teratology Information Specialists (OTIS) in North America, MotherSafe in Australia and European institutions conducting public health research were invited to take part in the project. Of these, 18 countries participated (Australia, Austria, Canada, Croatia, Finland, France, Iceland, Italy, Netherlands, Norway, Poland, Russia, Serbia, Slovenia, Sweden, Switzerland, United Kingdom and USA). Data originating from some South and Central American countries were also collected through OTIS. Because of the low number of participants on the individual country level, the region of Central America was excluded and countries in South America were aggregated into one region. Data selection to achieve the final study sample was performed as depicted in Figure 1. Participants were categorized according to the reported country of residency and grouped into six regions: Western Europe, Northern Europe, Eastern Europe, North America, South America and Australia.

Data were collected through an anonymous on-line questionnaire administered by Quest Back (http://www.questback.com) and accessible for a period of two months in each participating country within the period 1-Oct-2011 to 29-Feb-2012. The complete questionnaire is presented in Appendix 1. The questionnaire was open to the public via utilization of banners (invitations to participate in the study) on national websites and/or social networks commonly visited and consulted by pregnant women and/or new mothers. Detailed information about recruitment tools utilized and internet penetration rates is summarized in Appendix 2.

The questionnaire was first developed in Norwegian and English and then translated into the other relevant languages. A pilot study was carried out in September 2011 (n=47) and elicited no major change to the questionnaire. Collected data were scrutinized for the presence of potential duplicates (based on reported country of residency, socio-demographic characteristics, date and exact time of questionnaire completion) but none were identified.

Exposure variables

Maternal socio-demographics (i.e. region of residency, age, educational level, mother tongue, working status at time of conception, previous children, marital status and unplanned pregnancy) and life-style characteristics (i.e. smoking status before and during pregnancy and alcohol consumption after awareness of pregnancy) constituted the exposure variables. To assess external validity, we compared socio-demographic and life-style characteristics of our study population on an individual country level with those of the general birthing population in the same country. Reports of National Statistics Bureaus or previous national studies were utilized for this purpose. The ratio

between the number of respondents and the estimated number of live births in the 2months period was also examined for each country (Appendix 3).

Outcome variables

Use of any medication, prescribed medication for acute/short-term illnesses, medication for chronic/long-term disorders and OTC medication use during pregnancy constituted the outcome variables. Participants were first confronted with a list of the most common acute/short-term illnesses (i.e. nausea, heartburn, constipation, common cold, urinary tract infections (UTIs), other infections, pain in the neck/back/pelvic girdle, headache, sleeping problems) and the most prevalent chronic/long-term disorders (i.e. asthma, allergy, hypothyroidism, rheumatic disorders, diabetes, epilepsy, depression, anxiety, cardiovascular disease, other disorders) and asked whether they suffered/had suffered from these conditions during pregnancy. In case of an affirmative response, women were questioned about medication use for each individual indication as a free-text entry. Use of OTC medications was also recorded. Recall was aided with a list of five OTC medication categories: painkillers, nasal spray/drops, antinauseants, antacids and laxatives, along with examples of brand name products of relevance in each country. It was optional to report timing of exposure for each of the medication use questions (the alternatives were gestational weeks 0-12 (1st trimester), 13-24 (2nd trimester) and 25-delivery (3rd trimester)).

We defined a medicine as a single product containing one or more active ingredients. We initially identified the main active ingredient(s) and formulation of the reported medicinal products either in the relevant national medicines database or in the "Martindale" textbook.[15] All recorded medications were coded into the corresponding Anatomical Therapeutic Chemical (ATC) codes at the ATC 5th level

BMJ Open

(i.e. the substance level) whenever possible, otherwise into the 2nd- 4th levels as appropriate, in accordance with the World Health Organization ATC index.[16] The OTC status of medications was crosschecked with the prescription policies within each country. Whenever a prescription medication was reported under the OTC question, this record was omitted from the analysis of OTC use but counted in the estimation of total medication use (including prescription and OTC). Iron, mineral supplements, vitamins, herbal remedies and any type of alternative medicine were recorded separately and excluded from the estimation of medication use.

The required sample size calculation for the outcome variables on region and individual country levels are outlined in Appendix 4. The expected prevalence estimates were set according to results of previous studies.[5-10,17,18]

Ethics

All participants gave informed consent by answering "Yes" to the question "Are you willing to participate in the study?" The study was approved by the Regional Ethics Committee, Region South-East in Norway. Ethical approval or study notification to the relevant national Ethics Boards was achieved in specific countries as required by national legislation. All data were handled and stored anonymously.

Statistical analysis

Descriptive statistics were utilized as appropriate. Univariate and multivariate logistic regression analyses were used to examine the association between maternal characteristic and three categorical outcome measures (Yes/No): Medication use for acute/short-term illnesses; medication use for chronic/long-term disorders; OTC medication use. P-values of <0.05 were considered statistically significant. Data are

presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). The analyzed explanatory variables included all maternal socio-demographics and lifestyle characteristics. After fitting the univariate logistic regression model for all explanatory variables, the multivariate model was built and adjusted for all remaining covariates. The Hosmer and Lemeshow test was used to assess goodness of fit of the final multivariate model.[19] Analogue sub-analyses on individual region level were performed. In these instances, region of residency was not included in the model. All statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM[®] SPSS[®] Statistics).

RESULTS

Population characteristics

A total of 9,615 women accessed the on-line questionnaire whereof 98.6% completed it. The participant flow-chart to achieve final study population (n=9,459) is depicted in Figure 1. A total of 5,089 women (53.8%) were pregnant at the time of completion of the questionnaire, whereas 4,370 women (46.2%) had delivered their babies within the previous year. Of the former group, 1,095 (21.5%), 1,702 (33.4%) and 2,291 (45.0%) women were in the first, second and third trimester of pregnancy, respectively. Of the latter group, 1,320 (30.2%), 947 (21.7%) and 2,102 (48.1%) had a baby of age \leq 16 weeks, 17-28 weeks, and \geq 29 weeks, respectively. For two women the time of gestation/baby's age was unknown. Overall, the birthing population in each participating country was reflected quite well by the sample with respect to age, parity and smoking habits (Appendix 3). However, there was a difference in terms of educational level; on average, the women in the study had higher education than the general birthing population in each country. In addition, participants in Sweden,

Austria, Iceland and Italy were slightly more often primiparous, whereas the responders in Australia, USA, The Netherlands, Slovenia and Croatia were somewhat older than the general birthing population.

Total medication use

After exclusion of vitamins, mineral supplements and iron, use of at least one medication either prescribed or OTC at any time during pregnancy was reported by 7,678 out of 9,459 women (81.2%). Figure 2 depicts prevalence estimates of total medication use during pregnancy by region and country of residence, with specific rates according to inclusion or exclusion of vitamins, mineral supplements and iron. The extent of OTC_-medication use, as well as medication use for acute/short-term illnesses and chronic/long-term disorders use is also outlined. The highest prevalence of total medication use during pregnancy was observed in The Netherlands (95.1%), Iceland (93.0%) and Finland (92.3%). The overall prevalence estimates of medication use in pregnancy according to timing and drug class (ATC level 1 and 2) are presented in Appendix 5. Medications for the nervous system (ATC class N) were the most commonly used during pregnancy (57.5%), mostly due to paracetamol (acetaminophen) and its combinations.

A corollary analysis according to pregnancy status showed that pregnant women reported in a significantly lower degree than new mothers any medication use during pregnancy (78.8% vs. 84.0%, p-value<0.001), as well as OTC medication use (63.0% vs. 71.5%, p-value<0.001) and medication use for acute/short-term illnesses (66.2% vs. 70.9%, p-value<0.001). In contrast, the difference in medication use for chronic/long-term disorders was not significant (17.4% vs. 16.5%, p-value=0.271). None of the rates differed significantly when women in the third trimester of pregnancy were compared to new mothers.

Medication use according to indication

Headache, heartburn, pain, nausea and UTIs constituted the leading indications for use of medication during pregnancy among the acute/short-term illnesses analyzed. Hypothyroidism, asthma, allergy and depression were the leading indications for chronic/long-term medication use. Observed prevalence rates of these disorders, overall and by region of residency, are presented in Appendices 6 and 7, respectively, along with rates of total and specific medication use. Table 1 outlines prevalence estimates of OTC medication use during pregnancy by region and indication for use. Only the most common medication groups reported are presented. Inter-region variations in rates and types of medication used during pregnancy were observed both for acute/short-term illnesses (e.g. nausea and UTIs), chronic/long-term disorders (e.g. asthma and depression) and OTC medications (e.g. nasal spray).

Factors associated with medication use

Factors associated with medication use during pregnancy according to type of medication utilized are presented in table 2. Use of chronic/long-term medications during pregnancy was reported in a significant larger extent by women in Northern Europe (aOR:1.68, 95% CI:1.46-1.94), North America (aOR:1.80, 95% CI:1.42-2.28) and Australia (aOR:2.76, 95% CI:2.03-3.76) compared to women in Western Europe. Older women or housewives, those with low education or with an unplanned pregnancy, were the ones most often reporting use of chronic/long-term medication. Sub-analysis on individual region level revealed that women not having the official

1	
2	
3	language of the country of residency as mother tongue were less likely to report
4	
5	chronic/long-term medication use in Western (aOR: 0.55, 95% CI: 0.34-0.87) and
6	
7	Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83), but not in the other regions.
8	
9 10	
11	
12 13	
13	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39 40	
40	
42	
42 43	
43	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
	For poor roviow only - http://bmiopon.hmi.com/site/shout/guidelines.yhtml

Table 1: Use of OTC medication at any time during pregnancy by ATC level, indication for use and region (n=9,459) **

	REGION						
OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n (%)</i>	Northern Europe n=2,820 <i>n</i> (%)	Eastern Europe n=2,342 <i>n (%)</i>	North America n=533 n (%)	South America n=346 n (%)	Australian n=217 n (%)	Total n=9,459 n (%)
OTC painkillers, total	1,714 (53.5)	1,773 (62.9)	734 (31.3)	284 (53.3)	127 (36.7)	151 (69.9)	4,783 (50.6
By drug group		, , , , , , , , , , , , , , , , , , ,					
Paracetamol (incl. combinations) (N02BE)	1,655 (51.7)	1,735 (61.5)	630 (26.9)	263 (49.3)	87 (25.1)	146 (67.3)	4,516 (47.7
Non-steroideal antiinflammatory drugs (M01A)	70 (2.2)	182 (6.5)	68 (2.9)	40 (7.5)	59 (17.1)	7 (3.2)	426 (4.5)
Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	11 (0.4)	32 (1.4)	2 (0.4)	2 (0.6)	1 (0.5)	55 (0.6)
Metamizole (N02BB02)	-	6 (0.2)	31 (1.3)	1 (0.2)	12 (3.5)	-	50 (0.5)
OTC antacids, total	1,011 (31.6)	883 (31.3)	583 (24.9)	129 (24.2)	48 (13.9)	76 (35.0)	2,730 (28.9
By drug group							
Antacids (aluminium, salts combinations, antiflatulents)	472 (14.7)	550 (19.5)	508 (21.7)	47 (8.8)	36 (10.4)	54 (24.9)	1,667 (17.6
Alginic acid complex/sucralfate/bismuth (A02BX)	606 (18.9)	421 (14.9)	87 (3.7)	4 (0.8)	1 (0.3)	17 (7.8)	1,136 (12.0
H ₂ receptor antagonists (A02BA)	20 (0.6)	20 (0.7)	16 (0.7)	57 (10.1)	10 (2.9)	17 (7.8)	137 (1.4)
Antacids with calcium (A02AC)	23 (0.7)	12 (0.4)	10 (0.4)	69 (12.9)	2 (0.6)	10 (4.6)	126 (1.3)
Proton pump inhibitors (A02BC)	38 (1.2)	52 (1.8)	-	10 (1.9)	2 (0.6)	5 (0.3)	107 (1.1)
OTC nasal sprays/drops, total	272 (8.5)	742 (26.3)	451 (19.3)	35 (6.6)	7 (2.0)	14 (6.5)	1,521 (16.1
By drug group							
Sympathomimetic nasal decongestants (R01AA/R01BB)	204 (6.4)	683 (24.2)	365 (15.6)	20 (3.8)	3 (0.9)	4 (1.8)	1,279 (13.5
Nasal corticosteroids (R01AD)	31 (1.0)	49 (1.7)	12 (0.5)	5 (0.9)	2 (0.6)	10 (4.6)	109 (1.2)
Nasal immunostimulants (low dose interferon) (L03A)	-	-	28 (1.2)	-	-	-	28 (0.3)
OTC laxatives, total	240 (7.5)	227 (8.0)	237 (10.1)	50 (9.4)	8 (2.3)	19 (8.8)	781 (8.3)
By drug group							
Osmotically acting laxatives (A06AD)	159 (5.0)	171 (6.1)	197 (8.4)	2 (0.4)	2 (0.6)	8 (3.7)	539 (5.7)
Contact laxatives (A06AB)	28 (0.9)	44 (1.6)	18 (0.8)	7 (1.3)	6 (1.7)	2 (0.9)	105 (1.1)
							16

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

			REG	ION			
OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n (%)</i>	Northern Europe n=2,820 <i>n</i> (%)	Eastern Europe n=2,342 <i>n</i> (%)	North America n=533 n (%)	South America n=346 <i>n</i> (%)	Australian n=217 n (%)	Total n=9,459 <i>n (%)</i>
Enemas (A06AG)	3 (0.1)	25 (0.9)	34 (1.5)	4 (0.8)	-	2 (0.9)	68 (0.7)
Softeners, emollients (A06AA)	8 (0.2)	-	-	38 (7.1)	-	6 (2.8)	52 (0.5)
OTC antinauseants, total	263 (8.2)	273 (9.7)	41 (1.8)	60 (11.3)	28 (8.1)	40 (18.4)	705 (7.5)
By drug group							
First generation antihistamines (R06A)	141 (4.4)	256 (9.1)	7 (1.5)	55 (10.3)	5 (1.4)	5 (2.3)	469 (5.0)
Metoclopramide/domperidone/bromopride (A03FA)	113 (3.5)	5 (0.2)	18 (0.8)	2 (0.4)	19 (5.5)	27 (12.4)	184 (1.9)
Total OTC medication use	2,163 (67.6)	2,155 (76.4)	1,347 (57.5)	342 (64.2)	156 (45.1)	168 (77.4)	6,331 (66.9)

*Countries are grouped into regions as shown in Figure 1.

*Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, and herbal or alternative medicine products.

Abbreviations: OTC: Over-The-Counter medications.

			Medi	cation use		
		For acute/short-term illnesses (n=6,469)		For chronic/long-term disorders (n=1,604)		OTC =6,331)
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)
Region of residency [†]						
Western Europe	2,224 (69.5)	Reference	462 (14.4)	Reference	2,163 (67.6)	Reference
Northern Europe	1,954 (69.3)	0.96 (0.86-1.08)	593 (21.0)	1.68 (1.46-1.94)	2,155 (76.4)	1.54 (1.36-1.74
Eastern Europe	1,474 (62.9)	0.69 (0.61-0.78)	322 (13.7)	1.03 (0.87-1.21)	1,347 (57.5)	0.60 (0.53-0.67
North America	403 (75.6)	1.28 (1.03-1.60)	119 (22.3)	1.80 (1.42-2.28)	342 (64.2)	0.81 (0.66-0.99
South America	250 (82.3)	1.03 (0.79-1.34)	38 (11.0)	0.70 (0.48-1.01)	156 (45.1)	0.34 (0.27-0.44
Australia	164 (75.6)	1.29 (0.93-1.79)	70 (32.3)	2.76 (2.03-3.76)	168 (77.4)	1.57 (1.12-2.20
Maternal age (years)						
≤20	232 (70.5)	1.22 (0.93-1.60)	761 (14.7)	0.58 (0.39-0.87)	205 (62.3)	1.05 (0.81-1.36
21-30	3,531 (68.2)	Reference	33 (10.0)	Reference	3,461 (66.8)	Reference
31-40	2,576 (68.6)	0.90 (0.82-1.00)	764 (20.4)	1.44 (1.27-1.63)	2,531 (67.4)	0.85 (0.77-0.94
<u>≥</u> 41	130 (66.3)	0.73 (0.54-1.00)	46 (23.5)	1.61 (1.13-2.29)	134 (68.4)	0.86 (0.62-1.19
Previous children						
No	3,082 (65.5)	Reference	735 (15.6)	Reference	2,949 (62.6)	Reference
Yes	3,387 (71.3)	1.34 (1.22-1.47)	869 (18.3)	1.08 (0.96-1.21)	3,382 (71.2)	1.58 (1.44-1.74
Marital status						
Married/cohabiting	6,066 (68.5)	Reference	1,503 (17.0)	Reference	5,960 (67.3)	Reference
Single/divorced/others	403 (66.3)	0.91 (0.75-1.10)	101 (16.6)	1.06 (0.83-1.35)	371 (61.0)	0.91 (0.75-1.10
Working status						
Employed, but not as HCP	3,737 (66.8)	Reference	905 (16.2)	Reference	3,667 (65.6)	Reference
HCP	934 (74.4)	1.41 (1.23-1.63)	240 (19.1)	1.13 (0.96-1.33)	944 (75.2)	1.42 (1.23-1.64
Student	592 (69.1)	1.11 (0.94-1.31)	128 (14.9)	1.04 (0.84-1.30)	578 (67.4)	1.10 (0.93-1.30
Housewife	608 (72.6)	1.14 (0.96-1.35)	170 (20.3)	1.34 (1.10-1.63)	577 (68.9)	1.05 (0.88-1.24
Job seeker	281 (66.0)	0.96 (0.78-1.20)	66 (15.5)	1.03 (0.78-1.36)	258 (60.6)	0.85 (0.68-1.05
Other than above	311 (65.2)	0.91 (0.75-1.12)	94 (19.7)	1.29 (1.01-1.65)	302 (63.3)	0.91 (0.74-1.12
Educational level						

Table 2: Factors	associated w	with medication 1	ise in nreonai	$ncv (n=9.459)^*$
Table 2. Factors	associated w		ise ili pregnai	ICY (II-2,432)

			Medi	ication use		
	For acute/short-term illnesses (n=6,469)			ong-term disorders =1,604)	OTC (n=6,331)	
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)
Less than high school	331 (72.7)	1.17 (0.93-1.49)	92 (20.2)	1.51 (1.15-1.97)	317 (69.7)	1.32 (1.04-1.67)
High school	1,864 (68.7)	Reference	428 (15.8)	Reference	1,779 (65.6)	Reference
More than high school	3,574 (68.4)	0.99 (0.89-1.11)	916 (17.5)	1.04 (0.91-1.20)	3,489 (66.8)	1.07 (0.96-1.19)
Others, unspecified	700 (65.7)	0.82 (0.70-0.96)	168 (15.8)	0.94 (0.77-1.16)	746 (70.0)	1.13 (0.97-1.33)
Alcohol use after awareness of pregn	ancy					
No	5,270 (67.1)	Reference	1,322 (16.8)	Reference	5,133 (65.3)	Reference
Yes	1,144 (75.7)	1.59 (1.39-1.81)	270 (17.9)	1.11 (0.95-1.29)	1,150 (76.1)	1.95 (1.71-2.23)
Smoking during pregnancy						
No	5,835 (68.5)	Reference	1,441 (16.9)	Reference	5,716 (67.0)	Reference
Yes, but less than before pregnancy Yes, the same or more than before	530 (69.0)	1.08 (0.91-1.27)	130 (16.9)	1.01 (0.82-1.25)	511 (66.5)	1.06 (0.90-1.26)
pregnancy	88 (67.7)	0.95 (0.64-1.40)	28 (21.5)	1.19 (0.74-1.90)	89 (68.5)	1.21 (0.81-1.82)
Planned pregnancy						× .
Yes	5,836 (68.4)	Reference	1,427 (16.7)	Reference	5,727 (67.2)	Reference
No	616 (68.4)	0.96 (0.82-1.12)	173 (19.2)	1.29 (1.06-1.56)	587 (65.1)	1.00 (0.85-1.17
First language different from the off	· · · ·	age in the country of				~
No	6,089 (68.5)	Reference	1,530 (17.2)	Reference	5,972 (67.1)	Reference
Yes	363 (67.2)	0.93 (0.76-1.12)	71 (13.1)	0.66 (0.50-0.86)	347 (64.3)	0.89 (0.74-1.08

Abbreviation: HCP: health care provider.

*Numbers may not add up due to missing values. Missing values are less than 5% of the total. Mineral supplements, vitamins, iron, herbal or alternative medicine products are not included in the medication use estimates.

[†]Countries are grouped into regions as shown in Figure 1.

DISCUSSION

This is the first internet-based study examining patterns and factors associated with medication use during pregnancy on a multinational level. In specific countries (Australia, Canada, France, Russia, The Netherlands, and the USA) the study sample was a small proportion of the general birthing population; hence the generalizability of our findings for these specific countries should be interpreted with caution. In all regions, approximately eight out of ten women reported use of at least one medication, either prescribed or OTC, during the course of their pregnancy. This finding is in line with previous research conducted in Europe, North America, South America and Australia,[4,20-25] though our estimates were somewhat higher in some of the Eastern European countries, e.g. Serbia, than those observed in a previous study.[5] Different recruitment strategies, i.e. internet-based in our study versus maternity care unit-/community pharmacy-based in the previous study could explain such discrepancy.

Overall, analgesics, antacids, nasal decongestants/antiallergics and systemic antibiotics were the medication groups dominating the drug utilization scenario, as also shown by previous research.[4,20-22] However, our study also provides insights into the proportion of medicated women among those suffering from a specific illness during pregnancy across the six regions. We found that approximately seven out of ten women who reported UTIs were treated with antibiotics during pregnancy. This related to all regions, except Eastern Europe where it was only four out of ten women. Since women may perceive dysuria without ascertainment of bacteriuria in the urine as UTI, an over-reporting of the illness could have occurred. Yet, a sub-optimal treatment of UTIs during pregnancy in Eastern Europe cannot be ruled out. The inter-country variability in the types of antibiotics used for UTIs could simply be explained by

BMJ Open

differences in prescribing practice, [26] presence of screening for bacteriuria in early pregnancy, or specific antibiotic resistance patterns.

Even though nausea was the condition affecting most women in all six regions, the corresponding proportions of medicated nausea were generally low. This scenario is probably due to two main factors: a) the predominantly mild character of nausea and the possibility of non-pharmacological management (e.g. dietary advices); b) the reluctance of general practitioners to prescribe antinauseants even though safety profile assessments are in place.[27,28] As also shown in previous studies,[4,29] use of serotonin antagonists in North America and Australia is increasing also in pregnancy compared to the other regions, eliciting the need of sound studies assessing the safety profile of this drug group in pregnancy.

In most regions, the self-reported prevalence of hypothyroidism was somewhat higher than the reported hormone substitution rate. Because of its known association with adverse pregnancy outcomes,[30] the unexpected finding of potential sub-optimal treatment of hypothyroidism during pregnancy deserves attention. It could probably be due to a lack of information about hypothyroidism typology and its diagnostic ascertainment in our study.

In our study, depression was self-reported and not based on any psychometric assessment, thus the observed substantial inter-regional variability in the extent of this disorder and related medication use could have certainly been affected by women's attitudes in reporting. Our estimate of medication use for depression in Australia was higher than that observed in a recent study (10.6% versus 2.1%).[31] However, the similarity in self-reported depression itself (11.5% versus 15.6%) suggests that our population might mostly comprise women who did not discontinue their pharmacological therapy once they became pregnant. Our estimates for North America and Western Europe were in line with recent literature showing an increase in antidepressant use in pregnancy during the last years.[4,32]

In most regions approximately 60-70% of women reported use of at least one OTC medication during the course of their pregnancy, mostly for pain conditions, heartburn and upper airways disorders, indicating a substantially high rate of self-medication during pregnancy. This estimate aligns with previous research carried out in North America.[17] Of note, self-medication with OTC sympathomimetic nasal decongestants was more extensive in Northern and Eastern Europe than in the remaining regions; this could be explained by the time of the year when the data collection was performed.

Region of residency was an important factor associated with medication use during pregnancy. As also shown by Cleary et al.,[33] we found that rates of medication use among women originally from Eastern Europe and South America were significantly lower than those observed in Western Europe, North America and Australia. Such geographical differences could be due to culture, variations in prenatal care assistance or access to medications in the various regions and the related costs.

Women working as health care providers, those consuming alcohol during pregnancy and those with previous children were those more likely to use short-term and OTC medications, possibly reflecting higher confidence in self-treatment and use of medications in general in the former instance, and less anxiety for the pregnancy outcome in the latter two instances. Contrary to previous studies indicating an association between higher maternal education and more prevalent use of medication during pregnancy,[14,17,23] we found that lower education was associated with a higher use of OTC medications as well as medication for chronic/long-term disorders (30-50% increased risk). Results of similar magnitude (30% increased risk) were also observed by Olesen et al.[34], whereas Stokholm et al. [35] identified a stronger association (2.3-fold increased risk) between low maternal education and use of antibiotic for respiratory tract infections during pregnancy. One factor negatively associated with

BMJ Open

chronic/long-term medication use was not having the official language of the country of residency as mother tongue. This tendency was detected in Western and Northern Europe, rising concerns about the potential health risks for immigrant women in these two regions. As shown by Hameen-Anttila et al., 57% of pregnant women have perceived information needs about medications during pregnancy.[36] Thus, identification of potential users or non-users of medication during pregnancy might be of clinical relevance, allowing tailored evidence-based information about medication safety or outcome of sub-optimal medication of severe medical conditions in pregnancy.

Strengths and limitations

The main strength is that data collection was performed uniformly across all participating countries, allowing for inter-country comparison of the prevalence of medication use during pregnancy. By quantifying the extent of self-medication with OTC drugs and medication use according to self-reported indication, it was possible to determine the leading causes for medication use among pregnant women. Categorization of maternal characteristics positively associated with the various types of medications used during pregnancy enabled us to identify which groups of women are more likely to need information about medication use during pregnancy. The utilization of an anonymous web-based questionnaire enabled us to reach a large proportion of the birthing population in several countries worldwide. However, we cannot exclude the possibility that the women who decided to participate in the study differed from the general birthing population in other ways that our analysis could not control for. In most participating countries the study sample was large enough to warrant calculation of prevalence estimates with a precision of 5%. However, less precise estimates were permitted by the study sample in Austria, Iceland and The Netherlands (precision of 9-11%), as well as in Australia, Canada, Croatia, Serbia, Slovenia, and USA (precision of 6-7%).

One main limitation of the study is the lack of validity of the self-reported diagnoses. All disorders were self-reported by the participants and hence dependent on the women's perception of the medical condition. Similarly, information about medication use during pregnancy was dependent on the accuracy of the women's reporting and recall. For new mothers, data were registered retrospectively; hence a risk of recall bias cannot be ruled out. In specific countries (Australia, Canada, France, Russia, The Netherlands, and the USA) the study sample was a small proportion of the general birthing population; hence the generalizability of our findings for these specific countries should be interpreted with caution.

The questionnaire was only available through internet websites; by using this kind of approach a conventional response rate cannot be calculated and a selection bias of the target population cannot be ruled out. However, recent epidemiological studies indicate reasonable validity of web-based recruitment methods.[37,38] Also, the penetration rate of the internet either in households or at work is relatively high among women in childbearing age.[39-43] Hence, the degree to which our findings can be extrapolated to the target population is based on the representativeness of the respondents to the general birthing populations in each country. The sample in each country had a somewhat higher educational level than the general birthing populations. Such a limitation might have led to biased estimates of the association between maternal education and medication use during pregnancy. Since many ailments requiring pharmacotherapy occur in mid or late pregnancy, inclusion of pregnant women at early gestation in the total material has somewhat inflated the prevalence of non-users of medications during pregnancy. Also, women with specific disorders or in need of information about medication use during pregnancy might have been more likely to consult internet websites and therefore participate in this study.

CONCLUSIONS

Use of medications for acute/short-term illnesses and chronic/long-term disorders as well as use of OTC medications, were common during pregnancy. The extent of medicated illnesses and types of medications used for the different indications varied across the six regions. This was especially relevant for acute/short-term illnesses such as nausea and UTIs, but also for chronic/long-term disorders such as hypothyroidism or depression. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting use of chronic/long-term medication use, as opposed to i-and may therefore be more in need of information about medication during pregnancy. Moreover, maternal-fetal health among immigrants residing in Western and Northern Europe who reported the least use of this medication category. might be jeopardized. Future research should definitely focus on this specific group of women, but also address more insights into the outcome of sub-optimal medication of severe conditions in pregnancy.

ACKNOWLEDGMENTS

 We thank OTIS, ENTIS Scientific Board who reviewed the study protocol and all website providers who contributed to the recruitment phase. We are grateful to all the participating women who took part in this study.

AUTHOR'S CONTRIBUTION: AL, OS and HN conceived the idea for the study and participated in its design and coordination. AL drafted the manuscript and analyzed the data. MJT, KZ, ACM, MEM, MD, AP, KHA, AR, RGJ, MO, DK, GR, HJ, AP and IB contributed to the data collection. All authors contributed to the interpretation of the results and revised the manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

DATA SHARING STATEMENT: No additional data are available. Researchers can apply for data access for subprojects within the overall aims of the main study 'The Multinational Medication Use in Pregnancy Study'.

BMJ Open

REFERENCES

ACOG Committee Opinion No. 377: Research involving women. Obstet Gynecol 2007;110(3):731-6.

 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157(3):175-82.
 Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. [S.l.]: Lippincott Williams & Wilkins 2011.

 Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205(1):51 e1-8.
 Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012;34(5):719-27.

6. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008;64(11):1125-32.

7. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;**65**(5):653-60.

8. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;**113**(5):559-68.

9. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009;65(8):839-46.
 10. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol 2003;59(2):127-33.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

11. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011;20(9):895-902. 12. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy. J Clin Epidemiol 1993;46(6):581-89. 13. McKenna L, McIntyre M. What over-the-counter preparations are pregnant women taking? A literature review. J Adv Nurs 2006;56(6):636-45. 14. Odalovic M, Vezmar Kovacevic S, Nordeng H, et al. Predictors of the use of medications before and during pregnancy. Int J Clin Pharm 2013;35(3):408-16. 15. Martindale W, Sweetman SC. Martindale : the complete drug reference. London: Pharmaceutical Press, 2011. 16. WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines for ATC classification and DDD assignment 2013. Oslo, 2012. Available at: http://www.whocc.no/atc ddd index/. Accessed 17 March, 2012. 17. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of Over-the-Counter Medications and Herbal Remedies in Pregnancy. Amer J Perinatol 2005;22(EFirst):321,24. 18. Sawicki E, Stewart K, Wong S, et al. Medication use for chronic health conditions by pregnant women attending an Australian maternity hospital. Aust N Z J Obstet Gynaecol 2011;51(4):333-38. 19. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley-Interscience 2000. 20. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66(2):207-14. 21. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from

the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;**60**(5):355-61.

1	
2 3 4	22. Medica
4 5 6	on Drug U
7 8	23. Donati
9 10	Clin Pharm
11 12	24. Henry
13 14	study. Aus
15 16	25. Marín
17 18 19	embarazad
20 21	26. Europe
22 23	consumpti
24 25	27. Smith
26 27 28	pregnancy
29 30	28. Gadsby
31 32	pregnancy
33 34	29. Raymo
35 36 27	pregnancy
37 38 39	30. Ross D
40 41	treatment.
42 43	31. Lewis
44 45	findings fr
46 47	2012; 36 (5)
48 49 50	32. Peterse
50 51 52	discontinu
53 54	Network. J
55 56	
57 58	
59 60	

22. Medication during pregnancy: an intercontinental cooperative study. Collaborative Group on Drug Use in Pregnancy (C.G.D.U.P.). Int J Gynaecol Obstet 1992;**39**(3):185-96.

23. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000;**56**(4):323-8.

24. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAP study. Aust N Z J Obstet Gynaecol 2000;**40**(2):165-72.

25. Marín G, Cañas M, Homar C, et al. Uso de fármacos durante el período de gestación en embarazadas de Buenos Aires, Argentina. Rev salud pública 2010;**12**(5):722-31.

26. European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2010. Stockholm: ECDC, 2013.

27. Smith J, Refuerzo J, Ramin S. Treatment and outcome of nausea and vomiting of pregnancy. In: Basow D, ed. UpToDate. Waltham, MA: UpToDate, 2013.

28. Gadsby R, Barnie-Adshead T, Sykes C. Why won't doctors prescribe antiemetics in pregnancy? BMJ 2011;**343**:d4387.

29. Raymond SH. A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. Aust N Z J Obstet Gynaecol 2013.

30. Ross DS. Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment. In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate, 2013.

31. Lewis AJ, Bailey C, Galbally M. Anti-depressant use during pregnancy in Australia: findings from the Longitudinal Study of Australian Children. Aust N Z J Public Health 2012;**36**(5):487-8.

32. Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011;**72**(7):979-85.

33. Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010;**19**(4):408-17.

34. Olesen C, Thrane N, Henriksen TB, et al. Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women. Eur J Clin Pharmacol 2006;**62**(7):547-53.

35. Stokholm J, Schjorring S, Pedersen L, et al. Prevalence and Predictors of Antibiotic Administration during Pregnancy and Birth. PLoS One 2013;**8**(12):e82932.

36. Hameen-Anttila K, Jyrkka J, Enlund H, et al. Medicines information needs during pregnancy: a multinational comparison. BMJ Open 2013;**3**(4).

37. Ekman A, Dickman P, Klint Å, et al. Feasibility of Using Web-based Questionnaires in Large Population-based Epidemiological Studies. Eur J Epidemiol 2006;**21**(2):103-11.

38. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am J Epidemiol 2010;**172**(11):1292-8.

39. Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus. 2011; Available at: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-11-

066/EN/KS-SF-11-066-EN.PDF. Accessed 13 November, 2012.

40. Internet World Stats. Usage and population statistics. 2012; Available at:

http://www.internetworldstats.com/. Accessed 13 November, 2012.

41. Australian Bureau of Statistics. Household Use of Information Technology, Australia,

2010-11. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main

Features12010-11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-

11&num=&view=. Accessed 13 November, 2012.

BMJ Open

2	
2	
5	
4	
5	
3 4 5 6 7	
7	
8	
9	
10	
10	
11	
12	
13	
10	
14	
15	
16	
17	
17	
8 9 10 11 12 13 14 15 16 17 18 19 20	
19	
20	
20	
21	
20 21 22 23 24 25 26 27 28 29 30 21	
23	
24	
24	
25	
26	
27	
21	
28	
29	
30	
24	
31 32 33 34 35 36 37 38 39	
32	
33	
31	
34	
35	
36	
37	
00	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

42. Statistics Canada. Individual Internet use and E-commerce (2010). 2011; Available at: http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed 13 November, 2012.

43. United States Census Bureau. The 2012 Statistical Abstract. Information &

Communications: Internet Publishing and Broadcasting and Internet Usage. 2010; Available

at:

.ndia/sta _internet_usage. http://www.census.gov/compendia/statab/cats/information communications/internet publishi ng and broadcasting and internet usage.html. Accessed 13 November, 2012.




Figure 1 shows the participant flow-chart to achieve the final sample analyzed 60x45mm (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml




Figure 2 shows the proportion of respondents (%) reporting use of any medication, over-the-counter (OTC) medication, medication for acute/short-term illnesses and medication for chronic/long-term disorders during pregnancy according to region and country of residency. The observed estimates do not include vitamins, mineral supplements, iron, and herbal or alternative medicine products.

100x69mm (300 x 300 DPI)

Appendix 1: Survey questionnaire

Internet questionnaire

Medication use in pregnancy with focus on attitudes, perception of risk and mental health

The Multinational Medication Use in Pregnancy Study



. In which country do you live?	In which region/province do you live?
Country:	Region:
2. Are you pregnant right now?	<u> </u>
□ Yes	□ No
If yes in Q2) In which pregnancy week are	(If No in Q2) How old is your newborn
ou?	child (in weeks)?
From 1 to 44	0-4 / 5-8 / 9-12 / 13-16 / 17-20 /
	21-24 / 25-28 / > 29
If yes in Q2) Is it a multiple pregnancy?	(If No in Q2) Do you breast feed your
□ No	child?
\Box Yes (e.g. twins, triplets, etc)	
8. How many children do you already have	from before?
□ None	
□ One	
More than two	
. What is your marital status?	
□ Married	
□ Cohabitant	
□ Single	
□ Divorced/Separated	
	1.4 10
5. What is the highest education you have c_{0}	
\Box Primary school (8-9 years of education	
□ High-school (11-13 years of education	1)
□ Other education	
6. What was your work situation when you	became pregnant?
□ Student	1 0
□ Housewife	
□ Health care personnel, i.e., physician,	nurse, or pharmacist
□ Employed in another sector	
□ Job seeker	
\square None of the above	
. Is English your mother tongue?	
□ Yes	
□ No	
(If No in Q7 above) What is your mother	tongue?
8. Your age: Years, from 15 to 55	

INFORMATION ABOUT YOURSELF

INFORMATION ABOUT YOUR PREGNANCY

9.	(If pregnant) Are you	attendir	ng any j	pregna	ncy/birth	n prepa	ration	course or similar?
	\square No, but I am plan	ning to a	ttend					
	\square No, I am not goin							
10.	(If pregnant) What ar to be?			s about	how the	experi	ence of	giving birth is going
	ase indicate your though		cale fro	m 1 to 6	, where	1 corre	sponds	to absolutely terrible
	d 6 to absolutely fantas	1	2	2	4		(A1
Abs	solutely terrible		2	3	4	5	6	Absolutely fantastic
11	Was your pregnancy							
	□ Yes	plannea	•					
	D No, but it was not	complet	ely une	xpected	l			
	🗆 No, it was not pla							
12.	Did you contact any h	ealthcar	e provi	ider du	e to infer	tility?		
	\Box Yes							
	□ No							
	(If Ves in O12 abo	ve) Did	vou in	this nr	egnanev	hecom	e nreg	nant secondarily to
	infertility treatmen		you, m	tins pr	cgnancy	, becom	ic preg	nant secondarity to
	□ Yes							
	□ No							
13.	Have you taken folic a	ncid? (al	one or a	as part	of multi	vitamir	is)	
	\Box Yes, before pregn	2						
	\Box Yes, before and d	01	U	T				
	\Box Yes, only during \Box	pregnanc	y					
	$\Box \text{ No}$							
1/	□ cannot remember • Did you smoke cigare	ttas hafa	ro booc	minan	rognant	9		
14.	□ Yes, regularly	ttes belo	re becc	nning p	regnant	é		
	\Box Yes, occasionally							
	\square No, never							
		0	occasio	onally) l	Do you/d	id you	smoke	during pregnancy?
	\Box Yes, more than be							
	\Box Yes, approximate	ly the sai	ne					
	□ Yes, but less □ No							
	(If yes) How many	cigarette	es (on a	verage) do you/	did you	ı smoke	e per day?
	$\square < 1$	0		8°)	v	v		
	□ 1-5							
	□ 6-10							
4.00	$\Box > 11$	1 1 44	<i>(</i> 1 · 1 ·		(1 4			40
15.	Did you drink any alc	onol afte	er tindi	ng out	tnat you	were p	regnan	IT?
	□ Yes □ No							
	\Box Cannot remember	-						

1
2
2 3 4 5 6 7
4
5
6
7
0
0
7 8 9 10
10
11
12
13
14
15
16
17
18
19
20
21
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
22 22
23
24
25
26
27
28
28 29 30
30
31
32
33
34
35
34 35 36 37 38
27
31
38 39
40
41
42
43
44
45
46
47
48
49
50
50 51
52
5∠ 53
55
54
55
56
57
58
59
60

1 1 2100	s) How much did you drink (in units)? shol unit is equivalent to:	
	5ml single measure of whisky (ABV 40%),	
	nird of a pint of beer (ABV 5-6%)	
	f a standard (175ml) glass of red wine (ABV 12%).	
or man	\square More than 1-2 units per week	
	\square 1-2 units per week	
	\square 1-2 units per week \square 1-4 units per month	
	\square 1-2 units during the pregnancy	
	\Box Can not remember	

HEALTH DISORDERS AND MEDICATIONS DURING PREGNANCY

16. Have you experienced any of the disorders listed below during this pregnancy? If you use or have used any medicines in relation to [each health disorder listed] please enter the names of the medicines.

In which weeks of pregnancy have you used them?

Health disorder		Medicine	Period of use (pregnancy weeks)		
Nausea	□ Yes □ No	(If Nausea ticked) If you use or have used any medicines in relation to nausea, please enter the names of the medicines	□ week 0-12 □ week 13-24 □ week 25- delivery		
Heartburn or reflux problems	□ Yes □ No	(If Heartburn ticked) If you use or have used any medicines in relation to heartburn or reflux problem, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 		
Constipation	□ Yes □ No	(If Constipation ticked) If you use or have used any medicines in relation to constipation, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 		
Common cold	□ Yes □ No	(If common cold ticked If you use or have used any medicines in relation to common cold, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 		
Urinary tract infections	□ Yes □ No	(If UTI ticked) If you use or have used any medicines in relation to urinary tract infections, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 		
Other infections	□ Yes □ No	(If other infections ticked) If you use or have used any medicines in relation to other infections, please enter the names of the medicines	□ week 0-12 □ week 13-24 □ week 25- delivery		
Pain in neck or back or pelvic girdle	□ Yes □ No	(If pain ticked) If you use or have used any medicines in relation to pain in neck or back or pelvic girdle, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 		
Headache	□ Yes □ No	(If headache ticked) If you use or have used any medicines in relation to headache, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 		
Sleeping problems	□ Yes □ No	(If sleeping problems ticked) If you use or have used any medicines in relation to sleeping problems, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 		

\Box Yes		□ No	
18. (If yes in Q17) on sick leave?	What w	as the reason for it? In which pregnancy v	veeks have you been
Reason of the sick	leave		Sick leave period (pregnancy week
			□ week 0-12 □ week 13-24 □ week 25-delivery
Please indicate Please enter the na	whether ame of all	ver-the-counter (OTC) medicines are men you have used any of them during pregna X medicines you have used. have you used them?	ancy.
Please indicate Please enter the na	whether ame of all	you have used any of them during pregnation of the state	

(If nasal spray ticked)

pregnancy.

pregnancy.

pregnancy.

pregnancy.

Please enter the name of all nasal

(If OTC for heartburn ticked)

(If OTC for nausea ticked)

Please enter the name of all medications

you have used against heartburn during

Please enter the name of all medications

Please enter the name of all medications

you have used against constipation during

you have used against nausea during

(If OTC for constipation ticked)

sprays/drops you have used during

Nasal spray/drops

(excluding salt

water solution)

(e.g. Otrivine,

Vicks Sinex

decongestant

Nasal spray)

heartburn

Rennie)

Legs)

Medication against

(e.g. Gaviscon or

Medication against

nausea/travel

sickness (e.g.

constipation

Dulcolax)

(e.g.Lactulose,

Cetirizine, Sea-

Medication against

 \Box Yes

 \square No

 \Box Yes

 \square No

 \Box Yes

 \square No

 \Box Yes

 \square No

□ week 0-12

□ week 13-24

□ week 25- delivery

□ week 25- delivery

□ week 25- delivery

□ week 25- delivery

□ Yes	\square No	Cannot remember
(If yes) What was the r	the name of all herbal preparations you l eason for taking herbal preparations (he ancy weeks did you take herbal preparat	alth disorder, illness)?
Name of herbal	Reason for use (health disorder,	Period of use
preparation used	illness)	(pregnancy week □ week 0-12
		$\square week 15-24$ $\square week 25- delivery$
		\square week 0-12
		\square week 13-24
		□ week 25- delivery
21. (If you used herbal	preparations during pregnancy) Who re	
 Herbal shop personnel Internet Magazines, media, etc. 		
Other (please specify:_)	
22. Did you use homeo	pathic products during pregnancy?	
	pathic products during pregnancy?	Cannot remember
22. Did you use homeo □ Yes		Cannot remember
22. Did you use homeo □ Yes	□ No e) What was the reason for use?	
22. Did you use homeo □ Yes	□ No e) What was the reason for use?	Cannot remember
22. Did you use homeo □ Yes	□ No e) What was the reason for use?	

A BIT MORE ABOUT MEDICATION USE DURING PREGNANCY

23. Have you deliberately avoided taking an over-the-counter medicine during your pregnancy?

□ Yes

 \square No

□ Cannot remember

(If yes in Q23 above) Which medicine was it?

(If yes in Q23 above) What was the reason for doing so?

24. Have you deliberately chosen not to use a medicine prescribed by a doctor because you were pregnant?

 \Box Yes

 $\square \ No$

 \Box Can not remember

(If yes in Q24 above) Which medicine was it?

(If yes in Q24 above) What was the reason for doing so?



YOUR NEEDS FOR INFORMATION

□ Yes	\square No	g the course of your pregnancy?
	n ala you turn to lor informa	ation? (<i>You may tick more than one</i>
answer)		
□ Family/friends		
 Physician Midwife/Nurse 		
	nal	
Pharmacy person Light a person		
Herbal shop pers Drug formulary/		
 Drug formulary/i Poison informati 		
Teratology inform		
	f information on medicines	
□ Internet		
□ Magazines, medi		
\Box Other (please spectrum)	•	P + 1
		from various sources, was such
information similar?		
□ Yes, completely		
	(only the wording or detail lev	vel was somewhat different)
· · · ·	nformation was different	
	tion was completely contradic	
		epancies among the sources, what did
•	ay tick more than one answe	r)
□ Nothing		
□ I became anxiou		
\Box I decided not to		
\Box I sought for a ne	w information source (Which	new source have you consulted?
\Box I chose to rely o	n one source and ignore the co	nflicting one (On which source have yo
relied?		ce have you ignored?
	ve someone help you read ho	
	······································	
\Box Often		
\Box Sometimes		
\square Never		
	ou filling out medical forms	hy vourself?
\Box Extremely	su ming out meater for my	oy yoursen.
\Box Quite a bit		
\Box Somewhat		
\Box A little bit		
\square Not at all		
	ve nrohlems learning about	your medical condition because of
	ling written information?	your meancar condition because 01
	mg written mior mation?	
\Box Always \Box Often		
\Box Sometimes		
□ Occasionally		
🗆 Never		

The following section will pop-up only if the subject has reported to be suffering from a chronic disease

I. MEDICATIONS FOR CHRONIC DISEASES DURING PREGNANCY

If you use or have used medicines for a chronic disease during your pregnancy fill out this part of the questionnaire (I, II, III) and provide some information about those medicines you use daily.

Some chronic diseases are asthma, allergy, hypothyroidism (low thyroid hormone), rheumatic diseases (incl. rheumatoid arthritis, psoriatic arthritis), diabetes (type I or II), epilepsy, depression, anxiety, cardiovascular diseases (incl. hypertension, high cholesterol, and heart diseases)

Do you suffer of any chronic disease?

 \Box Yes \Box No

(If Yes above) Please indicate whether you suffer of any of the following chronic

diseases.					
	0	If you use or have used medicines for X during your pregnancy, please	In which weeks of pregnancy did you use them?		
		enter the name of the			
Asthma Allergy	□ Yes □ No □ Yes □ No	medicines.(If Asthma ticked) If you use or have used medicines for asthma during pregnancy, please enter the names of the medicines.(If Allergy ticked) If you use or have used medicines for allergy during pregnancy, please enter the	 □ week 0-12 □ week 13-24 □ week 25-delivery □ week 0-12 □ week 13-24 		
Hypothyroidism (low thyroid hormone)	□ Yes □ No	names of the medicines. (If Hypothyroidism ticked) If you use or have used medicines for hypothyroidism during pregnancy, please enter the names of the medicines.	 week 25-delivery week 0-12 week 13-24 week 25-delivery 		
Rheumatic disorders (incl. rheumatoid arthritis, psoriatic arthritis)	□ Yes □ No	(If Rheumatic disorders ticked) If you use or have used medicines for rheumatic disorder during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery 		
Diabetes (type I or II)	□ Yes □ No	(If Diabetes ticked) If you use or have used medicines for diabetes during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery 		
Epilepsy	□ Yes □ No	(If Epilepsy ticked) If you use or have used medicines for epilepsy during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery 		
Depression	□ Yes □ No	(If Depression ticked) If you use or have used medicines for depression, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery 		
Anxiety	□ Yes □ No	(If Anxiety ticked) If you use or have used medicines for anxiety during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery 		

		If you use or have used medicines for X during your pregnancy, please enter the name of the medicines.	In which weeks of pregnancy did you use them?
Cardiovascular diseases (incl. hypertension, high cholesterol, heart diseases)	□ Yes □ No	(If Cardio disease ticked) If you use or have used medicines for cardiovascular diseases during pregnancy, please enter the names of the medicines.	 □ week 0-12 □ week 13-24 □ week 25-delivery
Others (If Others ticked) (Please specify which other disease(s):	□ Yes □ No	(If Other disease ticked) If you use or have used medicines for your chronic disease during pregnancy, please enter the names of the medicines.	 □ week 0-12 □ week 13-24 □ week 25-delivery

II. YOUR VIEWS ABOUT PRESCRIBED MEDICINES

In this section of the survey questionnaire, the **Belief About Prescribed Medicine Questionnaire (BMQ-Specific)** was presented (Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1-24).

Section III will pop-up only if the subject has reported to be suffering of a chronic disease. There will be one single scale for each chronic condition reported

III. QUESTION ABOUT YOUR USE OF MEDICATIONS FOR X

<text> In this section of the survey questionnaire, the 8-item Morisky Medication Adherence Questionnaire (MMAS-8) was presented (Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

YOUR VIEWS ABOUT MEDICATIONS

In this section of the survey questionnaire, the Belief About Medicine Questionnaire (BMQ-General) was presented (Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the

	once per lin		1	1	
	Strongly agree	Agree	Uncertain	Disagree	Strongly disagree
I have a higher threshold for using medicines when I am pregnant than when I'm not pregnant	o	o	o	0	o
Even though I am ill and could have taken medicines, it is better for the foetus that I refrain from using them	0	o	o	o	o
Pregnant women should preferably use herbal remedies than conventional medicines	0	o	o	0	o

YOUR ASSESSMENT OF PREGNANCY RISKS

33. Among 100 healthy women in a healthy environment, how many do you think will give birth to a child with a birth defect?

34. Here below is a list with various medicines, food and other substances.

Please indicate how harmful you think they are for the foetus in a scale from 0 to 10, where $\underline{0}$ corresponds to 'not harmful' and 10 to 'very harmful'.

If you have not heard before about such substance, tick 'unknown substance'.

	Unknown substance	0	1	2	3	4	5	6	7	8	9	10
Paracetamol/acetaminophen	o	0	0	o	ο	0	o	0	o	o	0	0
Antibiotics (e.g. Penicillins)	0	0	0	o	ο	ο	o	o	o	0	o	0
Antidepressants	0	0	0	o	0	0	o	o	o	o	o	0
Thalidomide	0	0	0	o	0	0	o	o	0	o	o	0
Swine influenza vaccine	0	0	0	o	0	0	o	o	o	o	o	0
OTC medicines against nausea/travel sickness	ο	0	0	o	o	o	o	o	o	o	o	0
Ginger	o	0	0	0	ο	ο	o	0	0	o	0	0
Cranberries	o	0	0	0	0	ο	o	o	0	o	o	0
Blue veined cheese (e.g. Gorgonzola)	0	0	o	o	o	o	o	o	o	o	o	o
Eggs	0	0	0	o	ο	0	o	0	o	ο	0	0
Alcohol during the 1. trimester (<i>e.g. wine, beer, spirits</i>)	O	0	0	0	o	o	0	0	0	0	0	0
Smoking (e.g. cigarettes)	o	o	o	o	o	o	o	o	o	o	o	o
Dental X-ray	0	0	0	0	0	ο	ο	ο	o	ο	ο	0



BMJ Open

HOW YOU ARE FEELING NOW

In this section of the survey questionnaire, the Edinburgh Postnatal Depression Scale (EPDS) was presented (Cox J, Holden J, Sagovsky R. Detection of postnatal depression. Development of the 10-item edinburgh postnatal depression scale. The British Journal of

- Fd. .postnatal dep .87 June 1, 1987;.

HOW YOU SEE YOURSELF

In this section of the survey questionnaire, the **Big Five Inventory (BFI)** was presented (John OP, Srivastava S, editors. The big five trait taxonomy: History, measurement, and theoretical perspectives: New York: Guilford; 1999; John OP, Robins RW, Pervin LA. Handbook of

 g, th

 g, 1999; Jo.;

 ory and research

60

Appendix 2: Websites used for recruitment and internet penetration rates in each country where data were collected

Website used for recruitment Country Internet penetration **EUROPE** Western Europe 93* [1] Austria www.schwangerschaft.at; www.schwangerschaftsblog.at; www.fratz.at; www.netdoctor.at; www.babycenter.at; www.baby-boom.at; www.ekizdachverband.at; www.babyguide.at 91^{*[1]} www.aufeminin.com (Including ipad application to France website subscribers) 70^{*[1]} Italy Pregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.mammole.it; www.pianetamamma.it; www.miobambino.it Targeted email to pregnancy forum subscribers: www.gravidanzaonline.it 84*[2] Switzerland www.bebe-bebe.com; www.swissmom.ch 98^{*[1]} The Netherlands www.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl 93^{*[1]} **United Kingdom** Targeted email to pregnancy forum subscribers: www.bounty.com Pregnancy Forums: www.pregnancyforum.co.uk; www.pregnancyforum.org.uk Northern Europe **99**^{*[1]} Finland www.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi $100^{*[1]}$ Iceland Pregnancy Forums: www.bland.is **99*** [1] Norway www.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no **99**^{*[1]} Sweden www.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se Eastern Europe 80^{*[1]}(data Croatia www.cybermed.hr from 2010) 84*[1] Poland www.zzief.umlub.pl Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl

Angela Lupattelli 12/29/13 11:18 AM Deleted: participating

Internet

48*[2]

penetration

52^{*[1]} (data

from 2009)

92*[1]

94^{† [3]}

80^{§ [4]}

23^[2]

43^[2]

 $25^{[2]}$

 $16^{[2]}$

16^[2]

 $14^{[2]}$

43^[2]

67^[2]

 $30^{[2]}$

46^[2]

59^[2]

59^[2]

44^[2]

24^[2]

37^[2]

2

Country	Website used for recruitment
Russia	www.babyblog.ru; www.littleone.ru
	Pregnancy Forums: www.woman.ru; www.9mo
	www.bemam; www.280dney.ru; www.iampreg
	www.pregnancy.org.ua; www.baby.ru;
	www.mama66.ru; www.spuzom.ru
Serbia	www.ringeraja.rs
Slovenia	Pregnancy Forums: www.med.over.net
AMERICAS	
	North America
Canada	www.otispregnancy.org; Facebook page of OTI
	www.babyontheway.com.ca
	Pregnancy Forums: www.babycentre.com.ca;
	www.thecradle.com; www.talk.sheknows.com;
	www.parenting.com
USA	www.otispregnancy.org; Facebook page of OTI
	www.justmommies.com
	Pregnancy Forums: www.babyandbump.com
	www.thecradle.com; www.talk.sheknows.com;
	www.parenting.com
	Central America
Belize	www.otispregnancy.org; Facebook page of OTI
Costa Rica	
El Salvador	
Guatemala	
Honduras	_
Nicaragua	
Panama	
	South America
Argentina	www.otispregnancy.org; Facebook page of OTI
Bolivia	
Brazil	Pregnancy Forums: www.semanaasemana.com www.univision.com; www.elembarazo.net
Chile	www.univision.com; www.elemoarazo.net
Colombia	
Ecuador	
Paraguay	_
Peru	

For	peer	review	only	- http://	/bmjop	en.bm	j.com/	site/ab	out/gu	ideline	s.xhtml

BMJ Open

Country	Website used for recruitment	Internet penetration rates (%)
Uruguay		56 ^[2]
Venezuela		41 ^[2]
	AUSTRALIA	
Australia	www.mothersafe.org.au; www.bubhub.com.au	83 ^{ζ [5]}
	<i>Pregnancy Forums</i> : www.abds.org.au; www.birth.com.au	

Indicates the frequency of internet access - at least once a week, including every day - among individuals aged 25- 34 years. Differences between men and women were relatively small. Slightly more than two thirds of men (70%) and 65% of women used the Internet regularly. [†]Indicates individuals aged 16-45 years who used the internet for personal use.

[§]Indicates individuals > 18 years old, access from anywhere; household internet for women is equal to 68.1%; higher percentages are observed for people aged 25-54 years.

^ζIndicates households with access to the internet at home.

Sources of internet penetration rates:

Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus; 1. 2011.

Internet World Stats. Usage and population statistics. Available at:

http://www.internetworldstats.com/. Accessed 29 December, 2013.

Statistics Canada. Individual Internet use and E-commerce (2010). Available at: 3.

http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed 20 November, 2012. United States Census Bureau. The 2012 Statistical Abstract. Information & Communications: 4.

Internet Publishing and Broadcasting and Internet Usage. Available at: http://www.census.gov/compendia/statab/cats/information communications/internet publishing and b

roadcasting_and_internet_usage.html. Accessed 13 November, 2012.

Australian Bureau of Statistics. Household Use of Information Technology, Australia, 2010-11 Available at:

http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main%20Features12010-

П&n. 11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11&num=&view=. Accessed 13 November, 2012.

Appendix 3: Socio-demographic characteristics of the study population and general birthing population on individual country

Appendix 3a: Socio-demographic characteristics in Western European countries (Switzerland, Italy and United Kingdom (UK))

	Study sample in Switzerland	General birthing population in Switzerland	Study sample in Italy	General birthing population in Italy	Study sample in the UK	General birthing population in UK [*]
	n=618	LB=80,808 ^[1]	n=926	LB=546,606 ^[1]	n=1,120	LB=723,165 ^[2]
	(%)	(%)	(%)	(%)	(%)	(%)
No. of respondents/No. live births ¶	4.6%		1.0%		0.9%	
Mean Age +/- sd	31.6 +/- 4.3	31.4 ^[3]	32.3 +/- 5.0	31.3 ^[4]	30.5 +/- 5.2	29.6 ^[2]
Marital status						
In marriage	80.0	80.7 ^[3]	68.8	75.1 ^[1]	63.3	53.2 ^[2]
Outside marriage	20.0	19.3 ^[3]	31.2	31.5 ^[1]	36.7	46.8 ^[2]
Parity						
No previous children	53.2	-	59.7	48.7 ^[5]	48.0^{\dagger}	41.9 ^{[2] †}
Educational level						
Less than high school	11.0	$11.7^{[6]}$	7.0	$25.2^{[6]}$	0.6	16.5 ^[2]
High school	13.6	$49.2^{[6]}$	47.2	49.2 ^[6]	27.9	37.2 ^[2]
More than high school	47.2	39 .1 ^[6]	44.3	25.6 ^[6]	52.1	46.3 ^[2]
Other	28.2	-	1.5		19.3	-
Women smoking before pregnancy	25.1	25.4 ^[7]	34.2	33.3 ^[4]	25.2	25.7 ^[7]
Women smoking during pregnancy	5.5	6.6 ^[8]	10.5	22.7 ^[9]	7.1 [‡]	13.2 ^[10] ‡
Use of alcohol during pregnancy	20.7	29.9 ^[8]	17.9	17.7 ^[9]	28.3	24.0 ^{[11] §}
Abbreviations: LB: Number of live births per	year.				5	

*The figures shown here are statistic estimates for England and Wales. Scotland and Northern Ireland have separate statistical reports. Since more than 85% of the study population in UK were resident in England and about 8% in Wales, we are only showing national statistic data for these two parts of the UK.

BMJ Open

[¶] The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (per of data collection). [†] Among married women only – as provided by the Statistics Bureau in the UK. [‡] Among women resident in England only (as provided by the Statistics Bureau in the UK, data on 4 th Quarter of 2011). [§] Women reporting at least one occasion during pregnancy of consuming more than four drinks in a day.	riod
	5
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Appendix 3b: Socio-demographic characteristics in Western European countries (Austria, France and The Netherlands)

	Study sample in Austria n=82	General birthing population in Austria LB=78,109 ^[1]	Study sample in France n=374	General birthing population in France LB=824,263 ^[1]	Study sample in The Netherlands n=81	General birthing population in The Netherlands LB=180,060 ^[1]
	(%)	(%)	(%)	(%)	(%)	(%)
No. of respondents/No. live births *	0.6%		0.3%		0.3%	
Mean Age +/- sd	30.6 +/- 4.6	30.0 ^[12]	29.6 +/- 4.9	30.1 ^[13]	32.0 +/- 6.4	31.0 ^[14]
Marital status						
In marriage	48.8	59.6 ^[15]	48.9	45.0 ^[1]	69.1	58.2 ^[14]
Outside marriage	51.2	40.4 ^[15]	51.1	55.0 ^[1]	30.8	41.8 ^[14]
Parity						
No previous children	63.4	47.96 ^[15]	52.9	44.2 ^[16]	38.3	46.4 ^[14]
Educational level						
Less than high school	9.8	13.3 ^[6]	1.6	15.4 ^[6]	9.9	15.9 ^[6]
High-school	32.9	64.1 ^[6]	25.1	37.4 ^[6]	66.7	40.2 ^[6]
More than high school	40.2	22.7 ^[6]	57.0	47.2 ^[6]	23.5	43.9 ^[6]
Other	17.1	-	16.3	-	-	-
Women smoking before pregnancy	31.7	32.1 ^[17]	39.3	39.0 ^[16]	34.6	29.5 ^[7]
Women smoking during pregnancy	4.9	-	14.2	28.0 ^[16]	14.8	$17.1^{[18]}$
Use of alcohol during pregnancy	13.4	-	11.5	52.0 ^[19]	11.1	16-35 ^[14]

Abbreviations: LB: Number of live births per year.

 *The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

BMJ Open

	Study sample in	General birthing	Study sample	General birthing	Study sample	General birthing
	Norway	population in	in Finland	population in	in Sweden	population in
		Norway		Finland		Sweden
	n=1,228	LB=60,220 ^[1]	n=574	LB=59,961 ^[1]	n=887	LB=111,770 ^[1]
	(%)	(%)	(%)	(%)	(%)	(%)
No. of respondents/No. live births *	12.2%		5.7%		4.8%	
Mean Age +/- sd	29.0 +/- 4.6	29.8 +/- 5.3 ^[20]	29.0+/-5.1	30.1 ^[21]	29.8 +/- 5.3	30.3 ^[22]
Marital status						
In marriage	39.1	46.0 ^[20]	59.4	57.8 ^[21]	40.7	45.8 ^[1]
Outside marriage	60.9	53.4 ^[20]	40.6	$42.0^{[21]}$	59.3	54.2 ^[1]
Unknown	-	$0.6^{[20]}$	-	$0.2^{[21]}$		
Parity						
No previous children	41.4	42.4 ^[20]	35.5	$42.2^{[21]}$	63.1	44.9 ^[22]
Educational level						
Less than high school	4.5	14.7 ^[6]	8.2	$7.1^{[6]}$	5.2	$11.1^{[6]}$
High-school	28.0	31.4 ^[6]	36.4	44.5 ^[6]	30.0	38.2 ^[6]
More than high school	46.9	53.9 ^[6]	52.6	48.4 ^[6]	60.6	50.6 ^[6]
Other	20.7	-	2.8	-	4.2	-
Women smoking before pregnancy	33.5	36.5 ^[7]	36.7	19.7 ^[7]	25.0	27.2 ^[7]
Women smoking during pregnancy	6.8	$7.0^{[20]}$	11.7	15.2 ^[21]	5.4	6.5 ^[22]
Use of alcohol during pregnancy	4.1	7.4 ^[23]	13.9		7.2	5.9 ^[24]

Appendix 3c: Socio-demographic characteristics in Northern European countries (Norway, Finland and Sweden)

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Study sample in Iceland n=71	General birthing population in Iceland LB=4,492 ^[1]
	(%)	(%)
No. of respondents/No. live births *	9.3%	
Age range (in years)		
15-20	11.3	5.1 ^[25]
21-25	16.9	19.3 ^[25]
26-30	42.3	34.2 ^[25]
31-35	15.5	27.3 ^[25]
36-40	12.7	11.7 ^[25]
≥41	1.4	2.4 ^[25]
Marital status		
In marriage	31.0	35.0 ^[25]
Outside marriage	69.0	65.0 ^[25]
Parity		
No previous children	47.9	38.1 ^[25]
Educational level		
Less than high school	25.4	$21.4^{[6]}$
High-school	18.3	30.5 ^[6]
More than high school	43.7	$48.1^{[6]}$
Other	12.7	-
Women smoking before pregnancy	40.8	35.5 ^[7]

Appendix 3d: Socio-demographic characteristics in Northern European countries (Iceland)

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

	Study sample in Croatia	General birthing population in Croatia	Study sample in Slovenia	General birthing population in Slovenia	Study sample in Serbia	General birthing population in Serbia
	n=286	LB=41,197 ^[1]	n=149	LB=21,947 ^[1]	n=220	LB=65,598 ^[1]
	n (%)	(%)	n (%)	(%)	n (%)	(%)
No. of respondents/No. live births *	4.2%		4.1%		2.0%	
Mean Age +/- sd	29 .1 +/- 4.5 [†]	27.7 ^[26]	31.7 +/- 4.5	30.4 ^[27]	29.2 +/- 3.9 [*]	$28.7^{[1,28]}$
Marital status						
In marriage	83.9	86.7 ^[26]	47.0	43.2 ^[27]	90.1	76.1 ^[28]
Outside marriage	16.1	13.3 ^[26]	53.0	56.8 ^[27]	9.9	23.9 ^[28]
Parity						
No previous children	50.7	46.9 ^[26]	45.6	48.5 ^[27]	46.8	51.1 ^[28,29]
Educational level						
Less than high school	1.0	3.1 ^[26]	2.0	$8.5^{[27]}$	0.9	15.9 ^[29]
High-school	36.7	52.5 ^[26]	24.8	48.5 ^[27]	33.6	54.9 ^[29]
More than high school	61.2	44.4 ^[26]	69.1	43.0 ^[27]	61.8	29.2 ^[29]
Other	1.0	-	4.0	-	3.6	-
Women smoking before pregnancy	50.0	34.4 ^[26]	32.9	34.4 ^[7]	49.1	29.9 ^[30,31]
Women smoking during pregnancy	18.8	23.1 ^[32]	6.7	9.6-11.2 ^[33]	18.2	18.4 ^[31]
Use of alcohol during pregnancy	12.6	15.5 ^[34]	32.2		15.0	-

Abbreviations: LB: Number of live births per year.

* The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

[†]Mean age for first child (as it is available from the Statistics Bureau reports in Croatia and Serbia).

Appendix 3f: Socio-demographic characteristics in Eastern European countries (Poland and Russia)

	Study sample in Poland n=679	General birthing population in Poland LB=388,416 ^[1]	Study sample in Russia n=1,008	General birthing population in Russia LB=1,796,629 ^[1]
	(%)	(%)	(%)	(%)
No. of respondents/No. live births [*]	1.0%		0.3%	
Mean Age +/- sd	27.1 +/- 4.1	28.6 ^[35] †	27.7 +/- 4.8	27.4 ^[36]
Marital status				
In marriage	85.0	79.4 ^[35]	85.3	73.9 ^[36]
Outside marriage	15.0	20.6 ^[35]	14.7	26.1 ^[36]
Parity				
No previous children	40.6	50.1 ^[35]	57.9	-
Educational level				
Less than high school	1.9	8.7 ^[35]	1.6	-
High-school	31.1	49.6 ^[35]	9.3	-
More than high school	65.1	41.6 ^[35]	75.1	-
Other	1.9	-	14.0	-
Women smoking before pregnancy	49.2	25.0 ^[37]	46.1	30.8 ^[38]
Women smoking during pregnancy	12.8	22-30 ^[37]	9.6	4.3-6.5 ^[39,40]
Use of alcohol during pregnancy	9.6	15.3 ^[41]	26.0	$60.0^{[42]}$

* The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

[†]Median age of women at birth, not mean age.

Page 93 of 109

 BMJ Open

	Study sample	General birthing	Study sample in The	General birthing
	in Canada	population in Canada ^[43]	USA	population in USA ^[44]
	n=236	LB=377,636	n=297	LB=3,999,386
	n (%)	(%)	n (%)	(%)
No. of respondents/No. live births [*]	0.4%		0.04%	
Age range (in years)				
15-19	2.1	3.9 ^[43]	4.7	9.3 ^[44]
20-24	25.0	14.6 ^[43]	18.2	23.8 ^[44]
25-29	30.1	30.2 ^[43]	28.3	28.3 ^[44]
30-34	30.5	32.2 ^[43]	29.3	$24.1^{[44]}$
35-39	11.0	15.6 ^[43]	15.2	11.6 ^[44]
40-44	1.3	3.1 ^[43]	4.0	$2.7^{[44]}$
<u>≥</u> 45	-	$0.2^{[43]}$	0.3	$0.2^{[44]}$
Mean Age +/- sd	28.3 +/- 5.2	29.6 ^[43]	29.3 +/- 6.1	-
Marital status				
In marriage	42.4	$60.4^{[43]}$	67.0	59.2 ^[45]
Outside marriage	57.6	$28.8^{[43]}$	33.0	39 .9 ^[45]
Unknown	-	$10.8^{[43]}$	-	$0.9^{[45]}$
Parity				
No previous children	48.3	43.3 ^[43]	41.1	40.1 ^[44]
Educational level				
Less than high school	1.3	$8.4^{[46]}$	2.7	17.4 ^[47]
High-school	24.6	-	25.3	24.4 ^[47]
More than high school	67.8	$69.6^{[46]}$	62.0	58.2 ^[47]
Other	6.4	-	10.1	- *
Women smoking before pregnancy	29.2	$22.0^{[48]}$	28.3	21.5 ^[49]

Appendix 3g: Socio-demographic characteristics in North American countries (Canada and USA)

	Study sample in Canada	General birthing population in Canada ^[43]	Study sample in The USA	General birthing population in USA ^[44]
	n=236	LB=377,636	n=297	LB=3,999,386
	n (%)	(%)	n (%)	(%)
Vomen smoking during pregnancy	16.1	13.4 ^[46]	8.1	10.2 ^[50]
Ise of alcohol during pregnancy	16.1	10.5 ^[46]	17.5	15.5 ^[49]
			ncies included in the study a	

Appendix 3h: Socio-demographic characteristics in Australia

	Study sample in	General birthing
	Australia	population in Australia[^{51]}
	n=217	LB=301,617
	n (%)	(%)
No. of respondents/No. live births [*]	0.4%	
Mean Age +/- sd	31.1 +/- 5.7	$30.7^{[51]}$
Marital status		
In marriage	70.5	65.8 ^[51]
Outside marriage	29.5	34.2 ^[51]
Parity		
No previous children	47.9	43.8 ^[51]
Educational level		
Less than high school	0.5	20.6 ^{† [52]}
High-school	29.0	
More than high school	63.1	56.0 ^[53]
Other	7.4	-
Women smoking before pregnancy	29.1	29.9 ^[54]
Women smoking during pregnancy	14.3	14.5 ^[55]
Use of alcohol during pregnancy	27.2	29.0 ^[56]

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months ~n/ (period of data collection).

[†]Refers to the educational levels "high school" and "less than high school" grouped together.

Sources of socio-demographic characteristics of the general birthing population:
. Eurostat. Live births by mother's age at last birthday and legal marital status. Available at: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_fagec⟨=en.
2. UK National Statistics. Characteristics of Birth 1 and 2/of mother 1 and 2, England and Wales. 2010. Available at: http://www.statistics.gov.uk/hub/population/births-and- ertility/maternities/index.html. Accessed 12 November, 2012.
B. Swiss Statistics. Components of population change – Data, indicators. Available at: http://www.bfs.admin.ch/bfs/portal/en/index/themen/01/06/blank/key/01.html. Accessed 6 November, 2012.
 4. Istat - Istituto nazionale di statistica. Demography in figures. 2011. Available at: http://demo.istat.it/index_e.html. Accessed 6 November, 2012. 5. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000;56(4):323-8.
b. Eurostat. Persons with a given education attainment level by sex and age groups (%). Available at: http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/dataset?p_product_code=EDAT_LFS_9903. Accessed 6 November, 2012.
<i>i.</i> Eurostat. Smokers by sex. Available at: http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/dataset?p_product_code=TPS00169. Accessed 6 November, 0012.
B. Lemola S, Grob A. Drinking and smoking in pregnancy: what questions do Swiss physicians ask? Swiss Med Wkly 2007; 137 (3-4):66-9. D. De Santis M, De Luca C, Mappa I, et al. Smoke, alcohol consumption and illicit drug use in an Italian population of pregnant women. Eur J Obstet Gynecol Reprod Biol
2011; 159 (1):106-10. 0. The Health and Social Care Information Centre. Statistics on women's smoking status at time of delivery: England, Quarter 1, 2012/13. 2012. Available at: http://www.ic.nhs.uk/pubs/wsstd1213q1. Accessed 12 November, 2012.
1. Sayal K, Heron J, Golding J, et al. Binge pattern of alcohol consumption during pregnancy and childhood mental health outcomes: longitudinal population-based study. Pediatrics 2009: 123 (2):e289-96.
2. Statistics Austria. Births. Long-term and current final annual results. 2011. Available at: http://www.statistik.at/web_en/statistics/population/births/index.html. Accessed
November 6th, 2012. 3. National Institute of Statistics and Economic Studies INSEE. Population. Available at: http://www.insee.fr/en/themes/theme.asp?theme=2. Accessed 7 November, 2012. 4. Statline, Centraal Bureaus voor de Statistiek. Population. 2012. Available at: http://www.cbs.nl/en-GB/menu/themas/bevolking/nieuws/default.htm. Accessed 10 November, 2012.
5. STATcube - Statistical Database of Statistics Austria. Available at: http://statcube.at/superweb/login.do?guest=guest. Accessed 6 November, 2012. 6. Menai M, Heude B, Slama R, et al. Association between maternal blood cadmium during pregnancy and birth weight and the risk of fetal growth restriction: The EDEN nother–child cohort study. Reprod Toxicol 2012; 34 (4):622-27.
 7. Jahrbuch der GESUNDHEITSSTATISTIK. Wein: Statistika Austria. 2011. 8. Leermakers ET, Taal HR, Bakker R, et al. A common genetic variant at 15q25 modifies the associations of maternal smoking during pregnancy with fetal growth: the generation R study. PLoS One 2012;7(4):e34584.
9. de Chazeron I, Llorca PM, Ughetto S, et al. Is pregnancy the time to change alcohol consumption habits in France? Alcohol Clin Exp Res 2008; 32 (5):868-73. 20. Norwegian Institue of Public Health. Medisinsk fødselsregisters statistikkbank - statistikk om alle fødsler i Norge. 2011. Available at: http://mfr-nesstar.uib.no/mfr/.
Accessed 6 November, 2012. 21. The National Institute for Health and Welfare, Helsinki Finland. Liitetaulukot - Bilagetabeller - Appendix Tables, 2010. 22. Heino A, Gissler M. Nordic Perinatal Statistics 2010: National Institute for Health and Welfare. Helsinki, Finland. 2012.
23. Ystrom E, Vollrath ME, Nordeng H. Effects of personality on use of medications, alcohol, and cigarettes during pregnancy. Eur J Clin Pharmacol 2012;68(5):845-51.
1
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

1	
2	24. Nilsen P, Holmqvist M, Hultgren E, et al. Alcohol use before and during pregnancy and factors influencing change among Swedish women. Acta Obstet Gynecol Scand
3	2008; 87 (7):768-74.
4	25. Births and Deaths. Statistics Iceland. Available at: http://www.statice.is/Statistics/Population/Births-and-deaths. Accessed 6 November, 2012.
5	26. Statistical Yearbook of the Republic of Croatia. Zagreb: Croatian Bureau of Statistics, 2011.
6	27. Statistical Office of the Republic of Slovenia. SI-STAT Data Portal. Population. Available at: http://pxweb.stat.si/pxweb/Database/Demographics/Demographics.asp.
7	Accessed 7 November, 2012.
8	28. Statistical Yearbook of the Republic of Serbia. Demographic Yearbook in Republic of Serbia. Belgrade: Statistical Office of the Republic of Serbia, 2011. 29. Krstev S, Marinkovic J, Simic S, et al. Prevalence and predictors of smoking and quitting during pregnancy in Serbia: results of a nationally representative survey. Int J
9	Public Health 2011.
9 10	30. Statistical Office of the Republic of Serbia. Women and Men in the Republic of Serbia, Belgrade, 2011.
	31. Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012; 34 (5):719-27.
11	32. Strinic T, Bukovic D, Sumilin L, et al. Socio-demographic characteristics and lifestyle habits of pregnant women smokers. Coll Antropol 2005;29(2):611-4.
12	33. Antolič B, Geršak K, Verdenik I, et al. Adverse effects of thyroid dysfunction on pregnancy and pregnancy outcome: Epidemiologic study in Slovenia. Journal of
13	Maternal-Fetal and Neonatal Medicine 2006;19(10):651-54.
14	34. Petkovic G, Barisic I. FAS prevalence in a sample of urban schoolchildren in Croatia. Reprod Toxicol 2010; 29 (2):237-41.
15	 Demographic Yearbook of Poland. Warsaw: Central Statistical Office of Poland, 2011. The Demographic Yearbook of Russia - statistical handbook. Moscow: Federal State Statistics Service (Rosstat), 2010.
16	 37. Przewoźniak K, Zatoński W. Ekspertyza "zachowania zdrowotne kobiet w ciąży". Warszawa: Zakład Epidemiologii i Prewencji Nowotworów, Centrum Onkologii –
17	Instytut w Warszawie. Posiedzenie Plenarne Rady Naukowej przy Ministrze Zdrowia, Ministerstwo Zdrowia, 2010.
18	38. Current tobacco use and secondhand smoke exposure among women of reproductive age - 14 countries, 2008-2010. MMWR Morb Mortal Wkly Rep 2012;61:877-82.
19	39. Kelmanson IA, Erman LV, Litvina SV. Maternal smoking during pregnancy and behavioural characteristics in 2 - 4-month-old infants. Klin Padiatr 2002;214(6):359-64.
20	40. Hugg TT, Jaakkola MS, Ruotsalainen RO, et al. Parental smoking behaviour and effects of tobacco smoke on children's health in Finland and Russia. Eur J Public Health
21	2008;18(1):55-62.
22	41. Wojtyla A, Kapka-Skrzypczak L, Diatczyk J, et al. Alcohol-related Developmental Origin of Adult Health - population studies in Poland among mothers and newborns (2010-2012). Ann Agric Environ Med 2012;19(3):365-77.
23	42. Kristjanson AF, Wilsnack SC, Zvartau E, et al. Alcohol use in pregnant and nonpregnant Russian women. Alcohol Clin Exp Res 2007; 31 (2):299-307.
24	43. Statistics Canada. Births. 2010. Available at: http://www.statcan.gc.ca/daily-quotidien/111220/dq111220g-eng.htm. Accessed 12 November 2012.
25	44. Hamilton B, Martin J, Ventura S. National Vital Statistics Reports. Births: Preliminary Data for 2010: U.S. Department of health and human services. Centers for Disease
26	Control and Prevention. National Center for Health Statistics. National Vital Statistics System, 2011.
20	45. OECD. Panorama de la société 2011: OECD Publishing.
28	 46. Canadian Perinatal Health Report, 2008 Edition. Ottawa: Public Health Agency of Canada, 2008. 47. The 2012 Statistical Abstract. The National Data Book. Women With Births in the Past 12 Months by Citizenship Status, Educational Attainment, and Poverty Status, by
	47. The 2012 Statistical Abstract. The National Data Book. women with Births in the Past 12 Months by Chizensing Status, Educational Attainment, and Poverty Status, by State. 2009. Available at: http://www.census.gov/compendia/statab/cats/births deaths marriages divorces/births.html. Accessed 12 November, 2012.
29	48. Public Health Agency of Canada. What Mothers Say: The Canadian Maternity Experiences Survey. Ottawa, 2009.
30	49. Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH
31	Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
32	50. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD: National Center for Health Statistics, 2012.
33	51. Australian Bureau of Statistics. Births, Australia. 2011. Available at: http://www.abs.gov.au/AUSSTATS/abs@.nsf/mf/3301.0. Accessed 13 November, 2012.
34	15
35	
36	
37	
38	
39	
40	
41	
42	
43	

. La conditions by pregnant w.
. F12. 2012: A valuable are:
. Materia valuable are:
. Materia valuable are:
. Materia valuable are:
. A valuabe are:
. A valuable are:
. A valuabe are:
. A 52. Sawicki E, Stewart K, Wong S, et al. Medication use for chronic health conditions by pregnant women attending an Australian maternity hospital. Aust N Z J Obstet Gynaecol 2011:51(4):333-38.

53. Australian Bureau Statistitics. Australian Social Trends, Sep 2012. 2012; Available at:

 http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4102.0Main+Features20Sep+2012. Accessed 13 November, 2012.

54. Hotham E, Ali R, White J, et al. Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. Aust N Z J Obstet Gynaecol 2008;48(3):248-54.

55. Australia's mothers and babies 2009. Perinatal statistics series no. 25. Cat. no. PER 52. Canberra: AIHW, 2011.

56. Maloney E, Hutchinson D, Burns L, et al. Prevalence and predictors of alcohol use in pregnancy and breastfeeding among Australian women. Birth 2011;38(1):3-9.

BMJ Open

	Study sample	Population size [*]		Exp	ected prevale	ence		
	-		Any medication use=80%	Any medication use=70%	OTC medication use=60%	Chronic medication use=30%	Chronic medication use=15%	
				Req	uired sample	size		
Western Europe	3,201	Not known	246	323	369	323	196	
United Kingdom	1,120	120,528	245	322	368	322	196	
Italy	926	91,101	245	322	367	322	195	
Switzerland	618	13,468	241	315	359	315	193	
France	374	137,377	245	322	368	322	196	
Austria [†]	82	13,018	241	315	359	315	193	
The Netherlands [†]	81	30,010	244	319	364	319	195	
Northern Europe	2,820	Not known	246	323	369	323	196	
Norway	1,228	10,037	240	313	356	313	192	
Sweden	887	18,628	243	317	362	317	194	
Finland	574	9,994	240	313	356	313	192	
Iceland [†]	71	749	185	225	247	225	155	
Eastern Europe	2,342	Not known	246	323	369	323	196	
Russia	1,008	299,438	246	322	368	322	196	
Poland	679	64,736	245	321	367	321	195	
Croatia [§]	286	6,866	237	308	350	308	190	
Serbia [¶]	220	10,933	240	313	357	313	192	
Slovenia**	149	3,658	230	297	335	297	186	
North America	533	Not known	246	323	369	323	196	
USA§	297	666,564	246	323	369	323	196	
Canada ^{††}	236	62,939	245	321	367	321	195	
South America [¶]	346	Not known	246	323	369	323	196	
Australia ^{§§}	217	50,270	245	321	366	321	195	

Sample size calculations were performed in Epi Info TM 7 available at: Center for DiseaseControl and Prevention (CDC), Epi Info. URL: http://wwwn.cdc.gov/epiinfo/. Accessed 2013 Dec 31.

*The population size indicates the number of live births in the country in two months (corresponds to the period of data collection) (cf. Appendix 3 for annual estimates of live births in each country). For the all regions except Australia, the population size is very large but not known exactly (i.e. infinite population). Infinite population size is therefore assumed in the calculation of the required sample size. [†]The sample size allows for prevalence estimates with a precision of 9% (expected prevalence=80%), 10% (expected prevalence=70% and 30%), 11% (expected prevalence=60%) and 8% (expected prevalence=15%). [§]The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=70%, 60% and 30%). ¹The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=80%) and 7% (expected prevalence=70%, 60% and 30%). **The sample size allows for prevalence estimates with a precision of 7% (expected prevalence=80%), 8% (expected prevalence=70%, 60% and 30%) and 6% (expected prevalence=15%). ^{††}The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=80%, 70% and 30%) and 7% (expected prevalence=60%). [¶]The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=60%). ^{§§}The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=80%) and 7% (expected prevalence=70%, 60% and 30%).

Page 101 of 109

BMJ Open

	Anatomical Therapeutic Chemical (ATC) classification index	Anytime during	1 st trimester	2 nd trimester	3 rd trimeste
	1 st and 2 nd levels	pregnancy n (%)	n (%)	n (%)	n (9/.)
A	Alimentary tract and metabolism	4,275 (45.2)	2,786 (29.5)	3,390 (35.8)	n (%) 3,160 (33.4
A A01	Stomatological preparations	4,273 (43.2) 62 (0.7)	42 (0.4)	52 (0.5)	46 (0.5)
A01 A02	Drugs for acid related disorders	3,242 (34.3)	2,034 (21.5)	2,634 (27.8)	2,615 (27.6
A02 A03	Drugs for functional gastrointestinal disorders	650 (6.9)	543 (5.7)	512 (5.4)	381 (4.0)
A03 A04	Antiemetics and antinauseants	136 (1.4)	124 (1.3)	114 (1.2)	81 (0.9)
A04 A05	Bile and liver therapy	24 (0.3)	15 (0.2)	17 (0.2)	16 (0.2)
A05 A06	Laxatives	978 (10.3)	696 (7.4)	835 (8.8)	735 (7.8)
A00 A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	89 (0.9)	61 (0.6)	69 (0.7)	57 (0.6)
A07 A09	Digestives, incl. enzymes	9 (0.1)	7 (0.1)	8 (0.1)	3 (0.0)
A09 A10	Drugs used in diabetes	85 (0.9)	57 (0.6)	58 (0.6)	45 (0.5)
AIU	Unspecified medications for nausea	6 (0.1)	5 (0.1)	4 (0.0)	3(0.0)
- B	Blood and blood forming organs	148 (1.6)	<u> </u>	102 (1.1)	<u> </u>
в В01	Antithrombotic agents	135 (1.4)	78 (0.8)	95 (1.0)	72 (0.8)
B01 B02	Antihemorrhagics	5 (0.1)	4 (0.0)	2 (0.0)	3 (0.0)
B02 B05	Blood substitutes and perfusion solutions	7 (0.1)	5 (0.1)	2 (0.0) 5 (0.1)	2(0.0)
B05 B06	Other hematological agents	3 (0.0)	2(0.0)	2(0.0)	2 (0.0) 3 (0.0)
C	Cardiovascular system	202 (2.1)	132 (1.4)	<u> </u>	133 (1.4)
C01	Cardiac therapy	7 (0.1)	4 (0.0)	5 (0.1)	4 (0.1)
C02	Antihypertensives	56 (0.6)	34 (0.4)	42 (0.4)	31 (0.3)
C02	Diuretics	6 (0.1)	5 (0.1)	3 (0.0)	2(0.0)
C03	Peripheral vasodilators	3 (0.0)	3 (0.0)	3 (0.0)	2 (0.0) 3 (0.0)
C04	Vasoprotectives	44 (0.5)	24 (0.3)	35 (0.4)	31 (0.3)
C07	Beta blocking agents	74 (0.8)	51 (0.5)	59 (0.6)	51 (0.5)
C08	Calcium channel blockers	21 (0.2)	16 (0.2)	18 (0.2)	13 (0.1)
C09	Agents acting on the renin-angiotensin system	4 (0.0)	2 (0.0)	2(0.0)	2(0.0)
C10	Lipid modifying agents	5 (0.1)	3 (0.0)	4 (0.0)	4 (0.0)
~10	Unspecified medications for hypertension	4 (0.0)	3 (0.0)	3 (0.0)	2 (0.0)

1 and .. .

	Anatomical Therapeutic Chemical (ATC) classification index	Anytime during	1 st trimester	2 nd trimester	3 rd trimester
	1 st and 2 nd levels	pregnancy			
		n (%)	n (%)	n (%)	n (%)
D	Dermatologicals	162 (1.7)	116 (1.2)	127 (1.3)	103 (1.1)
D01	Antifungals for dermatological use	38 (0.4)	28 (0.3)	33 (0.3)	27 (0.3)
D02	Emollients and protectives	14 (0.1)	11 (0.1)	12 (0.1)	10 (0.1)
D03	Preparations for treatment of wounds and ulcers	4 (0.0)	3 (0.0)	3 (0.0)	3 (0.0)
D04	Antipruritics, incl. antihistamines, anaesthetics, etc.	6 (0.1)	3 (0.0)	5 (0.1)	4 (0.0)
D05	Antipsoriatics	3 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)
D06	Antibiotics and chemotherapeutics for dermatological use	21 (0.2)	15 (0.2)	16 (0.2)	13 (0.1)
D07	Corticosteroids, dermatological preparations	56 (0.6)	40 (0.4)	39 (0.4)	31 (0.3)
D08	Antiseptics and disinfectants	14 (0.1)	9 (0.1)	10 (0.1)	9 (0.1)
D09	Medicated dressings	5 (0.1)	5 (0.1)	5 (0.1)	3 (0.0)
D10	Anti-acne preparations	4 (0.0)	4 (0.0)	4 (0.0)	2 (0.0)
D11	Other dermatological preparations	1 (0.0)	-	1 (0.0)	1 (0.0)
-	Unspecified medications for skin disorders	5 (0.1)	4 (0.0)	4 (0.0)	3 (0.0)
G	Genitourinary system and sex hormones	488 (5.2)	318 (3.4)	394 (4.2)	303 (3.2)
G01	Gynaecological antiinfective and antiseptics	406 (4.3)	255 (2.7)	337 (3.6)	258 (2.7)
G02	Other gynecologicals	13 (0.1)	10 (0.1)	10 (0.1)	8 (0.1)
G03	Sex hormones and modulators of the genital system	68 (0.7)	55 (0.6)	50 (0.5)	36 (0.4)
G04	Urologicals	12 (0.1)	8 (0.1)	7 (0.1)	8 (0.1)
Н	Systemic hormonal preparations, excl. sex hormones and insulins	486 (5.1)	304 (3.2)	346 (3.7)	262 (2.8)
H01	Pituitary and hypothalamic hormones and analogues	4 (0.0)	4 (0.0)	3 (0.0)	4 (0.0)
H02	Corticosteroids for systemic use	93 (1.0)	64 (0.7)	78 (0.8)	63 (0.7)
H03	Thyroid therapy	397 (4.2)	242 (2.6)	273 (2.9)	201 (2.1)
J	Anti-infective for systemic use	1,381 (14.6)	874 (9.2)	1,107 (11.7)	943 (10.0)
J01	Antibacterials for systemic use	1,325 (14.0)	840 (8.9)	1,061 (11.2)	908 (9.6)
J02	Antimycotics for systemic use	23 (0.2)	16 (0.2)	21 (0.2)	17 (0.2)
J05	Antivirals for systemic use	39 (0.4)	27 (0.3)	30 (0.3)	26 (0.3)
J06	Immune sera and immunoglobulins	4 (0.0)	2 (0.0)	3 (0.0)	4 (0.0)
J07	Vaccines	10 (0.1)	5 (0.1)	8 (0.1)	5 (0.1)

BMJ Open

	Anatomical Therapeutic Chemical (ATC) classification index	Anytime during	1 st trimester	2 nd trimester	3 rd trimester
1 st and 2 nd levels		pregnancy			
		n (%)	n (%)	n (%)	n (%)
L	Antineoplastic and immunomodulating agents	134 (1.4)	83 (0.9)	117 (1.2)	97 (1.0)
L01	Antineoplastic agents	4 (0.0)	3 (0.0)	4 (0.0)	1 (0.0)
L03	Immunostimulants	96 (1.0)	58 (0.6)	86 (0.9)	78 (0.8)
L04	Immunosuppressants	34 (0.4)	22 (0.2)	27 (0.3)	18 (0.2)
Μ	Musculo-skeletal system	571 (6.0)	416 (4.4)	437 (4.6)	380 (4.0)
M01	Antiinflammatory and antirheumatic products	515 (5.4)	378 (4.0)	396 (4.2)	342 (3.6)
M02	Topical products for joint and muscular pain	54 (0.6)	37 (0.4)	41 (0.4)	41 (0.4)
M03	Muscle relaxants	8 (0.1)	8 (0.1)	4 (0.0)	1 (0.0)
M05	Drugs for treatment of bone diseases	1 (0.0)	-	1 (0.0)	-
M09	Other drugs for disorders of the musculo-skeletal system	2 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)
-	Unspecified medications for headache	2 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)
N	Nervous system	5,441 (57.5)	3,638 (38.5)	4,247 (44.9)	3,449 (36.5)
N01	Anaesthetics	13 (0.1)	10 (0.1)	7 (0.1)	8 (0.1)
N02	Analgesics	5,297 (56.0)	3,562 (37.7)	4,171 (44.1)	3,387 (35.8)
N03	Antiepileptics	76 (0.8)	46 (0.5)	49 (0.5)	42 (0.4)
N05	Psycholeptics	210 (2.2)	173 (1.8)	164 (1.7)	138 (1.5)
N06	Psychoanaleptics	275 (2.9)	211 (2.2)	213 (2.3)	179 (1.9)
N07	Other nervous system drugs	6 (0.1)	4 (0.0)	5 (0.1)	3 (0.0)
-	Unspecified analgesics/medications for the nervous system	52 (0.5)	38 (0.4)	43 (0.5)	35 (0.4)
Р	Antiparasitic products, insecticides and repellents	26 (0.3)	20 (0.2)	22 (0.2)	16 (0.2)
P01	Antiprotozoals	25 (0.3)	20 (0.2)	22 (0.2)	16 (0.2)
P02	Anthelmintics	1 (0.0)	-	-	-
R	Respiratory system	2,609 (27.6)	1,878 (19.9)	2,047 (21.6)	1,702 (18.0)
R01	Nasal preparations	1,547 (16.4)	1,079 (11.4)	1,229 (13.0)	1,046 (11.1)
R02	Throat preparations	167 (1.8)	110 (1.2)	131 (1.4)	122 (1.3)
R03	Drugs for obstructive airway diseases	396 (4.2)	269 (2.8)	304 (3.2)	242 (2.6)
R05	Cough and cold preparations	152 (1.6)	103 (1.1)	125 (1.3)	101 (1.1)
R06	Antihistamines for systemic use	912 (9.6)	777 (8.2)	740 (7.8)	580 (6.1)

	Anatomical Therapeutic Chemical (ATC) classification index 1 st and 2 nd levels	Anytime during pregnancy	1 st trimester	2 nd trimester	3 rd trimester
		n (%)	n (%)	n (%)	n (%)
R07	Other respiratory system products	3 (0.0)	2 (0.0)	3 (0.0)	3 (0.0)
-	Unspecified medications of the respiratory system	142 (1.5)	101 (1.1)	118 (1.2)	99 (1.0)
S	Sensory organs	45 (0.5)	33 (0.3)	38 (0.4)	28 (0.3)
S01	Ophthalmologicals	33 (0.3)	24 (0.3)	28 (0.3)	23 (0.2)
S02	Otologicals	5 (0.1)	3 (0.0)	4 (0.0)	2 (0.0)
S03	Ophthalmological and otological preparations	3 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)
-	Unspecified medications for eye disorders	5 (0.1)	4 (0.0)	5 (0.1)	2 (0.0)
V	Various	15 (0.2)	10 (0.1)	11 (0.1)	9 (0.1)
Total	medication use (any ATC)	7,678 (81.2)	4,710 (49.8)	5,538 (58.5)	4,663 (49.3)

italies. Exposure timing us a to childbirth). *The most common medication groups within each ATC class are in italics. Exposure timing is defined as follows: 1st trimester (gestational weeks 0-12), 2nd trimester (gestational week 13-24), 3rd trimester (gestational week 25 and up to childbirth).

BMJ Open

46	
47	

Appendix 6: Prevalence of acute/short-term illnesses and most common medications used at any time during pregnancy by ATC level, indication for use and region $(n=9,459)^{*\dagger}$

- · · · · ·			REGI	ON			-
Prevalence of acute/short-term illnesses in pregnancy and related medication use, overall and by drug groups	Western Europe	Northern Europe	Eastern Europe	North America	South America	Australia	Total
related incurcation use, over an and by drug groups	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
0 Prevalence of headache	1,699 (53.1)	1,657 (58.8)	1,138 (48.6)	373 (70.0)	197 (56.9)	147 (67.7)	5,211 (55.1)
1 Medication use for headache, total	1,027 (32.1)	1,057 (37.5)	522 (22.3)	226 (42.4)	121 (35.0)	109 (50.2)	3,062 (32.4)
2 By drug group		· · · · ·	~ /			· · · ·	
Daracetamol (incl. combinations) (N02BE)	994 (31.1)	1,009 (35.8)	372 (15.9)	206 (38.6)	92 (26.6)	101 (46.5)	2,774 (29.3)
5 Non-steroidal antiinflammatory drugs (M01A)	28 (0.9)	78 (2.8)	37 (1.6)	18 (3.0)	18 (5.2)	2 (0.9)	179 (1.9)
6 Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	4 (0.1)	81 (3.5)	1 (0.2)	4 (1.2)	2 (0.9)	99 (1.0)
7 Opioid analgesics (N02A)	14 (0.4)	46 (1.6)	3 (0.1)	3 (0.6)	-	13 (6.0)	79 (0.8)
8 Selective serotonin (5-HT ₁) agonists (N02CC)	6 (0.2)	22 (0.8)	2 (0.1)	3 (0.6)	-	1 (0.5)	34 (0.4)
9 Prevalence of heartburn	2,196 (68.6)	1,875 (66.5)	1,425 (60.8)	374 (70.2)	248 (71.7)	141 (65.0)	6,259 (66.2)
0 Medication use for heartburn, total	984 (30.7)	885 (31.4)	525 (22.4)	202 (37.9)	88 (25.4)	72 (33.2)	2,756 (29.1)
1 By drug group							
2 Antacids (aluminium, salts combinations, antiflatulents)	384 (12.0)	503 (17.8)	440 (18.8)	51 (9.6)	63 (18.2)	20 (9.2)	1,461 (15.4)
3 Alginic acid complex/sucralfate/bismuth (A02BX)	569 (17.8)	332 (11.8)	86 (3.7)	4 (0.8)	3 (0.9)	14 (6.5)	1,008 (10.7)
4 Proton pump inhibitors (A02BC)	77 (2.4)	86 (3.0)	4 (0.2)	13 (2.4)	3 (0.9)	7 (3.2)	190 (2.0)
5 Antacid with calcium (A02AC)	20 (0.6)	13 (0.5)	10 (0.4)	123 (23.1)	2 (0.6)	9 (4.1)	177 (1.9)
H_2 receptor antagonists (A02BA)	27 (0.8)	27 (1.0)	7 (0.3)	45 (8.4)	5 (1.4)	38 (17.5)	149 (1.6)
7 Prevalence of pain	2,150 (67.2)	2,067 (73.3)	1,484 (63.4)	369 (69.2)	248 (71.7)	157 (72.4)	6,475 (68.5)
⁸ Medication use for pain, total	533 (16.7)	426 (15.1)	147 (6.3)	110 (20.6)	80 (23.1)	59 (27.2)	1,355 (14.3)
9 By drug group							
Paracetamol (incl. combinations) (N02BE)	444 (13.9)	374 (13.3)	65 (2.8)	99 (18.6)	44 (12.7)	55 (25.3)	1,081 (11.4)
Non-steroidal antiinflammatory drugs (M01A)	19 (0.6)	36 (1.3)	21 (0.9)	11 (2.1)	24 (6.9)	3 (1.4)	114 (1.2)
2 Opioid analgesics (N02A)	39 (1.2)	51 (1.8)	2 (0.1)	4 (0.8)	-	12 (5.5)	108 (1.1)

			REGI	ON			-
Prevalence of acute/short-term illnesses in pregnancy and related medication use, overall and by drug groups	Western Europe n=3,201 <i>n (%)</i>	Northern Europe n=2,820 n (%)	Eastern Europe n=2,342 n (%)	North America n=533 n (%)	South America n=346 <i>n</i> (%)	Australia n=217 n (%)	Total n=9,459 n (%)
Prevalence of nausea	2,324 (72.6)	2,244 (79.6)	1,503 (64.2)	409 (76.7)	238 (68.8)	173 (79.7)	6,891 (72.9)
Medication use for nausea, total	413 (12.9)	380 (13.5)	140 (6.0)	128 (24.0)	71 (20.5)	39 (18.0)	1,171 (12.4)
By drug group							
First generation antihistamines (R06A)	150 (4.7)	259 (9.2)	21 (0.9)	84 (15.9)	9 (2.6)	4 (1.8)	527 (5.6)
Metoclopramide/domperidone/bromopride (A03FA)	134 (4.2)	69 (2.4)	27 (1.2)	10 (1.9)	45 (13.0)	25 (11.5)	310 (3.3)
Serotonin antagonists (A04AA)	4 (0.1)	8 (0.3)	1 (0.0)	28 (5.3)	1 (0.3)	11 (5.1)	53 (0.6)
Prevalence of UTI	513 (16.0)	327 (11.6)	452 (19.3)	93 (17.4)	92 (26.6)	25 (11.5)	1,502 (15.9)
Medication use for UTI, total	315 (9.8)	221 (7.8)	192 (8.2)	56 (10.5)	63 (18.2)	17 (7.8)	864 (9.1)
By drug group							
Unspecified penicillins (J01C-)	94 (2.9)	99 (3.5)	46 (2.0)	16 (3.0)	17 (4.9)	1 (0.5)	273 (2.9)
NOS Antibacterials for systemic use (J01-)	116 (3.6)	85 (3.0)	25 (1.1)	20 (3.8)	14 (4.0)	6 (2.8)	266 (2.8)
Penicillins with extended spectrum +/- beta-lactamase inhibitors (J01CA/J01CR)	85 (2.7)	78 (2.8)	44 (1.9)	14 (2.6)	17 (4.9)	1 (0.5)	239 (2.5)
Nitrofurantoin (J01XE)	7 (0.2)	25 (0.9)	54 (2.3)	10 (1.9)	3 (0.9)	1 (0.5)	100 (1.1)
Cephalosporins (J01D)	20 (0.6)	10 (0.4)	36 (1.5)	2 (0.4)	11 (3.2)	6 (2.8)	85 (0.9)
Total prevalence of any acute/short-term illness	3,159 (98.7)	2,803 (99.4)	2,299 (98.2)	523 (98.1)	341 (98.6)	214 (98.6)	9,339 (98.7)
Total medication use for any acute/short-term illness	2,224 (69.5)	1,954 (69.3)	1,474 (62.9)	403 (75.6)	250 (72.3)	164 (75.6)	6,469 (68.4)

*Countries are grouped into regions as shown in Figure 1.

[†]Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron,

and herbal or alternative medicine products.

 Abbreviations: UTI: Urinary tract infection; NOS: Not otherwise specified.

BMJ Open

Appendix 7: Prevalence of chronic/long-term disorders and most common medications used at any time during pregnancy by ATC level, indication for use and region $(n=9,459)^{*\dagger}$

indication for use and region (n=9,459) $^{*\uparrow}$							
			REG	ION			
Prevalence of chronic/long-term disorders in pregnancy	Western	Northern	Eastern	North	South	Australia	Total
and related medication use, overall and by drug groups	Europe	Europe	Europe	America	America		
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Prevalence of hypothyroidism	130 (4.1)	118 (4.2)	105 (4.5)	22 (4.1)	11 (3.2)	6 (2.8)	392 (4.1)
Medication use for hypothyroidism, total	118 (3.7)	113 (4.0)	96 (4.1)	21 (3.9)	9 (2.6)	6 (2.8)	363 (3.8)
By drug group							
Thyroid hormone, levothyroxine (H03AA01)	117 (3.7)	112 (4.0)	89 (3.8)	21 (3.9)	9 (2.6)	6 (2.8)	354 (3.7)
Prevalence of asthma	163 (5.1)	193 (6.8)	58 (2.5)	43 (8.1)	12 (3.5)	24 (11.1)	493 (5.2)
Medication use for asthma, total	122 (3.8)	133 (4.7)	38 (1.6)	35 (6.6)	8 (2.3)	24 (11.1)	360 (3.8)
By drug group							
Inhalant selective beta-2 agonists (R03AC)	94 (2.9)	66 (2.3)	26 (1.1)	32 (6.0)	7 (2.0)	24 (11.1)	249 (2.6)
Adrenergics and other drugs for COPD (R03AK)	33 (1.0)	46 (1.6)	10 (0.4)	3 (0.6)	2 (0.6)	7 (3.2)	101 (1.1)
Inhalant glucocorticoids (R03BA)	28 (0.9)	40 (1.4)	13 (0.6)	12 (2.3)	-	4 (1.8)	97 (1.0)
Systemic selective beta-2 agonists (R03CC)	-	30 (1.1)		2 (0.4)	-	-	32 (0.3)
Prevalence of allergy	205 (6.4)	372 (13.2)	163 (7.0)	51 (9.6)	20 (5.8)	23 (10.6)	834 (8.8)
3 Medication use for allergy, total	66 (2.1)	171 (6.1)	65 (2.8)	24 (4.5)	13 (3.8)	17 (7.8)	356 (3.8)
4 By drug group							
5 Second generation antihistamines (R06A)	29 (0.9)	104 (3.7)	27 (1.2)	17 (3.2)	4 (1.2)	5 (2.3)	186 (2.0)
S Nasal corticosteroids (R01AD)	11 (0.3)	32 (1.1)	17 (0.7)	_	-	7 (3.2)	67 (0.7)
7 First generation antihistamines (R06A)	13 (0.4)	29 (1.0)	10 (0.4)	9 (1.7)	6 (1.7)	4 (1.8)	71 (0.8)
Prevalence of depression	95 (3.0)	144 (5.1)	29 (1.2)	52 (9.8)	4 (1.2)	25 (11.5)	349 (3.7)
Medication use for depression, total	61 (1.9)	100 (3.5)	11 (0.5)	29 (5.4)	1 (0.3)	23 (10.6)	225 (2.4)
) By drug group							
SSRI antidepressants (N06AB)	44 (1.4)	82 (2.9)	6 (0.3)	14 (2.6)	-	14 (6.5)	160 (1.7)
SNRIs/mianserin/trazodone/mirtazapine/bupropion	9 (0.3)	11 (0.4)	1 (0.0)	15 (2.8)	-	7 (3.2)	43 (0.5)

			REG	ION			
Prevalence of chronic/long-term disorders in pregnancy and related medication use, overall and by drug groups	Western Europe	Northern Europe	Eastern Europe	North America	South America	Australia	Total
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Anxiolytics, benzodiazepine (N05BA)	6 (0.2)	2 (0.1)	5 (0.2)	-	-	1 (0.5)	14 (0.1)
Antipsychotics quetiapine/olanzapine (N05AH)	2 (0.1)	4 (0.1)	-	3 (0.6)	-	3 (1.4)	12 (0.1)
Total prevalence of any chronic/long-term disorder	617 (19.3)	831 (29.5)	576 (24.6)	154 (28.9)	51 (14.7)	72 (33.2)	2,301 (24.3)
Total medication use for any chronic/long-term disorder	462 (14.4)	593 (21.0)	322 (13.7)	119 (22.3)	38 (11.0)	70 (32.3)	1,604 (17.0

*Countries are grouped into regions as shown in Figure 1.

 *Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, 1: Selective serotonin re-uptake IIIII and herbal or alternative medicine products.

Abbreviations: COPD: Chronic obstructive pulmonary disease; SSRI: Selective serotonin re-uptake inhibitors; SNRI: Serotonin-noradrenaline reuptake inhibitors.

	Item	Description of the second s
T'd J. b	No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the
		abstract
		(b) Provide in the abstract an informative and balanced summary of what was
		done and what was found
Introduction		
Background/rationale	2	\checkmark Explain the scientific background and rationale for the investigation being
		reported
Objectives	3	X State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	X Present key elements of study design early in the paper
Setting	5	X Describe the setting, locations, and relevant dates, including periods of
		recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of
		participants
Variables	7	X Clearly define all outcomes, exposures, predictors, potential confounders, and
		effect modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	✗ For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group
Bias	9	X Describe any efforts to address potential sources of bias
Study size	10	\checkmark Explain how the study size was arrived at
Quantitative variables	11	X Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for
		confounding
		(b) Describe any methods used to examine subgroups and interactions
		✗ (c) Explain how missing data were addressed
		(<i>d</i>) If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
p		eligible, examined for eligibility, confirmed eligible, included in the study,
		completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	 ✗ (a) Give characteristics of study participants (eg demographic, clinical, social)
Descriptive data	17	and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
Outcomo doto	15*	
Outcome data Main results	15*	 Report numbers of outcome events or summary measures (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates
ivialii iesults	10	
		and their precision (eg, 95% confidence interval). Make clear which confounders
		were adjusted for and why they were included
		X (b) Report category boundaries when continuous variables were categorized

		meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and
		sensitivity analyses
Discussion		
Key results	18	\boldsymbol{X} Summarise key results with reference to study objectives
Limitations	19	\bigstar Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	X Give a cautious overall interpretation of results considering objectives,
		limitations, multiplicity of analyses, results from similar studies, and other relevant
		evidence
Generalisability	21	\mathbf{X} Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	X Give the source of funding and the role of the funders for the present study and, if
		applicable, for the original study on which the present article is based


*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.



Medication use in pregnancy: a cross-sectional, multinational web-based study

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-004365.R2
Article Type:	Research
Date Submitted by the Author:	20-Jan-2014
Complete List of Authors:	Lupattelli, Angela; University of Oslo, School of Pharmacy Spigset, Olav; St Olav's University Hospital, Department of Clinical Pharmacology; Children's and Women's Health, Norwegian University of Science and Technology, Department of Laboratory Medicine Twigg, Michael; University of East Anglia, School of Pharmacy Zagorodnikova, Ksenia; Northwest State Medical University n.a.I.I. Mechnikov, Northwest Medical Center for Drug Safety in Pregnancy & Lactation Mårdby, Ann-Charlotte ; The Sahlgrenska Academy, University of Gothenburg, Department of Public Health and Community Medicine Moretti, Myla; The Hospital for Sick Children, University of Toronto, The Motherisk Program, Division of Clinical Pharmacology and Toxicology Drozd, Mariola; Medical University of Lublin, Faculty of Pharmacy Panchaud, Alice; University of Geneva and Lausanne, School of Pharmaceutical Sciences Hämeen-Anttila, Katri; Finnish Medicines Agency, Rieutord, Andre; APHP, GH HUPS, Hop Antoine Béclère,, Service Pharmacien, Clamart France and Européenne de Formation pour les Pharmaciens Gjergja Juraski, Romana; Children's Hospital Srebrnjak, Neuropediatric Unit Odalovic, Marina; Faculty of pharmacy, University of Belgrade, Department of Social Pharmacy and Pharmaceutical Legislation Kennedy, Debra; Royal Hospital for Women and University of NSW, MotherSafe Rudolf, Gorazd; University Medical Centre Ljubljana, Clinical Institute of Medical Genetics Juch, Herbert; Medical University of Graz, Research Unit Human Teratogens, Institute for Cell Biology, Histology and Embryology Passier, Anneke; Netherlands Pharmacovigilance Centre Lareb, Teratology Information Service (TIS), Björnsdóttir, Ingunn; University of Oslo, School of Pharmacy; Norwegian Institute of Public Health, Division of Mental Health
Primary Subject Heading :	Obstetrics and gynaecology
Secondary Subject Heading:	Obstetrics and gynaecology, Pharmacology and therapeutics, Public health
Keywords:	Maternal medicine < OBSTETRICS, THERAPEUTICS, PUBLIC HEALTH



Medication use in pregnancy: a cross-sectional, multinational web-based study

Lupattelli A,¹ Spigset O,^{2,3} Twigg MJ,⁴ Zagorodnikova K,⁵ Mårdby AC,⁶ Moretti ME,⁷ Drozd M,⁸ Panchaud A,⁹ Hämeen-Anttila K,¹⁰ Rieutord A,¹¹ Gjergja Juraski R,¹² Odalovic M,¹³ Kennedy D,¹⁴ Rudolf G,¹⁵ Juch H,¹⁶ Passier A,¹⁷ Björnsdóttir I,¹ Nordeng H^{1,18}.

¹School of Pharmacy, University of Oslo, Norway

²Department of Clinical Pharmacology, St Olav's University Hospital, Trondheim, Norway

³Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway

⁴School of Pharmacy, University of East Anglia, Norwich Research Park, United Kingdom

³Northwest Medical Center for Drug Safety in Pregnancy & Lactation, Northwest State Medical University n.a.I.I.Mechnikov, St. Petersburg, Russia

⁶Department of Public Health and Community Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁷The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The

Hospital for Sick Children, University of Toronto, Ontario, Canada

⁸*Faculty of Pharmacy, Medical University of Lublin, Poland*

⁹School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland

¹⁰Finnish Medicines Agency, Kuopio, Finland

¹¹APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacie, Clamart France and Européenne de Formation pour les Pharmaciens, France

¹²Children's Hospital Srebrnjak, Neuropediatric Unit, Zagreb, Croatia

¹³Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of pharmacy, University of Belgrade, Serbia

¹⁴MotherSafe, Royal Hospital for Women and University of NSW, Randwick, Australia

¹⁵Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Slovenia

¹⁶Research Unit Human Teratogens, Institute for Cell Biology, Histology and Embryology, Medical University of Graz, Austria

¹⁷*Teratology Information Service (TIS), Netherlands Pharmacovigilance Centre Lareb, the Netherlands*

¹⁸Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway

Corresponding author:

Angela Lupattelli, MScPharm,

1	
2 3 4	
4	
5 6	
7	
8 9	
10	
11	
12 13	
14	
15 16	
17	
18 19	
20	
21 22	
23	
 13 14 15 16 17 18 19 20 21 22 23 24 25 	
26	
27 28 29	
29	
30 31	
32	
33 34	
35	
36 37	
38	
39 40	
41	
42 43	
44	
45 46	
47	
48 49	
50	
51	
52 53	
54	
55 56	
57	
58 59	
60	

Department of Pharmacy, School of Pharmacy, University of Oslo,

PO Box 1068 Blindern, 0316 Oslo, Norway

e-mail: angela.lupattelli@farmasi.uio.no; phone: +47 41343628 ; fax: +4722854402

Key words: pregnancy; drug utilization, maternal health; health behaviour; public

health

Word count (excluding title page, abstract, references, figures and tables): 3637

.xcluding title page,

ABSTRACT

Objectives: Inter-country comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and factors associated with medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilized and indication for use.

Design: Cross-sectional, web-based study performed within the period from 1-Oct-2011 to 29-Feb-2012. Uniform collection of drug utilization data was performed via an anonymous online questionnaire.

Setting: Multinational study in Europe (Western, Northern, and Eastern), North and South America, and Australia.

Participants: Pregnant women and new mothers with children less than one year of age.

Primary and secondary outcome measures: Prevalence of and factors associated with medication use for acute/short-term illnesses, chronic/long-term disorders and over-the-counter (OTC) medication use.

Results: The study population included 9,459 women whereof 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. Overall, OTC medication use occurred in 66.9% of the pregnancies, whereas 68.4% and 17.0% of women reported use of at least one medication for treatment of acute/short-term illnesses and chronic/long-term disorders, respectively. The extent of self-reported

BMJ Open

medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting use of medication for chronic/long-term disorders. Immigrant women in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83) were less likely to report use of medication for chronic/long-term disorders during pregnancy than nonimmigrants.

Conclusions:

In this study, the majority of women in Europe, North America, South America and Australia used at least one medication during pregnancy. There was a substantial inter-region variability in the types of medication used.

ARTICLE SUMMARY

Strengths and limitations of this study

- Uniform data collection of drug utilization data across all participating countries allows for inter-country comparability of the prevalence of medication use during pregnancy, up to now impeded by differences in study design and methodology.
- The study adds a multinational perspective on OTC medication use during pregnancy to the limited number of studies quantifying the extent of self-medication during pregnancy.
- Lack of validity of the self-reported diagnoses is a limitation since all disorders and related medication use were self-reported by the study participants.
- A web-based survey as a study method impedes calculation of a conventional response rate and may cause selection bias of the target population.

INTRODUCTION

Ethical reasons preclude inclusion of pregnant women in the vast majority of premarketing clinical trials.[1] As a consequence, most medications are placed onto the market without a directly established safety profile in human pregnancy.[2] So far, few medications have been shown to be major teratogens, yet the risk of minor teratogenicity or of more subtle effects on fetal development still have to be determined for most of them.[3] Despite this, medication use during pregnancy is common. Mitchell et al. found that use of medications, either prescribed or purchased over-the-counter (OTC), occurred in 88.8% of all pregnancies in the USA.[4] In Europe, prevalence estimates of prescribed medication use vary considerably across countries, ranging from 26% in Serbia to 93% in France.[5-10] Such inter-country variability could, at least in part, be caused by differences in study design, methodology and exposure ascertainment across studies.[11] Uniform collection of drug utilization data during pregnancy between countries may overcome such drawbacks, allowing for inter-country comparability of prevalence estimates and shedding light on differences in prenatal care in the various countries.

Prior studies have addressed research priorities in this area such as presenting results on an individual drug level according to the indication of use, quantifying the extent of OTC and prescribed medication use during pregnancy, and taking into account inter-country comparability.[4] Only a few studies have individually examined maternal factors associated with specific types of medication use during pregnancy.[11-14]

The objectives of the current study were to examine patterns of medication use in pregnancy from a multinational perspective, with special emphasis on type of medication utilized, including OTC medications, and self-reported indications for use, and to identify maternal background factors potentially associated with medication use for acute/short-term illnesses, medication use for chronic/long-term disorders and OTC medication use during pregnancy.

METHODS

Study design and data collection

This is a multinational, cross-sectional, web-based study. Pregnant women at any gestational week and mothers with children less than one year of age were eligible to participate. Member countries of the European Network of Teratology Information Services (ENTIS), The Organization of Teratology Information Specialists (OTIS) in North America, MotherSafe in Australia and European institutions conducting public health research were invited to take part in the project. Of these, 18 countries participated (Australia, Austria, Canada, Croatia, Finland, France, Iceland, Italy, Netherlands, Norway, Poland, Russia, Serbia, Slovenia, Sweden, Switzerland, United Kingdom and USA). Data originating from some South and Central American countries were also collected through OTIS. Because of the low number of participants on the individual country level, the region of Central America was excluded and countries in South America were aggregated into one region. Data selection to achieve the final study sample was performed as depicted in Figure 1. Participants were categorized according to the reported country of residency and grouped into six regions: Western Europe, Northern Europe, Eastern Europe, North America, South America and Australia.

BMJ Open

Data were collected through an anonymous on-line questionnaire administered by Quest Back (http://www.questback.com) and accessible for a period of two months in each participating country within the period 1-Oct-2011 to 29-Feb-2012. The questionnaire was open to the public via utilization of banners (invitations to participate in the study) on national websites and/or social networks commonly visited and consulted by pregnant women and/or new mothers. The complete questionnaire is presented in Appendix 1. Detailed information about recruitment tools utilized and internet penetration rates is summarized in Appendix 2.

The questionnaire was first developed in Norwegian and English and then translated into the other relevant languages. A pilot study was carried out in September 2011 (n=47) and elicited no major change to the questionnaire. Collected data were scrutinized for the presence of potential duplicates (based on reported country of residency, socio-demographic characteristics, date and exact time of questionnaire completion) but none were identified.

Exposure variables

Maternal socio-demographics (i.e. region of residency, age, educational level, mother tongue, working status at time of conception, previous children, marital status and unplanned pregnancy) and life-style characteristics (i.e. smoking status before and during pregnancy and alcohol consumption after awareness of pregnancy) constituted the exposure variables. To assess external validity, we compared socio-demographic and life-style characteristics of our study population on an individual country level with those of the general birthing population in the same country. Reports of National Statistics Bureaus or previous national studies were utilized for this purpose. The ratio

between the number of respondents and the estimated number of live births in the 2months period was also examined for each country (Appendix 3).

Outcome variables

Use of any medication, medication for acute/short-term illnesses, medication for chronic/long-term disorders and OTC medication use during pregnancy constituted the outcome variables. Participants were first confronted with a list of the most common acute/short-term illnesses (i.e. nausea, heartburn, constipation, common cold, urinary tract infections (UTIs), other infections, pain in the neck/back/pelvic girdle, headache, sleeping problems) and the most prevalent chronic/long-term disorders (i.e. asthma, allergy, hypothyroidism, rheumatic disorders, diabetes, epilepsy, depression, anxiety, cardiovascular disease, other disorders) and asked whether they suffered/had suffered from these conditions during pregnancy. In case of an affirmative response, women were questioned about medication use for each individual indication as a freetext entry. Use of OTC medications was also recorded. Recall was aided with a list of five OTC medication categories: painkillers, nasal spray/drops, antinauseants, antacids and laxatives, along with examples of brand name products of relevance in each country. It was optional to report timing of exposure for each of the medication use questions (the alternatives were gestational weeks 0-12 (1st trimester), 13-24 (2nd trimester) and 25-delivery (3rd trimester)).

We defined a medicine as a single product containing one or more active ingredients. We initially identified the main active ingredient(s) and formulation of the reported medicinal products either in the relevant national medicines database or in the "Martindale" textbook.[15] All recorded medications were coded into the corresponding Anatomical Therapeutic Chemical (ATC) codes at the ATC 5th level

BMJ Open

(i.e. the substance level) whenever possible, otherwise into the 2nd- 4th levels as appropriate, in accordance with the World Health Organization ATC index.[16] The OTC status of medications was crosschecked with the prescription policies within each country. Whenever a prescription medication was reported under the OTC question, this record was omitted from the analysis of OTC use but counted in the estimation of total medication use (including prescription and OTC). Iron, mineral supplements, vitamins, herbal remedies and any type of alternative medicine were recorded separately and excluded from the estimation of medication use.

The required sample size calculation for the outcome variables on region and individual country levels are outlined in Appendix 4. The expected prevalence estimates were set according to results of previous studies.[5-10,17,18]

Ethics

All participants gave informed consent by answering "Yes" to the question "Are you willing to participate in the study?" The study was approved by the Regional Ethics Committee, Region South-East in Norway. Ethical approval or study notification to the relevant national Ethics Boards was achieved in specific countries as required by national legislation. All data were handled and stored anonymously.

Statistical analysis

Descriptive statistics were utilized as appropriate. Univariate and multivariate logistic regression analyses were used to examine the association between maternal characteristic and three categorical outcome measures (Yes/No): Medication use for acute/short-term illnesses; medication use for chronic/long-term disorders; OTC medication use. P-values of <0.05 were considered statistically significant. Data are

presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). The analyzed explanatory variables included all maternal socio-demographics and lifestyle characteristics. After fitting the univariate logistic regression model for all explanatory variables, the multivariate model was built and adjusted for all remaining covariates. The Hosmer and Lemeshow test was used to assess goodness of fit of the final multivariate model.[19] Analogue sub-analyses on individual region level were performed. In these instances, region of residency was not included in the model. All statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM[®] SPSS[®] Statistics).

RESULTS

Population characteristics

A total of 9,615 women accessed the on-line questionnaire whereof 98.6% completed it. The participant flow-chart to achieve final study population (n=9,459) is depicted in Figure 1. A total of 5,089 women (53.8%) were pregnant at the time of completion of the questionnaire, whereas 4,370 women (46.2%) had delivered their babies within the previous year. Of the former group, 1,095 (21.5%), 1,702 (33.4%) and 2,291 (45.0%) women were in the first, second and third trimester of pregnancy, respectively. Of the latter group, 1,320 (30.2%), 947 (21.7%) and 2,102 (48.1%) had a baby of age \leq 16 weeks, 17-28 weeks, and \geq 29 weeks, respectively. For two women the time of gestation/baby's age was unknown. Overall, the birthing population in each participating country was reflected quite well by the sample with respect to age, parity and smoking habits (Appendix 3). However, there was a difference in terms of educational level; on average, the women in the study had higher education than the general birthing population in each country. In addition, participants in Sweden,

Austria, Iceland and Italy were slightly more often primiparous, whereas the responders in Australia, USA, The Netherlands, Slovenia and Croatia were somewhat older than the general birthing population.

Total medication use

After exclusion of vitamins, mineral supplements and iron, use of at least one medication either prescribed or OTC at any time during pregnancy was reported by 7,678 out of 9,459 women (81.2%). Figure 2 depicts prevalence estimates of total medication use during pregnancy by region and country of residence. The extent of OTC medication use, as well as medication use for acute/short-term illnesses and chronic/long-term disorders is also outlined. The highest prevalence of total medication use during pregnancy was observed in The Netherlands (95.1%), Iceland (93.0%) and Finland (92.3%). The overall prevalence estimates of medication use in pregnancy according to timing and drug class (ATC level 1 and 2) are presented in Appendix 5. Medications for the nervous system (ATC class N) were the most commonly used during pregnancy (57.5%), mostly due to paracetamol (acetaminophen) and its combinations.

A corollary analysis according to pregnancy status showed that pregnant women reported in a significantly lower degree than new mothers any medication use during pregnancy (78.8% vs. 84.0%, p-value<0.001), as well as OTC medication use (63.0% vs. 71.5%, p-value<0.001) and medication use for acute/short-term illnesses (66.2% vs. 70.9%, p-value<0.001). In contrast, the difference in medication use for chronic/long-term disorders was not significant (17.4% vs. 16.5%, p-value=0.271). None of the rates differed significantly when women in the third trimester of pregnancy were compared to new mothers.

Medication use according to indication

Headache, heartburn, pain, nausea and UTIs constituted the leading indications for use of medication during pregnancy among the acute/short-term illnesses analyzed. Hypothyroidism, asthma, allergy and depression were the leading indications for chronic/long-term medication use. Observed prevalence rates of these disorders, overall and by region of residency, are presented in Appendices 6 and 7, respectively, along with rates of total and specific medication use. Table 1 outlines prevalence estimates of OTC medication use during pregnancy by region and indication for use. Only the most common medication groups reported are presented. Inter-region variations in rates and types of medication used during pregnancy were observed both for acute/short-term illnesses (e.g. nausea and UTIs), chronic/long-term disorders (e.g. asthma and depression) and OTC medications (e.g. nasal spray).

Factors associated with medication use

Factors associated with medication use during pregnancy according to type of medication utilized are presented in table 2. Use of chronic/long-term medications during pregnancy was reported in a significant larger extent by women in Northern Europe (aOR: 1.68, 95% CI: 1.46-1.94), North America (aOR: 1.80, 95% CI: 1.42-2.28) and Australia (aOR: 2.76, 95% CI: 2.03-3.76) compared to women in Western Europe. Older women or housewives, those with low education or with an unplanned pregnancy, were the ones most often reporting use of chronic/long-term medication. Sub-analysis on individual region level revealed that women not having the official language of the country of residency as mother tongue were less likely to report chronic/long-term medication use in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83), but not in the other regions.

BMJ Open

Table 1: Use of OTC medication at any time during pregnancy by ATC level, indication for use and region (n=9,459) *†

3			REG	GION			-
OTC medication use, overall and by drug groups	Western Europe n=3,201	Northern Europe n=2,820	Eastern Europe n=2,342	North America n=533	South America n=346	Australian n=217	Total n=9,459
	<u>n (%)</u>	n (%)	n (%)	n (%)	n (%)	<i>n (%)</i>	n (%)
 OTC painkillers, total By drug group 	1,714 (53.5)	1,773 (62.9)	734 (31.3)	284 (53.3)	127 (36.7)	151 (69.9)	4,783 (50.6)
le by arag group							
Paracetamol (incl. combinations) (N02BE)	1,655 (51.7)	1,735 (61.5)	630 (26.9)	263 (49.3)	87 (25.1)	146 (67.3)	4,516 (47.7)
Non-steroideal antiinflammatory drugs (M01A)	70 (2.2)	182 (6.5)	68 (2.9)	40 (7.5)	59 (17.1)	7 (3.2)	426 (4.5)
Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	11 (0.4)	32 (1.4)	2 (0.4)	2 (0.6)	1 (0.5)	55 (0.6)
20 Metamizole (N02BB02)	-	6 (0.2)	31 (1.3)	1 (0.2)	12 (3.5)	-	50 (0.5)
OTC antacids, total	1,011 (31.6)	883 (31.3)	583 (24.9)	129 (24.2)	48 (13.9)	76 (35.0)	2,730 (28.9)
By arug group							
Antacids (aluminium, salts combinations, antiflatulents)	472 (14.7)	550 (19.5)	508 (21.7)	47 (8.8)	36 (10.4)	54 (24.9)	1,667 (17.6)
Alginic acid complex/sucralfate/bismuth (A02BX)	606 (18.9)	421 (14.9)	87 (3.7)	4 (0.8)	1 (0.3)	17 (7.8)	1,136 (12.0)
H ₂ receptor antagonists (A02BA)	20 (0.6)	20 (0.7)	16 (0.7)	57 (10.1)	10 (2.9)	17 (7.8)	137 (1.4)
Antacids with calcium (A02AC)	23 (0.7)	12 (0.4)	10 (0.4)	69 (12.9)	2 (0.6)	10 (4.6)	126 (1.3)
Proton pump inhibitors (A02BC)	38 (1.2)	52 (1.8)	_	10 (1.9)	2 (0.6)	5 (0.3)	107 (1.1)
OTC nasal sprays/drops, total	272 (8.5)	742 (26.3)	451 (19.3)	35 (6.6)	7 (2.0)	14 (6.5)	1,521 (16.1)
By drug group							
Sympathomimetic nasal decongestants (R01AA/R01BB)	204 (6.4)	683 (24.2)	365 (15.6)	20 (3.8)	3 (0.9)	4 (1.8)	1,279 (13.5)
Nasal corticosteroids (R01AD)	31 (1.0)	49 (1.7)	12 (0.5)	5 (0.9)	2 (0.6)	10 (4.6)	109 (1.2)
Nasal immunostimulants (low dose interferon) (L03A)	-	-	28 (1.2)		-	-	28 (0.3)
B5 OTC levelings total	240 (7.5)	227 (8.0)	237 (10.1)	50 (9.4)	8 (2.3)	19 (8.8)	781 (8.3)
Bo By drug group	、		× ,	~ /		、 /	、 <i>,</i>
38 Osmotically acting laxatives (A06AD)	159 (5.0)	171 (6.1)	197 (8.4)	2 (0.4)	2 (0.6)	8 (3.7)	539 (5.7)
39 Contact laxatives (A06AB)	28 (0.9)	44 (1.6)	18 (0.8)	7 (1.3)	6 (1.7)	2 (0.9)	105 (1.1)
40	×)	× /	× /	× /	~ /	~ /	14
41							17

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	REGION						
OTC medication use, overall and by drug groups	Western Europe	Northern Europe	Eastern Europe	North America	South America	Australian	Total
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Enemas (A06AG)	3 (0.1)	25 (0.9)	34 (1.5)	4 (0.8)	-	2 (0.9)	68 (0.7)
Softeners, emollients (A06AA)	8 (0.2)	-	-	38 (7.1)	-	6 (2.8)	52 (0.5)
OTC antinauseants, total	263 (8.2)	273 (9.7)	41 (1.8)	60 (11.3)	28 (8.1)	40 (18.4)	705 (7.5)
By drug group							
First generation antihistamines (R06A)	141 (4.4)	256 (9.1)	7 (1.5)	55 (10.3)	5 (1.4)	5 (2.3)	469 (5.0)
Metoclopramide/domperidone/bromopride (A03FA)	113 (3.5)	5 (0.2)	18 (0.8)	2 (0.4)	19 (5.5)	27 (12.4)	184 (1.9)
Total OTC medication use	2,163 (67.6)	2,155 (76.4)	1,347 (57.5)	342 (64.2)	156 (45.1)	168 (77.4)	6,331 (66.9)

Abbreviations: OTC: Over-The-Counter medications.

*Countries are grouped into regions as shown in Figure 1.

*Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, and herbal

or alternative medicine products.

 BMJ Open

			Medi	ication use		
		ort-term illnesses =6,469)		ong-term disorders =1,604)		OTC =6,331)
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)
Region of residency [†]						
Western Europe	2,224 (69.5)	Reference	462 (14.4)	Reference	2,163 (67.6)	Reference
Northern Europe	1,954 (69.3)	0.96 (0.86-1.08)	593 (21.0)	1.68 (1.46-1.94)	2,155 (76.4)	1.54 (1.36-1.74)
Eastern Europe	1,474 (62.9)	0.69 (0.61-0.78)	322 (13.7)	1.03 (0.87-1.21)	1,347 (57.5)	0.60 (0.53-0.67)
North America	403 (75.6)	1.28 (1.03-1.60)	119 (22.3)	1.80 (1.42-2.28)	342 (64.2)	0.81 (0.66-0.99)
South America	250 (82.3)	1.03 (0.79-1.34)	38 (11.0)	0.70 (0.48-1.01)	156 (45.1)	0.34 (0.27-0.44
Australia	164 (75.6)	1.29 (0.93-1.79)	70 (32.3)	2.76 (2.03-3.76)	168 (77.4)	1.57 (1.12-2.20
Maternal age (years)						
≤20	232 (70.5)	1.22 (0.93-1.60)	761 (14.7)	0.58 (0.39-0.87)	205 (62.3)	1.05 (0.81-1.36
21-30	3,531 (68.2)	Reference	33 (10.0)	Reference	3,461 (66.8)	Reference
31-40	2,576 (68.6)	0.90 (0.82-1.00)	764 (20.4)	1.44 (1.27-1.63)	2,531 (67.4)	0.85 (0.77-0.94
<u>≥</u> 41	130 (66.3)	0.73 (0.54-1.00)	46 (23.5)	1.61 (1.13-2.29)	134 (68.4)	0.86 (0.62-1.19
Previous children						
No	3,082 (65.5)	Reference	735 (15.6)	Reference	2,949 (62.6)	Reference
Yes	3,387 (71.3)	1.34 (1.22-1.47)	869 (18.3)	1.08 (0.96-1.21)	3,382 (71.2)	1.58 (1.44-1.74
Marital status						
Married/cohabiting	6,066 (68.5)	Reference	1,503 (17.0)	Reference	5,960 (67.3)	Reference
Single/divorced/others	403 (66.3)	0.91 (0.75-1.10)	101 (16.6)	1.06 (0.83-1.35)	371 (61.0)	0.91 (0.75-1.10
Working status						
Employed, but not as HCP	3,737 (66.8)	Reference	905 (16.2)	Reference	3,667 (65.6)	Reference
HCP	934 (74.4)	1.41 (1.23-1.63)	240 (19.1)	1.13 (0.96-1.33)	944 (75.2)	1.42 (1.23-1.64
Student	592 (69.1)	1.11 (0.94-1.31)	128 (14.9)	1.04 (0.84-1.30)	578 (67.4)	1.10 (0.93-1.30
Housewife	608 (72.6)	1.14 (0.96-1.35)	170 (20.3)	1.34 (1.10-1.63)	577 (68.9)	1.05 (0.88-1.24
Job seeker	281 (66.0)	0.96 (0.78-1.20)	66 (15.5)	1.03 (0.78-1.36)	258 (60.6)	0.85 (0.68-1.05
Other than above	311 (65.2)	0.91 (0.75-1.12)	94 (19.7)	1.29 (1.01-1.65)	302 (63.3)	0.91 (0.74-1.12

	Medication use									
		ort-term illnesses =6,469)		ong-term disorders =1,604)	OTC (n=6,331)					
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)				
Less than high school	331 (72.7)	1.17 (0.93-1.49)	92 (20.2)	1.51 (1.15-1.97)	317 (69.7)	1.32 (1.04-1.67)				
High school	1,864 (68.7)	Reference	428 (15.8)	Reference	1,779 (65.6)	Reference				
More than high school	3,574 (68.4)	0.99 (0.89-1.11)	916 (17.5)	1.04 (0.91-1.20)	3,489 (66.8)	1.07 (0.96-1.19)				
Others, unspecified	700 (65.7)	0.82 (0.70-0.96)	168 (15.8)	0.94 (0.77-1.16)	746 (70.0)	1.13 (0.97-1.33)				
Alcohol use after awareness of pregn	ancy									
No	5,270 (67.1)	Reference	1,322 (16.8)	Reference	5,133 (65.3)	Reference				
Yes	1,144 (75.7)	1.59 (1.39-1.81)	270 (17.9)	1.11 (0.95-1.29)	1,150 (76.1)	1.95 (1.71-2.23)				
Smoking during pregnancy										
No	5,835 (68.5)	Reference	1,441 (16.9)	Reference	5,716 (67.0)	Reference				
Yes, but less than before pregnancy	530 (69.0)	1.08 (0.91-1.27)	130 (16.9)	1.01 (0.82-1.25)	511 (66.5)	1.06 (0.90-1.26)				
Yes, the same or more than before										
pregnancy	88 (67.7)	0.95 (0.64-1.40)	28 (21.5)	1.19 (0.74-1.90)	89 (68.5)	1.21 (0.81-1.82)				
Planned pregnancy										
Yes	5,836 (68.4)	Reference	1,427 (16.7)	Reference	5,727 (67.2)	Reference				
No	616 (68.4)	0.96 (0.82-1.12)	173 (19.2)	1.29 (1.06-1.56)	587 (65.1)	1.00 (0.85-1.17)				
First language different from the offi	cial main langu	age in the country of	f residency							
No	6,089 (68.5)	Reference	1,530 (17.2)	Reference	5,972 (67.1)	Reference				
Yes	363 (67.2)	0.93 (0.76-1.12)	71 (13.1)	0.66 (0.50-0.86)	347 (64.3)	0.89 (0.74-1.08				

Abbreviation: HCP: health care provider.

*Numbers may not add up due to missing values. Missing values are less than 5% of the total. Mineral supplements, vitamins, iron, herbal or alternative medicine products are not included in the medication use estimates. [†]Countries are grouped into regions as shown in Figure 1.

DISCUSSION

This is the first web-based study examining patterns and factors associated with medication use during pregnancy on a multinational level. In all regions, approximately eight out of ten women reported use of at least one medication, either prescribed or OTC, during the course of their pregnancy. This finding is in line with previous research conducted in Europe, North America, South America and Australia,[4,20-25] though our estimates were somewhat higher in some of the Eastern European countries, e.g. Serbia, than those observed in a previous study.[5] Different recruitment strategies, i.e. web-based in our study versus maternity care unit-/community pharmacy-based in the previous study could explain such discrepancy.

Overall, analgesics, antacids, nasal decongestants/antiallergics and systemic antibiotics were the medication groups dominating the drug utilization scenario, as also shown by previous research.[4,20-22] However, our study also provides insights into the proportion of medicated women among those suffering from a specific illness during pregnancy across the six regions. We found that approximately seven out of ten women who reported UTIs were treated with antibiotics during pregnancy. This related to all regions, except Eastern Europe where it was only four out of ten women. Since women may perceive dysuria without ascertainment of bacteriuria in the urine as UTI, an over-reporting of the illness could have occurred. Yet, a sub-optimal treatment of UTIs during pregnancy in Eastern Europe cannot be ruled out. The inter-country variability in the types of antibiotics used for UTIs could simply be explained by differences in prescribing practice,[26] presence of screening for bacteriuria in early pregnancy, or specific antibiotic resistance patterns.

Even though nausea was the condition affecting most women in all six regions, the corresponding proportions of medicated nausea were generally low. This scenario is probably

due to two main factors: a) the predominantly mild character of nausea and the possibility of non-pharmacological management (e.g. dietary advices); b) the reluctance of general practitioners to prescribe antinauseants even though safety profile assessments are in place.[27,28] As also shown in previous studies,[4,29] use of serotonin antagonists in North America and Australia is increasing also in pregnancy compared to the other regions, eliciting the need of sound studies assessing the safety profile of this drug group in pregnancy.

In most regions, the self-reported prevalence of hypothyroidism was somewhat higher than the reported hormone substitution rate. Because of its known association with adverse pregnancy outcomes,[30] the unexpected finding of potential sub-optimal treatment of hypothyroidism during pregnancy deserves attention. It could probably be due to a lack of information about hypothyroidism typology and its diagnostic ascertainment in our study.

In our study, depression was self-reported and not based on any psychometric assessment, thus the observed substantial inter-regional variability in the extent of this disorder and related medication use could have certainly been affected by women's attitudes in reporting. Our estimate of medication use for depression in Australia was higher than that observed in a recent study (10.6% versus 2.1%).[31] However, the similarity in self-reported depression itself (11.5% versus 15.6%) suggests that our population might mostly comprise women who did not discontinue their pharmacological therapy once they became pregnant. Our estimates for North America and Western Europe were in line with recent literature showing an increase in antidepressant use in pregnancy during the last years.[4,32] Selective serotonin reuptake inhibitors (SSRIs) were the most widely used antidepressant class. Recent meta-analyses have shown that antidepressants, including SSRIs, do increase the risk of poor neonatal adaptation syndrome, specific cardiovascular malformations and persistent pulmonary hypertension of the newborn.[33-35] However, the clinical impact of the latter two outcomes, in absolute

BMJ Open

terms, is small and the risk of pharmacotherapy should always be weighted versus the risk of undertreated depression in pregnancy.

In most regions approximately 60-70% of women reported use of at least one OTC medication during the course of their pregnancies, mostly for pain conditions, heartburn and upper airways disorders, indicating a substantially high rate of self-medication during pregnancy. This estimate aligns with previous research carried out in North America.[17] Of note, self-medication with OTC sympathomimetic nasal decongestants was more extensive in Northern and Eastern Europe than in the remaining regions; this could be explained by the time of the year when the data collection was performed.

Region of residency was an important factor associated with medication use during pregnancy. As also shown by Cleary et al.,[36] we found that rates of medication use among women originally from Eastern Europe and South America were significantly lower than those observed in Western Europe, North America and Australia. Such geographical differences could be due to culture, variations in prenatal care assistance or access to medications in the various regions and the related costs.

Women working as health care providers, consuming alcohol during pregnancy, or with previous children were those more likely to use short-term and OTC medications, possibly reflecting higher confidence in self-treatment and use of medications in general in the former instance, and less anxiety for the pregnancy outcome in the latter two instances. Contrary to previous studies indicating an association between higher maternal education and more prevalent use of medication during pregnancy,[14,17,23] we found that lower education was associated with a higher use of OTC medications as well as medication for chronic/long-term disorders (30-50% increased risk). Results of similar magnitude (30% increased risk)

were also observed by Olesen et al.[37], whereas Stokholm et al. [38] identified a stronger association (2.3-fold increased risk) between low maternal education and use of antibiotic for respiratory tract infections during pregnancy. One factor negatively associated with chronic/long-term medication use was not having the official language of the country of residency as mother tongue. This tendency was detected in Western and Northern Europe, rising concerns about the potential health risks for immigrant women in these two regions. As shown by Hämeen-Anttila et al., 57% of pregnant women have perceived information needs about medications during pregnancy.[39] Thus, identification of potential users or non-users of medication during pregnancy might be of clinical relevance. Indeed, this may allow tailored evidence-based information about medication safety or outcome of sub-optimal medication of severe medical conditions in pregnancy.

Strengths and limitations

The main strength is that data collection was performed uniformly across all participating countries, allowing for inter-country comparison of the prevalence of medication use during pregnancy. By quantifying the extent of self-medication with OTC drugs and medication use according to self-reported indication, it was possible to determine the leading causes for medication use among pregnant women. Categorization of maternal characteristics positively associated with the various types of medications used during pregnancy enabled us to identify which groups of women are more likely to need information about medication use during pregnancy. The utilization of an anonymous web-based questionnaire enabled us to reach a large proportion of the birthing population in several countries worldwide. However, we cannot exclude the possibility that the women who decided to participate in the study differed from the general birthing population in other ways that our analysis could not control for. In most participating countries the study sample was large enough to warrant calculation of

BMJ Open

prevalence estimates with a precision of 5%. However, less precise estimates were permitted by the study sample in Austria, Iceland and The Netherlands (precision of 9-11%), as well as in Australia, Canada, Croatia, Serbia, Slovenia, and USA (precision of 6-7%).

One main limitation of the study is the lack of validity of the self-reported diagnoses. All disorders were self-reported by the participants and hence dependent on the women's perception of the medical condition. Similarly, information about medication use during pregnancy was dependent on the accuracy of the women's reporting and recall. For new mothers, data were registered retrospectively; hence a risk of recall bias cannot be ruled out. In specific countries (Australia, Canada, France, Russia, The Netherlands, and USA) the study sample was a small proportion of the general birthing population; hence the generalizability of our findings for these specific countries should be interpreted with caution.

The questionnaire was only available through internet websites; by using this kind of approach a conventional response rate cannot be calculated and a selection bias of the target population cannot be ruled out. However, recent epidemiological studies indicate reasonable validity of web-based recruitment methods.[40,41] Also, the penetration rate of the internet either in households or at work is relatively high among women in childbearing age.[42-46] Hence, the degree to which our findings can be extrapolated to the target population is based on the representativeness of the respondents to the general birthing populations in each country. The sample in each country had a somewhat higher educational level than the general birthing populations. Such a limitation might have led to an underestimation of the prevalence of medication during pregnancy. Since many ailments requiring pharmacotherapy occur in mid or late pregnancy, inclusion of pregnant women at early gestation in the total material has somewhat inflated the prevalence of non-users of medications during pregnancy. Also, women with specific disorders or in need of information about medication use during

pregnancy might have been more likely to consult internet websites and therefore participate in this study.

CONCLUSIONS

Use of medications for acute/short-term illnesses and chronic/long-term disorders as well as use of OTC medications, were common during pregnancy. The extent of medicated illnesses and types of medications used for the different indications varied across the six regions. This was especially relevant for acute/short-term illnesses such as nausea and UTIs, but also for chronic/long-term disorders such as hypothyroidism or depression. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting chronic/long-term medication use, as opposed to immigrants residing in Western and Northern Europe who reported the least use of this medication category. Future research should definitely focus on this specific group of women, but also address more insights into the outcome of sub-optimal medication of severe conditions in pregnancy.

ACKNOWLEDGMENTS

We thank OTIS, ENTIS Scientific Board who reviewed the study protocol and all website providers who contributed to the recruitment phase. We are grateful to all the participating women who took part in this study.

FUNDING STATEMENT

This work was supported by the Norwegian Research Council grant number 216771/F11 and by the Foundation for Promotion of Norwegian Pharmacies and the Norwegian Pharmaceutical Society.

AUTHOR'S CONTRIBUTION: AL, OS and HN conceived the idea for the study and participated in its design and coordination. AL drafted the manuscript and analyzed the data. MJT, KZ, ACM, MEM, MD, AP, KHA, AR, RGJ, MO, DK, GR, HJ, AP and IB contributed to the data collection. All authors contributed to the interpretation of the results and revised the manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

DATA SHARING STATEMENT: No additional data are available. Researchers can apply for data access for subprojects within the overall aims of the main study 'The Multinational Medication Use in Pregnancy Study'.

COMPETING INTERESTS: None declared

REFERENCES

ACOG Committee Opinion No. 377: Research involving women. Obstet Gynecol 2007;110(3):731-6.

 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157(3):175-82.
 Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. [S.l.]: Lippincott

Williams & Wilkins 2011.

 Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205(1):51 e1-8.
 Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012;34(5):719-27.

6. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008;**64**(11):1125-32.

7. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;**65**(5):653-60.

8. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;**113**(5):559-68.

9. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009;65(8):839-46.
 10. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol 2003;59(2):127-33.

BMJ Open

e 27 of 108	BMJ Open
	11. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during pregnancy in
	developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011; 20 (9):895-902.
	12. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in
	pregnancy. J Clin Epidemiol 1993;46(6):581-89.
	13. McKenna L, McIntyre M. What over-the-counter preparations are pregnant women taking?
	A literature review. J Adv Nurs 2006;56(6):636-45.
	14. Odalovic M, Vezmar Kovacevic S, Nordeng H, et al. Predictors of the use of medications
	before and during pregnancy. Int J Clin Pharm 2013; 35 (3):408-16.
	15. Martindale W, Sweetman SC. Martindale : the complete drug reference. London:
	Pharmaceutical Press, 2011.
	16. WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines for ATC
	classification and DDD assignment 2013. Oslo, 2012. Available at:
	http://www.whocc.no/atc_ddd_index/. Accessed 17 March, 2012.
	17. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of Over-the-Counter Medications and
	Herbal Remedies in Pregnancy. Amer J Perinatol 2005;22(EFirst):321,24.
	18. Sawicki E, Stewart K, Wong S, et al. Medication use for chronic health conditions by
	pregnant women attending an Australian maternity hospital. Aust N Z J Obstet Gynaecol
	2011; 51 (4):333-38.
	19. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley-Interscience
	2000.
	20. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications
	and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66(2):207-14.
	21. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from
	the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;60(5):355-
	61.
	26

22. Medication during pregnancy: an intercontinental cooperative study. Collaborative Group on Drug Use in Pregnancy (C.G.D.U.P.). Int J Gynaecol Obstet 1992;**39**(3):185-96.

23. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000;**56**(4):323-8.

24. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAP study. Aust N Z J Obstet Gynaecol 2000;**40**(2):165-72.

25. Marín G, Cañas M, Homar C, et al. Uso de fármacos durante el período de gestación en embarazadas de Buenos Aires, Argentina. Rev salud pública 2010;**12**(5):722-31.

26. European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2010. Stockholm: ECDC, 2013.

27. Smith J, Refuerzo J, Ramin S. Treatment and outcome of nausea and vomiting of pregnancy. In: Basow D, ed. UpToDate. Waltham, MA: UpToDate, 2013.

28. Gadsby R, Barnie-Adshead T, Sykes C. Why won't doctors prescribe antiemetics in pregnancy? BMJ 2011;**343**:d4387.

29. Raymond SH. A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. Aust N Z J Obstet Gynaecol 2013;**53**(4):358-62.

30. Ross DS. Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment. In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate, 2013.

31. Lewis AJ, Bailey C, Galbally M. Anti-depressant use during pregnancy in Australia: findings from the Longitudinal Study of Australian Children. Aust N Z J Public Health 2012;**36**(5):487-8.

32. Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011;**72**(7):979-85.

BMJ Open

33. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74(4):e293-e308.
34. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014;348:f6932.
35. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal

antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis. J Clin Psychiatry 2013;**74**(4):e309-e20.

36. Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010;**19**(4):408-17.

37. Olesen C, Thrane N, Henriksen TB, et al. Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women. Eur J Clin Pharmacol 2006;**62**(7):547-53.

38. Stokholm J, Schjorring S, Pedersen L, et al. Prevalence and Predictors of Antibiotic Administration during Pregnancy and Birth. PLoS One 2013;8(12):e82932.

39. Hämeen-Anttila K, Jyrkkä J, Enlund H, et al. Medicines information needs during pregnancy: a multinational comparison. BMJ Open 2013;**3**(4).

40. Ekman A, Dickman P, Klint Å, et al. Feasibility of Using Web-based Questionnaires in Large Population-based Epidemiological Studies. Eur J Epidemiol 2006;**21**(2):103-11.

41. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am J Epidemiol 2010;**172**(11):1292-8.

 42. Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus. 2011; Available at: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-11-066/EN/KS-SF-11-066-EN.PDF. Accessed 13 November, 2012.
43. Internet World Stats. Usage and population statistics. 2012; Available at: http://www.internetworldstats.com/. Accessed 13 November, 2012.
44. Australian Bureau of Statistics. Household Use of Information Technology, Australia, 2010-11. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main Features12010-11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11&num=&view=. Accessed 13 November, 2012.
45. Statistics Canada. Individual Internet use and E-commerce (2010). 2011; Available at: http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed 13 November, 2012.
46. United States Census Bureau. The 2012 Statistical Abstract. Information & Communications: Internet Publishing and Broadcasting and Internet Usage. 2010; Available at:

http://www.census.gov/compendia/statab/cats/information_communications/internet_publishi ng and broadcasting and internet usage.html. Accessed 13 November, 2012.

BMJ Open

1	
2	
3	Medication use in pregnancy: <u>a cross-sectional, multinational web-based study</u>
4	
5	multinational perspective
6	
7	
8	Lumattalli A ¹ Spissot O ^{2,3} Turing MI ⁴ Zagana duilana K ⁵ Måndhu AC ⁶ Manatti
9	Lupattelli A, ¹ Spigset O, ^{2,3} Twigg MJ, ⁴ Zagorodnikova K, ⁵ Mårdby AC, ⁶ Moretti
10	ME, ⁷ Drozd M, ⁸ Panchaud A, ⁹ Hämeen-Anttila K, ¹⁰ Rieutord A, ¹¹ Gjergja Juraski
11	R, ¹² Odalovic M, ¹³ Kennedy D, ¹⁴ Rudolf G, ¹⁵ Juch H, ¹⁶ Passier A, ¹⁷ Björnsdóttir I, ¹
12	Nordeng $H^{1,18}$.
13	
14	¹ School of Pharmacy, University of Oslo, Norway
15	
16	² Department of Clinical Pharmacology, St Olav's University Hospital, Trondheim,
17	Norway
18	³ Department of Laboratory Medicine, Children's and Women's Health, Norwegian
19	University of Science and Technology, Trondheim, Norway
20	
21	⁴ School of Pharmacy, University of East Anglia, Norwich Research Park, United
22	Kingdom
23	⁵ Northwest Medical Center for Drug Safety in Pregnancy & Lactation, Northwest
24	
25	State Medical University n.a.I.I.Mechnikov, St. Petersburg, Russia
26	⁶ Department of Public Health and Community Medicine, The Sahlgrenska Academy,
27	University of Gothenburg, Gothenburg, Sweden
28	⁷ The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The
29	
30	Hospital for Sick Children, University of Toronto, Ontario, Canada
31	⁸ Faculty of Pharmacy, Medical University of Lublin, Poland
32	⁹ School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva,
33	Switzerland
34	
35	¹⁰ Finnish Medicines Agency, Kuopio, Finland
36	¹¹ APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacie, Clamart France and
37	Européenne de Formation pour les Pharmaciens, France
38	¹² Children's Hospital Srebrnjak, Neuropediatric Unit, Zagreb, Croatia
39	¹³ Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of
40	
41	pharmacy, University of Belgrade, Serbia
42	¹⁴ MotherSafe, Royal Hospital for Women and University of NSW, Randwick,
43	Australia
44	¹⁵ Clinical Institute of Medical Genetics, University Medical Centre Ljubljana,
45	
46	Slovenia
47	¹⁶ Research Unit Human Teratogens, Institute for Cell Biology, Histology and
48	Embryology, Medical University of Graz, Austria
49	¹⁷ Teratology Information Service (TIS), Netherlands Pharmacovigilance Centre
50	
51	Lareb, the Netherlands
52	¹⁸ Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway
53	
54	
55	Corresponding author:
56	Corresponding authors
57	
58	

Angela Lupattelli, MScPharm,

Department of Pharmacy, School of Pharmacy, University of Oslo,

PO Box 1068 Blindern, 0316 Oslo, Norway

e-mail: angela.lupattelli@farmasi.uio.no; phone: +47 41343628 ; fax: +4722854402

Key words: pregnancy; drug utilization, maternal health; health behaviour; public

health

 Word count (excluding title page, abstract, references, figures and tables): 3637

ABSTRACT

Objectives: Inter-country comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and factors associated with medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilized and indication for use.

Design: Cross-sectional, <u>webinternet</u>-based study performed within the period from 1-Oct-2011 to 29-Feb-2012. Uniform collection of drug utilization data was performed via an anonymous online questionnaire.

Setting: Multinational study in Europe (Western, Northern, and Eastern), North and South America, and Australia.

Participants: Pregnant women and new mothers with children less than one year of age.

Primary and secondary outcome measures: Prevalence <u>of</u> and factors associated with medication use for acute/short-term illnesses, chronic/long-term disorders and over-the-counter (OTC) medication use.

Results: The study population included 9,459 women whereof 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. Overall, OTC medication use occurred in 66.9% of the pregnancies, whereas 68.4% and 17.0% of women reported use of at least one medication for treatment of acute/short-term illnesses and chronic/long-term disorders, respectively. The extent of self-reported

medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting use of medication for chronic/long-term disorders. Immigrant women in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83) were less likely to report use of medication for chronic/long-term disorders during pregnancy than nonimmigrants.

Conclusions:

In this study, the majority of women in Europe, North America, South America and Australia used at least one medication during pregnancy. There was a substantial inter-region variability in the types of medication used.

ARTICLE SUMMARY

Strengths and limitations of this study

- Uniform data collection of drug utilization data across all participating countries allows for inter-country comparability of the prevalence of medication use during pregnancy, up to now impeded by differences in study design and methodology.
- The study adds a multinational perspective on OTC medication use during pregnancy to the limited number of studies quantifying the extent of self-medication during pregnancy.
- Lack of validity of the self-reported diagnoses is a limitation since all disorders and related medication use were self-reported by the study participants.
- An internet-web-based survey as a study method impedes calculation of a conventional response rate and may cause selection bias of the target population.

FUNDING STATEMENT

This work was supported by the Norwegian Research Council grant number

216771/F11 and by the Foundation for Promotion of Norwegian Pharmacies and the

Norwegian Pharmaceutical Society.

COMPETING INTERESTS: None declared

INTRODUCTION

Ethical reasons preclude inclusion of pregnant women in the vast majority of premarketing clinical trials.[1] As a consequence, most medications are placed onto the market without a directly established safety profile in human pregnancy.[2] So far, few medications have been shown to be major teratogens, yet the risk of minor teratogenicity or of more subtle effects on fetal development still have to be determined for most of them.[3] Despite this, medication use during pregnancy is common. Mitchell et al. found that use of medications, either prescribed or purchased over-the-counter (OTC), occurred in 88.8% of all pregnancies in the USA.[4] In Europe, prevalence estimates of prescribed medication use vary considerably across countries, ranging from 26% in Serbia to 93% in France.[5-10] Such inter-country variability could, at least in part, be caused by differences in study design, methodology and exposure ascertainment across studies.[11] Uniform collection of drug utilization data during pregnancy between countries may overcome such drawbacks, allowing for inter-country comparability of prevalence estimates and shedding light on differences in prenatal care in the various countries.

Prior studies have addressed research priorities in this area such as presenting results on an individual drug level according to the indication of use, quantifying the extent of OTC and prescribed medication use during pregnancy, and taking into account inter-country comparability.[4] Only a few studies have individually examined maternal factors associated with specific types of medication use during pregnancy.[11-14]

The objectives of the current study were to examine patterns of medication use in pregnancy from a multinational perspective, with special emphasis on type of medication utilized, including OTC medications, and self-reported indications for use, and to identify maternal background factors potentially associated with medication use for acute/short-term illnesses, medication use for chronic/long-term disorders and OTC medication use during pregnancy.

METHODS

Study design and data collection

This is a multinational, cross-sectional, internetweb-based study. Pregnant women at any gestational week and mothers with children less than one year of age were eligible to participate. Member countries of the European Network of Teratology Information Services (ENTIS), The Organization of Teratology Information Specialists (OTIS) in North America, MotherSafe in Australia and European institutions conducting public health research were invited to take part in the project. Of these, 18 countries participated (Australia, Austria, Canada, Croatia, Finland, France, Iceland, Italy, Netherlands, Norway, Poland, Russia, Serbia, Slovenia, Sweden, Switzerland, United Kingdom and USA). Data originating from some South and Central American countries were also collected through OTIS. Because of the low number of participants on the individual country level, the region of Central America was excluded and countries in South America were aggregated into one region. Data selection to achieve the final study sample was performed as depicted in Figure 1. Participants were categorized according to the reported country of residency and grouped into six regions: Western Europe, Northern Europe, Eastern Europe, North America, South America and Australia.

BMJ Open

Data were collected through an anonymous on-line questionnaire administered by Quest Back (http://www.questback.com) and accessible for a period of two months in each participating country within the period 1-Oct-2011 to 29-Feb-2012. The questionnaire was open to the public via utilization of banners (invitations to participate in the study) on national websites and/or social networks commonly visited and consulted by pregnant women and/or new mothers. The complete questionnaire is presented in Appendix 1. Detailed information about recruitment tools utilized and internet penetration rates is summarized in Appendix 2.

The questionnaire was first developed in Norwegian and English and then translated into the other relevant languages. A pilot study was carried out in September 2011 (n=47) and elicited no major change to the questionnaire. Collected data were scrutinized for the presence of potential duplicates (based on reported country of residency, socio-demographic characteristics, date and exact time of questionnaire completion) but none were identified.

Exposure variables

Maternal socio-demographics (i.e. region of residency, age, educational level, mother tongue, working status at time of conception, previous children, marital status and unplanned pregnancy) and life-style characteristics (i.e. smoking status before and during pregnancy and alcohol consumption after awareness of pregnancy) constituted the exposure variables. To assess external validity, we compared socio-demographic and life-style characteristics of our study population on an individual country level with those of the general birthing population in the same country. Reports of National Statistics Bureaus or previous national studies were utilized for this purpose. The ratio

between the number of respondents and the estimated number of live births in the 2months period was also examined for each country (Appendix 3).

Outcome variables

Use of any medication, medication for acute/short-term illnesses, medication for chronic/long-term disorders and OTC medication use during pregnancy constituted the outcome variables. Participants were first confronted with a list of the most common acute/short-term illnesses (i.e. nausea, heartburn, constipation, common cold, urinary tract infections (UTIs), other infections, pain in the neck/back/pelvic girdle, headache, sleeping problems) and the most prevalent chronic/long-term disorders (i.e. asthma, allergy, hypothyroidism, rheumatic disorders, diabetes, epilepsy, depression, anxiety, cardiovascular disease, other disorders) and asked whether they suffered/had suffered from these conditions during pregnancy. In case of an affirmative response, women were questioned about medication use for each individual indication as a freetext entry. Use of OTC medications was also recorded. Recall was aided with a list of five OTC medication categories: painkillers, nasal spray/drops, antinauseants, antacids and laxatives, along with examples of brand name products of relevance in each country. It was optional to report timing of exposure for each of the medication use questions (the alternatives were gestational weeks 0-12 (1st trimester), 13-24 (2nd trimester) and 25-delivery (3rd trimester)).

We defined a medicine as a single product containing one or more active ingredients. We initially identified the main active ingredient(s) and formulation of the reported medicinal products either in the relevant national medicines database or in the "Martindale" textbook.[15] All recorded medications were coded into the corresponding Anatomical Therapeutic Chemical (ATC) codes at the ATC 5th level

BMJ Open

(i.e. the substance level) whenever possible, otherwise into the 2nd- 4th levels as appropriate, in accordance with the World Health Organization ATC index.[16] The OTC status of medications was crosschecked with the prescription policies within each country. Whenever a prescription medication was reported under the OTC question, this record was omitted from the analysis of OTC use but counted in the estimation of total medication use (including prescription and OTC). Iron, mineral supplements, vitamins, herbal remedies and any type of alternative medicine were recorded separately and excluded from the estimation of medication use.

The required sample size calculation for the outcome variables on region and individual country levels are outlined in Appendix 4. The expected prevalence estimates were set according to results of previous studies.[5-10,17,18]

Ethics

All participants gave informed consent by answering "Yes" to the question "Are you willing to participate in the study?" The study was approved by the Regional Ethics Committee, Region South-East in Norway. Ethical approval or study notification to the relevant national Ethics Boards was achieved in specific countries as required by national legislation. All data were handled and stored anonymously.

Statistical analysis

Descriptive statistics were utilized as appropriate. Univariate and multivariate logistic regression analyses were used to examine the association between maternal characteristic and three categorical outcome measures (Yes/No): Medication use for acute/short-term illnesses; medication use for chronic/long-term disorders; OTC medication use. P-values of <0.05 were considered statistically significant. Data are

presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). The analyzed explanatory variables included all maternal socio-demographics and lifestyle characteristics. After fitting the univariate logistic regression model for all explanatory variables, the multivariate model was built and adjusted for all remaining covariates. The Hosmer and Lemeshow test was used to assess goodness of fit of the final multivariate model.[19] Analogue sub-analyses on individual region level were performed. In these instances, region of residency was not included in the model. All statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM[®] SPSS[®] Statistics).

RESULTS

Population characteristics

A total of 9,615 women accessed the on-line questionnaire whereof 98.6% completed it. The participant flow-chart to achieve final study population (n=9,459) is depicted in Figure 1. A total of 5,089 women (53.8%) were pregnant at the time of completion of the questionnaire, whereas 4,370 women (46.2%) had delivered their babies within the previous year. Of the former group, 1,095 (21.5%), 1,702 (33.4%) and 2,291 (45.0%) women were in the first, second and third trimester of pregnancy, respectively. Of the latter group, 1,320 (30.2%), 947 (21.7%) and 2,102 (48.1%) had a baby of age \leq 16 weeks, 17-28 weeks, and \geq 29 weeks, respectively. For two women the time of gestation/baby's age was unknown. Overall, the birthing population in each participating country was reflected quite well by the sample with respect to age, parity and smoking habits (Appendix 3). However, there was a difference in terms of educational level; on average, the women in the study had higher education than the general birthing population in each country. In addition, participants in Sweden,

BMJ Open

Austria, Iceland and Italy were slightly more often primiparous, whereas the responders in Australia, USA, The Netherlands, Slovenia and Croatia were somewhat older than the general birthing population.

Total medication use

After exclusion of vitamins, mineral supplements and iron, use of at least one medication either prescribed or OTC at any time during pregnancy was reported by 7,678 out of 9,459 women (81.2%). Figure 2 depicts prevalence estimates of total medication use during pregnancy by region and country of residence. The extent of OTC medication use, as well as medication use for acute/short-term illnesses and chronic/long-term disorders is also outlined. The highest prevalence of total medication use during pregnancy was observed in The Netherlands (95.1%), Iceland (93.0%) and Finland (92.3%). The overall prevalence estimates of medication use in pregnancy according to timing and drug class (ATC level 1 and 2) are presented in Appendix 5. Medications for the nervous system (ATC class N) were the most commonly used during pregnancy (57.5%), mostly due to paracetamol (acetaminophen) and its combinations.

A corollary analysis according to pregnancy status showed that pregnant women reported in a significantly lower degree than new mothers any medication use during pregnancy (78.8% vs. 84.0%, p-value<0.001), as well as OTC medication use (63.0% vs. 71.5%, p-value<0.001) and medication use for acute/short-term illnesses (66.2% vs. 70.9%, p-value<0.001). In contrast, the difference in medication use for chronic/long-term disorders was not significant (17.4% vs. 16.5%, p-value=0.271). None of the rates differed significantly when women in the third trimester of pregnancy were compared to new mothers.

Medication use according to indication

Headache, heartburn, pain, nausea and UTIs constituted the leading indications for use of medication during pregnancy among the acute/short-term illnesses analyzed. Hypothyroidism, asthma, allergy and depression were the leading indications for chronic/long-term medication use. Observed prevalence rates of these disorders, overall and by region of residency, are presented in Appendices 6 and 7, respectively, along with rates of total and specific medication use. Table 1 outlines prevalence estimates of OTC medication use during pregnancy by region and indication for use. Only the most common medication groups reported are presented. Inter-region variations in rates and types of medication used during pregnancy were observed both for acute/short-term illnesses (e.g. nausea and UTIs), chronic/long-term disorders (e.g. asthma and depression) and OTC medications (e.g. nasal spray).

Factors associated with medication use

Factors associated with medication use during pregnancy according to type of medication utilized are presented in table 2. Use of chronic/long-term medications during pregnancy was reported in a significant larger extent by women in Northern Europe (aOR: 1.68, 95% CI: 1.46-1.94), North America (aOR: 1.80, 95% CI: 1.42-2.28) and Australia (aOR: 2.76, 95% CI: 2.03-3.76) compared to women in Western Europe. Older women or housewives, those with low education or with an unplanned pregnancy, were the ones most often reporting use of chronic/long-term medication. Sub-analysis on individual region level revealed that women not having the official language of the country of residency as mother tongue were less likely to report chronic/long-term medication use in Western (aOR: 0.55, 95% CI: 0.34-0.87) and Northern Europe (aOR: 0.50, 95% CI: 0.31-0.83), but not in the other regions.

BMJ Open

Table 1: Use of OTC medication at any time during pregnancy by ATC level, indication for use and region (n=9,459) **

			REG	ION			
OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n</i> (%)	Northern Europe n=2,820 <i>n (%)</i>	Eastern Europe n=2,342 n (%)	North America n=533 n (%)	South America n=346 <i>n</i> (%)	Australian n=217 <i>n</i> (%)	Total n=9,459 n (%)
OTC painkillers, total	1,714 (53.5)	1,773 (62.9)	734 (31.3)	284 (53.3)	127 (36.7)	151 (69.9)	4,783 (50.6
By drug group							
Paracetamol (incl. combinations) (N02BE)	1,655 (51.7)	1,735 (61.5)	630 (26.9)	263 (49.3)	87 (25.1)	146 (67.3)	4,516 (47.7
Non-steroideal antiinflammatory drugs (M01A)	70 (2.2)	182 (6.5)	68 (2.9)	40 (7.5)	59 (17.1)	7 (3.2)	426 (4.5)
Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	11 (0.4)	32 (1.4)	2 (0.4)	2 (0.6)	1 (0.5)	55 (0.6)
Metamizole (N02BB02)	_	6 (0.2)	31 (1.3)	1 (0.2)	12 (3.5)	-	50 (0.5)
OTC antacids, total	1,011 (31.6)	883 (31.3)	583 (24.9)	129 (24.2)	48 (13.9)	76 (35.0)	2,730 (28.
By drug group							
Antacids (aluminium, salts combinations, antiflatulents)	472 (14.7)	550 (19.5)	508 (21.7)	47 (8.8)	36 (10.4)	54 (24.9)	1,667 (17.
Alginic acid complex/sucralfate/bismuth (A02BX)	606 (18.9)	421 (14.9)	87 (3.7)	4 (0.8)	1 (0.3)	17 (7.8)	1,136 (12.
H ₂ receptor antagonists (A02BA)	20 (0.6)	20 (0.7)	16 (0.7)	57 (10.1)	10 (2.9)	17 (7.8)	137 (1.4)
Antacids with calcium (A02AC)	23 (0.7)	12 (0.4)	10 (0.4)	69 (12.9)	2 (0.6)	10 (4.6)	126 (1.3)
Proton pump inhibitors (A02BC)	38 (1.2)	52 (1.8)	_	10 (1.9)	2 (0.6)	5 (0.3)	107 (1.1)
OTC nasal sprays/drops, total	272 (8.5)	742 (26.3)	451 (19.3)	35 (6.6)	7 (2.0)	14 (6.5)	1,521 (16.
By drug group							
Sympathomimetic nasal decongestants (R01AA/R01BB)	204 (6.4)	683 (24.2)	365 (15.6)	20 (3.8)	3 (0.9)	4 (1.8)	1,279 (13.
Nasal corticosteroids (R01AD)	31 (1.0)	49 (1.7)	12 (0.5)	5 (0.9)	2 (0.6)	10 (4.6)	109 (1.2)
Nasal immunostimulants (low dose interferon) (L03A)	-	-	28 (1.2)		-	-	28 (0.3)
OTC laxatives, total	240 (7.5)	227 (8.0)	237 (10.1)	50 (9.4)	8 (2.3)	19 (8.8)	781 (8.3)
By drug group							
Osmotically acting laxatives (A06AD)	159 (5.0)	171 (6.1)	197 (8.4)	2 (0.4)	2 (0.6)	8 (3.7)	539 (5.7)
Contact laxatives (A06AB)	28 (0.9)	44 (1.6)	18 (0.8)	7 (1.3)	6 (1.7)	2 (0.9)	105 (1.1)
							15

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	REGION						
OTC medication use, overall and by drug groups	Western Europe n=3,201 <i>n</i> (%)	Northern Europe n=2,820 <i>n</i> (%)	Eastern Europe n=2,342 <i>n</i> (%)	North America n=533 n (%)	South America n=346 <i>n</i> (%)	Australian n=217 n (%)	Total n=9,459 <i>n</i> (%)
Enemas (A06AG)	3 (0.1)	25 (0.9)	34 (1.5)	4 (0.8)	-	2 (0.9)	68 (0.7)
Softeners, emollients (A06AA)	8 (0.2)	-	-	38 (7.1)	-	6 (2.8)	52 (0.5)
OTC antinauseants, total	263 (8.2)	273 (9.7)	41 (1.8)	60 (11.3)	28 (8.1)	40 (18.4)	705 (7.5)
By drug group							
First generation antihistamines (R06A)	141 (4.4)	256 (9.1)	7 (1.5)	55 (10.3)	5 (1.4)	5 (2.3)	469 (5.0)
Metoclopramide/domperidone/bromopride (A03FA)	113 (3.5)	5 (0.2)	18 (0.8)	2 (0.4)	19 (5.5)	27 (12.4)	184 (1.9)
Total OTC medication use	2,163 (67.6)	2,155 (76.4)	1,347 (57.5)	342 (64.2)	156 (45.1)	168 (77.4)	6,331 (66.9)

Abbreviations: OTC: Over-The-Counter medications.

*Countries are grouped into regions as shown in Figure 1.

*Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, and herbal

or alternative medicine products.

 BMJ Open

Region of residency*Western Europe2,224 (69.5)Reference462 (14.4)Reference2,153 (67.6)ReferenceNorthern Europe1,954 (69.3)0.96 (0.86-1.08)593 (21.0)1.68 (1.46-1.94)2,155 (76.4)1.54 (1.36-1Eastern Europe1,474 (62.9)0.69 (0.61-0.78)322 (13.7)1.03 (0.87-1.21)1,347 (57.5)0.60 (0.53-0North America403 (75.6)1.28 (1.03-1.60)119 (22.3)1.80 (1.42-2.28)342 (64.2)0.81 (0.66-0South America250 (82.3)1.03 (0.79-1.34)38 (11.0)0.70 (0.48-1.01)156 (45.1)0.34 (0.27-0Australia164 (75.6)1.29 (0.93-1.79)70 (32.3)2.76 (2.03-3.76)168 (77.4)1.57 (1.12-2Maternal age (years) ≤ 20 232 (70.5)1.22 (0.93-1.60)761 (14.7)0.58 (0.39-0.87)205 (62.3)1.05 (0.81-121-303,531 (68.2)Reference33 (10.0)Reference3,461 (66.8)Reference31-402,576 (68.6)0.90 (0.82-1.00)764 (20.4)1.44 (1.27-1.63)2,531 (67.4)0.85 (0.77-0 ≥ 41 130 (66.3)0.73 (0.54-1.00)46 (23.5)1.61 (1.13-2.29)134 (68.4)0.86 (0.62-1Previous childrenNo3,082 (65.5)Reference735 (15.6)Reference2,949 (62.6)ReferenceYes3,387 (71.3)1.34 (1.22-1.47)869 (18.3)1.08 (0.96-1.21)3,382 (71.2)1.58 (1.44-1Married/cohabiting6,066 (68.5)Reference1,503 (17.0)Referen	$\begin{array}{c c c c c c c c c c c c c c c c c c c $				Medi	cation use			
Region of residency [↑] 2,224 (69.5)Reference462 (14.4)Reference2,163 (67.6)ReferenceNorthern Europe1,954 (69.3)0.96 (0.86-1.08)593 (21.0)1.68 (1.46-1.94)2,155 (76.4)1.54 (1.36-1Eastern Europe1,474 (62.9)0.69 (0.61-0.78)322 (13.7)1.03 (0.87-1.21)1,347 (57.5)0.60 (0.53-0North America403 (75.6)1.28 (1.03-1.60)119 (22.3)1.80 (1.42-2.28)342 (64.2)0.81 (0.66-0South America250 (82.3)1.03 (0.79-1.34)38 (11.0)0.70 (0.48-1.01)156 (45.1)0.34 (0.27-0Australia164 (75.6)1.29 (0.93-1.79)70 (32.3)2.76 (2.03-3.76)168 (77.4)1.57 (1.12-2Maternal age (years)≤20232 (70.5)1.22 (0.93-1.60)761 (14.7)0.58 (0.39-0.87)205 (62.3)1.05 (0.81-121-303,531 (68.2)Reference33 (10.0)Reference3,461 (66.8)Reference31-402,576 (68.6)0.90 (0.82-1.00)764 (20.4)1.44 (1.27-1.63)2,531 (67.4)0.85 (0.77-0≥41130 (66.3)0.73 (0.54-1.00)46 (23.5)1.61 (1.13-2.29)134 (68.4)0.86 (0.62-1Previous childrenNo3,082 (65.5)Reference735 (15.6)Reference2,949 (62.6)ReferenceYes3,387 (71.3)1.34 (1.22-1.47)869 (18.3)1.08 (0.96-1.21)3,382 (71.2)1.58 (1.44-1Married/cohabiting6,066 (68.5)Reference1,503 (17.0)Reference5,960 (67.3)Reference<	Region of residency ³ 2,224 (69.5)Reference462 (14.4)Reference2,153 (67.6)ReferenceNorthern Europe1,954 (69.3)0.96 (0.86-1.08)593 (21.0)1.68 (1.46-1.94)2,155 (76.4)1.54 (1.Eastern Europe1,474 (62.9)0.69 (0.61-0.78)322 (13.7)1.03 (0.87-1.21)1,347 (57.5)0.60 (0.North America403 (75.6)1.28 (1.03-1.60)119 (22.3)1.80 (1.42-2.28)342 (64.2)0.81 (0.South America250 (82.3)1.03 (0.79-1.34)38 (11.0)0.70 (0.48-1.01)156 (45.1)0.34 (0.Australia164 (75.6)1.29 (0.93-1.79)70 (32.3)2.76 (2.03-3.76)168 (77.4)1.57 (1.Maternal age (years) ≤ 20 232 (70.5)1.22 (0.93-1.60)761 (14.7)0.58 (0.39-0.87)205 (62.3)1.05 (0. ≤ 20 232 (70.5)1.22 (0.93-1.60)764 (20.4)1.44 (1.27-1.63)2,531 (67.4)0.85 (0. $\geq 21-30$ 3,531 (68.2)Reference33 (10.0)Reference3,461 (66.8)Refe $\geq 21-30$ 3,531 (68.2)Reference735 (15.6)Reference2,949 (62.6)Refe ≥ 241 130 (66.3)0.73 (0.54-1.00)46 (23.5)1.61 (1.13-2.29)134 (68.4)0.86 (0. ≥ 241 130 (66.3)0.91 (0.75-1.10)101 (16.6)1.08 (0.96-1.21)3,382 (71.2)1.58 (1.Mariad status6,066 (68.5)Reference1,503 (17.0)Reference5,960 (67.3)RefeMarried/cohabiting6,066 (68.5)Refe								
Northern Europe $1,954 (69.3)$ $0.96 (0.86-1.08)$ $593 (21.0)$ $1.68 (1.46-1.94)$ $2,155 (76.4)$ $1.54 (1.36-1)$ Eastern Europe $1,474 (62.9)$ $0.69 (0.61-0.78)$ $322 (13.7)$ $1.03 (0.87-1.21)$ $1,347 (57.5)$ $0.60 (0.63-0)$ North America $403 (75.6)$ $1.28 (1.03-1.60)$ $119 (22.3)$ $1.80 (1.42-2.28)$ $342 (64.2)$ $0.81 (0.66-0)$ South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.27-0)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (7.4)$ $1.57 (1.12-2)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.81-1)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Reference $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.77-0)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.62-1)$ No $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferenceYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.21)$ $3,382 (71.2)$ $1.58 (1.44-1)$ Marited/cohabiting $6,066 (68.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferenceSingle/divorced/others <th>Western Europe2,224 (69.5)Reference462 (14.4)Reference2,163 (67.6)ReferenceNorthern Europe1,954 (69.3)0.96 (0.86-1.08)593 (21.0)1.68 (1.46-1.94)2,155 (76.4)1.54 (1.Eastern Europe1,474 (62.9)0.69 (0.61-0.78)322 (13.7)1.03 (0.87-1.21)1,347 (57.5)0.60 (0.North America250 (82.3)1.03 (0.79-1.34)38 (11.0)0.70 (0.48-1.01)156 (45.1)0.34 (0.South America250 (82.3)1.03 (0.79-1.34)38 (11.0)0.70 (0.48-1.01)156 (45.1)0.34 (0.Australia164 (75.6)1.29 (0.93-1.79)70 (32.3)2.76 (2.03-3.76)168 (77.4)1.57 (1.Maternal age (years)$\leq 20$232 (70.5)1.22 (0.93-1.60)761 (14.7)0.58 (0.39-0.87)205 (62.3)1.05 (0.21-303,531 (68.2)Reference33 (10.0)Reference3,461 (66.8)Refe31-402,576 (68.6)0.90 (0.82-1.00)764 (20.4)1.44 (1.27-1.63)2,531 (67.4)0.85 (0.241130 (66.3)0.73 (0.54-1.00)46 (23.5)1.61 (1.13-2.29)134 (68.4)0.86 (0.Previous childrenNo3,082 (65.5)Reference735 (15.6)Reference2,949 (62.6)RefeYes3,387 (71.3)1.34 (1.22-1.47)869 (18.3)1.06 (0.93-1.35)371 (61.0)0.91 (0.Maritel/cohabiting6,066 (68.5)Reference1,503 (17.0)Reference3,667 (65.6)Refe<tr <tr="">Single/divorce</tr></th> <th></th> <th>n (%)</th> <th>aOR (95% CI)</th> <th>n (%)</th> <th>aOR (95% CI)</th> <th>n (%)</th> <th>aOR (95% CI)</th>	Western Europe2,224 (69.5)Reference462 (14.4)Reference2,163 (67.6)ReferenceNorthern Europe1,954 (69.3)0.96 (0.86-1.08)593 (21.0)1.68 (1.46-1.94)2,155 (76.4)1.54 (1.Eastern Europe1,474 (62.9)0.69 (0.61-0.78)322 (13.7)1.03 (0.87-1.21)1,347 (57.5)0.60 (0.North America250 (82.3)1.03 (0.79-1.34)38 (11.0)0.70 (0.48-1.01)156 (45.1)0.34 (0.South America250 (82.3)1.03 (0.79-1.34)38 (11.0)0.70 (0.48-1.01)156 (45.1)0.34 (0.Australia164 (75.6)1.29 (0.93-1.79)70 (32.3)2.76 (2.03-3.76)168 (77.4)1.57 (1.Maternal age (years) ≤ 20 232 (70.5)1.22 (0.93-1.60)761 (14.7)0.58 (0.39-0.87)205 (62.3)1.05 (0.21-303,531 (68.2)Reference33 (10.0)Reference3,461 (66.8)Refe31-402,576 (68.6)0.90 (0.82-1.00)764 (20.4)1.44 (1.27-1.63)2,531 (67.4)0.85 (0.241130 (66.3)0.73 (0.54-1.00)46 (23.5)1.61 (1.13-2.29)134 (68.4)0.86 (0.Previous childrenNo3,082 (65.5)Reference735 (15.6)Reference2,949 (62.6)RefeYes3,387 (71.3)1.34 (1.22-1.47)869 (18.3)1.06 (0.93-1.35)371 (61.0)0.91 (0.Maritel/cohabiting6,066 (68.5)Reference1,503 (17.0)Reference3,667 (65.6)Refe <tr <tr="">Single/divorce</tr>		n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	
Northern Europe $1,954 (69.3)$ $0.96 (0.86-1.08)$ $593 (21.0)$ $1.68 (1.46-1.94)$ $2,155 (76.4)$ $1.54 (1.36-1)$ Eastern Europe $1,474 (62.9)$ $0.69 (0.61-0.78)$ $322 (13.7)$ $1.03 (0.87-1.21)$ $1,347 (57.5)$ $0.60 (0.63-0)$ North America $403 (75.6)$ $1.28 (1.03-1.60)$ $119 (22.3)$ $1.80 (1.42-2.28)$ $342 (64.2)$ $0.81 (0.66-0)$ South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.27-0)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.12-2)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.81-1)$ $\leq 1-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Reference $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.77-0)$ ≥ 41 $130 (66.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferenceNo $3,082 (65.5)$ Reference $750 (17.0)$ Reference $5,960 (67.3)$ ReferenceYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.33)$ $371 (61.0)$ $0.91 (0.75-1.10)$ Marited/cohabiting $6,066 (68.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferenceSingle/divorced/others $403 (66.3)$ <	Northern Europe $1,954 (69.3)$ $0.96 (0.86-1.08)$ $593 (21.0)$ $1.68 (1.46-1.94)$ $2,155 (76.4)$ $1.54 (1.$ Eastern Europe $1,474 (62.9)$ $0.69 (0.61-0.78)$ $322 (13.7)$ $1.03 (0.87-1.21)$ $1,347 (57.5)$ $0.60 (0.6)$ North America $403 (75.6)$ $1.28 (1.03-1.60)$ $119 (22.3)$ $1.80 (1.42-2.28)$ $342 (64.2)$ $0.81 (0.6)$ South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.6)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.6)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.6)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Refe $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.2)$ 241 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.2)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ RefeNo $3,082 (65.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ RefeYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.21)$ $3,382 (71.2)$ $1.58 (1.6)$ Mariiel statusMariiel schabilting	gion of residency [†]							
Eastern Europe $1,474 (62.9)$ $0.69 (0.61-0.78)$ $322 (13.7)$ $1.03 (0.87-1.21)$ $1,347 (57.5)$ $0.60 (0.53-0)$ North America $403 (75.6)$ $1.28 (1.03-1.60)$ $119 (22.3)$ $1.80 (1.42-2.28)$ $342 (64.2)$ $0.81 (0.66-0)$ South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.27-0)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.12-2)$ Matemal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.81-1)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Reference $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.77-0)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.62-1)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ Reference $Marital status$ $3,087 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.21)$ $3,382 (71.2)$ $1.58 (1.44-1)$ Marital status $Marital status$ $Marital (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$	Eastern Europe $1,474 (62.9)$ $0.69 (0.61-0.78)$ $322 (13.7)$ $1.03 (0.87-1.21)$ $1,347 (57.5)$ $0.60 (0.60)$ North America $403 (75.6)$ $1.28 (1.03-1.60)$ $119 (22.3)$ $1.80 (1.42-2.28)$ $342 (64.2)$ $0.81 (0.5)$ South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.5)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.5)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.5)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Refe $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.2)$ 241 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.6)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferenceYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.21)$ $3,382 (71.2)$ $1.58 (1.9)$ Marital statusMarital status $1.03 (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.94-1.31)$ Marital status $403 (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.04 (0.84-1.30)$ $578 (67.4)$ $1.00 (0.91 (0.9$	estern Europe	2,224 (69.5)	Reference	462 (14.4)	Reference	2,163 (67.6)	Reference	
North America $403 (75.6)$ $1.28 (1.03-1.60)$ $119 (22.3)$ $1.80 (1.42-2.28)$ $342 (64.2)$ $0.81 (0.66-0)$ South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.27-0)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.12-2)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.81-1)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Reference $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.77-0)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.62-1)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferenceNo $3,082 (65.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferenceMartial status $0.966 (68.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferenceSingle/divorced/others $403 (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.75-1)$ Working statusEmployed, but not as HCP $3,737 (66.8)$ Reference $905 (16.2)$ Reference $3,667 (65.6)$ ReferenceHCP 9	North America $403 (75.6)$ $1.28 (1.03-1.60)$ $119 (22.3)$ $1.80 (1.42-2.28)$ $342 (64.2)$ $0.81 (0.64)$ South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.64)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.66)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.62)$ ≥ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.62)$ $\geq 1-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Refer $\geq 21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Refer $\geq 1-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.6)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.6)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ RefeMarital statusMarital status $Marital status$ $Marital status$ $1.03 (0.66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.94-1.36)$ Marital status $Marital status$ $Marital status$ $Marital status$ $Marital status$ $Marital status$ <td>orthern Europe</td> <td>1,954 (69.3)</td> <td>0.96 (0.86-1.08)</td> <td>593 (21.0)</td> <td>1.68 (1.46-1.94)</td> <td>2,155 (76.4)</td> <td>1.54 (1.36-1.74</td>	orthern Europe	1,954 (69.3)	0.96 (0.86-1.08)	593 (21.0)	1.68 (1.46-1.94)	2,155 (76.4)	1.54 (1.36-1.74	
South America $250 (82.3)$ $1.03 (0.79-1.34)$ $38 (11.0)$ $0.70 (0.48-1.01)$ $156 (45.1)$ $0.34 (0.27-0)$ Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.12-2)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.81-1)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Reference $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.77-0)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.62-1)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferenceYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.21)$ $3,382 (71.2)$ $1.58 (1.44-1)$ Married/cohabiting $6,066 (68.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferenceSingle/divorced/others $403 (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.75-1)$ Working statusEmployed, but not as HCP $3,737 (66.8)$ Reference $905 (16.2)$ Reference $3,667 (65.6)$ ReferenceHCP $934 (74.4)$ $1.41 (1.23-1.63)$ $240 (19.1)$ $1.13 (0.96-1.33)$ $944 (75.2)$ $1.42 (1.23-1)$ <	South America 250 (82.3) 1.03 ($0.79-1.34$) 38 (11.0) 0.70 ($0.48-1.01$) 156 (45.1) 0.34 (0.34 (0.34)Australia 164 (75.6) 1.29 ($0.93-1.79$) 70 (32.3) 2.76 ($2.03-3.76$) 168 (77.4) 1.57 (1.74)Maternal age (years) ≤ 20 232 (70.5) 1.22 ($0.93-1.60$) 761 (14.7) 0.58 ($0.39-0.87$) 205 (62.3) 1.05 (0.23) $21-30$ $3,531$ (68.2)Reference 33 (10.0)Reference $3,461$ (66.8)Refer $31-40$ $2,576$ (68.6) 0.90 ($0.82-1.00$) 764 (20.4) 1.44 ($1.27-1.63$) $2,531$ (67.4) 0.85 (0.243) 241 130 (66.3) 0.73 ($0.54-1.00$) 46 (23.5) 1.61 ($1.13-2.29$) 134 (68.4) 0.86 (0.86)Previous childrenNo $3,082$ (65.5)Reference 735 (15.6)Reference $2,949$ (62.6)ReferYes $3,387$ (71.3) 1.34 ($1.22-1.47$) 869 (18.3) 1.08 ($0.96-1.21$) $3,382$ (71.2) 1.58 (1.61)Married/cohabiting $6,066$ (68.5)Reference 905 (16.2)Reference $5,960$ (67.3)RefeSingle/divorced/others 403 (66.3) 0.91 ($0.75-1.10$) 101 (16.6) 1.06 ($0.83-1.35$) 371 (61.0) 0.91 (0.91 ($0.99-1.33$)Warking statusEmployed, but not as HCP $3,737$ (66.8)Reference 905 (16.2)Reference $3,667$ (65.6)RefeHCP 934 (74.4) 1.41 ($1.23-1.63$) </td <td>stern Europe</td> <td>1,474 (62.9)</td> <td>0.69 (0.61-0.78)</td> <td>322 (13.7)</td> <td>1.03 (0.87-1.21)</td> <td>1,347 (57.5)</td> <td>0.60 (0.53-0.67</td>	stern Europe	1,474 (62.9)	0.69 (0.61-0.78)	322 (13.7)	1.03 (0.87-1.21)	1,347 (57.5)	0.60 (0.53-0.67	
Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.12-2)$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.81-1)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Reference $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.77-0)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.62-1)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferenceYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.21)$ $3,382 (71.2)$ $1.58 (1.44-1)$ Married/cohabiting $6,066 (68.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferenceSingle/divorced/others $403 (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.75-1.10)$ Working statusEmployed, but not as HCP $3,737 (66.8)$ Reference $905 (16.2)$ Reference $3,667 (65.6)$ ReferenceHCP $934 (74.4)$ $1.41 (1.23-1.63)$ $240 (19.1)$ $1.13 (0.96-1.33)$ $944 (75.2)$ $1.42 (1.23-1)$ Student $592 (69.1)$ $1.11 (0.94-1.31)$ $128 (14.9)$ $1.04 (0.84-1.30)$ $578 (67.4)$ $1.10 (0.93-1)$ <td>Australia$164 (75.6)$$1.29 (0.93-1.79)$$70 (32.3)$$2.76 (2.03-3.76)$$168 (77.4)$$1.57 (1.$Maternal age (years)$\leq 20$$232 (70.5)$$1.22 (0.93-1.60)$$761 (14.7)$$0.58 (0.39-0.87)$$205 (62.3)$$1.05 (0.21-30)$$21-30$$3,531 (68.2)$Reference$33 (10.0)$Reference$3,461 (66.8)$Refer$31-40$$2,576 (68.6)$$0.90 (0.82-1.00)$$764 (20.4)$$1.44 (1.27-1.63)$$2,531 (67.4)$$0.85 (0.21-21)$$\geq 41$$130 (66.3)$$0.73 (0.54-1.00)$$46 (23.5)$$1.61 (1.13-2.29)$$134 (68.4)$$0.86 (0.21-21)$Previous childrenNo$3,082 (65.5)$Reference$735 (15.6)$Reference$2,949 (62.6)$ReferNo$3,082 (65.5)$Reference$1,503 (17.0)$Reference$5,960 (67.3)$ReferYes$3,387 (71.3)$$1.34 (1.22-1.47)$$869 (18.3)$$1.06 (0.83-1.35)$$371 (61.0)$$0.91 (0.91 (0.91 (0.21-21))$Married/cohothers$403 (66.3)$$0.91 (0.75-1.10)$$101 (16.6)$$1.06 (0.83-1.35)$$371 (61.0)$$0.91 (0.92 (0.91$</td> <td>orth America</td> <td>403 (75.6)</td> <td>1.28 (1.03-1.60)</td> <td>119 (22.3)</td> <td>1.80 (1.42-2.28)</td> <td>342 (64.2)</td> <td>0.81 (0.66-0.99</td>	Australia $164 (75.6)$ $1.29 (0.93-1.79)$ $70 (32.3)$ $2.76 (2.03-3.76)$ $168 (77.4)$ $1.57 (1.$ Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.21-30)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Refer $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.21-21)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.21-21)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferNo $3,082 (65.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.91 (0.91 (0.21-21))$ Married/cohothers $403 (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.92 (0.91$	orth America	403 (75.6)	1.28 (1.03-1.60)	119 (22.3)	1.80 (1.42-2.28)	342 (64.2)	0.81 (0.66-0.99	
Maternal age (years) ≤ 20 $232 (70.5)$ $1.22 (0.93-1.60)$ $761 (14.7)$ $0.58 (0.39-0.87)$ $205 (62.3)$ $1.05 (0.81-1)$ $21-30$ $3,531 (68.2)$ Reference $33 (10.0)$ Reference $3,461 (66.8)$ Reference $31-40$ $2,576 (68.6)$ $0.90 (0.82-1.00)$ $764 (20.4)$ $1.44 (1.27-1.63)$ $2,531 (67.4)$ $0.85 (0.77-0)$ ≥ 41 $130 (66.3)$ $0.73 (0.54-1.00)$ $46 (23.5)$ $1.61 (1.13-2.29)$ $134 (68.4)$ $0.86 (0.62-1)$ Previous childrenNo $3,082 (65.5)$ Reference $735 (15.6)$ Reference $2,949 (62.6)$ ReferenceYes $3,387 (71.3)$ $1.34 (1.22-1.47)$ $869 (18.3)$ $1.08 (0.96-1.21)$ $3,382 (71.2)$ $1.58 (1.44-1)$ Married/cohabiting $6,066 (68.5)$ Reference $1,503 (17.0)$ Reference $5,960 (67.3)$ ReferenceSingle/divorced/others $403 (66.3)$ $0.91 (0.75-1.10)$ $101 (16.6)$ $1.06 (0.83-1.35)$ $371 (61.0)$ $0.91 (0.75-1)$ Working statusEmployed, but not as HCP $3,737 (66.8)$ Reference $905 (16.2)$ Reference $3,667 (65.6)$ ReferenceHCP $934 (74.4)$ $1.41 (1.23-1.63)$ $240 (19.1)$ $1.13 (0.96-1.33)$ $944 (75.2)$ $1.42 (1.23-1)$ Student $592 (69.1)$ $1.11 (0.94-1.31)$ $128 (14.9)$ $1.04 (0.84+1.30)$ $578 (67.4)$ $1.10 (0.93-1)$ Housewife $608 (72.6)$ $1.14 (0.96-1.35)$ $170 (20.3)$ $1.34 (1.10-1.63)$ $577 (68.9)$ <	Maternal age (years) ≤ 20 232 (70.5)1.22 (0.93-1.60)761 (14.7)0.58 (0.39-0.87)205 (62.3)1.05 (0.200)21-303,531 (68.2)Reference33 (10.0)Reference3,461 (66.8)Reference31-402,576 (68.6)0.90 (0.82-1.00)764 (20.4)1.44 (1.27-1.63)2,531 (67.4)0.85 (0.200) ≥ 41 130 (66.3)0.73 (0.54-1.00)46 (23.5)1.61 (1.13-2.29)134 (68.4)0.86 (0.200)Previous childrenNo3,082 (65.5)Reference735 (15.6)Reference2,949 (62.6)ReferYes3,387 (71.3)1.34 (1.22-1.47)869 (18.3)1.08 (0.96-1.21)3,382 (71.2)1.58 (1.200)Married/cohabiting6,066 (68.5)Reference1,503 (17.0)Reference5,960 (67.3)ReferSingle/divorced/others403 (66.3)0.91 (0.75-1.10)101 (16.6)1.06 (0.83-1.35)371 (61.0)0.91 (0.991 (0.200)Working statusEmployed, but not as HCP3,737 (66.8)Reference905 (16.2)Reference3,667 (65.6)ReferHCP934 (74.4)1.41 (1.23-1.63)240 (19.1)1.13 (0.96-1.33)944 (75.2)1.42 (1.200)Student592 (69.1)1.111 (0.94-1.31)128 (14.9)1.04 (0.84-1.30)577 (68.9)1.05 (0.300)Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.300)	uth America	250 (82.3)	1.03 (0.79-1.34)	38 (11.0)	0.70 (0.48-1.01)	156 (45.1)	0.34 (0.27-0.44	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Istralia	164 (75.6)	1.29 (0.93-1.79)	70 (32.3)	2.76 (2.03-3.76)	168 (77.4)	1.57 (1.12-2.20)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	aternal age (years)							
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0	232 (70.5)	1.22 (0.93-1.60)	761 (14.7)	0.58 (0.39-0.87)	205 (62.3)	1.05 (0.81-1.36	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	-30	3,531 (68.2)	Reference	33 (10.0)	Reference	3,461 (66.8)	Reference	
Previous children No 3,082 (65.5) Reference 735 (15.6) Reference 2,949 (62.6) Reference Yes 3,387 (71.3) 1.34 (1.22-1.47) 869 (18.3) 1.08 (0.96-1.21) 3,382 (71.2) 1.58 (1.44-1) Marital status Married/cohabiting 6,066 (68.5) Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0.75-1 Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1.23-1 Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0.93-1 Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0.88-1 Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) <td< td=""><td>Previous children 3,082 (65.5) Reference 735 (15.6) Reference 2,949 (62.6) Reference Yes 3,387 (71.3) 1.34 (1.22-1.47) 869 (18.3) 1.08 (0.96-1.21) 3,382 (71.2) 1.58 (1. Marital status Married/cohabiting 6,066 (68.5) Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0. Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1. Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0. Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0. Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (6</td><td>-40</td><td>2,576 (68.6)</td><td>0.90 (0.82-1.00)</td><td>764 (20.4)</td><td>1.44 (1.27-1.63)</td><td>2,531 (67.4)</td><td>0.85 (0.77-0.94</td></td<>	Previous children 3,082 (65.5) Reference 735 (15.6) Reference 2,949 (62.6) Reference Yes 3,387 (71.3) 1.34 (1.22-1.47) 869 (18.3) 1.08 (0.96-1.21) 3,382 (71.2) 1.58 (1. Marital status Married/cohabiting 6,066 (68.5) Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0. Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1. Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0. Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0. Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (6	-40	2,576 (68.6)	0.90 (0.82-1.00)	764 (20.4)	1.44 (1.27-1.63)	2,531 (67.4)	0.85 (0.77-0.94	
No 3,082 (65.5) Reference 735 (15.6) Reference 2,949 (62.6) Reference Yes 3,387 (71.3) 1.34 (1.22-1.47) 869 (18.3) 1.08 (0.96-1.21) 3,382 (71.2) 1.58 (1.44-1) Marital status 6,066 (68.5) Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0.75-1 Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1.23-1) Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0.93-1) Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0.88-1) Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.68-1)	No 3,082 (65.5) Reference 735 (15.6) Reference 2,949 (62.6) Reference Yes 3,387 (71.3) 1.34 (1.22-1.47) 869 (18.3) 1.08 (0.96-1.21) 3,382 (71.2) 1.58 (1. Marital status Married/cohabiting 6,066 (68.5) Reference 1,503 (17.0) Reference 5,960 (67.3) Refe Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0. Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1. Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0. Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0. Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.	1	130 (66.3)	0.73 (0.54-1.00)	46 (23.5)	1.61 (1.13-2.29)	134 (68.4)	0.86 (0.62-1.19	
Yes $3,387(71.3)$ $1.34(1.22-1.47)$ $869(18.3)$ $1.08(0.96-1.21)$ $3,382(71.2)$ $1.58(1.44-1)$ Marital statusMarried/cohabiting $6,066(68.5)$ Reference $1,503(17.0)$ Reference $5,960(67.3)$ ReferenceSingle/divorced/others $403(66.3)$ $0.91(0.75-1.10)$ $101(16.6)$ $1.06(0.83-1.35)$ $371(61.0)$ $0.91(0.75-1)$ Working statusEmployed, but not as HCP $3,737(66.8)$ Reference $905(16.2)$ Reference $3,667(65.6)$ ReferenceHCP $934(74.4)$ $1.41(1.23-1.63)$ $240(19.1)$ $1.13(0.96-1.33)$ $944(75.2)$ $1.42(1.23-1)$ Student $592(69.1)$ $1.11(0.94-1.31)$ $128(14.9)$ $1.04(0.84-1.30)$ $578(67.4)$ $1.10(0.93-1)$ Housewife $608(72.6)$ $1.14(0.96-1.35)$ $170(20.3)$ $1.34(1.10-1.63)$ $577(68.9)$ $1.05(0.88-1)$ Job seeker $281(66.0)$ $0.96(0.78-1.20)$ $66(15.5)$ $1.03(0.78-1.36)$ $258(60.6)$ $0.85(0.68-1)$	Yes $3,387(71.3)$ $1.34(1.22-1.47)$ $869(18.3)$ $1.08(0.96-1.21)$ $3,382(71.2)$ $1.58(1.5)$ Married/cohabiting $6,066(68.5)$ Reference $1,503(17.0)$ Reference $5,960(67.3)$ ReferenceSingle/divorced/others $403(66.3)$ $0.91(0.75-1.10)$ $101(16.6)$ $1.06(0.83-1.35)$ $371(61.0)$ $0.91(0.91(0.91))$ Working statusEmployed, but not as HCP $3,737(66.8)$ Reference $905(16.2)$ Reference $3,667(65.6)$ ReferenceHCP $934(74.4)$ $1.41(1.23-1.63)$ $240(19.1)$ $1.13(0.96-1.33)$ $944(75.2)$ $1.42(1.91)$ Student $592(69.1)$ $1.11(0.94-1.31)$ $128(14.9)$ $1.04(0.84-1.30)$ $578(67.4)$ $1.10(0.96-1.35)$ Housewife $608(72.6)$ $1.14(0.96-1.35)$ $170(20.3)$ $1.34(1.10-1.63)$ $577(68.9)$ $1.05(0.98)$ Job seeker $281(66.0)$ $0.96(0.78-1.20)$ $66(15.5)$ $1.03(0.78-1.36)$ $258(60.6)$ $0.85(0.98)$	evious children							
Marital status Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0.75-1 Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1.23-1) Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0.93-1) Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0.88-1) Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.68-1)	Marital status Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0.75-1.10) Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1. Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0. Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0. Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.)	3,082 (65.5)	Reference	735 (15.6)	Reference	2,949 (62.6)	Reference	
Married/cohabiting 6,066 (68.5) Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0.75-1.10) Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1.23-1) Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0.93-1) Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0.88-1) Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.68-1)	Married/cohabiting 6,066 (68.5) Reference 1,503 (17.0) Reference 5,960 (67.3) Reference Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0.75-1.10) Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1. Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0. Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0. Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.	S	3,387 (71.3)	1.34 (1.22-1.47)	869 (18.3)	1.08 (0.96-1.21)	3,382 (71.2)	1.58 (1.44-1.74	
Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0.75-1 Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1.23-1 Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0.93-1) Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0.88-1) Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.68-1)	Single/divorced/others 403 (66.3) 0.91 (0.75-1.10) 101 (16.6) 1.06 (0.83-1.35) 371 (61.0) 0.91 (0. Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1. Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0. Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0. Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.	arital status							
Working status Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1.23-1 Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0.93-1) Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0.88-1) Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.68-1)	Working status Employed, but not as HCP 3,737 (66.8) Reference 905 (16.2) Reference 3,667 (65.6) Reference HCP 934 (74.4) 1.41 (1.23-1.63) 240 (19.1) 1.13 (0.96-1.33) 944 (75.2) 1.42 (1. Student 592 (69.1) 1.11 (0.94-1.31) 128 (14.9) 1.04 (0.84-1.30) 578 (67.4) 1.10 (0. Housewife 608 (72.6) 1.14 (0.96-1.35) 170 (20.3) 1.34 (1.10-1.63) 577 (68.9) 1.05 (0. Job seeker 281 (66.0) 0.96 (0.78-1.20) 66 (15.5) 1.03 (0.78-1.36) 258 (60.6) 0.85 (0.	arried/cohabiting	6,066 (68.5)	Reference	1,503 (17.0)	Reference	5,960 (67.3)	Reference	
Employed, but not as HCP3,737 (66.8)Reference905 (16.2)Reference3,667 (65.6)ReferenceHCP934 (74.4) 1.41 (1.23-1.63) 240 (19.1)1.13 (0.96-1.33)944 (75.2) 1.42 (1.23-1 Student592 (69.1)1.11 (0.94-1.31)128 (14.9)1.04 (0.84-1.30)578 (67.4)1.10 (0.93-1Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3) 1.34 (1.10-1.63) 577 (68.9)1.05 (0.88-1)Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.68-1)	Employed, but not as HCP3,737 (66.8)Reference905 (16.2)Reference3,667 (65.6)ReferenceHCP934 (74.4) 1.41 (1.23-1.63) 240 (19.1)1.13 (0.96-1.33)944 (75.2) 1.42 (1. Student592 (69.1)1.11 (0.94-1.31)128 (14.9)1.04 (0.84-1.30)578 (67.4)1.10 (0.Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3) 1.34 (1.10-1.63) 577 (68.9)1.05 (0.Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.	ngle/divorced/others	403 (66.3)	0.91 (0.75-1.10)	101 (16.6)	1.06 (0.83-1.35)	371 (61.0)	0.91 (0.75-1.10	
HCP934 (74.4)1.41 (1.23-1.63)240 (19.1)1.13 (0.96-1.33)944 (75.2)1.42 (1.23-1Student592 (69.1)1.11 (0.94-1.31)128 (14.9)1.04 (0.84-1.30)578 (67.4)1.10 (0.93-1Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3)1.34 (1.10-1.63)577 (68.9)1.05 (0.88-1Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.68-1	HCP934 (74.4)1.41 (1.23-1.63)240 (19.1)1.13 (0.96-1.33)944 (75.2)1.42 (1.Student592 (69.1)1.11 (0.94-1.31)128 (14.9)1.04 (0.84-1.30)578 (67.4)1.10 (0.Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3)1.34 (1.10-1.63)577 (68.9)1.05 (0.Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.	orking status							
Student592 (69.1)1.11 (0.94-1.31)128 (14.9)1.04 (0.84-1.30)578 (67.4)1.10 (0.93-1Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3) 1.34 (1.10-1.63) 577 (68.9)1.05 (0.88-1Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.68-1	Student592 (69.1)1.11 (0.94-1.31)128 (14.9)1.04 (0.84-1.30)578 (67.4)1.10 (0.Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3) 1.34 (1.10-1.63) 577 (68.9)1.05 (0.Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.	nployed, but not as HCP	3,737 (66.8)	Reference	905 (16.2)	Reference	3,667 (65.6)	Reference	
Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3) 1.34 (1.10-1.63) 577 (68.9)1.05 (0.88-1Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.68-1	Housewife608 (72.6)1.14 (0.96-1.35)170 (20.3) 1.34 (1.10-1.63) 577 (68.9)1.05 (0.Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.	CP	934 (74.4)	1.41 (1.23-1.63)	240 (19.1)	1.13 (0.96-1.33)	944 (75.2)	1.42 (1.23-1.64	
Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.68-1	Job seeker281 (66.0)0.96 (0.78-1.20)66 (15.5)1.03 (0.78-1.36)258 (60.6)0.85 (0.	ıdent	592 (69.1)	1.11 (0.94-1.31)	128 (14.9)	1.04 (0.84-1.30)	578 (67.4)	1.10 (0.93-1.30	
		ousewife	608 (72.6)	1.14 (0.96-1.35)	170 (20.3)	1.34 (1.10-1.63)	577 (68.9)	1.05 (0.88-1.24	
Other than above 311 (65.2) 0.91 (0.75-1.12) 94 (19.7) 1.29 (1.01-1.65) 302 (63.3) 0.91 (0.74-1	Other than above311 (65.2)0.91 (0.75-1.12)94 (19.7) 1.29 (1.01-1.65) 302 (63.3)0.91 (0.	o seeker	281 (66.0)	0.96 (0.78-1.20)	66 (15.5)	1.03 (0.78-1.36)	. ,	0.85 (0.68-1.05	
		her than above	311 (65.2)	0.91 (0.75-1.12)	94 (19.7)	1.29 (1.01-1.65)	302 (63.3)	0.91 (0.74-1.12	

	Medication use									
		ort-term illnesses =6,469)		ong-term disorders =1,604)	OTC (n=6,331)					
	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)	n (%)	aOR (95% CI)				
Less than high school	331 (72.7)	1.17 (0.93-1.49)	92 (20.2)	1.51 (1.15-1.97)	317 (69.7)	1.32 (1.04-1.67)				
High school	1,864 (68.7)	Reference	428 (15.8)	Reference	1,779 (65.6)	Reference				
More than high school	3,574 (68.4)	0.99 (0.89-1.11)	916 (17.5)	1.04 (0.91-1.20)	3,489 (66.8)	1.07 (0.96-1.19)				
Others, unspecified	700 (65.7)	0.82 (0.70-0.96)	168 (15.8)	0.94 (0.77-1.16)	746 (70.0)	1.13 (0.97-1.33)				
Alcohol use after awareness of pregn	ancy									
No	5,270 (67.1)	Reference	1,322 (16.8)	Reference	5,133 (65.3)	Reference				
Yes	1,144 (75.7)	1.59 (1.39-1.81)	270 (17.9)	1.11 (0.95-1.29)	1,150 (76.1)	1.95 (1.71-2.23)				
Smoking during pregnancy										
No	5,835 (68.5)	Reference	1,441 (16.9)	Reference	5,716 (67.0)	Reference				
Yes, but less than before pregnancy	530 (69.0)	1.08 (0.91-1.27)	130 (16.9)	1.01 (0.82-1.25)	511 (66.5)	1.06 (0.90-1.26)				
Yes, the same or more than before	~ /									
pregnancy	88 (67.7)	0.95 (0.64-1.40)	28 (21.5)	1.19 (0.74-1.90)	89 (68.5)	1.21 (0.81-1.82)				
Planned pregnancy										
Yes	5,836 (68.4)	Reference	1,427 (16.7)	Reference	5,727 (67.2)	Reference				
No	616 (68.4)	0.96 (0.82-1.12)	173 (19.2)	1.29 (1.06-1.56)	587 (65.1)	1.00 (0.85-1.17)				
First language different from the off	icial main langu	age in the country of	f residency							
No	6,089 (68.5)	Reference	1,530 (17.2)	Reference	5,972 (67.1)	Reference				
Yes	363 (67.2)	0.93 (0.76-1.12)	71 (13.1)	0.66 (0.50-0.86)	347 (64.3)	0.89 (0.74-1.08				

Abbreviation: HCP: health care provider.

*Numbers may not add up due to missing values. Missing values are less than 5% of the total. Mineral supplements, vitamins, iron, herbal or alternative medicine products are not included in the medication use estimates. [†]Countries are grouped into regions as shown in Figure 1.

DISCUSSION

This is the first internetweb-based study examining patterns and factors associated with medication use during pregnancy on a multinational level. In all regions, approximately eight out of ten women reported use of at least one medication, either prescribed or OTC, during the course of their pregnancy. This finding is in line with previous research conducted in Europe, North America, South America and Australia,[4,20-25] though our estimates were somewhat higher in some of the Eastern European countries, e.g. Serbia, than those observed in a previous study.[5] Different recruitment strategies, i.e. webinternet-based in our study versus maternity care unit-/community pharmacy-based in the previous study could explain such discrepancy.

Overall, analgesics, antacids, nasal decongestants/antiallergics and systemic antibiotics were the medication groups dominating the drug utilization scenario, as also shown by previous research.[4,20-22] However, our study also provides insights into the proportion of medicated women among those suffering from a specific illness during pregnancy across the six regions. We found that approximately seven out of ten women who reported UTIs were treated with antibiotics during pregnancy. This related to all regions, except Eastern Europe where it was only four out of ten women. Since women may perceive dysuria without ascertainment of bacteriuria in the urine as UTI, an over-reporting of the illness could have occurred. Yet, a sub-optimal treatment of UTIs during pregnancy in Eastern Europe cannot be ruled out. The inter-country variability in the types of antibiotics used for UTIs could simply be explained by differences in prescribing practice,[26] presence of screening for bacteriuria in early pregnancy, or specific antibiotic resistance patterns.

Even though nausea was the condition affecting most women in all six regions, the corresponding proportions of medicated nausea were generally low. This scenario is probably due to two main factors: a) the predominantly mild character of nausea and the possibility of non-pharmacological management (e.g. dietary advices); b) the reluctance of general practitioners to prescribe antinauseants even though safety profile assessments are in place.[27,28] As also shown in previous studies,[4,29] use of serotonin antagonists in North America and Australia is increasing also in pregnancy compared to the other regions, eliciting the need of sound studies assessing the safety profile of this drug group in pregnancy.

In most regions, the self-reported prevalence of hypothyroidism was somewhat higher than the reported hormone substitution rate. Because of its known association with adverse pregnancy outcomes,[30] the unexpected finding of potential sub-optimal treatment of hypothyroidism during pregnancy deserves attention. It could probably be due to a lack of information about hypothyroidism typology and its diagnostic ascertainment in our study.

In our study, depression was self-reported and not based on any psychometric assessment, thus the observed substantial inter-regional variability in the extent of this disorder and related medication use could have certainly been affected by women's attitudes in reporting. Our estimate of medication use for depression in Australia was higher than that observed in a recent study (10.6% versus 2.1%).[31] However, the similarity in self-reported depression itself (11.5% versus 15.6%) suggests that our population might mostly comprise women who did not discontinue their pharmacological therapy once they became pregnant. Our estimates for North America and Western Europe were in line with recent literature showing an increase in antidepressant use in pregnancy during the last years.[4,32] <u>Selective serotonin reuptake</u> inhibitors (SSRIs) were the most widely used antidepressant class. Recent meta-analyses have shown that antidepressants, including SSRIs, do increase the risk of poor neonatal adaptation

BMJ Open

syndrome, specific cardiovascular malformations and persistent pulmonary hypertension of the newborn.[33-35] However, the clinical impact of the latter two outcomes, in absolute terms, is small and the risk of pharmacotherapy should always be weighted versus the risk of undertreated depression in pregnancy.

In most regions approximately 60-70% of women reported use of at least one OTC medication during the course of their pregnancies, mostly for pain conditions, heartburn and upper airways disorders, indicating a substantially high rate of self-medication during pregnancy. This estimate aligns with previous research carried out in North America.[17] Of note, self-medication with OTC sympathomimetic nasal decongestants was more extensive in Northern and Eastern Europe than in the remaining regions; this could be explained by the time of the year when the data collection was performed.

Region of residency was an important factor associated with medication use during pregnancy. As also shown by Cleary et al.,[36] we found that rates of medication use among women originally from Eastern Europe and South America were significantly lower than those observed in Western Europe, North America and Australia. Such geographical differences could be due to culture, variations in prenatal care assistance or access to medications in the various regions and the related costs.

Women working as health care providers, consuming alcohol during pregnancy, or with previous children were those more likely to use short-term and OTC medications, possibly reflecting higher confidence in self-treatment and use of medications in general in the former instance, and less anxiety for the pregnancy outcome in the latter two instances. Contrary to previous studies indicating an association between higher maternal education and more prevalent use of medication during pregnancy.[14,17,23] we found that lower education

was associated with a higher use of OTC medications as well as medication for chronic/longterm disorders (30-50% increased risk). Results of similar magnitude (30% increased risk) were also observed by Olesen et al.[37], whereas Stokholm et al. [38] identified a stronger association (2.3-fold increased risk) between low maternal education and use of antibiotic for respiratory tract infections during pregnancy. One factor negatively associated with chronic/long-term medication use was not having the official language of the country of residency as mother tongue. This tendency was detected in Western and Northern Europe, rising concerns about the potential health risks for immigrant women in these two regions. As shown by Hämeen-Anttila et al., 57% of pregnant women have perceived information needs about medications during pregnancy.[39] Thus, identification of potential users or non-users of medication during pregnancy might be of clinical relevance. Indeed, this may allow tailored evidence-based information about medication safety or outcome of sub-optimal medication of severe medical conditions in pregnancy.

Strengths and limitations

The main strength is that data collection was performed uniformly across all participating countries, allowing for inter-country comparison of the prevalence of medication use during pregnancy. By quantifying the extent of self-medication with OTC drugs and medication use according to self-reported indication, it was possible to determine the leading causes for medication use among pregnant women. Categorization of maternal characteristics positively associated with the various types of medications used during pregnancy enabled us to identify which groups of women are more likely to need information about medication use during pregnancy. The utilization of an anonymous web-based questionnaire enabled us to reach a large proportion of the birthing population in several countries worldwide. However, we cannot exclude the possibility that the women who decided to participate in the study differed

BMJ Open

from the general birthing population in other ways that our analysis could not control for. In most participating countries the study sample was large enough to warrant calculation of prevalence estimates with a precision of 5%. However, less precise estimates were permitted by the study sample in Austria, Iceland and The Netherlands (precision of 9-11%), as well as in Australia, Canada, Croatia, Serbia, Slovenia, and USA (precision of 6-7%).

One main limitation of the study is the lack of validity of the self-reported diagnoses. All disorders were self-reported by the participants and hence dependent on the women's perception of the medical condition. Similarly, information about medication use during pregnancy was dependent on the accuracy of the women's reporting and recall. For new mothers, data were registered retrospectively; hence a risk of recall bias cannot be ruled out. In specific countries (Australia, Canada, France, Russia, The Netherlands, and USA) the study sample was a small proportion of the general birthing population; hence the generalizability of our findings for these specific countries should be interpreted with caution.

The questionnaire was only available through internet websites; by using this kind of approach a conventional response rate cannot be calculated and a selection bias of the target population cannot be ruled out. However, recent epidemiological studies indicate reasonable validity of web-based recruitment methods.[40,41] Also, the penetration rate of the internet either in households or at work is relatively high among women in childbearing age.[42-46] Hence, the degree to which our findings can be extrapolated to the target population is based on the representativeness of the respondents to the general birthing populations in each country. The sample in each country had a somewhat higher educational level than the general birthing populations. Such a limitation might have led to biased estimates of the association between maternal education and medication use during pregnancyan underestimation of the prevalence of medication during pregnancy. Since many ailments requiring pharmacotherapy

occur in mid or late pregnancy, inclusion of pregnant women at early gestation in the total material has somewhat inflated the prevalence of non-users of medications during pregnancy. Also, women with specific disorders or in need of information about medication use during pregnancy might have been more likely to consult internet websites and therefore participate in this study.

CONCLUSIONS

 Use of medications for acute/short-term illnesses and chronic/long-term disorders as well as use of OTC medications, were common during pregnancy. The extent of medicated illnesses and types of medications used for the different indications varied across the six regions. This was especially relevant for acute/short-term illnesses such as nausea and UTIs, but also for chronic/long-term disorders such as hypothyroidism or depression. Women with higher age or lower educational level, housewives, or women with an unplanned pregnancy were those most often reporting chronic/long-term medication use, as opposed to immigrants residing in Western and Northern Europe who reported the least use of this medication category. Future research should definitely focus on this specific group of women, but also address more insights into the outcome of sub-optimal medication of severe conditions in pregnancy.



ACKNOWLEDGMENTS

We thank OTIS, ENTIS Scientific Board who reviewed the study protocol and all website providers who contributed to the recruitment phase. We are grateful to all the participating women who took part in this study.

AUTHOR'S CONTRIBUTION: AL, OS and HN conceived the idea for the study and participated in its design and coordination. AL drafted the manuscript and analyzed the data. MJT, KZ, ACM, MEM, MD, AP, KHA, AR, RGJ, MO, DK, GR, HJ, AP and IB contributed to the data collection. All authors contributed to the interpretation of the results and revised the manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

DATA SHARING STATEMENT: No additional data are available. Researchers can apply for data access for subprojects within the overall aims of the main study 'The Multinational Medication Use in Pregnancy Study'.

REFERENCES

ACOG Committee Opinion No. 377: Research involving women. Obstet Gynecol 2007;110(3):731-6.

 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157(3):175-82.
 Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. [S.l.]: Lippincott

Williams & Wilkins 2011.

 Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205(1):51 e1-8.
 Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012;34(5):719-27.

6. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008;**64**(11):1125-32.

7. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;**65**(5):653-60.

8. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;**113**(5):559-68.

9. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009;65(8):839-46.
 10. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol 2003;59(2):127-33.

BMJ Open

e 57 of 108	BMJ Open
	11. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during pregnancy in
	developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011; 20 (9):895-902.
	12. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in
	pregnancy. J Clin Epidemiol 1993; 46 (6):581-89.
	13. McKenna L, McIntyre M. What over-the-counter preparations are pregnant women taking?
	A literature review. J Adv Nurs 2006; 56 (6):636-45.
	14. Odalovic M, Vezmar Kovacevic S, Nordeng H, et al. Predictors of the use of medications
	before and during pregnancy. Int J Clin Pharm 2013; 35 (3):408-16.
	15. Martindale W, Sweetman SC. Martindale : the complete drug reference. London:
	Pharmaceutical Press, 2011.
	16. WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines for ATC
	classification and DDD assignment 2013. Oslo, 2012. Available at:
	http://www.whocc.no/atc_ddd_index/. Accessed 17 March, 2012.
	17. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of Over-the-Counter Medications and
	Herbal Remedies in Pregnancy. Amer J Perinatol 2005;22(EFirst):321,24.
	18. Sawicki E, Stewart K, Wong S, et al. Medication use for chronic health conditions by
	pregnant women attending an Australian maternity hospital. Aust N Z J Obstet Gynaecol
	2011; 51 (4):333-38.
	19. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley-Interscience
	2000.
	20. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications
	and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66(2):207-14.
	21. Headley J, Northstone K, Simmons H, et al. Medication use during pregnancy: data from
	the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;60(5):355-
	61.
	27

22. Medication during pregnancy: an intercontinental cooperative study. Collaborative Group on Drug Use in Pregnancy (C.G.D.U.P.). Int J Gynaecol Obstet 1992;39(3):185-96. 23. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000;56(4):323-8. 24. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAP study. Aust N Z J Obstet Gynaecol 2000;40(2):165-72. 25. Marín G, Cañas M, Homar C, et al. Uso de fármacos durante el período de gestación en embarazadas de Buenos Aires, Argentina. Rev salud pública 2010;12(5):722-31. 26. European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2010. Stockholm: ECDC, 2013. 27. Smith J, Refuerzo J, Ramin S. Treatment and outcome of nausea and vomiting of pregnancy. In: Basow D, ed. UpToDate. Waltham, MA: UpToDate, 2013. 28. Gadsby R, Barnie-Adshead T, Sykes C. Why won't doctors prescribe antiemetics in pregnancy? BMJ 2011;**343**:d4387. 29. Raymond SH. A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. Aust N Z J Obstet Gynaecol 2013;53(4):358-62. 30. Ross DS. Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment. In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate, 2013.

31. Lewis AJ, Bailey C, Galbally M. Anti-depressant use during pregnancy in Australia: findings from the Longitudinal Study of Australian Children. Aust N Z J Public Health 2012;**36**(5):487-8.

32. Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011;**72**(7):979-85.

ert RE, Evans S antidepressants ychiatry 2011;7

BMJ Open

33. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74(4):e293-e308.
34. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014;348:f6932.

35. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis. J Clin Psychiatry 2013;74(4):e309-e20.

36. Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010;**19**(4):408-17.

37. Olesen C, Thrane N, Henriksen TB, et al. Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women. Eur J Clin Pharmacol 2006;**62**(7):547-53.

38. Stokholm J, Schjorring S, Pedersen L, et al. Prevalence and Predictors of Antibiotic Administration during Pregnancy and Birth. PLoS One 2013;8(12):e82932.

39. Hämeen-Anttila K, Jyrkkä J, Enlund H, et al. Medicines information needs during pregnancy: a multinational comparison. BMJ Open 2013;**3**(4).

40. Ekman A, Dickman P, Klint Å, et al. Feasibility of Using Web-based Questionnaires in Large Population-based Epidemiological Studies. Eur J Epidemiol 2006;**21**(2):103-11.

41. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am J Epidemiol 2010;**172**(11):1292-8.

 42. Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus. 2011; Available at: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-11-066/EN/KS-SF-11-066-EN.PDF. Accessed 13 November, 2012.
43. Internet World Stats. Usage and population statistics. 2012; Available at: http://www.internetworldstats.com/. Accessed 13 November, 2012.
44. Australian Bureau of Statistics. Household Use of Information Technology, Australia, 2010-11. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main Features12010-11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11&num=&view=. Accessed 13 November, 2012.
45. Statistics Canada. Individual Internet use and E-commerce (2010). 2011; Available at: http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed 13 November, 2012.
46. United States Census Bureau. The 2012 Statistical Abstract. Information & Communications: Internet Publishing and Broadcasting and Internet Usage. 2010; Available at:

http://www.census.gov/compendia/statab/cats/information_communications/internet_publishi ng and broadcasting and internet usage.html. Accessed 13 November, 2012.

Page 61 of 108

BMJ Open





Figure 1 shows the participant flow-chart to achieve the final sample analyzed 60x45mm (300 x 300 DPI)






Figure 2 shows the proportion of respondents (%) reporting use of any medication, over-the-counter (OTC) medication, medication for acute/short-term illnesses and medication for chronic/long-term disorders during pregnancy according to region and country of residency. The observed estimates do not include vitamins, mineral supplements, iron, and herbal or alternative medicine products.

100x69mm (300 x 300 DPI)

Appendix 1: Survey questionnaire

Internet questionnaire

BMJ Open

Medication use in pregnancy with focus on attitudes, perception of risk and mental health

The Multinational Medication Use in Pregnancy Study

INFORMATION ABOUT YOURSELF

1. In which country do you live?	In which region/province do you live?
Country:	Region:
2. Are you pregnant right now?	
□ Yes	
If yes in Q2) In which pregnancy week are	(If No in Q2) How old is your newborn
you?	child (in weeks)?
From 1 to 44	0-4 / 5-8 / 9-12 / 13-16 / 17-20 /
	21-24 / 25-28 / > 29
(If yes in Q2) Is it a multiple pregnancy?	(If No in Q2) Do you breast feed your
□ No	child?
\Box Yes (e.g. twins, triplets, etc)	
3. How many children do you already have	from before?
□ None □ One	
\Box Two	
\square More than two	
4. What is your marital status?	
□ Married	
□ Divorced/Separated	
5. What is the highest education you have c	ompleted?
□ Primary school (8-9 years of education	
□ High-school (11-13 years of education	
□ University	
□ Other education	
6. What was your work situation when you	became pregnant?
□ Student	• ~
□ Housewife	
□ Health care personnel, i.e., physician,	nurse, or pharmacist
□ Employed in another sector	
□ Job seeker	
\square None of the above	
7. Is English your mother tongue?	
\Box Yes	
\square No	
(If No in Q7 above) What is your mother	tongue?
8. Your age: Years, from 15 to 55	

2	
3	
4	
5	
2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 14 5 16 17 18 19 20 1 22 23 24 25 26 27 28 29 30 4	
6	
7	
8	
õ	
9	
10	
11	
12	
13	
10	
14	
15	
16	
17	
10	
10	
19	
20	
21	
22	
~~	
23	
24	
25	
26	
20	
21	
28	
29	
30	
24	
31 32 33 34 35	
32	
33	
34	
25	
35	
36 37 38 39	
37	
38	
20	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

9. (If pregnant) Are you	attendin	ig any p	oregnar	ncy/birth	n prepa	ration	course or similar?
□ Yes □ No, but I am plan	ning to a	ttend					
□ No, I am not going							
10. (If pregnant) What ar	e your tl	houghts	s about	how the	experi	ence of	giving birth is going
to be?							
Please indicate your though	nts in a so	cale from	m 1 to 6	where 1	1 corre	sponds	to absolutely terrible
and 6 to absolutely fantas				, <u>-</u>		- <u>-</u>	
Absolutely terrible	1	2	3	4	5	6	Absolutely fantastic
11. Was your pregnancy p	planned	?					
□ Yes □ No, but it was not	complet	alu una	vnactad				
\square No, but it was not plan		cry unc.	xpecieu				
12. Did you contact any h		e provi	der due	e to infer	tilitv?		
□ Yes		1			v		
□ No							
(If Yes in Q12 abov infertility treatmen		you, in	this pro	egnancy,	, becom	ie preg	nant secondarily to
□ Yes							
\square No							
13. Have you taken folic a	cid? (al	one or a	as part	of multiv	vitamin	is)	
□ Yes, before pregn			-				
\Box Yes, before and du							
\Box Yes, only during p	pregnanc	У					
□ No □ cannot remember							
14. Did you smoke cigaret	ttes hefo	re heco	ming n	regnant	?		
\Box Yes, regularly			ming p	regnant	•		
\Box Yes, occasionally							
\square No, never							
						_	
		occasio	nally) I)o you/d	id you	smoke	during pregnancy?
□ Yes, more than be □ Yes, approximatel		ne					
\Box Yes, but less	ly the sui	ne					
□ No Î							
(If yes) How many o	cigarette	es (on a	verage)	do you/	did you	ı smok	e per day?
□ < 1 □ 1-5							
□ f-10							
□ > 11							
15. Did you drink any alco	ohol afte	er findi	ng out f	hat you	were p	regnan	ıt?
□ Yes							
□ No							
Cannot remember							

(If yes) How much did you drink (in units)?
1 alcohol unit is equivalent to: one 25ml single measure of whisky (ABV 40%), or a third of a pint of beer (ABV 5-6%) or half a standard (175ml) glass of red wine (ABV 12%).
a More than 1-2 units per week
a 1-2 units per week
a 1-4 units per month
a 1-2 units during the pregnancy
b Can not remember

HEAT TH DISORDERS AND	MEDICATIONS DURING PREGNANCY
IIEALI II DISOKDEKS AND	

16. Have you experienced any of the disorders listed below during this pregnancy? If you use or have used any medicines in relation to [each health disorder listed] please enter the names of the medicines.

In which weeks of pregnancy hav	ve you used them?
---------------------------------	-------------------

Health disorder		Medicine	Period of use (pregnancy weeks)	
Nausea	□ Yes □ No	(If Nausea ticked) If you use or have used any medicines in relation to nausea, please enter the names of the medicines	□ week 0-12 □ week 13-24 □ week 25- delivery	
Heartburn or reflux problems	□ Yes □ No	(If Heartburn ticked) If you use or have used any medicines in relation to heartburn or reflux problem, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 	
Constipation	□ Yes □ No	(If Constipation ticked) If you use or have used any medicines in relation to constipation, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 	
Common cold	□ Yes □ No	(If common cold ticked If you use or have used any medicines in relation to common cold, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 	
Urinary tract infections	□ Yes □ No	(If UTI ticked) If you use or have used any medicines in relation to urinary tract infections, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 	
Other infections	□ Yes □ No	(If other infections ticked) If you use or have used any medicines in relation to other infections, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 	
Pain in neck or back or pelvic girdle	□ Yes □ No	(If pain ticked) If you use or have used any medicines in relation to pain in neck or back or pelvic girdle, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 	
Headache	□ Yes □ No	(If headache ticked) If you use or have used any medicines in relation to headache, please enter the names of the medicines	 week 0-12 week 13-24 week 25- delivery 	
Sleeping problems	□ Yes □ No	(If sleeping problems ticked) If you use or have used any medicines in relation to sleeping problems, please enter the names of the medicines	 □ week 0-12 □ week 13-24 □ week 25- delivery 	

17. Have you been on sick	leave during this pregnancy?
□ Yes	□ No
18. (If yes in Q17) What yon sick leave?	as the reason for it? In which pregnancy weeks have you been
Reason of the sick leave	Sick leave period (pregnancy week)
	□ week 0-12 □ week 13-24 □ week 25-delivery

19. Below, some common over-the-counter (OTC) medicines are mentioned. Please indicate whether you have used any of them during pregnancy.

Please enter the name of all X medicines you have used. In which pregnancy weeks have you used them?

		Name of the medicine(s) you have used	Period of use
			(pregnancy week)
Pain killers	🗆 Yes	(If painkillers ticked)	□ week 0-12
(e.g. paracetamol)	🗆 No	Please enter the name of all pain killers	□ week 13-24
		you have used during pregnancy.	□ week 25- delivery
Nasal spray/drops	□ Yes	(If nasal spray ticked)	□ week 0-12
(excluding salt	🗆 No	Please enter the name of all nasal	□ week 13-24
water solution)		sprays/drops you have used during	□ week 25- delivery
(e.g. Otrivine,		pregnancy.	
Vicks Sinex			
decongestant			
Nasal spray)			
Medication against	🗆 Yes	(If OTC for heartburn ticked)	□ week 0-12
heartburn	🗆 No	Please enter the name of all medications	□ week 13-24
(e.g. Gaviscon or		you have used against heartburn during	□ week 25- delivery
Rennie)		pregnancy.	
Medication against	🗆 Yes	(If OTC for nausea ticked)	□ week 0-12
nausea/travel	🗆 No	Please enter the name of all medications	□ week 13-24
sickness (<i>e.g.</i>		you have used against nausea during	□ week 25- delivery
Cetirizine, Sea-		pregnancy.	
Legs)			
Medication against	🗆 Yes	(If OTC for constipation ticked)	□ week 0-12
constipation	□ No	Please enter the name of all medications	□ week 13-24
(e.g.Lactulose, Dulcolax)		you have used against constipation during pregnancy.	□ week 25- delivery

 Yes □ No □ Cannot remember (If yes) Please provide the name of all herbal preparations you have taken during pregnancy (if yes) What was the reason for taking herbal preparations (health disorder, illness)? Name of herbal Reason for use (health disorder, illness)? Name of herbal Reason for use (health disorder, illness)? Name of herbal Reason for use (health disorder, illness)? Wate of herbal Reason for use (health disorder, illness)? Wate of herbal Reason for use (health disorder, illness)? Wate of herbal Reason for use (health disorder, illness)? Week 0-12 week 13-24 week 13-24 week 13-24 week 13-24 week 25- delivery 21. (If you used herbal preparations during pregnancy? (You may tick more than one answer) My own initiative Family/friends Physician Midwife/Nurse Pharmacy personnel Herbal shop personnel Herbal shop personnel Herbal shop personnel Yes No Cannot remember (If yes in Q22 above) What was the reason for use?	20. Did you take any herl cranberries)?	oal preparations during pregn	ancy (e.g. ginger, echinacea, valerian,
(If yes) What was the reason for taking herbal preparations (health disorder, illness)? (If yes) In which pregnancy weeks did you take herbal preparations? Name of herbal preparation used Reason for use (health disorder, illness)? (If yes) In which pregnancy weeks did you take herbal preparations? Name of herbal preparation used Reason for use (health disorder, illness)? (If yes) In which pregnancy weeks did you take herbal preparations? Period of use (pregnancy week (If yes) In which pregnancy weeks did you take herbal preparations? Period of use (pregnancy week (If yes yeek 0.12 week 0.12 (If you used herbal preparations during pregnancy) Who recommended to you to take herbal preparations during pregnancy? (You may tick more than one answer) Week 0.12 (If you used herbal preparations during pregnancy? (You may tick more than one answer) Week 25- delivery 21. (If you used herbal preparations during pregnancy? (You may tick more than one answer) Midwife/Nurse Family/friends Physician Midwife/Nurse Pharmacy personnel Herbal shop personnel Internet Magazines, media, etc. No Other (please specify: No Yes No Yes No If yes in Q22 above) What was the reason for use?	,	□ No	□ Cannot remember
Name of herbal preparation used Reason for use (health disorder, illness) Period of use (pregnancy week	(If yes) What was the rea	son for taking herbal preparat	tions (health disorder, illness)?
week 0-12 week 13-24 week 25- delivery week 0-12 week 0-12 week 0-12 week 25- delivery week 0-12 week 0-10	Name of herbal	Reason for use (health diso	order, Period of use
 week 13-24 week 25- delivery week 25- delivery week 25- delivery week 13-24 week 13-24 week 25- delivery week 25- delivery	preparation used	illness)	
 week 25- delivery week 0-12 week 13-24 week 25- delivery 21. (If you used herbal preparations during pregnancy) Who recommended to you to take herbal preparations during pregnancy? (You may tick more than one answer) My own initiative Family/friends Physician Midwife/Nurse Pharmacy personnel Herbal shop personnel Internet Magazines, media, etc. Other (please specify:) 22. Did you use homeopathic products during pregnancy? Yes No Cannot remember 			
□ week 0-12 □ week 13-24 □ week 25- delivery 21. (If you used herbal preparations during pregnancy) Who recommended to you to take herbal preparations during pregnancy? (You may tick more than one answer) □ My own initiative □ Family/friends □ Physician □ Midwife/Nurse □ Pharmacy personnel □ Internet □ Magazines, media, etc. □ Other (please specify:) 22. Did you use homeopathic products during pregnancy? □ □ Yes □ No			
□ □ week 13-24 □ week 25- delivery 21. (If you used herbal preparations during pregnancy) Who recommended to you to take herbal preparations during pregnancy? (You may tick more than one answer) □ My own initiative □ Family/friends □ Physician □ Midwife/Nurse □ Pharmacy personnel □ Internet □ Magazines, media, etc. □ Other (please specify: □ No □ Yes □ No □ Cannot remember			
Image: specify:			
21. (If you used herbal preparations during pregnancy) Who recommended to you to take herbal preparations during pregnancy? (You may tick more than one answer) My own initiative Family/friends Physician Midwife/Nurse Pharmacy personnel Herbal shop personnel Internet Magazines, media, etc. Other (please specify: Yes No Cannot remember (If yes in Q22 above)		-	
herbal preparations during pregnancy? (You may tick more than one answer) My own initiative Family/friends Physician Midwife/Nurse Pharmacy personnel Herbal shop personnel Internet Magazines, media, etc. Other (please specify:) 22. Did you use homeopathic products during pregnancy? Yes No Cannot remember			
□ Yes □ No □ Cannot remember (If yes in Q22 above) What was the reason for use?	 Midwife/Nurse Pharmacy personnel Herbal shop personnel Internet Magazines, media, etc. Other (please specify:) thic products during pregnanc	· v ?
	•		•
	(If yes in Q22 above)	What was the reason for use?	

A BIT MORE ABOUT MEDICATION USE DURING PREGNANCY

23. Have you deliberately avoided taking an over-the-counter medicine during your pregnancy?

 \sqcap Yes

 \square No

 \square Cannot remember

(If yes in Q23 above) Which medicine was it?

(If yes in Q23 above) What was the reason for doing so?

24. Have you deliberately chosen not to use a medicine prescribed by a doctor because you were pregnant?

 \Box Yes

 $\square \ No$

 \Box Can not remember

(If yes in Q24 above) Which medicine was it?

(If yes in Q24 above) What was the reason for doing so?



		g the course of your pregnancy?
□ Yes	□ No	Cannot remember
26. (If yes in Q25) Who	m did you turn to for inform:	ation? (You may tick more than one
answer)		
□ Family/friends		
Physician		
□ Midwife/Nurse		
Pharmacy perso		
Herbal shop per		
	information leaflet	
Poison information		
□ Teratology info		
	of information on medicines	
Internet		
□ Magazines, mea		
□ Other (please sp		
		from various sources, was such
information similar		
\Box Yes, complete	-	
	e (only the wording or detail le	vel was somewhat different)
-	information was different	
	ation was completely contradic	-
		epancies among the sources, what o
•	nay tick more than one answe	<i>r</i>)
Nothing		
I became anxio		
	use the medication	
□ I sought for a n	ew information source (Which	new source have you consulted?
\Box I chose to rely	on one source and ignore the co	onflicting one (On which source have
relied?		ce have you ignored?
29. How often do you h	ave someone help you read ho	ospital materials?
\Box Always	1.	-
□ Often		
□ Sometimes		
Occasionally		
□ Never		
30. How confident are	ou filling out medical forms	by yourself?
□ Extremely		
Quite a bit		
□ Somewhat		
\Box A little bit		
□ Not at all		
-		your medical condition because of
-	ding written information?	
□ Always		
□ Often		
□ Sometimes		
□ Occasionally		
□ Never		

YOUR NEEDS FOR INFORMATION

The following section will pop-up only if the subject has reported to be suffering from a chronic disease

I. MEDICATIONS FOR CHRONIC DISEASES DURING PREGNANCY

If you use or have used medicines for a chronic disease during your pregnancy fill out this part of the questionnaire (I, II, III) and provide some information about those medicines you use daily.

Some chronic diseases are asthma, allergy, hypothyroidism (low thyroid hormone), rheumatic diseases (incl. rheumatoid arthritis, psoriatic arthritis), diabetes (type I or II), epilepsy, depression, anxiety, cardiovascular diseases (incl. hypertension, high cholesterol, and heart diseases)

Do you suffer of any chronic disease?

 \Box Yes \Box No

(If Yes above) Please indicate whether you suffer of any of the following chronic

		diseases.	
		If you use or have used medicines for X during your pregnancy, please enter the name of the	In which weeks of pregnancy did you use them?
Asthma	□ Yes □ No	medicines. (If Asthma ticked) If you use or have used medicines for asthma during pregnancy, please enter the names of the medicines	□ week 0-12 □ week 13-24 □ week 25-delivery
Allergy	□ Yes □ No	 names of the medicines. (If Allergy ticked) If you use or have used medicines for allergy during pregnancy, please enter the names of the medicines. 	□ week 0-12 □ week 13-24 □ week 25-delivery
Hypothyroidism (low thyroid hormone)	□ Yes □ No	(If Hypothyroidism ticked) If you use or have used medicines for hypothyroidism during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery
Rheumatic disorders (incl. rheumatoid arthritis, psoriatic arthritis)	□ Yes □ No	(If Rheumatic disorders ticked) If you use or have used medicines for rheumatic disorder during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery
Diabetes (type I or II)	□ Yes □ No	(If Diabetes ticked) If you use or have used medicines for diabetes during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery
Epilepsy	□ Yes □ No	(If Epilepsy ticked) If you use or have used medicines for epilepsy during pregnancy, please enter the names of the medicines.	 □ week 0-12 □ week 13-24 □ week 25-delivery
Depression	□ Yes □ No	(If Depression ticked) If you use or have used medicines for depression, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery
Anxiety	□ Yes □ No	(If Anxiety ticked) If you use or have used medicines for anxiety during pregnancy, please enter the names of the medicines.	 week 0-12 week 13-24 week 25-delivery

		If you use or have used medicines for X during your pregnancy, please enter the name of the medicines.	In which weeks of pregnancy did you use them?
Cardiovascular diseases (incl. hypertension, high cholesterol, heart diseases)	□ Yes □ No	(If Cardio disease ticked) If you use or have used medicines for cardiovascular diseases during pregnancy, please enter the names of the medicines.	 □ week 0-12 □ week 13-24 □ week 25-delivery
Others (If Others ticked) (Please specify which other disease(s):	□ Yes □ No	(If Other disease ticked) If you use or have used medicines for your chronic disease during pregnancy, please enter the names of the medicines.	 □ week 0-12 □ week 13-24 □ week 25-delivery

Section II will pop-up only if the subject has reported to be suffering of a chronic disease

II. YOUR VIEWS ABOUT PRESCRIBED MEDICINES

In this section of the survey questionnaire, the **Belief About Prescribed Medicine Questionnaire (BMQ-Specific)** was presented (Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1-24).

Section III will pop-up only if the subject has reported to be suffering of a chronic disease. There will be one single scale for each chronic condition reported

III. QUESTION ABOUT YOUR USE OF MEDICATIONS FOR X

In this section of the survey questionnaire, the 8-item Morisky Medication Adherence Questionnaire (MMAS-8) was presented (Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

<text>

E COR DE CERTER MONT

Do you have any other comments about your medication use during pregnancy?

YOUR VIEWS ABOUT MEDICATIONS In this section of the survey questionnaire, the Belief About Medicine Questionnaire (BMQ-General) was presented (Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the

32. Below are some statements about use of medicines in pregnancy. Please specify how much you agree or disagree with these statements by ticking where appropriate. (You may only tick once per line)

	Strongly agree	Agree	Uncertain	Disagree	Strongly disagree
I have a higher threshold for using medicines when I am pregnant than when I'm not pregnant	o	0	o	0	o
Even though I am ill and could have taken medicines, it is better for the foetus that I refrain from using them	0	0	o	0	o
Pregnant women should preferably use herbal remedies than conventional medicines	o	0	o	0	o

YOUR ASSESSMENT OF PREGNANCY RISKS

33. Among 100 healthy women in a healthy environment, how many do you think will give birth to a child with a birth defect?

34. Here below is a list with various medicines, food and other substances.

Please indicate how harmful you think they are for the foetus in a scale from 0 to 10, where $\underline{0}$ corresponds to 'not harmful' and 10 to 'very harmful'.

If you have not heard before about such substance, tick 'unknown substance'.

	Unknown substance	0	1	2	3	4	5	6	7	8	9	10
Paracetamol/acetaminophen	o	0	0	0	ο	o	0	o	o	ο	o	0
Antibiotics (e.g. Penicillins)	0	0	0	0	ο	o	ο	o	o	o	o	0
Antidepressants	o	0	0	0	ο	o	0	o	o	ο	o	0
Thalidomide	o	0	0	0	0	0	0	o	0	0	ο	0
Swine influenza vaccine	0	0	0	0	ο	o	ο	o	o	ο	o	0
OTC medicines against nausea/travel sickness	0	o	o	o	o	o	o	o	o	o	o	o
Ginger	0	0	0	0	ο	o	ο	o	0	ο	0	o
Cranberries	o	0	0	0	ο	ο	ο	o	0	ο	o	0
Blue veined cheese (e.g. Gorgonzola)	0	0	o	o	o	0	o	0	o	o	0	o
Eggs	0	0	0	0	ο	ο	0	o	o	0	o	0
Alcohol during the 1. trimester (<i>e.g. wine, beer, spirits</i>)	O	0	0	o	o	o	o	o	o	o	0	o
Smoking (e.g. cigarettes)	o	o	o	o	o	o	o	o	o	o	o	o
Dental X-ray	0	0	0	0	0	ο	ο	0	0	ο	0	0



HOW YOU ARE FEELING NOW

In this section of the survey questionnaire, the Edinburgh Postnatal Depression Scale (EPDS) was presented (Cox J, Holden J, Sagovsky R. Detection of postnatal depression. Development of the 10-item edinburgh postnatal depression scale. The British Journal of

re, the n. J. Sagos je. 1987 June 1, 19.

BMJ Open

HOW YOU SEE YOURSELF

In this section of the survey questionnaire, the **Big Five Inventory (BFI)** was presented (John OP, Srivastava S, editors. The big five trait taxonomy: History, measurement, and theoretical perspectives: New York: Guilford; 1999; John OP, Robins RW, Pervin LA. Handbook of

, the trait tas, is 1999; John Joy and research.

Appendix 2: Websites used for recruitment and internet penetration rates in each country where data were collected

Western Europe Austria www.schwangerschaft.at, www.schwangerschafts- blog.at; www.fratz.at, www.netdoctor.at; www.babycenter.at; www.babyujde.at 93* ^[11] France www.aufeminin.com (Including ipad application to website subscribers) 91* ^[11] Italy Pregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.mammole.it; www.gravidanzaonline.it 70* ^[11] Switzerland www.bebe-bebe.com; www.swissmom.ch 84* ^[21] The Netherlands www.babybytes.nl 98* ^[11] United Kingdom Targeted email to pregnancy forum subscribers: www.babybytes.nl 93* ^[11] Www.babybytes.nl 93* ^[11] United Kingdom Targeted anali to pregnancy forum subscribers: www.babybytes.nl 93* ^[11] Www.babybytes.nl 93* ^[11] 93* ^[11] Www.babybytes.nl 93* ^[11] Www.bauva.fi; www.micanperhe.fi; www.kaksplus.fi 99* ^[11] Korthern Europe 93* ^[11] Finland www.barnitiagen.com; www.tikk.no; 99* ^[11] Www.seubabycenter.com; www.susterno; 99* ^[11] Kestern Europe 93* ^[11] Fregnancy Forums: www.enroel.gu.se 99* ^[11] Www.barbybend.p; www.wininbebis.com; www.seabycenter.com; www.scor	Country	Website used for recruitment	Internet penetration rates (%)
Austria www.schwangerschaft.at; www.schwangerschafts- blog.at; www.fratz.at; www.netdoctor.at; www.babycenter.at; www.baby-boom.at; www.ekiz- dachverband.at; www.babyguide.at 93* ^[11] France www.aufeminin.com (Including ipad application to website subscribers) 91* ^[11] Italy Pregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.miobambino.it 70* ^[11] Switzerland www.separate amamma.it; www.miobambino.it 84* ^[21] The Netherlands www.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl 98* ^[11] United Kingdom Targeted email to pregnancy forum subscribers: www.babybytes.nl 93* ^[11] United Kingdom Targeted email to pregnancy forum subscribers: www.bounty.com 93* ^[11] Pregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com 93* ^[11] Northern Europe 93* ^[11] Finland www.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi 99* ^[11] Northern Europe 99* ^[11] Sweden www.barntotal.se; www.minbebis.con; www.se.babycenter.com; www.socmed.gu.se 99* ^[11] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zaptajpolozna.pl; www.babyboom.pl; www.zaptajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl	EUROPE		
InitialInitial of the state of t		Western Europe	
www.babycenter.at; www.baby-boom.at; www.ekiz- dachverband.at; www.babyguide.at91*11Francewww.auferminin.com (Including ipad application to website subscribers)91*11ItalyPregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.mammole.it; www.gravidanzaonline.it70*10ItalyPregnancy Forums: www.gravidanzaonline.it; www.gravidanzaonline.it70*11Switzerlandwww.bebe-bebe.com; www.swissmom.ch84*12The Netherlands www.babybytes.nl98*111United KingdomTargeted email to pregnancy forum subscribers: www.babybytes.nl93*111United KingdomTargeted email to pregnancy forum subscribers: www.babybytes.nl93*111United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93*111Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99*111IcelandPregnancy Forums: www.bland.is100*111Norwaywww.barntotal.se; www.minbebis.com; www.barntotal.se; www.socmed.gu.se99*111Swedenwww.cybermed.hr80*111Katern EuropeEastern Europe100*111Pregnancy Forums: www.socmed.gu.se99*101www.se.babycenter.com; www.socmed.gu.se99*101www.se.babycenter.com; www.socmed.gu.se80*111Hatern Europe100*111Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zaytajpolozna.pl; www.babyboom.pl; www.socmed.gu.ac,pl; www.babyboom.pl; www.socmed.gu.ac,pl; www.babyboom.pl; www.socmed.gu.ac,pl; www.babyboom.pl; www.socmed.gu.ac,pl; www.babyboom.pl; www.socma.pl; www.babyboom.pl; www.so	Austria	www.schwangerschaft.at; www.schwangerschafts-	93* [1]
dachverband.at; www.babyguide.atFrancewww.aufeminin.com (Including ipad application to website subscribers)91**[1]ItalyPregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.mammole.it; www.gravidanzaonline.it70**[1]Switzerlandwww.forumsalute.it; www.moiobambino.it70**[1]Switzerlandwww.bebe-bebe.com; www.swissmom.ch84**[2]The Netherlandswww.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl98**[1]United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93**[1]Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi www.bounty.com99**[1]Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi www.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99**[1]Swedenwww.barnitotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99**[1]Croatiawww.cybermed.hr80** ^[1] (data from 2010)Polandwww.szief.umlub.pl84** ^[1] Pregnancy Forums: www.eprzyszek.pl; www.babyboom.pl; www.toyia-ciaza.com,pl90** ^[1]		blog.at; www.fratz.at; www.netdoctor.at;	
Francewww.aufeminin.com (Including ipad application to website subscribers)91*[1]ItalyPregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.mammole.it; www.pianetamamma.it; www.miobambino.it70*[1]ItalyPregnancy Forums: www.gravidanzaonline.it; www.gravidanzaonline.it; www.gravidanzaonline.it70*[1]Switzerlandwww.bebe-bebe.com; www.swissmom.ch84*[2]The Netherlands www.bebe-bebe.com; www.swissmom.ch84*[1]www.beb-bebe.com; www.gravidanzaonline.it98*[1]Www.babybytes.nl98*[1]United Kingdom www.bounty.com7argeted email to pregnancy forum subscribers: www.bounty.com93*[1]Pregnancy Forums: www.pregnancyforum.co.uk; www.brengnancyforum.org.uk93*[1]Northern Europe1Finlandwww.auva.fi; www.miedanperhe.fi; www.kaksplus.fi99*[1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamanedisin.no99*[1]Swedenwww.se.babycenter.com; www.socomed.gu.se99*[1]Croatiawww.cybermed.hr80*[1]Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.babyboom.pl; www.tonja-ciaza.com,pl84*[1]		www.babycenter.at; www.baby-boom.at; www.ekiz-	
website subscribers)ItalyPregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.mammole.it; www.pianetamamma.it; www.miobambino.it70* ^[1] Targeted email to pregnancy forum subscribers: www.gravidanzaonline.it70* ^[1] Switzerlandwww.bebe-bebe.com; www.swissmom.ch84* ^[2] The Netherlands www.baybytes.nl98* ^[1] United KingdomTargeted email to pregnancy forum subscribers: www.babybytes.nl93* ^[1] United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93* ^[1] Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi www.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.klikk.no; www.se.babycenter.com; www.socmed.gu.se99* ^[1] Swedenwww.cytermed.hr80* ^[1] Croatiawww.cytermed.hr80* ^[1] Www.szief.umlub.pl84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.babyboom.pl; www.twoja-ciaza.com.pl84* ^[1]		dachverband.at; www.babyguide.at	
Italy Pregnancy Forums: www.gravidanzaonline.it; www.forumsalute.it; www.mammole.it; www.pianetamamma.it; www.miobambino.it 70* ^[1] Targeted email to pregnancy forum subscribers: www.gravidanzaonline.it 84* ^[2] Switzerland www.bebe-bebe.com; www.swissmom.ch 84* ^[2] The Netherlands www.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl 98* ^[1] United Kingdom Targeted email to pregnancy forum subscribers: www.bounty.com 93* ^[1] Pregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com 93* ^[1] Finland www.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi 99* ^[1] Iceland Pregnancy Forums: www.bland.is 100* ^[1] Norway www.barnimagen.com; www.kikk.no; www.jormorsrir.no; www.tryggmamamedisin.no 99* ^[1] Sweden www.eybermed.hr 80* ^[1] Www.vauva.fi; unub.pl 84* ^[1] Pregnancy Forums: www.socmed.gu.se 99* ^[1] Www.barnitotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se 99* ^[1] Www.vebermed.hr 80* ^[1] (data from 2010) Poland www.zzief.umlub.pl 84* ^[1]	France	www.aufeminin.com (Including ipad application to	91 ^{* [1]}
www.forumsalute.it; www.mammole.it; www.pianetamamma.it; www.miobambino.it Targeted email to pregnancy forum subscribers: www.gravidanzaonline.it Switzerland www.bebe-bebe.com; www.swissmom.ch Www.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl United Kingdom Targeted email to pregnancy forum subscribers: Www.bounty.com Pregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com Pregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com Pregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com Pregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com Pregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com Pregnancy Forums: www.bland.is 100* ^[1] Iceland Pregnancy Forums: www.bland.is 100* ^[1] Norway www.barnimagen.com; www.tkikk.no; www.jormorsrin.com; www.tkikk.no; www.jormorsrin.com; www.tyggmamamedisin.no Sweden www.barnitotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se Eastern Europe Croatia www.cybermed.hr Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.babyboom.pl; www.twoja-ciaza.com.pl		website subscribers)	
www.pianetamamma.it; www.miobambino.itTargeted email to pregnancy forum subscribers: www.gravidanzaonline.itSwitzerlandwww.bebe-bebe.com; www.swissmom.ch84* [2]The Netherlands www.babybytes.nl98* [1] www.babybytes.nlUnited KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93* [1] www.babybytes.nlPregnancy Forums: www.pregnancyforum.co.uk; www.bounty.com93* [1]Finlandwww.vauva.fi; www.megnancyforum.co.uk; www.pregnancyforum.org.uk99* [1]IcelandPregnancy Forums: www.bland.is99* [1]IcelandPregnancy Forums: www.bland.is99* [1]Norwaywww.barninagen.com; www.klikk.no; www.jormorsri.no; www.tryggmamamedisin.no99* [1]Swedenwww.cybermed.hr80* [1]Croatiawww.cybermed.hr80* [1]Pregnancy Forums: www.socmed.gu.se80* [1]Pregnancy Forums: www.sochad.js99* [1]Www.se.babyconter.com; www.socmed.gu.se99* [1]Pregnancy Forums: www.socmed.gu.se80* [1]Pregnancy Forums: www.socmed.gu.se80* [1]Pregnancy Forums: www.socmed.gu.se80* [1]Pregnancy Forums: www.socmed.gu.se84* [1]	Italy	Pregnancy Forums: www.gravidanzaonline.it;	70 ^{* [1]}
Targeted email to pregnancy forum subscribers: www.gravidanzaonline.itSwitzerlandwww.bebe-bebe.com; www.swissmom.ch84*121The Netherlandswww.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl98*111United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93*111Pregnancy Forums: www.bounty.com93*111Finlandwww.vauva.fi; www.pregnancyforum.co.uk; www.pregnancyforum.org.uk99*111IcelandPregnancy Forums: www.bland.is99*111IcelandPregnancy Forums: www.jormorsiri.no; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*111Swedenwww.cybermed.hr99*111Www.cybermed.hr80*111100*111Polandwww.zzief.umlub.pl84*111Pregnancy Forums: www.ebabyboom.pl; www.reoja-ciaza.com.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl84*11			
www.gravidanzaonline.itSwitzerlandwww.bebe-bebe.com; www.swissmom.ch84*[2]The Netherlandswww.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl98*[1]United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93*[1]Pregnancy Forums: www.pregnancyforum.co.uk; www.pregnancyforum.org.uk93*[1]Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99*[1]IcelandPregnancy Forums: www.bland.is100*[1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*[1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se80*[1](data from 2010)Polandwww.zzief.umlub.pl84*[1]Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.babyboom.pl; www.twoja-ciaza.com.pl84*[1]		www.pianetamamma.it; www.miobambino.it	
www.gravidanzaonline.itSwitzerlandwww.bebe-bebe.com; www.swissmom.ch84*[2]The Netherlandswww.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl98*[1]United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93*[1]Pregnancy Forums: www.pregnancyforum.co.uk; www.pregnancyforum.org.uk93*[1]Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99*[1]IcelandPregnancy Forums: www.bland.is100*[1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*[1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se80*[1](data from 2010)Polandwww.zzief.umlub.pl84*[1]Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.babyboom.pl; www.twoja-ciaza.com.pl84*[1]			
Switzerlandwww.bebe-bebe.com; www.swissmom.ch84*The Netherlandswww.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl98*United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93*Pregnancy Forums: www.pregnancyforum.org.uk93*Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi www.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tlikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99*Croatiawww.cybermed.hr80*Pregnancy Forums: www.bayd.hr80*10011Pregnancy Forums: www.socmed.gu.se99*Internet www.se.babycenter.com; www.socmed.gu.se99*Polandwww.cybermed.hr80*Pregnancy Forums: www.baygipolozna.pl; www.babyboom.pl; www.twoja-ciaza.com.pl84*			
The Netherlandswww.lareb.nl; www.gezondzwangerzijn.nl; www.babybytes.nl98* ^[1] United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93* ^[1] Pregnancy Forums: www.pregnancyforum.co.uk; www.pregnancyforum.org.uk93* ^[1] Northern EuropeFinlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi 100* ^[1] IcelandPregnancy Forums: www.bland.is www.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99* ^[1] Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99* ^[1] Croatiawww.cybermed.hr80* ^[1] (data from 2010)Polandwww.zzief.umlub.pl84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.twoja-ciaza.com.pl84* ^[1]			+ 101
Initial www.babybytes.nlInitial www.babybytes.nlUnited KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93* [1]Pregnancy Forums: www.pregnancyforum.co.uk; www.pregnancyforum.org.uk93* [1]Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99* [1]IcelandPregnancy Forums: www.bland.is100* [1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99* [1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99* [1]Croatiawww.cybermed.hr80* [1] (data from 2010)Polandwww.zzief.umlub.pl84* [1]Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.twoja-ciaza.com.pl84* [1]			
United KingdomTargeted email to pregnancy forum subscribers: www.bounty.com93*[1]Www.bounty.comPregnancy Forums: www.pregnancyforum.co.uk; www.pregnancyforum.org.uk99*[1]Northern EuropeFinlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99*[1]IcelandPregnancy Forums: www.bland.is100*[1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*[1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99*[1]Croatiawww.cybermed.hr80*[1] (data from 2010)Polandwww.zzief.umlub.pl84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.twoja-ciaza.com.pl84* ^[1]	The Netherlands		98 ^{* [1]}
Initial angle is initial program y function of the program y function of the program y for the program y		www.babybytes.nl	
Pregnancy Forums: www.pregnancyforum.co.uk; www.pregnancyforum.org.ukNorthern EuropeFinlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99*[1]IcelandPregnancy Forums: www.bland.is100*[1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*[1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99*[1]Eastern EuropeCroatiawww.cybermed.hr80* ^[1] (data from 2010)Polandwww.zzief.umlub.pl84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl#################################	United Kingdom		93 ^{*[1]}
www.pregnancyforum.org.ukNorthern EuropeFinlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99* ^[1] IcelandPregnancy Forums: www.bland.is100* ^[1] Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99* ^[1] Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99* ^[1] Eastern EuropeCroatiawww.cybermed.hr80* ^[1] (data from 2010)Polandwww.zzief.umlub.pl84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.twoja-ciaza.com.pl		www.bounty.com	
Northern EuropeFinlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99* [1]IcelandPregnancy Forums: www.bland.is100* [1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99* [1]Swedenwww.barnitotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99* [1]Croatiawww.cybermed.hr80* [1] (data from 2010)Polandwww.zzief.umlub.pl84* [1]		Pregnancy Forums: www.pregnancyforum.co.uk;	
Finlandwww.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi99* [1]IcelandPregnancy Forums: www.bland.is100* [1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99* [1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99* [1]Eastern EuropeCroatiawww.cybermed.hr80* [1] (data from 2010)Polandwww.zzief.umlub.pl84* [1]Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.twoja-ciaza.com.pl54* [1]		www.pregnancyforum.org.uk	
IcelandPregnancy Forums: www.bland.is100*[1]Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*[1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99*[1]Croatiawww.cybermed.hr80*[1] (data from 2010)Polandwww.zzief.umlub.pl84*[1]		Northern Europe	
Norwaywww.barnimagen.com; www.klikk.no; www.jormorsiri.no; www.tryggmamamedisin.no99*[1]Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99*[1]Croatiawww.cybermed.hr80*[1]Polandwww.zzief.umlub.pl84*[1]Pregnancy Forums:www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.twoja-ciaza.com.pl99*[1]	Finland	www.vauva.fi; www.meidanperhe.fi; www.kaksplus.fi	99 ^{* [1]}
Interneting www.internetingeneeting, www.initiation, www.ebrauszek.pl; Vertified Eastern Europe Poland www.zzief.umlub.pl 84* ^[1] Pregnancy Forums: www.ebrauszek.pl; www.initiation, www.itwoja-ciaza.com.pl www.babyboom.pl; www.twoja-ciaza.com.pl www.itwoja-ciaza.com.pl Itematical waveleting	Iceland	Pregnancy Forums: www.bland.is	100* [1]
Swedenwww.barntotal.se; www.minbebis.com; www.se.babycenter.com; www.socmed.gu.se99*[1]Eastern EuropeCroatiawww.cybermed.hr80*[1] (data from 2010)Polandwww.zzief.umlub.pl84*[1]Pregnancy Forums:www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.twoja-ciaza.com.pl99*[1]	Norway	www.barnimagen.com; www.klikk.no;	99 ^{* [1]}
www.se.babycenter.com; www.socmed.gu.se Eastern Europe Croatia www.cybermed.hr 80* ^[1] (data from 2010) Poland www.zzief.umlub.pl 84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl	-	www.jormorsiri.no; www.tryggmamamedisin.no	
Eastern Europe Croatia www.cybermed.hr 80* ^[1] (data from 2010) Poland www.zzief.umlub.pl 84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl	Sweden	www.barntotal.se; www.minbebis.com;	99 ^{* [1]}
Croatia www.cybermed.hr 80* ^[1] (data from 2010) Poland www.zzief.umlub.pl 84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl		www.se.babycenter.com; www.socmed.gu.se	
Poland from 2010) Poland www.zzief.umlub.pl 84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl		Eastern Europe	
Poland www.zzief.umlub.pl 84* ^[1] Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl	Croatia	www.cybermed.hr	80 ^{* [1]} (data
Pregnancy Forums: www.ebrzuszek.pl; www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl			from 2010)
www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl	Poland	www.zzief.umlub.pl	84* [1]
www.babyboom.pl; www.zapytajpolozna.pl; www.planujemydziecko.pl; www.twoja-ciaza.com.pl		Pregnancy Forums: www.ebrzuszek.pl;	
www.planujemydziecko.pl; www.twoja-ciaza.com.pl			
	Russia		48* [2]

Country	Website used for recruitment	Internet penetration rates (%)
	<i>Pregnancy Forums</i> : www.woman.ru; www.9months.ru; www.bemam; www.280dney.ru; www.iampregnant.ru www.pregnancy.org.ua; www.baby.ru;	
	www.mama66.ru; www.spuzom.ru	
Serbia	www.ringeraja.rs	52 ^{* [1]} (data from 2009)
Slovenia	Pregnancy Forums: www.med.over.net	92* [1]
AMERICAS		
	North America	
Canada	www.otispregnancy.org; Facebook page of OTIS; www.babyontheway.com.ca <i>Pregnancy Forums</i> : www.babycentre.com.ca;	94 ^{† [3]}
	www.thecradle.com; www.talk.sheknows.com; www.parenting.com	
USA	www.otispregnancy.org; Facebook page of OTIS; www.justmommies.com	80 ^{§ [4]}
	Pregnancy Forums: www.babyandbump.com www.thecradle.com; www.talk.sheknows.com; www.parenting.com	
	Central America	
Belize	www.otispregnancy.org; Facebook page of OTIS	23 ^[2]
Costa Rica		43 ^[2]
El Salvador	_	25 ^[2]
Guatemala	-	16 ^[2]
Honduras	_	16 ^[2]
Nicaragua	- 2	14 ^[2]
Panama	_	43 ^[2]
	South America	
Argentina	www.otispregnancy.org; Facebook page of OTIS	67 ^[2]
Bolivia		30 ^[2]
Brazil	Pregnancy Forums: www.semanaasemana.com;	46 ^[2]
Chile	www.univision.com; www.elembarazo.net	59 ^[2]
Colombia		59 ^[2]
Ecuador		44 ^[2]
Paraguay	—	24 ^[2]
Peru	—	37 ^[2]
Uruguay		56 ^[2]
Venezuela	<u> </u>	41 ^[2]

Country	Website used for recruitment	Internet penetrati rates (%)
	AUSTRALIA	
Australia	www.mothersafe.org.au; www.bubhub.com.au	83 ^{ζ [5]}
	Pregnancy Forums: www.abds.org.au;	
	www.birth.com.au	

*Indicates the frequency of internet access - at least once a week, including every day - among individuals aged 25- 34 years. Differences between men and women were relatively small. Slightly more than two thirds of men (70%) and 65% of women used the Internet regularly.

[†]Indicates individuals aged 16-45 years who used the internet for personal use.

[§]Indicates individuals > 18 years old, access from anywhere; household internet for women is equal to 68.1%; higher percentages are observed for people aged 25-54 years.

^ζIndicates households with access to the internet at home.

Sources of internet penetration rates:

Seybert H. Internet use in households and by individuals in 2011. Eurostat Statistics in focus;

2. Internet World Stats. Usage and population statistics. Available at:

http://www.internetworldstats.com/. Accessed 29 December, 2013.

3. Statistics Canada. Individual Internet use and E-commerce (2010). Available at:

http://www.statcan.gc.ca/daily-quotidien/111012/dq111012a-eng.htm. Accessed 20 November, 2012.
4. United States Census Bureau. The 2012 Statistical Abstract. Information & Communications:

Internet Publishing and Broadcasting and Internet Usage. Available at: http://www.census.gov/compendia/statab/cats/information_communications/internet_publishing_and_b roadcasting_and_internet_usage.html. Accessed 13 November, 2012.

5. Australian Bureau of Statistics. Household Use of Information Technology, Australia, 2010-11 Available at:

http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/8146.0Main%20Features12010-

11?opendocument&tabname=Summary&prodno=8146.0&issue=2010-11&num=&view=. Accessed 13 November, 2012.

BMJ Open

Appendix 3: Socio-demographic characteristics of the study population and general birthing population on individual country

Appendix 3a: Socio-demographic characteristics in Western European countries (Switzerland, Italy and United Kingdom (UK))

	Study sample in Switzerland n=618	General birthing population in Switzerland LB=80,808 ^[1]	Study sample in Italy n=926	General birthing population in Italy LB=546,606 ^[1]	Study sample in the UK n=1,120	General birthing population in UK [*] LB=723,165 ^[2]
	(%)	(%)	(%)	(%)	(%)	(%)
No. of respondents/No. live births [¶]	4.6%		1.0%		0.9%	
Mean Age +/- sd	31.6 +/- 4.3	31.4 ^[3]	32.3 +/- 5.0	31.3 ^[4]	30.5 +/- 5.2	29.6 ^[2]
Marital status						
In marriage	80.0	80.7 ^[3]	68.8	75.1 ^[1]	63.3	53.2 ^[2]
Outside marriage	20.0	19.3 ^[3]	31.2	31.5 ^[1]	36.7	46.8 ^[2]
Parity						
No previous children	53.2	-	59.7	48.7 ^[5]	48.0^{\dagger}	41.9 ^[2] †
Educational level						
Less than high school	11.0	$11.7^{[6]}$	7.0	25.2 ^[6]	0.6	16.5 ^[2]
High school	13.6	$49.2^{[6]}$	47.2	49.2 ^[6]	27.9	37.2 ^[2]
More than high school	47.2	39 .1 ^[6]	44.3	25.6 ^[6]	52.1	46.3 ^[2]
Other	28.2	-	1.5	-	19.3	-
Women smoking before pregnancy	25.1	25.4 ^[7]	34.2	33.3 ^[4]	25.2	25.7 ^[7]
Women smoking during pregnancy	5.5	6.6 ^[8]	10.5	$22.7^{[9]}$	7.1 [‡]	13.2 ^[10] ‡
Use of alcohol during pregnancy	20.7	29.9 ^[8]	17.9	17.7 ^[9]	28.3	24.0 ^[11] §

Abbreviations: LB: Number of live births per year.

*The figures shown here are statistic estimates for England and Wales. Scotland and Northern Ireland have separate statistical reports. Since more than 85% of the study population in UK were resident in England and about 8% in Wales, we are only showing national statistic data for these two parts of the UK.

BMJ Open

. the proportion (%) of pregnan. . statics Bureau in the UK. . sed by the Statistics Bureau in the UK, data on 4th Quart. . pregnancy of consuming more than four drinks in a day. The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

[†]Among married women only – as provided by the Statistics Bureau in the UK.

[‡]Among women resident in England only (as provided by the Statistics Bureau in the UK, data on 4th Quarter of 2011).

[§]Women reporting at least one occasion during pregnancy of consuming more than four drinks in a day.

BMJ Open

Appendix 3b: Socio-demographic characteristics in Western European countries (Austria, France and The Netherlands)

	Study sample in Austria n=82	General birthing population in Austria LB=78,109 ^[1]	Study sample in France n=374	General birthing population in France LB=824,263 ^[1]	Study sample in The Netherlands n=81	General birthing population in The Netherlands LB=180,060 ^[1]
	(%)	(%)	(%)	(%)	(%)	(%)
No. of respondents/No. live births [*]	0.6%		0.3%		0.3%	
Mean Age +/- sd	30.6 +/- 4.6	30.0 ^[12]	29.6 +/- 4.9	30.1 ^[13]	32.0 +/- 6.4	31.0 ^[14]
Marital status						
In marriage	48.8	59 .6 ^[15]	48.9	45.0 ^[1]	69.1	$58.2^{[14]}$
Outside marriage	51.2	40.4 ^[15]	51.1	55.0 ^[1]	30.8	$41.8^{[14]}$
Parity						
No previous children	63.4	47.96 ^[15]	52.9	$44.2^{[16]}$	38.3	46.4 ^[14]
Educational level						
Less than high school	9.8	13.3 ^[6]	1.6	15.4 ^[6]	9.9	15.9 ^[6]
High-school	32.9	64.1 ^[6]	25.1	37.4 ^[6]	66.7	$40.2^{[6]}$
More than high school	40.2	$22.7^{[6]}$	57.0	47.2 ^[6]	23.5	43.9 ^[6]
Other	17.1	-	16.3	-	-	-
Women smoking before pregnancy	31.7	32.1 ^[17]	39.3	39.0 ^[16]	34.6	29 .5 ^[7]
Women smoking during pregnancy	4.9	-	14.2	28.0 ^[16]	14.8	$17.1^{[18]}$
Use of alcohol during pregnancy	13.4	-	11.5	52.0 ^[19]	11.1	16-35 ^[14]
Abbreviations: LB: Number of live births	ner vear					

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

	Study sample in	General birthing	Study sample	General birthing	Study sample	General birthing
	Norway	population in	in Finland	population in	in Sweden	population in
		Norway		Finland		Sweden
	n=1,228	LB=60,220 ^[1]	n=574	LB=59,961 ^[1]	n=887	LB=111,770 ^[1]
	(%)	(%)	(%)	(%)	(%)	(%)
<i>No. of respondents/No. live births</i> [*]	12.2%		5.7%		4.8%	
Mean Age +/- sd	29.0 +/- 4.6	29.8 +/- 5.3 ^[20]	29.0+/-5.1	30.1 ^[21]	29.8 +/- 5.3	30.3 ^[22]
Marital status						
In marriage	39.1	46.0 ^[20]	59.4	57.8 ^[21]	40.7	45.8 ^[1]
Outside marriage	60.9	53.4 ^[20]	40.6	$42.0^{[21]}$	59.3	54.2 ^[1]
Unknown	-	$0.6^{[20]}$	-	$0.2^{[21]}$		
Parity						
No previous children	41.4	42.4 ^[20]	35.5	$42.2^{[21]}$	63.1	44.9 ^[22]
Educational level						
Less than high school	4.5	$14.7^{[6]}$	8.2	7.1 ^[6]	5.2	$11.1^{[6]}$
High-school	28.0	31.4 ^[6]	36.4	$44.5^{[6]}$	30.0	$38.2^{[6]}$
More than high school	46.9	53.9 ^[6]	52.6	48.4 ^[6]	60.6	50.6 ^[6]
Other	20.7	-	2.8		4.2	-
Women smoking before pregnancy	33.5	36.5 ^[7]	36.7	19.7 ^[7]	25.0	$27.2^{[7]}$
Women smoking during pregnancy	6.8	$7.0^{[20]}$	11.7	$15.2^{[21]}$	5.4	$6.5^{[22]}$
Use of alcohol during pregnancy	4.1	7.4 ^[23]	13.9	_	7.2	5.9 ^[24]

Appendix 3c: Socio-demographic characteristics in Northern European countries (Norway, Finland and Sweden)

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

BMJ Open

2	
3	
4 5	
5 6	
7	
8 9	
10	
11	
13	
14	
15 16	
17	
18	
20	
21	
22 23	
24	
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	
27	
28	
29 30	
31 32	
32 33	
34	
35	
34 35 36 37 38 39	
38	
39 40	
41	
42	
43 44	
45	
46 47	
47	

	Study sample in Iceland n=71	General birthing population in Iceland LB=4,492 ^[1]
	(%)	(%)
No. of respondents/No. live births [*]	9.3%	
ge range (in years)		
5-20	11.3	$5.1^{[25]}$
21-25	16.9	19.3 ^[25]
26-30	42.3	34.2 ^[25]
31-35	15.5	27.3 ^[25]
36-40	12.7	11.7 ^[25]
<u>-</u> 41	1.4	2.4 ^[25]
Aarital status		
n marriage	31.0	35.0 ^[25]
Dutside marriage	69.0	65.0 ^[25]
Parity		
No previous children	47.9	38.1 ^[25]
Educational level		
Less than high school	25.4	21.4 ^[6]
High-school	18.3	30.5 ^[6]
More than high school	43.7	$48.1^{[6]}$
Other	12.7	-
Women smoking before pregnancy	40.8	35.5 ^[7]

Appendix 3d: Socio-demographic characteristics in Northern European countries (Iceland)

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

Appendix 3e: Socio-demographic characteristics in Eastern European countries (Croatia, Slovenia and Serbia)

No. of respondents/No. live births*4.2Mean Age +/- sd29.1 +Marital status29.1 +In marriage82Outside marriage16Parity16No previous children56Educational level1Less than high school1High-school36	286 LB=41,1' %) (%) 2%	n (%) 4.1% 6] 31.7 +/- 4 6] 47.0	(%) 4.5 30.4 ^[27] 43.2 ^[27]	$ \begin{array}{c cccc} n & (\%) \\ \hline 2.0\% \\ \hline 29.2 + - 3.9 \\ \hline 90.1 \\ 9.9 \\ \end{array} $	LB=65,598 ^[1] (%) * 28.7 ^[1,28] 76.1 ^[28] 23.9 ^[28]
Mean Age +/- sd29.1 +Marital status83In marriage83Outside marriage16Parity50Educational level50Less than high school1High-school36	-/- 4.5 [†] 27.7 ^{[20} 8.9 86.7 ^{[20}	^{6]} 31.7 +/- 4 ^{6]} 47.0	4.5 30.4 ^[27] 43.2 ^[27]	29.2 +/- 3.9 90.1	76.1 ^[28]
Marital statusIn marriage83Outside marriage16Parity16No previous children50Educational level11Less than high school1High-school36	8.9 86.7 ^{[20}	6] 47.0	43.2 ^[27]	90.1	76.1 ^[28]
In marriage83Outside marriage10Parity50Educational level50Less than high school1High-school30					
Outside marriage10Parity50No previous children50Educational level1Less than high school1High-school30					
ParityNo previous children50Educational level1Less than high school1High-school30	13 3[20	^{6]} 53.0	[27]	0.0	$22 0^{[28]}$
No previous children50Educational level1Less than high school1High-school30			56.8 ^[27]	7.9	23.9
Educational levelLess than high school1High-school36					
Less than high school1High-school30	$46.9^{[20]}$	6] 45.6	48.5 ^[27]	46.8	51.1 ^[28,29]
High-school 30					
e	.0 3.1 ^[26]	2.0	8.5 ^[27]	0.9	15.9 ^[29]
More than high school 61	5.7 52.5 ^{[20}	6] 24.8	48.5 ^[27]	33.6	54.9 ^[29]
	.2 44.4 ^{[20}	^{6]} 69.1	43.0 ^[27]	61.8	$29.2^{[29]}$
Other 1	- 0.	4.0		3.6	-
Women smoking before pregnancy 50	24.4[2(6] 32.9	34.4 ^[7]	49.1	29.9 ^[30,31]
Women smoking during pregnancy 18	$34.4^{[20]}$	2]	9.6-11.2 ^[33]	18.2	18.4 ^[31]
Use of alcohol during pregnancy 12	$\frac{34.4^{1-5}}{3.8}$	6.7			

Abbreviations: LB: Number of live births per year.

* The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

[†]Mean age for first child (as it is available from the Statistics Bureau reports in Croatia and Serbia).

BMJ Open

Appendix 3f: Socio-demographic characteristics in Eastern European countries (Poland and Russia)

	Study sample in Poland n=679	General birthing population in Poland LB=388,416 ^[1]	Study sample in Russia n=1,008	General birthing population in Russia LB=1,796,629 ^[1]
	(%)	(%)	(%)	(%)
No. of respondents/No. live births [*]	1.0%		0.3%	
Mean Age +/- sd	27.1 +/- 4.1	28.6 ^{[35] †}	27.7 +/- 4.8	$27.4^{[36]}$
Marital status				
In marriage	85.0	79.4 ^[35]	85.3	73.9 ^[36]
Outside marriage	15.0	20.6 ^[35]	14.7	26 .1 ^[36]
Parity				
No previous children	40.6	50 .1 ^[35]	57.9	-
Educational level				
Less than high school	1.9	8.7 ^[35]	1.6	-
High-school	31.1	49.6 ^[35]	9.3	-
More than high school	65.1	41.6 ^[35]	75.1	-
Other	1.9	-	14.0	-
Women smoking before pregnancy	49.2	25.0 ^[37]	46.1	30.8 ^[38]
Women smoking during pregnancy	12.8	22-30 ^[37]	9.6	4.3-6.5 ^[39,40]
Use of alcohol during pregnancy	9.6	15.3 ^[41]	26.0	60.0 ^[42]
Abbreviations: LB: Number of live births per	vear.			

Abbreviations: LB: Number of live births per year.

* The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

[†]Median age of women at birth, not mean age.

	Study sample in Canada	General birthing population in Canada ^[43]	Study sample in The USA	General birthing population in USA ^[44]
	n=236	LB=377,636	n=297	LB=3,999,386
	n (%)	(%)	n (%)	(%)
No. of respondents/No. live births [*]	0.4%		0.04%	
Age range (in years)				
15-19	2.1	3.9 ^[43]	4.7	9.3 ^[44]
20-24	25.0	14.6 ^[43]	18.2	23.8 ^[44]
25-29	30.1	30.2 ^[43]	28.3	$28.3^{[44]}$
30-34	30.5	32.2 ^[43]	29.3	$24.1^{[44]}$
35-39	11.0	15.6 ^[43]	15.2	$11.6^{[44]}$
40-44	1.3	3.1 ^[43]	4.0	$2.7^{[44]}$
≥45	-	$0.2^{[43]}$	0.3	$0.2^{[44]}$
Mean Age +/- sd	28.3 +/- 5.2	29.6 ^[43]	29.3 +/- 6.1	-
Marital status				
In marriage	42.4	60.4 ^[43]	67.0	59.2 ^[45]
Outside marriage	57.6	$28.8^{[43]}$	33.0	39 .9 ^[45]
Unknown	-	$10.8^{[43]}$	-	$0.9^{[45]}$
Parity				
No previous children	48.3	43.3 ^[43]	41.1	40.1 ^[44]
Educational level				
Less than high school	1.3	$8.4^{[46]}$	2.7	$17.4^{[47]}$
High-school	24.6	-	25.3	$24.4^{[47]}$
More than high school	67.8	69.6 ^[46]	62.0	58.2 ^[47]
Other	6.4	-	10.1	-

Appendix 3g: Socio-demographic characteristics in North American countries (Canada and USA)

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Study sample in Canada	General birthing population in Canada ^[43]	Study sample in The USA	General birthing population in USA ^[44]
	n=236	LB=377,636	n=297	LB=3,999,386
	n (%)	(%)	n (%)	(%)
Women smoking before pregnancy	29.2	$22.0^{[48]}$	28.3	21.5 ^[49]
Women smoking during pregnancy	16.1	13.4 ^[46]	8.1	$10.2^{[50]}$
Use of alcohol during pregnancy	16.1	10.5 ^[46]	17.5	15.5 ^[49]

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months (period of data collection).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Appendix 3h: Socio-demographic characteristics in Australia

	Study sample in	General birthing
	Australia	population in
		Australia[^{51]}
	n=217	LB=301,617
	n (%)	(%)
No. of respondents/No. live births *	0.4%	
Mean Age +/- sd	31.1 +/- 5.7	30.7 ^[51]
Marital status		
In marriage	70.5	65 .8 ^[51]
Outside marriage	29.5	34.2 ^[51]
Parity		
No previous children	47.9	43.8 ^[51]
Educational level		
Less than high school	0.5	20.6 ^{† [52]}
High-school	29.0	
More than high school	63.1	56.0 ^[53]
Other	7.4	-
Women smoking before pregnancy	29.1	29 .9 ^[54]
Women smoking during pregnancy	14.3	14.5 ^[55]
Use of alcohol during pregnancy	27.2	29.0 ^[56]

Abbreviations: LB: Number of live births per year.

*The ratio "No. of respondents/No. live births" is calculated as the proportion (%) of pregnancies included in the study among live births in the country in two months

(period of data collection).

 [†]Refers to the educational levels "high school" and "less than high school" grouped together.

1	
2	
3	
4	
5	Sources of socio-demographic characteristics of the general birthing population:
6	
7	1. Eurostat. Live births by mother's age at last birthday and legal marital status. Available at: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo fagec⟨=en.
8	Accessed 6 November, 2012.
9	2. UK National Statistics. Characteristics of Birth 1 and 2/of mother 1 and 2, England and Wales. 2010. Available at: http://www.statistics.gov.uk/hub/population/births-and-
9 10	fertility/maternities/index.html. Accessed 12 November, 2012.
	3. Swiss Statistics. Components of population change – Data, indicators. Available at: http://www.bfs.admin.ch/bfs/portal/en/index/themen/01/06/blank/key/01.html.
11	Accessed 6 November, 2012.
12	4. Istat - Istituto nazionale di statistica. Demography in figures. 2011. Available at: http://demo.istat.it/index e.html. Accessed 6 November, 2012.
13	5. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol 2000; 56 (4):323-8.
14	6. Eurostat. Persons with a given education attainment level by sex and age groups (%). Available at:
15	http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/dataset?p_product_code=EDAT_LFS_9903. Accessed 6 November , 2012.
16	
17	7. Eurostat. Smokers by sex. Available at: http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/dataset?p_product_code=TPS00169. Accessed 6 November,
18	
19	8. Lemola S, Grob A. Drinking and smoking in pregnancy: what questions do Swiss physicians ask? Swiss Med Wkly 2007;137(3-4):66-9.
20	9. De Santis M, De Luca C, Mappa I, et al. Smoke, alcohol consumption and illicit drug use in an Italian population of pregnant women. Eur J Obstet Gynecol Reprod Biol
21	2011;159(1):106-10.
22	10. The Health and Social Care Information Centre. Statistics on women's smoking status at time of delivery: England, Quarter 1, 2012/13. 2012. Available at:
23	http://www.ic.nhs.uk/pubs/wsstd1213q1. Accessed 12 November, 2012.
24	11. Sayal K, Heron J, Golding J, et al. Binge pattern of alcohol consumption during pregnancy and childhood mental health outcomes: longitudinal population-based study.
25	Pediatrics 2009; 123 (2):e289-96.
26	12. Statistics Austria. Births. Long-term and current final annual results. 2011. Available at: http://www.statistik.at/web_en/statistics/population/births/index.html. Accessed
27	November 6th, 2012.
28	13. National Institute of Statistics and Economic Studies INSEE. Population. Available at: http://www.insee.fr/en/themes/theme.asp?theme=2. Accessed 7 November, 2012.
29	14. Statline, Centraal Bureaus voor de Statistiek. Population. 2012. Available at: http://www.cbs.nl/en-GB/menu/themas/bevolking/nieuws/default.htm. Accessed 10
30	November, 2012.
30 31	15. STATcube - Statistical Database of Statistics Austria. Available at: http://statcube.at/superweb/login.do?guest=guest. Accessed 6 November, 2012.
	16. Menai M, Heude B, Slama R, et al. Association between maternal blood cadmium during pregnancy and birth weight and the risk of fetal growth restriction: The EDEN
32	mother-child cohort study. Reprod Toxicol 2012; 34 (4):622-27.
33	17. Jahrbuch der GESUNDHEITSSTATISTIK. Wein: Statistika Austria. 2011.
34	18. Leermakers ET, Taal HR, Bakker R, et al. A common genetic variant at 15q25 modifies the associations of maternal smoking during pregnancy with fetal growth: the
35	generation R study. PLoS One 2012;7(4):e34584.
36	19. de Chazeron I, Llorca PM, Ughetto S, et al. Is pregnancy the time to change alcohol consumption habits in France? Alcohol Clin Exp Res 2008; 32 (5):868-73.
37	20. Norwegian Institue of Public Health. Medisinsk fødselsregisters statistikkbank - statistikk om alle fødsler i Norge. 2011. Available at: http://mfr-nesstar.uib.no/mfr/.
38	Accessed 6 November, 2012.
39	21. The National Institute for Health and Welfare, Helsinki Finland. Liitetaulukot - Bilagetabeller - Appendix Tables, 2010.
40	21. The National Institute for meanin and wenare, meisniki Philand. Enteradiukot - Dhagetabener - Appendix Tables, 2010.
41	
42	
43	
44	
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
45 46	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xntml

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

45 46 47

22. Heino A, Gissler M. Nordic Perinatal Statistics 2010: National Institute for Health and Welfare. Helsinki, Finland. 2012. 23. Ystrom E, Vollrath ME, Nordeng H. Effects of personality on use of medications, alcohol, and cigarettes during pregnancy. Eur J Clin Pharmacol 2012;68(5):845-51. 24. Nilsen P, Holmqvist M, Hultgren E, et al. Alcohol use before and during pregnancy and factors influencing change among Swedish women. Acta Obstet Gynecol Scand 2008;87(7):768-74. 25. Births and Deaths. Statistics Iceland. Available at: http://www.statice.is/Statistics/Population/Births-and-deaths. Accessed 6 November, 2012. 26. Statistical Yearbook of the Republic of Croatia. Zagreb: Croatian Bureau of Statistics, 2011. 27. Statistical Office of the Republic of Slovenia. SI-STAT Data Portal. Population. Available at: http://pxweb.stat.si/pxweb/Database/Demographics.asp. Accessed 7 November, 2012. 28. Statistical Yearbook of the Republic of Serbia. Demographic Yearbook in Republic of Serbia. Belgrade: Statistical Office of the Republic of Serbia, 2011. 29. Krstev S, Marinkovic J, Simic S, et al. Prevalence and predictors of smoking and quitting during pregnancy in Serbia: results of a nationally representative survey. Int J Public Health 2011. 30. Statistical Office of the Republic of Serbia. Women and Men in the Republic of Serbia, Belgrade, 2011. 31. Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and during pregnancy in Serbia. Int J Clin Pharm 2012;34(5):719-27. 32. Strinic T, Bukovic D, Sumilin L, et al. Socio-demographic characteristics and lifestyle habits of pregnant women smokers. Coll Antropol 2005;29(2):611-4. 33. Antolič B, Geršak K, Verdenik I, et al. Adverse effects of thyroid dysfunction on pregnancy and pregnancy outcome: Epidemiologic study in Slovenia. Journal of Maternal-Fetal and Neonatal Medicine 2006;19(10):651-54. 34. Petkovic G, Barisic I, FAS prevalence in a sample of urban schoolchildren in Croatia. Reprod Toxicol 2010;29(2):237-41. 35. Demographic Yearbook of Poland. Warsaw: Central Statistical Office of Poland, 2011. 36. The Demographic Yearbook of Russia - statistical handbook. Moscow: Federal State Statistics Service (Rosstat), 2010. 37. Przewoźniak K, Zatoński W. Ekspertyza "zachowania zdrowotne kobiet w ciąży". Warszawa: Zakład Epidemiologii i Prewencji Nowotworów, Centrum Onkologii – Instytut w Warszawie. Posiedzenie Plenarne Rady Naukowej przy Ministrze Zdrowia, Ministerstwo Zdrowia, 2010. 38. Current tobacco use and secondhand smoke exposure among women of reproductive age - 14 countries, 2008-2010. MMWR Morb Mortal Wkly Rep 2012;61:877-82. 39. Kelmanson IA, Erman LV, Litvina SV. Maternal smoking during pregnancy and behavioural characteristics in 2 - 4-month-old infants. Klin Padiatr 2002;214(6):359-64. 40. Hugg TT, Jaakkola MS, Ruotsalainen RO, et al. Parental smoking behaviour and effects of tobacco smoke on children's health in Finland and Russia. Eur J Public Health 2008;18(1):55-62. 41. Wojtyla A, Kapka-Skrzypczak L, Diatczyk J, et al. Alcohol-related Developmental Origin of Adult Health - population studies in Poland among mothers and newborns (2010-2012). Ann Agric Environ Med 2012;19(3):365-77. 42. Kristjanson AF, Wilsnack SC, Zvartau E, et al. Alcohol use in pregnant and nonpregnant Russian women. Alcohol Clin Exp Res 2007;31(2):299-307. 43. Statistics Canada. Births. 2010. Available at: http://www.statcan.gc.ca/daily-quotidien/111220/dg111220g-eng.htm. Accessed 12 November 2012. 44. Hamilton B, Martin J, Ventura S, National Vital Statistics Reports. Births: Preliminary Data for 2010: U.S. Department of health and human services. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System, 2011. 45. OECD. Panorama de la société 2011: OECD Publishing. 46. Canadian Perinatal Health Report, 2008 Edition. Ottawa: Public Health Agency of Canada, 2008. 47. The 2012 Statistical Abstract. The National Data Book. Women With Births in the Past 12 Months by Citizenship Status, Educational Attainment, and Poverty Status, by State. 2009. Available at: http://www.census.gov/compendia/statab/cats/births deaths marriages divorces/births.html. Accessed 12 November, 2012. 48. Public Health Agency of Canada. What Mothers Say: The Canadian Maternity Experiences Survey. Ottawa, 2009. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

1	
2	
3	
4	
4 5	49. Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH
	Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
6	
7	50. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD: National Center for Health Statistics, 2012.
8	51. Australian Bureau of Statistics. Births, Australia. 2011. Available at: http://www.abs.gov.au/AUSSTATS/abs@.nsf/mf/3301.0. Accessed 13 November, 2012.
9	52. Sawicki E, Stewart K, Wong S, et al. Medication use for chronic health conditions by pregnant women attending an Australian maternity hospital. Aust N Z J Obstet
10	Gynaecol 2011; 51 (4):333-38.
11	53. Australian Bureau Statistitics. Australian Social Trends, Sep 2012. 2012; Available at:
12	http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4102.0Main+Features20Sep+2012. Accessed 13 November, 2012.
	54. Hotham E, Ali R, White J, et al. Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia.
13	Aust N Z J Obstet Gynaecol 2008;48(3):248-54.
14	
15	55. Australia's mothers and bables 2009. Permatal statistics series no. 25. Cat. no. PEK 52. Canberra. Airw, 2011.
16	56. Maloney E, Hutchinson D, Burns L, et al. Prevalence and predictors of alcohol use in pregnancy and breastfeeding among Australian women. Birth 2011;38(1):3-9.
17	
18	
19	
20	
21	
22	
23	
23 24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	 55. Australia's mothers and babies 2009. Perinatal statistics series no. 25. Cat. no. PER 52. Canberra: AIHW, 2011. 56. Maloney E, Hutchinson D, Burns L, et al. Prevalence and predictors of alcohol use in pregnancy and breastfeeding among Australian women. Birth 2011;38(1):3-9.
35	
36	
30 37	
38	
39	
40	
41	
42	
43	
44	
45	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
46	
47	

Appendix 4: Sample size calculation (using 5% precision with 95% confidence interval) for the population survey on region and individual country levels.

	Study sample	Population size [*]		Exp	bected prevale	ence	
	-		Any medication use=80%	Any medication use=70%	OTC medication use=60%	Chronic medication use=30%	Chronic medication use=15%
				Req	uired sample	size	
Western Europe	3,201	Not known	246	323	369	323	196
United Kingdom	1,120	120,528	245	322	368	322	196
Italy	926	91,101	245	322	367	322	195
Switzerland	618	13,468	241	315	359	315	193
France	374	137,377	245	322	368	322	196
Austria [†]	82	13,018	241	315	359	315	193
The Netherlands [†]	81	30,010	244	319	364	319	195
Northern Europe	2,820	Not known	246	323	369	323	196
Norway	1,228	10,037	240	313	356	313	192
Sweden	887	18,628	243	317	362	317	194
Finland	574	9,994	240	313	356	313	192
Iceland [†]	71	749	185	225	247	225	155
Eastern Europe	2,342	Not known	246	323	369	323	196
Russia	1,008	299,438	246	322	368	322	196
Poland	679	64,736	245	321	367	321	195
Croatia [§]	286	6,866	237	308	350	308	190
Serbia [¶]	220	10,933	240	313	357	313	192
Slovenia**	149	3,658	230	297	335	297	186
North America	533	Not known	246	323	369	323	196
USA [§]	297	666,564	246	323	369	323	196
Canada ^{††}	236	62,939	245	321	367	321	195
South America [¶]	346	Not known	246	323	369	323	196
Australia ^{§§}	217	50,270	245	321	366	321	195

42 43 44

45 46 47

BMJ Open

2	
3	
4 5 6	Sample size calculations were performed in Epi Info TM 7 available at: Center for DiseaseControl and Prevention (CDC), Epi Info. URL: http://wwwn.cdc.gov/epiinfo/. Accessed 2013 Dec 31.
7 8 9	*The population size indicates the number of live births in the country in two months (corresponds to the period of data collection) (cf. Appendix 3 for annual estimates of live births in each country). For the all regions except Australia, the population size is very large but not known exactly (i.e. infinite population). Infinite population size is
10 11 12	therefore assumed in the calculation of the required sample size. [†] The sample size allows for prevalence estimates with a precision of 9% (expected prevalence=80%), 10% (expected prevalence=70% and 30%), 11% (expected prevalence=60%) and 8% (expected prevalence=15%).
13	[§] The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=70%, 60% and 30%).
14	[¶] The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=80%) and 7% (expected prevalence=70%, 60% and 30%).
15 16	** The sample size allows for prevalence estimates with a precision of 7% (expected prevalence=80%), 8% (expected prevalence=70%, 60% and 30%) and 6% (expected
17	prevalence=15%).
18	^{††} The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=80%, 70% and 30%) and 7% (expected prevalence=60%).
19	[¶] The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=60%).
20	^{§§} The sample size allows for prevalence estimates with a precision of 6% (expected prevalence=80%) and 7% (expected prevalence=70%, 60% and 30%).
21	
22	
23 24	
25	
26	
27	
28	
29	
30	
31	
32	
33 34	
34 35	
36	
37	
38	
39	
40	
41	

BMJ Open

Appendix 5: Overall medication use on 1st and 2nd ATC level according to timing of use in pregnancy (n=9,459)*

Anatomical Therapeutic Chemical (ATC) classification index		Anytime during	1 st trimester	2 nd trimester	3 rd trimeste
	1 st and 2 nd levels	pregnancy			
		n (%)	n (%)	n (%)	n (%)
A	Alimentary tract and metabolism	4,275 (45.2)	2,786 (29.5)	3,390 (35.8)	3,160 (33.4)
A01	Stomatological preparations	62 (0.7)	42 (0.4)	52 (0.5)	46 (0.5)
A02	Drugs for acid related disorders	3,242 (34.3)	2,034 (21.5)	2,634 (27.8)	2,615 (27.6)
A03	Drugs for functional gastrointestinal disorders	650 (6.9)	543 (5.7)	512 (5.4)	381 (4.0)
A04	Antiemetics and antinauseants	136 (1.4)	124 (1.3)	114 (1.2)	81 (0.9)
A05	Bile and liver therapy	24 (0.3)	15 (0.2)	17 (0.2)	16 (0.2)
A06	Laxatives	978 (10.3)	696 (7.4)	835 (8.8)	735 (7.8)
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	89 (0.9)	61 (0.6)	69 (0.7)	57 (0.6)
A09	Digestives, incl. enzymes	9 (0.1)	7 (0.1)	8 (0.1)	3 (0.0)
A10	Drugs used in diabetes	85 (0.9)	57 (0.6)	58 (0.6)	45 (0.5)
-	Unspecified medications for nausea	6 (0.1)	5 (0.1)	4 (0.0)	3 (0.0)
B	Blood and blood forming organs	148 (1.6)	89 (0.9)	102 (1.1)	79 (0.8)
B01	Antithrombotic agents	135 (1.4)	78 (0.8)	95 (1.0)	72 (0.8)
B02	Antihemorrhagics	5 (0.1)	4 (0.0)	2 (0.0)	3 (0.0)
B05	Blood substitutes and perfusion solutions	7 (0.1)	5 (0.1)	5 (0.1)	2 (0.0)
B06	Other hematological agents	3 (0.0)	2 (0.0)	2 (0.0)	3 (0.0)
С	Cardiovascular system	202 (2.1)	132 (1.4)	161 (1.7)	133 (1.4)
C01	Cardiac therapy	7 (0.1)	4 (0.0)	5 (0.1)	4 (0.1)
C02	Antihypertensives	56 (0.6)	34 (0.4)	42 (0.4)	31 (0.3)
C03	Diuretics	6 (0.1)	5 (0.1)	3 (0.0)	2 (0.0)
C04	Peripheral vasodilators	3 (0.0)	3 (0.0)	3 (0.0)	3 (0.0)
C05	Vasoprotectives	44 (0.5)	24 (0.3)	35 (0.4)	31 (0.3)
C07	Beta blocking agents	74 (0.8)	51 (0.5)	59 (0.6)	51 (0.5)
C08	Calcium channel blockers	21 (0.2)	16 (0.2)	18 (0.2)	13 (0.1)
C09	Agents acting on the renin-angiotensin system	4 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)

	Anatomical Therapeutic Chemical (ATC) classification index	Anytime during	1 st trimester	2 nd trimester	3 rd trimeste
	1 st and 2 nd levels	pregnancy			
		n (%)	n (%)	n (%)	n (%)
C10	Lipid modifying agents	5 (0.1)	3 (0.0)	4 (0.0)	4 (0.0)
-	Unspecified medications for hypertension	4 (0.0)	3 (0.0)	3 (0.0)	2 (0.0)
D	Dermatologicals	162 (1.7)	116 (1.2)	127 (1.3)	103 (1.1)
D01	Antifungals for dermatological use	38 (0.4)	28 (0.3)	33 (0.3)	27 (0.3)
D02	Emollients and protectives	14 (0.1)	11 (0.1)	12 (0.1)	10 (0.1)
D03	Preparations for treatment of wounds and ulcers	4 (0.0)	3 (0.0)	3 (0.0)	3 (0.0)
D04	Antipruritics, incl. antihistamines, anaesthetics, etc.	6 (0.1)	3 (0.0)	5 (0.1)	4 (0.0)
D05	Antipsoriatics	3 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)
D06	Antibiotics and chemotherapeutics for dermatological use	21 (0.2)	15 (0.2)	16 (0.2)	13 (0.1)
D07	Corticosteroids, dermatological preparations	56 (0.6)	40 (0.4)	39 (0.4)	31 (0.3)
D08	Antiseptics and disinfectants	14 (0.1)	9 (0.1)	10 (0.1)	9 (0.1)
D09	Medicated dressings	5 (0.1)	5 (0.1)	5 (0.1)	3 (0.0)
D10	Anti-acne preparations	4 (0.0)	4 (0.0)	4 (0.0)	2 (0.0)
D11	Other dermatological preparations	1 (0.0)	-	1 (0.0)	1 (0.0)
-	Unspecified medications for skin disorders	5 (0.1)	4 (0.0)	4 (0.0)	3 (0.0)
G	Genitourinary system and sex hormones	488 (5.2)	318 (3.4)	394 (4.2)	303 (3.2)
G01	Gynaecological antiinfective and antiseptics	406 (4.3)	255 (2.7)	337 (3.6)	258 (2.7)
G02	Other gynecologicals	13 (0.1)	10 (0.1)	10 (0.1)	8 (0.1)
G03	Sex hormones and modulators of the genital system	68 (0.7)	55 (0.6)	50 (0.5)	36 (0.4)
G04	Urologicals	12 (0.1)	8 (0.1)	7 (0.1)	8 (0.1)
H	Systemic hormonal preparations, excl. sex hormones and insulins	486 (5.1)	304 (3.2)	346 (3.7)	262 (2.8)
H01	Pituitary and hypothalamic hormones and analogues	4 (0.0)	4 (0.0)	3 (0.0)	4 (0.0)
H02	Corticosteroids for systemic use	93 (1.0)	64 (0.7)	78 (0.8)	63 (0.7)
H03	Thyroid therapy	397 (4.2)	242 (2.6)	273 (2.9)	201 (2.1)
J	Anti-infective for systemic use	1,381 (14.6)	874 (9.2)	1,107 (11.7)	943 (10.0)
J01	Antibacterials for systemic use	1,325 (14.0)	840 (8.9)	1,061 (11.2)	908 (9.6)
J02	Antimycotics for systemic use	23 (0.2)	16 (0.2)	21 (0.2)	17 (0.2)

	Anatomical Therapeutic Chemical (ATC) classification index 1 st and 2 nd levels	Anytime during pregnancy	1 st trimester	2 nd trimester	3 rd trimester
		n (%)	n (%)	n (%)	n (%)
J05	Antivirals for systemic use	39 (0.4)	27 (0.3)	30 (0.3)	26 (0.3)
J06	Immune sera and immunoglobulins	4 (0.0)	2 (0.0)	3 (0.0)	4 (0.0)
J07	Vaccines	10 (0.1)	5 (0.1)	8 (0.1)	5 (0.1)
L	Antineoplastic and immunomodulating agents	134 (1.4)	83 (0.9)	117 (1.2)	97 (1.0)
L01	Antineoplastic agents	4 (0.0)	3 (0.0)	4 (0.0)	1 (0.0)
L03	Immunostimulants	96 (1.0)	58 (0.6)	86 (0.9)	78 (0.8)
L04	Immunosuppressants	34 (0.4)	22 (0.2)	27 (0.3)	18 (0.2)
Μ	Musculo-skeletal system	571 (6.0)	416 (4.4)	437 (4.6)	380 (4.0)
M01	Antiinflammatory and antirheumatic products	515 (5.4)	378 (4.0)	396 (4.2)	342 (3.6)
M02	Topical products for joint and muscular pain	54 (0.6)	37 (0.4)	41 (0.4)	41 (0.4)
M03	Muscle relaxants	8 (0.1)	8 (0.1)	4 (0.0)	1 (0.0)
M05	Drugs for treatment of bone diseases	1 (0.0)	-	1 (0.0)	-
M09	Other drugs for disorders of the musculo-skeletal system	2 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)
-	Unspecified medications for headache	2 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)
N	Nervous system	5,441 (57.5)	3,638 (38.5)	4,247 (44.9)	3,449 (36.5)
N01	Anaesthetics	13 (0.1)	10 (0.1)	7 (0.1)	8 (0.1)
N02	Analgesics	5,297 (56.0)	3,562 (37.7)	4,171 (44.1)	3,387 (35.8)
N03	Antiepileptics	76 (0.8)	46 (0.5)	49 (0.5)	42 (0.4)
N05	Psycholeptics	210 (2.2)	173 (1.8)	164 (1.7)	138 (1.5)
N06	Psychoanaleptics	275 (2.9)	211 (2.2)	213 (2.3)	179 (1.9)
N07	Other nervous system drugs	6 (0.1)	4 (0.0)	5 (0.1)	3 (0.0)
-	Unspecified analgesics/medications for the nervous system	52 (0.5)	38 (0.4)	43 (0.5)	35 (0.4)
Р	Antiparasitic products, insecticides and repellents	26 (0.3)	20 (0.2)	22 (0.2)	16 (0.2)
P01	Antiprotozoals	25 (0.3)	20 (0.2)	22 (0.2)	16 (0.2)
P02	Anthelmintics	1 (0.0)	-	-	-
R	Respiratory system	2,609 (27.6)	1,878 (19.9)	2,047 (21.6)	1,702 (18.0)
R01	Nasal preparations	1,547 (16.4)	1,079 (11.4)	1,229 (13.0)	1,046 (11.1)

	Anatomical Therapeutic Chemical (ATC) classification index 1 st and 2 nd levels	Anytime during pregnancy	1 st trimester	2 nd trimester	3 rd trimester
		n (%)	n (%)	n (%)	n (%)
R02	Throat preparations	167 (1.8)	110 (1.2)	131 (1.4)	122 (1.3)
R03	Drugs for obstructive airway diseases	396 (4.2)	269 (2.8)	304 (3.2)	242 (2.6)
R05	Cough and cold preparations	152 (1.6)	103 (1.1)	125 (1.3)	101 (1.1)
R06	Antihistamines for systemic use	912 (9.6)	777 (8.2)	740 (7.8)	580 (6.1)
R07	Other respiratory system products	3 (0.0)	2 (0.0)	3 (0.0)	3 (0.0)
-	Unspecified medications of the respiratory system	142 (1.5)	101 (1.1)	118 (1.2)	99 (1.0)
S	Sensory organs	45 (0.5)	33 (0.3)	38 (0.4)	28 (0.3)
S01	Ophthalmologicals	33 (0.3)	24 (0.3)	28 (0.3)	23 (0.2)
S02	Otologicals	5 (0.1)	3 (0.0)	4 (0.0)	2 (0.0)
S03	Ophthalmological and otological preparations	3 (0.0)	2 (0.0)	2 (0.0)	2 (0.0)
-	Unspecified medications for eye disorders	5 (0.1)	4 (0.0)	5 (0.1)	2 (0.0)
V	Various	15 (0.2)	10 (0.1)	11 (0.1)	9 (0.1)
Total	medication use (any ATC)	7,678 (81.2)	4,710 (49.8)	5,538 (58.5)	4,663 (49.3)

*The most common medication groups within each ATC class are in italics. Exposure timing is defined as follows: 1st trimester (gestational weeks 0-12), 2nd trimester (gestational week 25 and up to childbirth).

Appendix 6: Prevalence of acute/short-term illnesses and most common medications used at any time during pregnancy by ATC level, indication for use and region (n=9,459) *†

			REGI	ON			-
Prevalence of acute/short-term illnesses in pregnancy and	Western	Northern	Eastern	North	South	Australia	Total
related medication use, overall and by drug groups	Europe	Europe	Europe	America	America	215	0.450
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Prevalence of headache	1,699 (53.1)	1,657 (58.8)	1,138 (48.6)	373 (70.0)	197 (56.9)	147 (67.7)	5,211 (55.1)
Medication use for headache, total	1,027 (32.1)	1,057 (37.5)	522 (22.3)	226 (42.4)	121 (35.0)	109 (50.2)	3,062 (32.4)
By drug group							
Paracetamol (incl. combinations) (N02BE)	994 (31.1)	1,009 (35.8)	372 (15.9)	206 (38.6)	92 (26.6)	101 (46.5)	2,774 (29.3
Non-steroidal antiinflammatory drugs (M01A)	28 (0.9)	78 (2.8)	37 (1.6)	18 (3.0)	18 (5.2)	2 (0.9)	179 (1.9)
Acetylsalicylic acid (incl. combinations) (N02BA)	7 (0.2)	4 (0.1)	81 (3.5)	1 (0.2)	4 (1.2)	2 (0.9)	99 (1.0)
Opioid analgesics (N02A)	14 (0.4)	46 (1.6)	3 (0.1)	3 (0.6)	-	13 (6.0)	79 (0.8)
Selective serotonin (5-HT ₁) agonists (N02CC)	6 (0.2)	22 (0.8)	2 (0.1)	3 (0.6)	-	1 (0.5)	34 (0.4)
Prevalence of heartburn	2,196 (68.6)	1,875 (66.5)	1,425 (60.8)	374 (70.2)	248 (71.7)	141 (65.0)	6,259 (66.2
Medication use for heartburn, total	984 (30.7)	885 (31.4)	525 (22.4)	202 (37.9)	88 (25.4)	72 (33.2)	2,756 (29.1
By drug group							
Antacids (aluminium, salts combinations, antiflatulents)	384 (12.0)	503 (17.8)	440 (18.8)	51 (9.6)	63 (18.2)	20 (9.2)	1,461 (15.4
Alginic acid complex/sucralfate/bismuth (A02BX)	569 (17.8)	332 (11.8)	86 (3.7)	4 (0.8)	3 (0.9)	14 (6.5)	1,008 (10.7
Proton pump inhibitors (A02BC)	77 (2.4)	86 (3.0)	4 (0.2)	13 (2.4)	3 (0.9)	7 (3.2)	190 (2.0)
Antacid with calcium (A02AC)	20 (0.6)	13 (0.5)	10 (0.4)	123 (23.1)	2 (0.6)	9 (4.1)	177 (1.9)
H ₂ receptor antagonists (A02BA)	27 (0.8)	27 (1.0)	7 (0.3)	45 (8.4)	5 (1.4)	38 (17.5)	149 (1.6)
Prevalence of pain	2,150 (67.2)	2,067 (73.3)	1,484 (63.4)	369 (69.2)	248 (71.7)	157 (72.4)	6,475 (68.5
Medication use for pain, total	533 (16.7)	426 (15.1)	147 (6.3)	110 (20.6)	80 (23.1)	59 (27.2)	1,355 (14.3
By drug group							
Paracetamol (incl. combinations) (N02BE)	444 (13.9)	374 (13.3)	65 (2.8)	99 (18.6)	44 (12.7)	55 (25.3)	1,081 (11.4

	REGION						
Prevalence of acute/short-term illnesses in pregnancy and related medication use, overall and by drug groups	Western Europe n=3,201 <i>n (%)</i>	Northern Europe n=2,820 n (%)	Eastern Europe n=2,342 n (%)	North America n=533 n (%)	South America n=346 n (%)	Australia n=217 n (%)	Total n=9,459 <i>n (%)</i>
Non-steroidal antiinflammatory drugs (M01A)	19 (0.6)	36 (1.3)	21 (0.9)	11 (2.1)	24 (6.9)	3 (1.4)	114 (1.2)
Opioid analgesics (N02A)	39 (1.2)	51 (1.8)	2 (0.1)	4 (0.8)	-	12 (5.5)	108 (1.1)
Prevalence of nausea Medication use for nausea, total	2,324 (72.6) 413 (12.9)	2,244 (79.6) 380 (13.5)	1,503 (64.2) 140 (6.0)	409 (76.7) 128 (24.0)	238 (68.8) 71 (20.5)	173 (79.7) 39 (18.0)	6,891 (72.9 1,171 (12. 4
By drug group					()		-, (
First generation antihistamines (R06A)	150 (4.7)	259 (9.2)	21 (0.9)	84 (15.9)	9 (2.6)	4 (1.8)	527 (5.6)
Metoclopramide/domperidone/bromopride (A03FA)	134 (4.2)	69 (2.4)	27 (1.2)	10 (1.9)	45 (13.0)	25 (11.5)	310 (3.3)
Serotonin antagonists (A04AA)	4 (0.1)	8 (0.3)	1 (0.0)	28 (5.3)	1 (0.3)	11 (5.1)	53 (0.6)
Prevalence of UTI	513 (16.0)	327 (11.6)	452 (19.3)	93 (17.4)	92 (26.6)	25 (11.5)	1,502 (15.
Medication use for UTI, total	315 (9.8)	221 (7.8)	192 (8.2)	56 (10.5)	63 (18.2)	17 (7.8)	864 (9.1)
By drug group							
Unspecified penicillins (J01C-)	94 (2.9)	99 (3.5)	46 (2.0)	16 (3.0)	17 (4.9)	1 (0.5)	273 (2.9)
NOS Antibacterials for systemic use (J01-)	116 (3.6)	85 (3.0)	25 (1.1)	20 (3.8)	14 (4.0)	6 (2.8)	266 (2.8)
Penicillins with extended spectrum +/- beta-lactamase inhibitors (J01CA/J01CR)	85 (2.7)	78 (2.8)	44 (1.9)	14 (2.6)	17 (4.9)	1 (0.5)	239 (2.5)
Nitrofurantoin (J01XE)	7 (0.2)	25 (0.9)	54 (2.3)	10 (1.9)	3 (0.9)	1 (0.5)	100 (1.1)
Cephalosporins (J01D)	20 (0.6)	10 (0.4)	36 (1.5)	2 (0.4)	11 (3.2)	6 (2.8)	85 (0.9)
Total prevalence of any acute/short-term illness	3,159 (98.7)	2,803 (99.4)	2,299 (98.2)	523 (98.1)	341 (98.6)	214 (98.6)	9,339 (98.
Total medication use for any acute/short-term illness	2,224 (69.5)	1,954 (69.3)	1,474 (62.9)	403 (75.6)	250 (72.3)	164 (75.6)	6,469 (68.

Countries are grouped into regions as shown in Figure 1. [†]Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, and herbal or alternative medicine products.

Abbreviations: UTI: Urinary tract infection; NOS: Not otherwise specified.

1 2 3 4 5 6 7 8 9 10]
$2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 101 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 8 \\ 9 \\ 201 \\ 22 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 31 \\ 32 \\ 33 \\ 4 \\ 35 \\ 6 \\ 7 \\ 8 \\ 39 \\ 33 \\ 34 \\ 35 \\ 6 \\ 7 \\ 8 \\ 39 \\ 31 \\ 33 \\ 35 \\ 37 \\ 38 \\ 39 \\ 31 \\ 31 \\ 31 \\ 31 \\ 31 \\ 31 \\ 31$	
40	
41 42 43 44 45 46	

Appendix 7: Prevalence of chronic/long-term disorders and most common medications used at any time during pregnancy by ATC level, indication for use and region $(n=9,459)^{*\dagger}$

			REG	ION			
Prevalence of chronic/long-term disorders in pregnancy	Western	Northern	Eastern	North	South	Australia	Total
and related medication use, overall and by drug groups	Europe	Europe	Europe	America	America		
	n=3,201	n=2,820	n=2,342	n=533	n=346	n=217	n=9,459
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Prevalence of hypothyroidism	130 (4.1)	118 (4.2)	105 (4.5)	22 (4.1)	11 (3.2)	6 (2.8)	392 (4.1)
Medication use for hypothyroidism, total	118 (3.7)	113 (4.0)	96 (4.1)	21 (3.9)	9 (2.6)	6 (2.8)	363 (3.8)
By drug group							
Thyroid hormone, levothyroxine (H03AA01)	117 (3.7)	112 (4.0)	89 (3.8)	21 (3.9)	9 (2.6)	6 (2.8)	354 (3.7)
Prevalence of asthma	163 (5.1)	193 (6.8)	58 (2.5)	43 (8.1)	12 (3.5)	24 (11.1)	493 (5.2)
Medication use for asthma, total	122 (3.8)	133 (4.7)	38 (1.6)	35 (6.6)	8 (2.3)	24 (11.1)	360 (3.8)
By drug group							
Inhalant selective beta-2 agonists (R03AC)	94 (2.9)	66 (2.3)	26 (1.1)	32 (6.0)	7 (2.0)	24 (11.1)	249 (2.6)
Adrenergics and other drugs for COPD (R03AK)	33 (1.0)	46 (1.6)	10 (0.4)	3 (0.6)	2 (0.6)	7 (3.2)	101 (1.1)
Inhalant glucocorticoids (R03BA)	28 (0.9)	40 (1.4)	13 (0.6)	12 (2.3)	-	4 (1.8)	97 (1.0)
Systemic selective beta-2 agonists (R03CC)	-	30 (1.1)		2 (0.4)	-	-	32 (0.3)
Prevalence of allergy	205 (6.4)	372 (13.2)	163 (7.0)	51 (9.6)	20 (5.8)	23 (10.6)	834 (8.8)
Medication use for allergy, total	66 (2.1)	171 (6.1)	65 (2.8)	24 (4.5)	13 (3.8)	17 (7.8)	356 (3.8)
By drug group							
Second generation antihistamines (R06A)	29 (0.9)	104 (3.7)	27 (1.2)	17 (3.2)	4 (1.2)	5 (2.3)	186 (2.0)
Nasal corticosteroids (R01AD)	11 (0.3)	32 (1.1)	17 (0.7)	-	-	7 (3.2)	67 (0.7)
First generation antihistamines (R06A)	13 (0.4)	29 (1.0)	10 (0.4)	9 (1.7)	6 (1.7)	4 (1.8)	71 (0.8)
Prevalence of depression	95 (3.0)	144 (5.1)	29 (1.2)	52 (9.8)	4 (1.2)	25 (11.5)	349 (3.7)
Medication use for depression, total	61 (1.9)	100 (3.5)	11 (0.5)	29 (5.4)	1 (0.3)	23 (10.6)	225 (2.4)
By drug group							
SSRI antidepressants (N06AB)	44 (1.4)	82 (2.9)	6 (0.3)	14 (2.6)	-	14 (6.5)	160 (1.7)
SNRIs/mianserin/trazodone/mirtazapine/bupropion	9 (0.3)	11 (0.4)	1 (0.0)	15 (2.8)	-	7 (3.2)	43 (0.5)
							1

tern ope 201	Northern Europe n=2,820	Eastern Europe n=2,342	North America n=533	South America	Australia	Total
201	n=2,820	-				
	,	n=2,342	n=533	216		
2				n=346	n=217	n=9,459
n (%) n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	
.2)	2 (0.1)	5 (0.2)	-	-	1 (0.5)	14 (0.1)
.1)	4 (0.1)	-	3 (0.6)	-	3 (1.4)	12 (0.1)
19.3)	831 (29.5)	576 (24.6)	154 (28.9)	51 (14.7)	72 (33.2)	2,301 (24.3)
14.4)	593 (21.0)	322 (13.7)	119 (22.3)	38 (11.0)	70 (32.3)	1,604 (17.0)
1	.1) . 9.3)	.1) 4 (0.1) 9.3) 831 (29.5)	.1) 4 (0.1) - 9.3) 831 (29.5) 576 (24.6)	.1) 4 (0.1) - 3 (0.6) 9.3) 831 (29.5) 576 (24.6) 154 (28.9)	.1) 4 (0.1) - 3 (0.6) - 9.3) 831 (29.5) 576 (24.6) 154 (28.9) 51 (14.7)	.1) 4 (0.1) - 3 (0.6) - 3 (1.4) 9.3) 831 (29.5) 576 (24.6) 154 (28.9) 51 (14.7) 72 (33.2)

and herbal or alternative medicine products.

Abbreviations: COPD: Chronic obstructive pulmonary disease; SSRI: Selective serotonin re-uptake inhibitors; SNRI: Serotonin-noradrenaline reuptake inhibitors. isease; SSRI. Science and

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2
2 3 4
5 6
7 8 9
10 11
12 13
14 15 16
17 18
19 20 21
22 23
24 25
20 27 28
$\begin{array}{c} -3\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 2\\ 3\\ 14\\ 15\\ 16\\ 17\\ 18\\ 9\\ 20\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 9\\ 30\\ 13\\ 23\\ 34\\ 55\\ 6\\ 7\\ 8\end{array}$
31 32 33
34 35
36 37 38
39 40
41 42 43
44 45
46 47 48
49 50
51 52 53
54 55
56 57
58 59 60

STROBE Statement—Checklist of items that should be included in reports of cross-sectional studi	ies
STROBE Statement Checking of Reins that should be included in reports of cross securitaria	

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the
		abstract
		(b) Provide in the abstract an informative and balanced summary of what was
		done and what was found
Introduction		
Background/rationale	2	✗ Explain the scientific background and rationale for the investigation being
		reported
Objectives	3	✗ State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	X Present key elements of study design early in the paper
Setting	5	X Describe the setting, locations, and relevant dates, including periods of
		recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of
I I I I I I		participants
Variables	7	X Clearly define all outcomes, exposures, predictors, potential confounders, and
	,	effect modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	✗ For each variable of interest, give sources of data and details of methods of
measurement	0	assessment (measurement). Describe comparability of assessment methods if there is
measurement		more than one group
Bias	9	✗ Describe any efforts to address potential sources of bias
Study size	10	 Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
Quarter the star	12	describe which groupings were chosen and why
Statistical methods	12	★ (a) Describe all statistical methods, including those used to control for
		confounding
		(b) Describe any methods used to examine subgroups and interactions
		✗ (c) Explain how missing data were addressed
		(d) If applicable, describe analytical methods taking account of sampling strategy
		(<u>e</u>) Describe any sensitivity analyses
Results		
Participants	13*	✗ (a) Report numbers of individuals at each stage of study—eg numbers potentially
-		eligible, examined for eligibility, confirmed eligible, included in the study,
		completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)
1		and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	✗ Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates
Main results	10	and their precision (eg, 95% confidence interval). Make clear which confounders
		were adjusted for and why they were included
		 (b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a

BMJ Open

		meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	X Summarise key results with reference to study objectives
Limitations	19	X Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	X Give a cautious overall interpretation of results considering objectives,
		limitations, multiplicity of analyses, results from similar studies, and other relevant
		evidence
Generalisability	21	\checkmark Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	K Give the source of funding and the role of the funders for the present study and, it
		applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.